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Abstract 
Hepatitis C virus (HCV) is a worldwide public health problem affecting an 
estimated 170 million individuals. Studies on the replication of the HCV genome 
have been facilitated by the development of selectable subgenomic replicons 
(SGRs) replicating in the human hepatoma cell line Huh-7. This system 
represents a powerful tool for studying viral RNA synthesis, but is limited by the 
HCV strains that can replicate in cell culture as well as the cell lines that can 
support replication. Improving these models would aid our current understanding 
of the role of intrinsic host and viral factors required for viral replication as well 
as providing valuable tools for the screening and identification of new antiviral 
compounds. Currently, replicon systems are available for genotype (gt) 1a, 1b 
and 2a isolates, which are able to replicate viral RNA both transiently and 
continuously in Huh-7 cells. In the UK, infection with gt3 accounts for about 44% 
of cases and has a similar prevalence to gt1. The lack of cell culture systems for 
gt3 has hampered studies on its pathogenesis and responsiveness to novel anti-
HCV therapeutics.  
Given that construction of a SGR entirely from gt3 sequences has previously 
failed, our approach examined the feasibility of replacing sequences at the C-
terminus of NS4B and the NS3/4A protease from the JFH1 SGR with those from 
the Glasgow-3 gt3a isolate. The approach adopted in these studies identified 
amino acids that vary between gt2a and gt3a at the C-terminus of NS4B, which 
can be tolerated without impairing HCV RNA replication. By contrast, cloning of 
NS3-4A sequences into the JFH1-SGR (Luc-2a3a-NS3-4A) abolished any detectable 
transient replication in Huh-7 cells. However, delayed replication was evident in 
Huh-7.5 cells, a clonal derivative of Huh-7 cells. 
A further aim was to expand the cell lines permissive for HCV RNA 
replication. To date, only Huh-7 cells are highly permissive for viral replication 
and virus production in culture. Huh-7 cells are hepatoma cells, and may not 
fully recapitulate the features of hepatocytes during normal infection by HCV. 
Therefore, the permissiveness of HepaRG cells, a cell line which retains many 
features of fully functional hepatocytes, to HCV replication was examined. 
Despite the ability to translate viral RNA, HepaRG cells were unable to initiate 
HCV RNA replication in short-term assays. Nevertheless, assessment of 
XVII
replication using colony forming assays did reveal that stable replication of SGR 
RNAs could be achieved in HepaRG cells, under selective pressure with an 
antibiotic. Thus, adaptation of the JFH1 SGR to the HepaRG cell environment 
may be required for efficient genome synthesis. Similar to the results with 
transient replication assays, HepaRG cells were not susceptible to infection by 
HCV. 
HCV typically establishes a chronic infection that can be successfully 
eradicated by interferon-alpha (IFNα) based therapies. However, the underlying 
mechanisms leading to viral clearance by IFNα are poorly understood. From a 
siRNA library screen, ISG15 was identified as an interferon-stimulated gene that 
modulated HCV RNA replication. In this study, the contribution of ISG15 to 
clearance of HCV infection was examined in greater detail. siRNA-mediated 
depletion of ISG15 from both Huh-7 and U2OS cells, which harboured the 
subgenomic replicon, repressed ISG15 expression, resulting in a suppression of 
the antiviral activity of IFNα. Moreover, lowering the expression of ISG15 
increased viral RNA levels in Huh-7 and U2OS cells in the absence of IFN. These 
data indicate that ISG15 plays an inhibitory role during HCV replication both by 
augmenting IFN-mediated antiviral activity and in a mechanism independent 
from IFN-activation. Further experiments using the infectious HCV system 
confirmed these results and demonstrated that infection of Huh-7 cells stably 
expressing short hairpin RNA (shRNA) directed against ISG15 resulted in higher 
levels of HCV RNA, when compared with shRNA-Ctrl cells. Together, these 
findings imply a role for ISG15 in limiting HCV replication. The mechanism used 
by ISG15 to modulate HCV infection is not known. Following the above findings, 
studies were conducted to determine whether ISG15 can affect the rates of 
synthesis or degradation of viral RNA. By metabolically labelling newly 
synthesised transcripts, it was shown that cells stably expressing ISG15 shRNAs 
generated higher levels of viral RNA compared with control cells. This increase 
in the levels of newly synthesised viral RNA mirrored the differences in total 
steady-state levels of viral RNA in both cell lines, indicating that ISG15 can 
negatively regulate the rate of viral RNA synthesis. Since ISG15 is an ubiquitin-
like protein and can form conjugates with an array of other proteins, the 
requirements of ISG15 conjugation for its anti-HCV activities were also explored.
XVIII
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1 Introduction 
1.1 Background 
1.1.1 Non-A, Non-B Hepatitis 
Viral hepatitis is a clinical condition which describes inflammation of the 
liver caused by viral infection. Originally, two types of viral hepatitis were 
recognized to describe infections caused by hepatitis A virus (named “infectious 
hepatitis”) or by hepatitis B virus (termed “serum hepatitis”) (Bayer et al., 
1968; Feinstone et al., 1973). With the advent of serological tests for HAV and 
HBV, it became clear that some patients with transfusion-associated hepatitis 
suffered from a different form of hepatitis. These patients did not have 
serological markers for either HAV or HBV, hence this transfusion-associated 
hepatitis was called non-A, non-B hepatitis (NANBH) (Feinstone et al., 1975). 
Studies in chimpanzees, showed that NANBH was caused by a transmissible 
agent, as inoculation of these animals with serum from patients diagnosed with 
NANBH resulted in enhancement of ALT levels similar to that seen in patients 
(Alter et al., 1978). Moreover, serum from infected chimpanzees was able to 
infect a second line of animals. The agent responsible for NANBH was sensitive 
to organic solvents and lost its infectivity after treatment with chloroform, 
indicative of a virus containing a lipid envelope (Feinstone et al., 1983). Further 
analysis from transmission studies in chimpanzees revealed that the NANBH 
agent caused distinctive membranous tubules in hepatocytes from infected 
animals (Shimizu et al., 1979). Simultaneously, other studies demonstrated that 
the infectivity of NANBH was not reduced on passage of the inoculum through an 
80nm filter (Bradley et al., 1985). Collectively, these observations indicated that 
the causative agent for NANBH was probably a small enveloped virus, which was 
capable of inducing the formation of membranous tubules in infected cells. 
Despite this progress, conventional immunological methods failed to 
identify viral antigens and antibodies associated with NANBH. It was not until 
1989 when Choo and co-workers, using recombinant DNA cloning technologies, 
identified the causative agent of NANBH (Choo et al., 1989). In their approach, 
small cDNA fragments were amplified from infectious material derived from 
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chronically infected chimpanzees and cloned into bacteriophage λgt11 to create 
an expression library that was screened with sera from chronic NANBH patients. 
From this screen, one positive clone (5-1-1) proved to be derived from the NANB 
genome. Using Southern blot analysis, the 5-1-1 cDNA clone was shown not to 
hybridise to either control human DNA or to DNA derived from NANBH-infected 
chimpanzees, thereby demonstrating that this cDNA clone was not derived from 
the host genome. Total RNA extracted from the liver of infected chimpanzees 
specifically hybridised to both cDNA clone 5-1-1 and 81 (a larger overlapping 
clone isolated from the same library), but not with total RNA extracted from 
control, uninfected chimpanzees (Choo et al., 1989). Furthermore, extracted 
nucleic acids from ultracentrifuged pellets of NANBH chimpanzee plasma lost the 
hybridization signal after treatment with ribonuclease but not with 
deoxyribonuclease, indicating that the infectious agent contained an RNA 
genome. Moreover, NANBH virus carried a single-stranded RNA molecule, since 
only one of the strands in clone 81 hybridized to the viral genome. Using 
Northern blot analysis the length of the viral genome was estimated to be about 
10,000 nucleotides. Sequencing of clone 5-1-1 revealed that it contained one 
continuous long open reading frame (ORF) of positive-sense. The infectious 
agent of NANBH was then designated hepatitis C virus (HCV) (Choo et al., 1989). 
1.1.2 Classification of HCV 
HCV was described as an enveloped positive-sense, single-stranded RNA 
virus and, due to its ability to induce membrane tubule formation, it was 
originally suggested to be related to the Togaviridae or Flaviviridae. From 
analysis of HCV amino acid sequences, greater similarity was found with 
members of the two genera of the Flaviviridae family (Pestivirus and Flavivirus). 
This led to the classification of HCV as a member of the Flaviviridae family 
(Miller & Purcell, 1990). Later, gene organisation and hydrophobicity profiles 
indicated that HCV was closer to the Pestivirus genus than the Flaviviruses (Choo 
et al., 1991). Subsequently, HCV was classified as a separate genus (Hepacivirus) 
within the Flaviviridae (Robertson et al., 1998) (Figure 1.1). 
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HCV has been divided into six closely related major genetic groups or 
genotypes (numbered 1 to 6) (Simmonds, 2004). Each of these genotypes is 
equally divergent, differing by about 30-35% at the nucleotide level, leading to 
approximately 30% amino acid sequence differences between the encoded 
polyproteins (Simmonds, 2004). Numerous subtypes (designated by a, b, c,..), 
corresponding to the more closely related sequences within some of genotypes 
(differing from each other by >15%) have also been described for HCV. The 
different HCV genotypes are also associated with distinct geographical 
distributions and with various groups at risk of infection (Simmonds, 2004). 
The HCV-encoded RNA polymerase (section 1.2.2.2-V) possesses no 
proofreading or 5’-3’ exonuclease activity, and therefore introduces mutations 
into the viral genome during replication. Consequently, neutral and adaptive 
evolution occurs during the course of chronic infection within an individual. 
These genetic variants within an infected individual have been referred to as 
quasispecies (Martell et al., 1992). Accordingly, quasispecies are closely related 
viral genomes that differ from each other by up to 5% at the nucleotide level. 
In addition to HCV, the genus Hepacivirus comprises also GB virus-B (GBV-B) 
and possibly canine hepacivirus (CHV) (Figure 1.1). GBV-B was isolated from 
plasma of an individual GB with unexplained hepatitis. However, this virus 
apparently did not originate from GB and doesn’t seem to infect humans or 
chimpanzees, although it can cause acute hepatitis in infected tamarins and 
other New World monkey species (Bukh et al., 2001; Stapleton et al., 2011). 
More recently, CHV was identified in respiratory samples of domestic dogs 
(Kapoor et al., 2011). CHV is the first non-primate hepacivirus discovered. 
Comparative phylogenetic analysis has confirmed that this virus is the closest 
genetic relative of HCV, however there is still some debate as to whether it 
should be classified as its own Hepacivirus species (Bukh, 2011). 
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(Family) Flaviviridae
(Genus) Flavivirus
(Species) Yellow fever virus
West Nile virus
Dengue virus
Japanese encephalitis virus
(Genus) Pestivirus
(Species) Bovine viral diarrhea virus
Border disease virus
Classical swine fever virus
(Genus) Hepacivirus
(Species) HCV
CHV
GBV‐B
 
Figure 1.1 – HCV classification. Three genera have been identified within the Flaviviridae 
family: Flavivirus, Pestivirus and Hepacivirus. HCV belongs to the Hepacivirus genus 
together with GBV-B. Recently CHV has been proposed to belong to the genus Hepacivirus. 
 
1.1.3 Epidemiology and transmission of HCV 
Since its discovery, HCV has been recognised as a global health problem. It 
is estimated to affect 2-4% of the world’s population (Alter, 2007). HCV is 
estimated to infect 0.6-1% of the population in UK, but almost 2% of the 
population in USA (Thomson, 2009). In Europe, prevalence ranges from 1.5% to 
5%. Countries with the highest prevalence are found in Africa (>10%) and Asia (3-
4%). Studies have shown that HCV positivity is particularly high in Egypt, with 
viral antibodies detected in 15-20% of the general population. 
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Prevalence of each genotype varies widely and can also be mapped 
geographically (Figure 1.2). For example, the dominant genotype found in 
Europe, USA and China is genotype 1. Genotype 4 is the most common genotype 
in Africa and the Middle East. Genotypes 5 and 6 are rare and found in isolated 
geographic areas; genotype 5 in South Africa and genotype 6 in Hong Kong and 
Southeast Asia. Recent data from the Health Protection Agency (HPA) indicates 
that the prevalence of genotype 3a is roughly similar to that for genotype 1 in 
the UK (HPA, 2011). 
 
 
 
 
 
 
 
 
 
. 
 
 
Figure 1.2 – Worldwide distribution of HCV genotypes 1-6. The distribution of the six HCV 
genotypes is highlighted across the globe. Pie charts generated for each genotype (based 
on the sequences available at http:hcv.lanl.gov) are shown. 
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HCV is transmitted predominantly by direct percutaneous exposure to 
infected blood, mainly through blood transfusions, intravenous drug use (IDU) or 
unsafe medical and surgical procedures (Shepard et al., 2005). Transfusion-
associated cases occurred prior to routine donor screening in blood banks, but 
this route of infection has been effectively eliminated in Western countries. 
However, in developing countries there is an ongoing risk of HCV transmission 
through transfused blood due to the lack of resources to implement adequate 
donor screening. The number of cases of acute HCV among injecting drug users 
has recently declined in the US and Europe because of implementation of harm 
reduction policies, syringe exchange programs, counseling of injecting drug users 
regarding protection from infection and changes in injecting behavior. 
Transmission can also occur through alternative percutaneous modes like 
tattooing and body piercing as a consequence of using inadequately sterilized 
equipment. Some cases of acute HCV have been related to sexual transmission; 
however the degree to which the virus is transmitted through this route is 
debatable. An epidemic of acute hepatitis C has been reported among HIV-
infected men who have sex with men (MSM) (Danta et al., 2007). This route of 
transmission is higher than in heterosexual couples and, HIV and HCV co-
infection is currently estimated to affect 4-5 millions of people worldwide 
(Alter, 2006). Given that transmission of HIV shares the same route, an 
increasing incidence of HCV infection in HIV-infected MSM can lead to serious 
health problems in the coming years and has serious implications on rapid 
transmission of drug-resistant variants as well as efficacy of future therapies 
(Thomson et al., 2011a; Thomson et al., 2011b). 
IDU and to a lesser extent sexual transmission represents the main risks for 
acute HCV in western countries. The picture is however different in developing 
countries, in which social and cultural differences result in a very different set 
of risk factors for HCV. Nosocomial and iatrogenic transmission, occupational 
exposure, sexual and intrafamilial transmission in addition to IDU contribute to 
acute HCV cases in developing countries. 
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1.1.4 Natural history of HCV infection 
HCV infection is a leading cause of chronic hepatitis, compensated and 
decompensated cirrhosis, and hepatocellular carcinoma. As a result, it is the 
most common indication for liver transplantation (Seeff, 2002). Initial infection 
leads to the establishment of an acute phase which, in the majority of cases, 
progresses to a chronic infection. 
1.1.4.1 Acute Hepatitis C 
Acute HCV infection is rarely identified, as the majority of infected 
individuals have mild or no symptoms. However, in 20 to 30% of infected 
individuals, acute infection can be accompanied by clinical symptoms, most of 
which are similar to other forms of hepatitis (flu-like symptoms, fever, jaundice, 
dark urine, fatigue, nausea, vomiting, loss of appetite and abdominal pain) 
(Lemon et al., 2007). Acute infection can lead to fulminant hepatitis but this 
condition is rare. 
HCV infection can be self-limiting and may spontaneously resolve. It is 
estimated that spontaneous clearance of acute HCV infection occurs in 15 to 20% 
of cases. However, in a single source outbreak of HCV infection of a group of 
healthy women, up to 50% of the cases resolved infection spontaneously (Pestka 
et al., 2007). Although it is difficult to determine these acutely infected 
patients who will spontaneously resolve infection, several clinical features have 
been associated with spontaneous clearance: 1) age - patients less than 40 years 
of age including children are more likely to undergo spontaneous resolution; 2) 
gender - women are more likely to resolve infection than men; 3) clinical 
symptoms - jaundice is a good predictor of spontaneous viral clearance, 
presumably because it reflects an effective host immune response, capable of 
eradicating the virus; 4) co-infections - individuals with co-infections, for 
example HIV, are less likely to spontaneously clear HCV. 
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Most studies have suggested that cellular immune responses play a crucial 
role in spontaneous resolution of acute HCV. Clearance of HCV is associated with 
the development of robust and multispecific CD4+ and CD8+ T-cell responses 
(Thimme et al., 2002). Persistence of HCV infection presumably occurs when the 
innate responses are weak or antagonised, thus diminishing their direct antiviral 
effects (Seeff, 2009). 
1.1.4.2 Chronic Hepatitis C 
It is thought that up to 80% of acute infections become persistent, 
culminating in a chronic state. Most patients with chronic hepatitis C are 
asymptomatic, however more severe symptoms can develop over a 5–35 year 
period in as many as 20% of infected patients. The most common symptom is 
intermittent fatigue, with others reporting right upper quadrant abdominal pain, 
nausea and poor appetite. These patients can eventually develop serious liver 
diseases such as hepatic fibrosis, cirrhosis and steatohepatitis. Among those with 
cirrhotic livers, 1- 4% develop hepatocellular carcinoma (HCC) (Heller & 
Rehermann, 2005). 
Progression to liver fibrosis is affected by many factors such as alcohol 
consumption, obesity, diabetes mellitus, gender and age of acquiring infection. 
Additionally, the degree of inflammation and fibrosis on liver biopsy, 
immunosuppression and genetic profile, HIV or HBV coinfection and comordid 
conditions are important factors influencing the course of chronic HCV infection. 
Chronic HCV is also associated with extrahepatic manifestations. Among them, 
the most common is mixed cryoglobulinemia (Charles & Dustin, 2009). 
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The various HCV genotypes also exhibit differences in HCV pathology and 
influence progression to liver complications. For example, higher rates of 
progression to chronicity have been associated with people infected with 
genotype 1 (Amoroso et al., 1998). Moreover, a relationship between genotype 3 
infections and hepatic steatosis has also been identified (Mihm et al., 1997; 
Rubbia-Brandt et al., 2001; Rubbia-Brandt et al., 2000). Although additional 
factors may be involved, this hepatic manifestation was suggested to be 
associated with genotype 3 infections, as improvement of steatosis was observed 
after elimination of the virus with interferon (IFN) (Castera et al., 2004; Kumar 
et al., 2002). 
1.1.5 Treatment of HCV infection 
A protective vaccine against HCV does not exist and the current standard of 
care consists of a combination of Pegylated interferon-α (Peg-IFNα) and ribavirin 
(RBV). This therapy is administered for 24-48 weeks, depending on the HCV 
genotype and baseline viraemia (NICE, 2004). Cure of infection is characterised 
by a sustained virologic response (SVR), which is defined as absence of HCV in 
the peripheral blood 24 weeks after cessation of treatment. With these 
regimens, approximately 70-80% of patients infected with genotypes 2 or 3 
achieve SVR, whereas only 40-50% of patients infected with genotypes 1 or 4 
successfully respond to therapy (Soriano et al., 2009). Moreover, Peg-IFNα/RBV 
therapy is frequently associated with side effects, including myalgia, fever, 
headaches, depression and anaemia (Fried et al., 2002). For those patients who 
develop cirrhosis and HCC, liver transplantation is the only available option. 
However, infection of the grafted organ occurs in all cases due to circulating 
virus and progression to serious liver disease is more rapid. Moreover, these 
patients respond less efficiently to therapy. 
The exact mode by which this combination therapy eradicates HCV 
infection is still not clear. IFNα belongs to the family of type I IFNs, host-cell 
synthesised cytokines, which play a central role in the innate immune response. 
In addition to their antiviral properties, type I IFNs have antiproliferative and 
immunomodulatory properties. The antiviral properties of these cytokines are 
described in more detail in section 1.5.1.1. Briefly, IFNα creates an antiviral 
state in the cells through inducing expression of IFN-stimulated genes (ISGs). It is 
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thought that the proteins encoded by these ISGs will mediate the antiviral 
activities of IFNα and play an essential role in clearance of infection. The 
mechanism of viral clearance by these ISG proteins is not yet understood. 
RBV is a broad-spectrum antiviral nucleoside analogue, capable of being 
incorporated into viral RNA during replication and can therefore prematurely 
terminate synthesis of viral RNA. The exact mode of action of ribavirin is not 
known. However, a combination of different mechanisms have been proposed 
(Paeshuyse et al., 2011): 1) immunomodulatory activities; 2) modulation of the 
ISG expression; 3) inhibition of inosine 5’-monophosphate dehydrogenase 
(IMPDH) by ribavirin 5’-monophosphate (RMP); 4) inhibition of eIF4E; 5) 
inhibition of the RNA-dependent RNA polymerase by ribavirin 5’-triphosphate 
(RTP) and 6) induction of viral mutagenesis (Figure 1.3). 
 
Figure 1.3 – Proposed possible mechanisms of action of ribavirin. [A] Structural formula of 
ribavirin. [B] Schematic diagram indicating the proposed mechanisms of action of ribavirin: 
(1) modulation of the TH1 and TH2 responses, (2) stimulation of ISG expression, (3) 
inhibition of IMPDH, (4) inhibition of the eukaryotic translation initiation factor eIF4E, (5) 
direct inhibition of the viral RdRP, (6) viral mutagenesis. The red dotted lines indicate an 
inhibitory or negative effect; blue arrows indicate a stimulatory or positive effect. ISG: 
interferon stimulated gene, CTL: cytotoxic T lymphocyte, IMPDH: inosine 5′-monophosphate 
dehydrogenase, HCV: hepatitis C virus, RdRp: RNA-dependent RNA polymerase, INFα: 
interferon-alpha, INFγ: interferon-gamma, TNFα: tumour necrosis factor alpha, ENT1: 
equilibrative nucleoside transporter 1. Extracted from Paeshuyse et al., 2011. 
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Over the past decade, the focus has been to refine the use of current 
therapies through an increased understanding of how viral kinetics predicts the 
success or failure of treatment. A major contribution was the discovery of a 
group of single nucleotide polymorphisms (SNPs) in the region of the interleukin-
28B gene (IL-28B, type III IFN) (Mangia et al., 2010; Ridruejo et al., 2011; 
Thompson et al., 2010). These studies have shown that patients with a CC 
genotype of the IL-28B polymorphism achieve higher SVR (more than 2-fold) 
after treatment with Peg-IFNα/RBV, compared to patients with the CT or TT 
genotype. 
Through developments with in vitro systems that have given a greater 
understanding of the HCV lifecycle, it has been possible to identify a number of 
potential new targets for direct acting antivirals (DAAs; antiviral agents 
targeting viral functions) and host-targeted agents (HTA; which inhibit host cell 
activities known to be required for viral replication). Among the DAAs, the 
NS3/4A protease inhibitors (PI), telaprevir and boceprevir, have recently been 
approved for treatment of patients infected with HCV genotype 1 (Jacobson et 
al., 2011; Poordad et al., 2011; Ramachandran et al., 2012). PI monotherapy is 
associated with a rapid emergence of drug-resistance viral variants, therefore 
current treatment strategies require co-administration with Peg-IFNα/RBV. 
These regimens have shown improved efficacy (60–75% SVR) compared with 
current standard of care in genotype 1-infected individuals. Interestingly, triple 
therapy also shows good efficacy in patients who previously failed to respond to 
therapy (Bacon et al., 2011). A number of other DAAs and HTAs are at the 
preclinical or early to late clinical development stage. These include other 
NS3/4A protease inhibitors, nucleoside/nucleotide analogues and non-nucleoside 
inhibitors of the HCV RNA-dependent RNA polymerase (RdRp), inhibitors of the 
HCV NS5A protein, and cyclophilin inhibitors. 
Drug resistance remains a potential problem for any new DAA against HCV. 
Because of the error-prone nature of the HCV RNA-dependent RNA polymerase 
and the generation of a vast number of quasispecies, drug resistance inevitably 
occurs in patients treated with antiviral drugs targeting distinct HCV specific 
enzymes and may limit their efficacy. Indeed, some studies have shown that 
amino acid changes within NS3-4A protease, such as R155, A156 and D168, 
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confer resistance to all protease inhibitors currently in clinical development 
(Romano et al., 2012). Thus, further work is required to understand the 
molecular basis of drug resistance, in order to develop drugs that can act in a 
broader spectrum of resistant viral variants. 
1.2 HCV virion 
HCV particles isolated from the sera of infected patients and from HCVcc 
particle preparations generated in cell culture demonstrated heterogeneity in 
their density. HCV particles have a spherical morphology and initial filtration 
studies with patient-derived material, indicated that they were 50 to 80nm in 
diameter (Bradley et al., 1985; He et al., 1987). Although advances with the 
production of infectious virions in tissue culture systems have been made, the 
biochemical and morphological features of HCV particles remain elusive. The 
density of HCV serum particles (HCVsp) depends on the method of analysis and 
on the patient sample. Electron microscopic analyses performed on cell-culture 
derived HCV indicates that mature, enveloped virions are 55-60nm in diameter 
(Gastaminza et al., 2010; Wakita et al., 2005). 
[A] [B]
VLDL/LDL
E1E2 glycoproteins
Envelope
Core
RNA genome
 
Figure 1.4 – The HCV virion. [A] Electron micrograph of HCV virion shown by immunogold 
labelling; scale bar 50nm (Wakita et al., 2005). [B] Schematic representation of the HCV 
particle and its components: the single-stranded RNA genome enclosed within the capsid 
composed of core protein. An envelope layer derived from host cell membranes surrounds 
the viral capsid and the HCV glycoprotein E1/E2 heterodimers are embedded within it. The 
virion is proposed to be associated with VLDL/LDL, generating lipoviroparticles (LVP). 
Density gradient analyses have shown that viral RNA exists within low- and 
high-density fractions (Andre et al., 2005). This is probably due to the tight 
association of virions with host cell components, most notably lipoproteins 
(Andre et al., 2002; Gastaminza et al., 2008; Gastaminza et al., 2006). 
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Association appears to occur during assembly, since HCV formation and secretion 
depend on components of very low density lipoprotein (VLDL) assembly and 
secretion pathways, including apolipoprotein B and E (apoB and apoE) and 
microsomal triglyceride transfer protein (Chang et al., 2007; Gastaminza et al., 
2008; Huang et al., 2007). Most particles containing viral RNA that are secreted 
from HCV-infected cells are poorly infectious and fractionate at high densities 
such as ~1.14g/ml. By contrast, highly infectious HCVcc are found within low 
density fractions of 1.09-1.1g/ml (Lindenbach et al., 2005). Moreover, only the 
low-density fractions derived from HCV-positive human serum exhibits high 
infectivity in chimpanzees (Bradley et al., 1991). The mature virion is thought to 
consist of a genome-containing nucleocapsid that is surrounded by an outer 
envelope (Figure 1.4). The envelope consists of a lipid membrane in which the 
viral glycoproteins E1 and E2 are embedded. 
1.2.1 Genome organisation 
The HCV genome is ~9600 nucleotides long and encodes a single open 
reading frame (ORF) flanked by two untranslated regions (UTRs) at the 5’ and 3’ 
termini (Figure 1.5). The ORF encodes a large polyprotein (~3000 amino acids) 
that is proteolytically cleaved by viral and cellular proteases to produce 10 viral 
proteins. The amino-terminal (N-terminal) one-third of the polyprotein encodes 
the virion structural (S) proteins, core (C) and the glycoproteins E1 and E2, 
followed by the non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, 
NS5B). Separating the S and NS proteins is p7, a short hydrophobic polypeptide. 
 
 
Figure 1.5 – Schematic representation of the HCV genome containing two untranslated 
regions (UTR) at the 5’ and 3’ ends flanking a single open reading frame (upper panel). 
Translation of the viral RNA generates a single polyprotein (central panel) that is processed 
by host and viral proteases to generate the individual mature proteins (lower panel). The 
host proteases SPP (blue arrowhead) and SP (red arrowhead) generate the structural 
proteins and the NS2/NS3 autoprotease (orange arrowhead) and NS3/4A protease (green 
arrowhead) cleave the polyprotein at the indicated boundaries. The topology of HCV 
proteins relative to the ER membrane is represented in the lower panel. 
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1.2.1.1 5’ and 3’ UTR regions 
I. 5’ UTR and HCV IRES 
The 5′ UTR is highly conserved among various isolates (Bukh et al., 1992). 
The 5′ UTR is ~341 nucleotides in length and contains an internal ribosomal entry 
site (IRES) (Bukh et al., 1992; Honda et al., 1999). Based on NMR and X-ray 
crystallography analysis, the 5’ UTR is predicted to contain four highly 
structured domains (domains I-IV) and a pseudoknot (Berry et al., 2011; Honda 
et al., 1996a; Honda et al., 1996b; Lukavsky et al., 2003; Lukavsky et al., 2000). 
The HCV IRES spans domains II, III and IV of the 5’ UTR, and together with the 
first 24-40 nucleotides of the core-coding sequence specifically interacts with 
the 40S ribosomal subunit and eIF3 to initiate cap-independent translation of 
viral RNA (He et al., 2003; Honda et al., 1996b; Kieft et al., 2001; Pestova et 
al., 1998). The pseudoknot domain is located at the centre of the HCV IRES, 
connecting domains II and III with the AUG-containing domain IV (Boehringer et 
al., 2005; Spahn et al., 2001) (Figure 1.6). This domain is the most highly 
structured region of the IRES and is therefore required for efficient translation 
(Berry et al., 2010; Kieft et al., 2001). Additionally, core is predicted to contain 
four highly conserved RNA secondary structures within the region encoding the 
first 62 amino acids of the protein. Within these structures two stem-loops (SL47 
and SL87) are important for efficient translation and replication of the viral RNA 
both in vitro and in vivo (McMullan et al., 2007). 
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In addition to its involvement in translation, the 5’ UTR is essential for 
genome replication. Several reports indicated that domains I and II are sufficient 
for viral RNA replication, although the efficiency of this process is enhanced by 
the presence of the complete 5’ UTR (Friebe et al., 2001; Kim et al., 2002). 
Several host factors can associate with the HCV 5’ UTR and these interactions 
regulate translation and replication of the viral genome. The polypyrimidine 
tract binding protein (PTB), La autoantigen and poly (rC)-binding protein are 
some of the factors known to bind to the 5’ UTR that also influence viral RNA 
replication (Ali & Siddiqui, 1995; 1997; Fukushi et al., 2001). Moreover, PTB and 
La autoantigen are required for translation (Domitrovich et al., 2005; Fukushi et 
al., 2001). More recently, interactions between the liver-specific microRNA, 
miR-122, which binds at two sites in the HCV 5′ UTR, were identified as essential 
for maintaining HCV RNA abundance during infection in cultured cells and in 
infected chimpanzees (Jopling et al., 2008; Jopling et al., 2005; Lanford et al., 
2010; Machlin et al., 2011). miR-122 is thought to protect HCV RNA from 
nucleolytic degradation or inhibit the activation of enzymes that induce innate 
immune responses, thereby enhancing viral replication (Machlin et al., 2011). 
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Figure 1.6 – Model of the secondary and tertiary RNA structures of the 5’UTR of HCV 
(genotype 1b). The major structural domains (I to IV) and subdomains (IIIa to IIIf) together 
with a small region corresponding to the core-coding sequence, are represented. The 
initiation AUG codon within stem-loop IV is highlighted. The HCV IRES extends from 
domains II to IV and is also represented. Extracted from Honda et al., 1999. 
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II. 3’ UTR 
The 3’ UTR varies between 200 and 235 nt in length, and forms a tripartite 
structure which includes a short variable region, a poly(U/UC) tract 
(approximately 80 nt in length), and a highly conserved X-tail region (98 nt in 
length) (Ito & Lai, 1997; Kolykhalov et al., 1996; Tanaka et al., 1996) (Figure 
1.7). The X-tail region comprises three stable stem–loop structures (designated 
SL1-SL3) that are almost invariant among HCV genotypes. The variable region is 
composed of two stem loops (VSL1 and VSL2) and, contrary to the X-tail region, 
is dispensable for viral RNA replication (Friebe & Bartenschlager, 2002). The poly 
(U/UC) tract is variable in length and composition, consisting of uridine residues 
that are interdispersed with occasional cytidine residues. The minimum length of 
this segment is 26 nt in order to direct viral RNA replication (Friebe & 
Bartenschlager, 2002). Deletion studies have shown that the 3’X-tail region, as 
well as the 52 nt upstream of the poly(U/C) tract, are crucial for RNA replication 
both in vitro and in vivo (Friebe & Bartenschlager, 2002; Yanagi et al., 1999; Yi 
& Lemon, 2003). Additionally, the variable region within the poly (U) tract and a 
part of the X-tail region stimulate IRES-mediated translation of viral RNA (Song 
et al., 2006). 
 
Figure 1.7 – Proposed secondary structure of the 3’ UTR of HCV (genotype 1b). Represented 
are the two stem-loops within the variable region (VSL1 and VSL2) the 83 nucleotide 
poly(U/UC) tract and the three stem-loops in the 3’X (SL1, SL2 and SL3). The stop codon of 
the polyprotein ORF is boxed. Extracted from Friebe & Bartenschlager, 2002. 
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1.2.2 HCV-encoded proteins 
1.2.2.1 Structural proteins 
I. Core 
Core protein is located at the N-terminus of the polyprotein and is released 
as a 191 residue precursor (23 KDa) by host signal peptidase (SP). SP cleaves at 
the N-terminal end of E1, leaving core anchored in the ER membrane (Hussy et 
al., 1996; Moradpour et al., 1996; Santolini et al., 1994). Complete maturation 
of core requires further processing at the C-terminus by a cellular signal peptide 
peptidase (SPP), which releases the protein (21KDa) from the ER membrane 
allowing its attachment to lipid droplets (LDs) (McLauchlan et al., 2002). 
The amino acid sequence of core is highly conserved among HCV genotypes. 
The mature form of the protein is estimated to be between 177 and 179 aa 
(Ogino et al., 2004), and consists of two domains distinguished by markedly 
different amino acid compositions and hydrophobicity profiles (Hope & 
McLauchlan, 2000; McLauchlan, 2000): a N-terminal domain D1 (~120 aa) and a 
C-terminal domain D2 (~60 aa). Domain D1 is characterized by a high proportion 
of positively-charged amino acids. This domain is thought to interact with viral 
RNA, but has also been shown to interact with a variety of cellular components 
(McLauchlan, 2000). One of the best characterized of these is the interaction 
with the DEAD-box RNA helicase DDX3, which occurs via residues 24-35 of core. 
Disrupting interaction with DDX3 via mutating key residues within the core 
binding region has no effect on HCV propagation in vitro, indicating that this 
virus-host interaction may be pathogenesis-related (Angus et al., 2010). Domain 
D2 has membrane-binding characteristics and is responsible for targeting core to 
the surface of LDs (Boulant et al., 2005). It has been proposed that the folding 
of domain D2 occurs in a membrane environment and is critical for folding of 
domain D1 (Boulant et al., 2005). Structural analysis of D2 revealed two 
amphipathic α-helices (helix-1 and helix-2), separated by a non-structured 
hydrophobic segment (hydrophobic loop, HL). Mutagenesis studies have 
demonstrated that both helices are required for the attachment of core to LDs 
(Boulant et al., 2006). 
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II. E1 and E2 
HCV encodes two glycoproteins, E1 and E2 (30KDa and ~68KDa, 
respectively), present as a heterodimer at the virion surface, which are essential 
for viral binding and entry into host cells. Both proteins are type I 
transmembrane glycoproteins, composed of a large N-terminal ectodomain, 
responsible for virus attachment to cell receptors, and a short C-terminal 
transmembrane domain, involved in anchoring the glycoproteins in a lipid bilayer 
(Cocquerel et al., 1999; Op De Beeck & Dubuisson, 2003). E1 and E2 are released 
from the polyprotein precursor through SP-mediated cleavage at the C/E1, 
E1/E2 and E2/p7 boundaries (Dubuisson et al., 2002). During their synthesis, E1 
and E2 ectodomains are translocated into the ER lumen (Deleersnyder et al., 
1997). 
The ectodomains of HCV envelope glycoproteins E1 and E2 are highly 
modified by N-linked glycans. E1 and E2 contain up to 6 and 11 glycosylation 
sites, respectively (Lavie et al., 2007). These modifications are believed to be 
involved in protein folding, receptor interactions to facilitate entry and shield 
the virion glycoproteins from neutralising antibodies during infection (Goffard et 
al., 2005; Helle et al., 2007; Lavie et al., 2007). Studies using both the HCVpp 
and HCVcc systems (section 1.3.1-I and -III) have demonstrated that the 
intracellular forms of E1 and E2 assemble as stable noncovalent heterodimers 
(Deleersnyder et al., 1997; Krey et al., 2010; Op De Beeck et al., 2004). In 
contrast, it was recently shown that E1 and E2 proteins change their oligomeric 
state after incorporation into the virus particle and form large covalent 
complexes stabilised by disulphide bridges (Vieyres et al., 2010). 
The structural organization of E2 has been obtained, based on disulphide 
mapping studies and modelling on the known Flavivirus glycoprotein E structure 
(Krey et al., 2010). According to this model, E2 is predicted to contain three 
separate domains (I, II and III). Domain I structural analysis revealed a bipartite 
composition, consisting of eight β-strands followed by hypervariable region 1 
(HVR1), which is the most genetically variable segment of the E2 protein, as well 
as highly conserved residues involved in CD81 binding (Krey et al., 2010; Weiner 
et al., 1991). HVR1 is implicated in facilitating E2/SR-BI mediated viral entry 
and escape from anti-HCV neutralising antibodies (Bartosch et al., 2003b; 
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Weiner et al., 1991). HVR1 is suggested to exist as a polypeptide loop exposed 
on the surface of the virion where it functions as an immunological decoy to 
shield the more conserved regions of the glycoproteins, such as the CD81 binding 
pocket (Weiner et al., 1991). HCV lacking the HRV1 region was found to retain 
infectivity, however this was shown to be strongly attenuated both in vivo and in 
vitro, supporting a functional role of this region in viral entry (Bartosch et al., 
2003b; Callens et al., 2005). Despite the sequence variability of HVR1, the 
physico-chemical properties of the residues at each position and the 
conformation of HVR1 are highly conserved among genotypes. Due to the basic 
nature of HVR1, this region has been shown to play a role in modulating virus 
entry (Callens et al., 2005). Domain II is proposed to be relatively unstructured, 
containing another hypervariable region (HVR2). The most conserved region in 
domain II (aa 502 to 520) is suggested to act as a fusion loop and thereby 
involved in receptor binding (Roccasecca et al., 2003). DI is connected to DIII by 
a linker region called the intergenotypic variable region (IgVR) and DIII is 
connected to the TM domain by the flexible stem region. 
While E2 has been shown to mediate direct binding of HCV to cell surface 
receptors and entry, little is known about the contribution of E1 to HCV 
infection, mostly due to difficulties in purifying this protein. The association 
between E1 and E2 is essential for HCVpp entry (Bartosch et al., 2003a; 
Drummer et al., 2003; Hsu et al., 2003). Several studies have identified 
conserved regions within E1 and E2 which may be involved in mediating 
membrane fusion (Flint et al., 1999; Lavillette et al., 2007; Perez-Berna et al., 
2006). Mutagenesis analysis of putative fusion peptides within the E1 coding 
region revealed that interaction between E1 and E2 is presumably required for 
proper E2 glycosylation and consequently, HCVcc and HCVpp entry (Russell et 
al., 2009). However, the mechanism by which E1 mediates this post-translational 
event in E2 remains unknown. 
III. P7 
The HCV p7 protein is a small, integral membrane protein of 63 amino acids 
that resides at the junction between the S and NS regions of the HCV 
polyprotein. Although most cleavage events in the HCV polyprotein precursor 
proceed to completion during or immediately after translation, proteolysis at 
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the E2-p7 and p7-NS2 junctions are delayed, leading to the production of an E2-
p7-NS2 precursor (Dubuisson et al., 1994). The E2-p7-NS2 precursor is liberated 
by SP-mediated cleavage at the E1/E2 boundary and the autoproteolytic 
cleavage mediated by NS2-3 protease at the NS2/NS3 boundary (Lin et al., 
1994a; Santolini et al., 1995). Processing between E2 and p7 is also incomplete 
resulting in the production of fully processed E2 and uncleaved E2-p7 (Lin et al., 
1994). p7 monomers comprise two transmembrane domains organized as α-
helices that are connected by a short basic loop (Montserret et al., 2010). Both 
the N- and C-termini are exposed to the ER lumen, with the hydrophilic loop 
facing the cytosol (Carrere-Kremer et al., 2002; Patargias et al., 2006). 
p7 is believed to self-organize in lipid membranes to form ion-conducting 
channels or pores that modify the permeability of the cell membrane to ions and 
other molecules (Griffin et al., 2003). Due to its ability to sustain ion fluxes, p7 
has been included into the family of viral proteins known as viroporins. 
Viroporins are small, virus-encoded polypeptides that interact with membranes 
and comprise at least one transmembrane segment. Moreover, oligomerization is 
an essential prerequisite for their ability to modify the membrane’s permeability 
(Gonzalez & Carrasco, 2003). Electron microscopy studies suggest that p7 
monomers assemble into both hexameric and heptameric structures in lipid 
bilayers (Clarke et al., 2006; Griffin et al., 2003; Luik et al., 2009). 
p7 is not required for RNA replication (Lohmann et al., 1999). However it is 
critical for release of infectious virions both in vitro and in vivo (Jones et al., 
2007; Sakai et al., 2003). It is likely to play an important role in later stages of 
viral assembly and potentially for cell entry. Recent studies showed that the ion 
channel activity of the protein is enhanced at low pH, suggesting that p7 
channels may be gated by acidic pH and facilitate the transport of protons 
(StGelais et al., 2007). Furthermore, substitution of M2 with p7 facilitated the 
transport of the influenza HA protein to the cell surface in a cell-based assay 
(Griffin et al., 2004). Thus, p7 may operate in an M2-like fashion to facilitate 
HCV particle production. Based on these observations it suggests that p7 plays a 
role in protecting the glycoproteins from low pH during assembly, however it has 
also been hypothesised that p7 is required for proper folding of the 
glycoproteins. Furthermore, recent evidence suggests that the proton-selective 
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ion-channel activity of p7 prevents the acidification of intracellular virions 
during their transit through otherwise acidic intracellular compartments 
(Wozniak et al., 2010). Several inhibitor compounds inhibit p7 ion channel 
activity in vitro, thereby resulting in a reduction of infectious virus particles 
(Griffin et al., 2008; Steinmann et al., 2007). The essential role of p7 in the 
virus life cycle has rendered it an attractive target for antiviral development. 
1.2.2.2 Non-structural proteins 
I. NS2 
NS2 is a 24kDa dimeric integral membrane protein, composed of two 
functionally and topologically distinct domains: a N-terminal membrane-binding 
domain (MBD) and a C-terminal cytosolic globular protease domain (Lorenz et 
al., 2006). Moreover, the X-ray crystal structure of the protease domain 
revealed a dimer with 2 composite active sites (Lorenz et al., 2006). Recently, 
using NMR analysis, the secondary structure of the N-terminal MBD has been 
solved and is proposed to contain three transmembrane α-helices (TM1-3), 
connected by flexible loop regions (Jirasko et al., 2008; Jirasko et al., 2010). 
Before cleavage from the polyprotein, NS2 participates in the protease 
activity responsible for cleavage at the NS2/NS3 junction (Lorenz et al., 2006; 
Santolini et al., 1995; Yamaga & Ou, 2002). As mentioned earlier, the N-
terminus of NS2 is released from the E2-p7-NS2 precursor by SP-mediated 
cleavage at the C-terminus of p7 (Lin et al., 1994). The catalytic activity of NS2-
3 autoprotease requires the N-terminal one-third of NS3 (Grakoui et al., 1993). 
Mutation of the amino acid residues at the NS3-4A catalytic triad does not affect 
NS2-3-mediated cleavage of NS2/NS3, indicating that this event does not require 
NS3-4A protease activity (Grakoui et al., 1993; Hijikata et al., 1993). Co-
immunoprecipitation studies revealed stable interaction of NS2 with NS3, p7 and 
E2, whereas with NS5A this interaction was shown to be weaker (Jirasko et al., 
2010). Apart from its protease activity, NS2 appears to play a crucial role for 
production of infectious virus particles. Mutagenesis studies have demonstrated 
that deletion or substitution mutations within NS2 significantly affect the 
production of infectious virus (Jones et al., 2007; Phan et al., 2009). Studies 
using intergenotypic chimeras also showed that the production of infectious virus 
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is highly dependent upon the specific position of the chimeric junction site 
within NS2 (Pietschmann et al., 2006; Yi et al., 2007). Moreover, the S168 
residue of NS2 has been shown to be involved in regulating a post-particle 
assembly step in infectious virus production (Yi et al., 2009). The defects in virus 
production caused by mutation of this residue could however be rescued by 
trans-complementation of ectopically expressed NS2 (Yi et al., 2009). 
Collectively, these observations suggest a role for NS2 in a later step of virion 
formation. 
II. NS3 and NS4A 
NS3 a is 70KDa multifunctional protein composed of two domains, an N-
terminal chymotrypsin-like serine protease domain (aa 1-180) and a C-terminal 
RNA helicase/NTPase domain (aa 181-631). The NS3 protease domain adopts a 
chymotrypsin-like fold, composed of two β-barrel domains. The small NS4A 
peptide (6KDa) forms a very stable heterodimer with NS3 and functions as a 
cofactor for NS3 serine protease activity (Bartenschlager et al., 1995; Lin et al., 
1995). The interaction of NS3 with the central region of NS4A (aa 21-32) is 
required for proper folding of NS3 (Kim et al., 1996). NS3 by itself has no 
transmembrane domain, but the N-terminal hydrophobic region of NS4A forms a 
transmembrane α-helix which is required for integral membrane association of 
the NS3-4A complex to the ER (Wolk et al., 2000). Mutagenic analysis of the C-
terminal acid region of NS4A (aa 40-54) demonstrated genetic interactions 
between NS4A, NS3 and NS4B protein and that are essential for RNA replication 
(Phan et al., 2011). Moreover, amino acid changes at the C-terminus of NS4A 
which did not affect RNA replication, were shown to block assembly of infectious 
particles, indicating that NS4A plays important roles not only in RNA replication 
but also virus assembly (Phan et al., 2011). In addition to its role in NS3 cofactor 
activity, NS4A has also been demonstrated to regulate the phosphorylation 
status of NS5A (Lindenbach et al., 2007). The NS3-4A protease is responsible for 
polyprotein cleavage at four sites: NS3-4A, NS4A-4B, NS4B-5A and NS5A-5B 
(Failla et al., 1994; Gallinari et al., 1998; Lin et al., 1994b). Cleavage mediated 
by NS3-4A follows a preferential order: first cleavage in cis at the NS3/4A site, 
followed by subsequent proteolysis in trans. Rapid processing is achieved at the 
NS5A/NS5B junction, producing the NS4A-NS4B-NS5A intermediate. Cleavage 
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then takes place between NS4A and NS4B, to generate a NS4B-NS5A precursor. 
The final cleavage event mediated by NS3-4A occurs between NS4B and NS5A. 
In addition to its role in the processing of the polyprotein and viral 
replication, the NS3-4A protease is also a key player in disrupting innate defence 
mechanisms. NS3-4A cleaves and thereby inactivates a mitochondrial protein, 
the caspase recruitment domain containing crucial adaptor molecule Cardif (also 
known as MAVS, IPS-1 or VISA), in the RIG-I viral RNA sensing pathway (Li et al., 
2005b; Loo et al., 2006; Meylan et al., 2005). NS3-4A also targets TRIF (toll/IL-1 
receptor homology (TIR) domain-containing adaptor inducing IFNβ), a key 
adaptor molecule in the TLR3 dsRNA sensing pathway (Ferreon et al., 2005; Li et 
al., 2005a). More recently, another cellular protein has been identified as a 
target for NS3-4A protease activity, the T-cell protein tyrosine phosphatase (TC-
PTP) (Brenndorfer et al., 2009). Epithelial growth factor (EGF) stimulation 
causes TC-PTP to exit from the nucleus and to dephosphorylate the EGF 
receptor, leading to decreased downstream activation of the 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway (Tiganis et al., 1999). Thus, 
cleavage of TC-PTP by NS3-4A resulted in enhancement of EGF-induced signalling 
and increased basal Akt activity, which is critical for efficient replication of HCV 
(Brenndorfer et al., 2009). This has been suggested to impact on development of 
hepatocellular carcinoma. 
The NS3 helicase/NTPase domain is a member of the DEXH/D-box subgroup 
of helicase superfamily 2 (Gorbalenya et al., 1989; Tai et al., 1996). The crystal 
structure of the HCV helicase reveals a Y-shaped molecule composed of 3 
subdomains (Kim et al., 1998; Yao et al., 1997). The NS3 helicase/NTPase has 
been implicated in several functions, including RNA binding, ATP hydrolysis, and 
unwinding of RNA. Kinetic analyses indicate that the NS3 helicase unwinds 
double-stranded RNA in highly coordinated cycles, triggered by ATP binding, of 
discrete steps of 11 base pairs. During replication, the NS3 helicase has been 
suggested to translocate along the RNA substrate by changing protein 
conformation. Gu and Rice (2010), obtained the crystal structures for a series of 
NS3 helicase structural transition states, including ground-state and transition-
state ternary complexes (Gu & Rice, 2010). These structures recapitulated the 
helicase activity along the reaction pathways of ATP binding and hydrolysis, 
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revealing the molecular basis of action of the NS3 helicase (Gu & Rice, 2010). 
The NS3 helicase activity can be modulated by interactions between the serine 
protease and helicase domains (Beran et al., 2009; Frick et al., 2004; Pang et 
al., 2002). Indeed the kinetics of duplex RNA unwinding is slower for the isolated 
helicase domain as compared with the full-length NS3 protein. The presence of 
NS4A enhances productive RNA binding of a full-length NS3-4A complex (Frick et 
al., 2004). Additionally, NS3 helicase interaction with other NS proteins, NS5A 
and NS5B, appears to also modulate its activity. 
III. NS4B 
NS4B is a 27KDa integral membrane protein. The precise membrane 
topology is still unknown, however it is predicted to contain a N-terminal region 
(aa 1–69), four transmembrane domains (aa 70–190) in the central region of the 
protein and a C-terminal region (aa 191–261) (Hugle et al., 2001; Lundin et al., 
2003). Both the N- and C-terminal regions of the protein are thought to reside on 
the cytosolic side of the ER. The N-terminal region is predicted to contain two 
two amphipathic α-helices, designated AH1 and AH2 (Elazar et al., 2004; 
Gouttenoire et al., 2009a). AH1 is believed to mediate targeting of NS4B to the 
ER by a co-translational mechanism (Elazar et al., 2004). AH2 on the other hand, 
has been proposed to translocate across the membrane into the ER lumen by a 
post-translational mechanism, leading to the formation of a fifth transmembrane 
domain (TMX) (Lundin et al., 2006). AH2 has also been proposed to oligomerise 
with itself and to mediate lipid vesicle aggregation (Cho et al., 2010). The 
central region of NS4B is predicted to harbour four transmembrane domains 
(TM1-4), which are connected via three transmembrane loops. The loop 
connecting TM2 and TM3 is predicted to be oriented towards the cytosolic side of 
ER (Lundin et al., 2003). This loop contains a nucleotide-binding motif (aa 129-
135), which has been implicated in GTPase and ATPase activities (Einav et al., 
2004; Thompson et al., 2009). Mutation at this motif which would disrupt the 
NS4B GTPase and ATPase activities resulted in a decrease in viral replication, 
indicating that these activities are important for RNA synthesis (Einav et al., 
2004; Thompson et al., 2009). Han et al (2011) recently identified two 
conserved dimerization motifs (GXXXG and S/T cluster) within the NS4B 
transmembrane domains TM2,3 and TM1 (Han et al., 2011). These motifs were 
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essential for NS4B function and regulate its ability to interact with membranes. 
Mutagenesis analysis within these motifs demonstrated that both regions were 
critical for virus replication (Han et al., 2011). The C-terminal region of NS4B is 
thought to reside in the cytoplasm (Hugle et al., 2001; Lundin et al., 2003). This 
region is well conserved and is predicted to contain two α-helices, H1 (aa201 to 
213) and H2 (aa228 to 253). H1 has not been shown to mediate interaction of the 
C-terminus of NS4B with membranes. However, mutagenesis analysis within this 
helix, demonstrated that it is important for virus replication (Jones et al., 2009; 
Paredes & Blight, 2008; Paul et al., 2011). By contrast, H2 associates with 
membranes (Aligo et al., 2009; Gouttenoire et al., 2009b; Liefhebber et al., 
2009). This helix is less well-conserved than H1, however mutation of some 
residues in H2 result in impairment of replication, indicating that H2 is also 
essential for virus replication (Aligo et al., 2009; Jones et al., 2009). The C-
terminus of NS4B also contains an arginine-rich motif (192RR193), which may 
mediate binding of NS4B to viral RNA (Einav et al., 2008). At the end of the C-
terminus, two cysteine residues (C257 and C261) have been suggested to 
undergo palmitoylation (Yu et al., 2006). Although the precise role of this 
modification is not clear, it has been suggested to be involved in NS4B 
oligomerization. 
Ectopic expression of NS4B typically induces rearrangement of the ER 
membrane, producing vesicular or pocket-like structures referred to as the 
“membranous web” or “membrane-associated foci” (MAF) (Egger et al., 2002; 
Gosert et al., 2003; Gretton et al., 2005). These structures can be visualised by 
electron microscopy and are thought to be the sites where replication complex 
assembly takes place (Gao et al., 2004). Initial observations using 
immunofluorescence analysis demonstrated that viral proteins involved in viral 
replication localize to these punctate structures (Elazar et al., 2004; Hugle et 
al., 2001). Moreover, these punctate sites on the ER were also shown to co-
localise with viral RNA (El-Hage & Luo, 2003; Gosert et al., 2003; Moradpour et 
al., 2004; Targett-Adams et al., 2008). Thus, the membrane rearrangements 
induced by NS4B are likely to play a central role in viral RNA replication. 
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Aside from its role in creating the environment suitable for HCV RNA 
synthesis, NS4B has also been suggested to play a direct role in viral replication. 
Site-directed mutagenesis studies within NS4B revealed that specific amino acid 
changes lead to enhanced as well as abolished phenotype on viral RNA 
replication (Blight, 2011; Jones et al., 2009; Lindstrom et al., 2006; Paredes & 
Blight, 2008; Paul et al., 2011). Moreover, studies on cell culture adaptive 
mutations have highlighted that adaptive mutations were found within NS4B and 
greatly enhanced RNA replication efficiency in cell culture (Lohmann et al., 
2003; Lohmann et al., 2001). 
The interactions of HCV proteins with cellular membranes is thought to 
result in the activation of ER stress pathways (Tardif et al., 2002). NS4B may 
play an important role in this process due to its multispanning membrane 
topology and its capacity to alter cellular membranes. Several studies suggested 
that NS4B expression may cause ER stress and induce the unfolded protein 
response (UPR). The induction of UPR by NS4B, and presumably other NS 
proteins, is thought to contribute positively to HCV infection by facilitating 
replication of viral RNA (Li et al., 2009; Zheng et al., 2005). 
IV. NS5A 
NS5A is a hydrophilic phosphoprotein that exists in two isoforms, basally 
phosphorylated (56KDa) and hyperphosphorylated (58KDa) forms. NS5A is 
predicted to comprise three distinct domains (I-III), separated by low complexity 
sequences (LCS I and LCS II) (Moradpour et al., 2005; Tellinghuisen et al., 2004). 
Domain I (aa 1-213), is the most conserved region between the NS5A sequences 
from all HCV genotypes. It comprises an amphipathic α-helix (AH; aa 5-25) and a 
zinc binding motif (ZBM), that is required for the RNA binding activities of NS5A 
(Brass et al., 2002; Huang et al., 2005; Liu et al., 2006; Tellinghuisen et al., 
2004). NS5A localizes to the site where RNA synthesis takes place via the 
amphipathic α-helix membrane anchor subdomain (Brass et al., 2002; Penin et 
al., 2004; Sapay et al., 2006). Analysis of the crystal structure of domain I 
revealed that it forms a dimer with a claw-like shape that can accommodate a 
single-stranded RNA molecule (Tellinghuisen et al., 2005). More recently, an 
alternative dimer structure has been reported. According to this structure, 
although the domain I of NS5A still forms a dimer, the claw-like shape is absent 
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and the residues involved in RNA binding are exposed between the flat surfaces 
(Love et al., 2009). The differences observed between the two structures are 
thought to result from two functional states of membrane-tethered NS5A. 
However, further characterisation is required for the support of this hypothesis. 
Interestingly, Foster et al (2010) have shown that not only domain I, but also 
domains II and III can bind to viral RNA, although domain I and II retain higher 
binding affinity than domain III. Moreover, they demonstrated that domain I can 
specifically bind to the polypyrimidine tract of the viral 3’ UTR suggesting a role 
of NS5A, presumably with other cellular and viral factors, in viral genome 
replication (Foster et al., 2010; Foster et al., 2011). The role of LCS I and II of 
NS5A in the HCV replication cycle is unknown. LCS II contains two closely-spaced 
polyproline motifs that have been shown to bind to SH3-domain containing 
proteins (e.g., Grb2, amphiphysin II/Bin1 and the Src-family of tyrosine kinases) 
(Macdonald et al., 2004; Nanda et al., 2006; Zech et al., 2003). Mutagenesis 
analysis of these proline motifs (PM1 and PM2) revealed that PM2 was 
dispensable for HCV RNA replication or other stages of the virus life cycle, 
whereas mutation of the P342 in PM1 led to a decrease in virus replication, 
suggesting a role of this motif in replication and virus production (Hughes et al., 
2009a). Thus, the two proline motifs within LSCII are likely to play distinct roles 
in the HCV life cycle. LSCI in the other hand, has been proposed to be essential 
for efficient RNA replication. Appearance of replicon enhancing mutations were 
found in the C-terminal part of domain I and LCS I supporting a role for these 
regions in RNA replication (Blight et al., 2000; Lohmann et al., 2003). 
Domain II (aa 250-342), is less well conserved than domain I and was shown 
to be flexible and disordered (Liang et al., 2006; Liang et al., 2007). Domain II 
contains a region referred to as the interferon-sensitivity-determining-region 
(ISDR), which has been suggested to interact with and antagonize the activity of 
the interferon-induced, double-stranded RNA-dependent protein kinase (PKR) 
(Gale et al., 1998; Gale et al., 1997). Domain III (aa 355-447) is mostly 
unstructured and is the most variable region in NS5A among HCV genotypes. 
Domain III is dispensable for RNA replication, as this region can tolerate 
insertions of large sequences, such as those encoding for the green fluorescent 
protein (GFP), without dramatic effects on RNA replication (Moradpour et al., 
2004). By contrast, large deletions in this domain were shown to significantly 
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impair virus infectivity, indicating that domain III of NS5A plays a role in virion 
assembly (Appel et al., 2008; Hughes et al., 2009b; Masaki et al., 2008; 
Tellinghuisen et al., 2008b). 
NS5A has been shown to interact with core protein and to associate with 
LDs. The functional importance of the core-NS5A interaction on the same 
organelles is not fully understood. However, mutagenesis analysis have shown 
that domain I of NS5A is required for its association with LDs, and this 
interaction was shown to be crucial for infectious virus production (Miyanari et 
al., 2007). Moreover, deletions in domain III impaired virus production, however 
these did not prevent attachment of NS5A to LDs. Instead, deletions in domain III 
abolished the association of NS5A with core protein on LDs (Appel et al., 2008). 
Several studies have focused on determining the NS5A phosphorylation sites 
and their functional role in the virus life cycle. The basal phopho-isoform of 
NS5A has been mapped at the centre of the molecule (aa 2200-2250) and near its 
C-terminus (aa 2351-2419) (Huang et al., 2007b). Hyperphosphorylation of NS5A 
(p58 isoform) is suggested to occur on serine residues found within LCSI, as well 
as domains II and III. Cell culture adaptive mutations that increase RNA 
replication resulted in a decrease in hyperphosphorylation, suggesting that NS5A 
phosphorylation may regulate viral replication (Blight et al., 2000). Moreover, 
deletion of serine residues in LCSI led to reduced NS5A hyperphosphorylation, 
which enhanced viral replication (Appel et al., 2005; Evans et al., 2004). 
Phosphorylation of domain III is thought to be required for the NS5A-core 
interaction and thus is essential for virion formation (Masaki et al., 2008; 
Tellinghuisen et al., 2008a). Indeed, mutagenesis analysis on a phosphoacceptor 
residue (S457) within this domain did not alter RNA replication efficiency, but 
blocked the production of infectious virus (Tellinghuisen et al., 2008a). 
Hyperphosphorylation of NS5A is dependent on the presence of other NS proteins 
within the same polyprotein, such as NS3, NS4A and NS4B (Kaneko et al., 1994). 
This suggests that these proteins are likely to interact with the cellular 
machinery to promote NS5A phosphorylation (Koch & Bartenschlager, 1999; 
Neddermann et al., 1999). Collectively, these observations indicate that the 
phosphorylation status of NS5A may act as a regulatory switch between viral 
replication and presumably virion assembly. 
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NS5A interacts with the human vesicle-associated membrane protein-
associated protein A (hVAP-A), a SNARE-like membrane protein, via the region of 
NS5A involved in hyperphosphorylation (Evans et al., 2004; Gao et al., 2004). 
hVAP-A, an ER/Golgi-localized protein involved in intracellular vesicle 
trafficking, has been shown to be essential for viral RNA synthesis (Evans et al., 
2004). Several reports suggest that disruption of NS5A hyperphosphorylation 
disrupts its interaction with VAP-A and consequently results in downregulation of 
HCV RNA replication (Evans et al., 2004; Gao et al., 2004). In addition, studies 
utilizing chemical inhibitors of protein kinases have demonstrated that inhibition 
of casein kinase 1α (CKIα) led to reduction of NS5A hyperphosphorylation, 
resulting in increased viral RNA replication levels (Neddermann et al., 2004). 
CKIα requires pre-phosphorylation of residues near sites of phosphorylation in 
NS5A for productive modification, suggesting that other kinases also play a role 
in NS5A phosphorylation (Quintavalle et al., 2007). 
NS5A can interact with numerous host-signalling pathways (Macdonald & 
Harris, 2004). As stated earlier, NS5A can interact and interfere with the activity 
of the interferon-induced double-strand RNA-dependent protein kinase (PKR) 
(Gale et al., 1998; Gale et al., 1997). PKR is involved in phosphorylation of the 
translation initiation factor eIF2α, which in turn results in blockage of protein 
translation (Williams, 2001). Binding of NS5A to PKR prevents PKR-dependent 
shutdown of protein synthesis, thereby allowing HCV translation to continue. In 
addition, NS5A has been shown to interact and regulate other signalling cascades 
involved in regulation of cell growth, such as the Ras-Erk and PI3K-AKT pathways 
(Macdonald et al., 2003; Macdonald et al., 2005; Mankouri et al., 2008; Street et 
al., 2004). 
V. NS5B 
NS5B is the RNA-dependent RNA polymerase (RdRP) and therefore the 
catalytic centre of the HCV RC. This protein uses the viral genomic RNA as a 
template for generation of a complementary negative-stranded RNA 
intermediate. The negative-stranded RNA is then used as the template for the 
synthesis of molar excess of positive-stranded progeny RNA molecules. NS5B is 
composed of an N-terminal catalytic domain and a C-terminal TM segment 
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responsible for membrane association (Lee et al., 2004; Schmidt-Mende et al., 
2001). Similar to other RdRp polymerases, NS5B possesses palm, fingers and 
thumb domains. The palm domain contains the active site of the enzyme, 
whereas the fingers and the thumb modulate the interaction with the RNA 
molecule. Interactions between the fingers and thumb domains result in a fully 
encircled catalytic site, creating a tunnel in which a single-stranded RNA 
molecule is directly guided to the active site (Ago et al., 1999; Bressanelli et al., 
1999; Lesburg et al., 1999). 
As stated earlier, the genotype 2 isolate JFH1 replicates with higher 
efficiency in cell culture than any isolate from other genotypes. In a study by 
Simister et al ( 2009), it was demonstrated that the higher replication efficiency 
of JFH1 to replicate is linked with greater capacity for the NS5B RdRP to initiate 
de novo RNA synthesis (Simister et al., 2009). Comparison analysis with other 
genotype 2 RdRp demonstrated that the improved activity of JFH1 RdRp results 
from a more closed structural conformation which promotes greater interaction 
affinity with the single-stranded RNA viral genome and consequently improves 
initiation of de novo synthesis of RNA replication (Simister et al., 2009). Further 
analysis, identified a key residue (I405), residing at the thumb domain, which is 
responsible for the enhanced efficiency of JFH1 RdRp (Schmitt et al., 2011). 
Mutation of this residue in the genotype 1b RdRp sequence, improved 
significantly replication efficiency of this isolate in cell culture (Schmitt et al., 
2011; Scrima et al., 2012). 
The RNA-dependent RNA polymerase activity appears to be modulated by 
interaction with other proteins. NS5A has been demonstrated to interact with 
NS5B and this interaction is critical for viral RNA replication (Shimakami et al., 
2004). Cyclophilin B, a peptidyl-prolyl cis-trans-isomerase, can also interact with 
the C-terminal region of NS5B and appears to stimulate its RNA binding activity 
(Watashi et al., 2005). However, more recently Kaul et al (2009) have 
demonstrated that in fact cyclophilin A, and not cyclophilin B, is essential for 
replication and production of infectious particles (Kaul et al., 2009). In addition, 
other cellular proteins have been demonstrated to interact with NS5B and to 
influence HCV RNA replication activity. For example, NS5B is phosphorylated by 
a protein kinase C-related kinase, PRK2, and this phosphorylation event is 
involved in regulating HCV RNA replication (Kim et al., 2004). More recently, it 
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was found that high RdRp activity is enhanced by a “kissing-loop” interaction 
between an RNA element present in NS5B (5BSL3.2) and the SL2 in the 3’ UTR 
region (Friebe et al., 2005; Murayama et al., 2010). 
1.3 Experimental model systems for studying HCV life 
cycle 
Since its discovery in 1989, research into the HCV life cycle and host-virus 
interactions that influence viral pathogenicity and outcome have been hampered 
by the lack of experimental HCV cell culture infection systems and suitable small 
animal models. However, from the late 1990s onwards, considerable progress 
has been made in developing models systems to study different aspects of the 
virus life cycle. Three laboratory-based models in particular have improved our 
understanding of HCV biology. These include HCV subgenomic replicons (SGR), 
pseudotyped particles (HCVpp) and the HCV cell culture system (HCVcc). More 
recently, small animal models have been developed which permit in vivo studies 
on HCV infection and assessment of the activity of new antiviral compounds. 
These include the uPA/SCID and Fah-/-/Rag2-/-/IL2rg-/- mouse models. 
 
 
 
Figure 1.8 – HCV in vitro model systems. [I.] HCVpp allows for the study of HCV entry. 
Recombinant retrovirus particles that contain HCV envelope glycoproteins on their surface 
are produced in HEK-293T cells by cotransfecting plasmids encoding the HCV 
glycoproteins, retroviral or lentiviral core and polymerase proteins and a proviral genome 
harbouring a reporter gene. Following infection of permissive cell lines, the retrovirus 
genomes express a reporter gene, such as luciferase, allowing for a quantitative measure of 
cell entry. [II.] HCV SGRs, allow for the study of viral RNA replication in cell culture. 
Bicistronic replicon RNAs, encoding a selectable marker, under control of the HCV IRES in 
the first cistron and the HCV non-structural NS3-NS5B proteins under the control of the 
encephalomyocarditis virus (EMCV) IRES in the second cistron, are electroporated into 
Huh-7 cells and derived sub-lines. RNA replication results in the expression of the 
selectable marker and allows for selection of cell colonies that support viral RNA 
replication. [III.] HCVcc allows for the study of the entire HCV lifecycle. This system uses 
either JFH1 HCV genomic RNA or chimeric versions of this genome. Electroporation of 
these RNAs into permissive cell lines allows for viral RNA replication and the production of 
infectious particles that can infect naïve cells. Productive infection can be monitored by 
several methods allowing the detection of intracellular viral RNA or protein levels. 
Reproduced from Tellinghuisen et al. (2007). 
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1.3.1 in vitro models 
I. HCV pseudoparticles (HCVpp) 
To study the process of HCV entry, the HCV pseudoparticle (HCVpp) system 
was generated using HCV glycoproteins which are exposed at the surface of 
retroviral particles (Bartosch et al., 2003a; Drummer et al., 2003; Hsu et al., 
2003). HCVpp are produced by cotransfection of 293T cells with three expression 
vectors encoding the HCV E1E2 proteins, the Gag-Pol proteins from either human 
immunodeficiency virus or murine leukemia virus, and a retroviral genome 
carrying a reporter marker gene (e.g luciferase or GFP). The marker gene 
packaged into HCVpp enables easy evaluation of infectivity mediated by HCV 
glycoproteins. This system has been developed using HCV glycoproteins from 
genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a, allowing the analysis of cross- and 
genotype-specific neutralization (Lavillette et al., 2005; Owsianka et al., 2005). 
Several reports have demonstrated that HCVpp has tropism for liver cells and the 
ability of anti-E2 antibodies in neutralising HCVpp has allowed studies on virus 
binding, attachment and internalization as well as the identification of the HCV 
receptors required for entry in the cells (Bartosch et al., 2003b; Evans et al., 
2007; Ploss et al., 2009). 
II. Sub-genomic replicons (SGR) 
Shortly after the cloning of the HCV genome in 1989 (Choo et al., 1989), 
the first apparent full-length HCV RNA generated was not successful in 
replicating viral sequences in vitro. These clones lacked the 3’ UTR region of the 
genome which was essential for efficient replication. In 1997, Kolykhalov et al 
(1997) generated the first full-length functional HCV cDNA clone, which included 
the 3’ UTR region. This full-length HCV RNA (H77 strain) was infectious in 
chimpanzees, however it was unable to replicate in vitro (Kolykhalov et al., 
1997). In 1999, Lohmann et al, overcame the in vitro replication barrier with the 
development of the first HCV replicon system based on sequences from Con-1, a 
genotype 1b strain of the virus (Lohmann et al., 1999). These HCV SGR RNAs 
were engineered as bicistronic constructs, in which the region encoding core to 
NS2 was replaced by a coding sequence for a selectable antibiotic resistant 
marker (neomycin phosphotransferase, neo). This gene was under the control of 
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the HCV IRES, and was followed downstream by an heterologous IRES from 
encephalomyocarditis virus (EMCV), to drive translation of the downstream HCV 
NS3 to NS5B coding region derived from the Con-1 consensus genome. The first 
48 nucleotides of the core coding sequence located at the 3’end of the HCV IRES 
were linked in-frame with the neo gene to ensure complete IRES activity. Upon 
transfection of human hepatoma Huh-7 cells with in vitro transcribed HCV SGRs, 
followed by selection with G418, a small number of resistant colonies of cells 
supporting autonomous HCV replication were obtained (Lohmann et al., 1999). 
Although this SGR system was a major breakthrough in propagating HCV in cell 
culture, replication of these RNAs was relatively inefficient. 
Sequence analysis of Con-1-derived HCV RNAs replicating in cell clones 
after G418 selection identified the presence of cell culture adaptive mutations. 
These mutations were located across all NS coding regions (NS3, NS4B, NS5A and 
NS5B). Introduction of selected subsets of these mutations into the original 
consensus Con-1 sequence resulted in enhancement of RNA replication by several 
orders of magnitude (Blight et al., 2000; Krieger et al., 2001). Full-length HCV 
replicons have also been generated using Con-1 cell culture adapted sequences, 
which are able to replicate in Huh-7 cells. However, replication efficiency was 
lower than that observed in SGRs and no virus production was observed in these 
cells (Pietschmann et al., 2002). In these full-length replicons, the presence of 
adaptive mutations was detrimental to viral particle assembly. In addition, 
inoculation of chimpanzees with a full-length Con1 replicon containing adaptive 
mutations failed to establish a productive infection (Bukh et al., 2002). Some of 
these mutations are not found in natural isolates in HCV-infected patients, 
suggesting that they represent a specific adaptation to the Huh-7 cell 
environment. 
In addition to cell culture adaptive mutations, cell permissiveness also 
influenced the ability of HCV SGR RNA to replicate in vitro. Several cell lines 
have been reported to support HCV replication, however Huh-7 cells still 
remained the most permissive line. Later, highly permissive clones of Huh-7 cells 
were generated that supported higher viral replication levels. To that end, a 
subpopulation of Huh-7 cells harbouring higher levels of HCV SGRs were cured of 
the replicon by co-culturing the cells with IFN. From this approach, two cell lines 
were generated, Huh-7-Lunet and Huh-7.5 (Blight et al., 2002; Friebe et al., 
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2005). Similarly, an additional subclone (Huh-7.5.1) was generated by curing 
Huh-7.5 cells of replicating HCV. Reintroduction of replicon RNAs into these 
“cured” cell lines resulted in much higher RNA replication levels when compared 
with the parental Huh-7 cell line (Blight et al., 2002). The reasons for higher 
replication in these cells is not fully understood, but was thought to result from 
a partial impairment of their antiviral immune responses (Lanford et al., 2003). 
Indeed, Huh-7 cells were shown to be defective dsRNA signaling through TLR3 
pathway (Li et al., 2005). In addition to the defect in TLR3 signalling, Huh-7.5 
cells were also found to contain a mutation in the RIG-I CARD domain, which 
blocked down-stream signalling and activation of IRF-3 (Sumpter et al., 2005). 
With the developments obtained from generating highly permissive cell 
lines as well as cell culture adapted HCV RNAs, further improvements to the SGR 
model have been achieved. For example, the neo resistance marker could be 
replaced by other antibiotic markers as well as reporter genes (Bartenschlager 
et al., 2003). The latter was a major improvement to this system, since 
measurement of replication activity in transient assays and high throughput 
screening of antiviral compounds was made possible. Moreover, other SGRs 
containing NS3-NS5B consensus sequences derived from other HCV strains (such 
as H77 strain, genotype 1a) were also developed (Blight et al., 2003). Similar to 
Con-1 SGR, H77 SGRs also required adaptive mutations for efficient replication in 
Huh-7 cells (Blight et al., 2003; Yi & Lemon, 2004). 
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Using a similar approach to that used for Con-1, an HCV genotype 2a 
replicon was generated using strain JFH-1, isolated from the serum of a 
Japanese patient with fulminant HCV (Kato et al., 2003). JFH-1 subgenomes 
replicated with higher efficiency in Huh-7 cells, producing 60 times more drug-
resistance colonies than the original Con-1-derived replicons harbouring highly 
adaptive mutations (Kato et al., 2003). Unlike Con-1 replicons, JFH1 replicons 
did not require adaptive mutations to achieve high levels of replication. In 
addition, JFH1 replicons containing the luciferase reporter gene gave much 
improved levels of replication in transient assays compared to equivalent Con-1 
replicons (Targett-Adams & McLauchlan, 2005). Given the higher replication 
efficiency of strain JFH1, the JFH1 SGR also replicated in cell lines other than 
Huh-7 cells, such as human cell lines of hepatic or nonhepatic origin (HepG2, 
IMY-N9, HeLa, HEK 293) and mouse embryonic fibroblasts (Chang et al., 2006; 
Date et al., 2004; Kato et al., 2005). 
III. HCV cell culture-derived virions (HCVcc) 
The successful development of the SGR system was followed a major 
breakthrough in the propagation of HCV in vitro using HCV strain JFH1. Prior to 
availability of this system, the sole source of HCV infectious particles was either 
the sera from infected patients or chimpanzees. Following the efficiency in 
replication achieved by the JFH1 SGRs, RNA derived from the full-length JFH1 
cDNA resulted in production of infectious virus, termed HCVcc, following 
transfection into Huh-7 cells (Lindenbach et al., 2005; Wakita et al., 2005; 
Zhong et al., 2005). This HCVcc-derived virus was infectious in both naive Huh-7 
cells and in chimpanzees. The success with isolation of JFH1 has allowed the 
development of chimeric viruses, in which the structural genes of JFH1 are 
replaced with those of Con1, H77 and J6 sequences of genotypes 1b, 1a and 2a, 
respectively (Pietschmann et al., 2006; Yi et al., 2007). The most efficient of 
these chimeras is JC-1 and consists of genotype 2 strain J6- and JFH1-derived 
sequences. This chimera is capable of yielding infectious titres up to 1000-fold 
higher than JFH1 (Pietschmann et al., 2006). This in vitro model, reproducing 
the entire life cycle of HCV in Huh-7 cells, has enabled extensive research into 
various areas of HCV biology. 
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1.3.2 in vivo models 
Although the development of in vitro model systems has represented a 
substantial advance in the understanding of HCV biology, the range of cells and 
viral strains that can be utilised is very limited. In addition, studies on adaptive 
immune responses, which determine the outcome of HCV infection, cannot be 
addressed with such models. To date, the chimpanzee is the only 
immunocompetent animal model available to study HCV. Chimpanzees support 
HCV infection and replication, and allow the recapitulation of the complete viral 
life cycle for all six HCV genotypes (Bukh et al., 2010). Chimpanzees have innate 
and adaptive immune responses similar to those observed in humans and 
therefore, are highly relevant to study the natural course of HCV infection. 
However, experiments in chimpanzees are no longer permitted due to ethical 
concerns in most countries. Although HCV is unable to infect mice, advances 
have been made in developing susceptible humanized mouse models. The most 
successful small animal model currently available for HCV infection is the human 
liver uPA/SCID mouse. These mice are immunodeficient (SCID – severe combined 
immunodeficient) and have liver-specific expression of the urokinase 
plasminogen activator (Alb-uPA), which allows repopulation of the liver with 
transplanted human hepatocytes. Human liver uPA/SCID mice are susceptible to 
HCV infection and they produce infectious virions to levels similar to those found 
in humans and chimpanzees (Lindenbach et al., 2006; Mercer et al., 2001; 
Meuleman & Leroux-Roels, 2008). The major drawbacks with this system are that 
the mice are immunodeficient, thus precluding studies on most aspects of 
immunity and pathogenesis, and the low success rate with xenotransplantation 
of human liver. Since the development of the uPA-SCID mouse system, there 
have been further improvements to the model. For example, Fah-/-/Rag2-/-
/IL2rg-/- mice which contain a partially reconstituted human immune system, has 
resolved some of the limitations observed with the uPA/SCID mouse (Bissig et 
al., 2010). This model has other limitations, such as absence of antibody 
responses due to the lack of reconstitution of fully functional B cells (Bissig et 
al., 2007). Thus, studies on mechanisms of immune escape from neutralizing 
antibodies or the evaluation of B cell vaccines are not possible with Fah-/-/Rag2-
/-/IL2rg-/- mice. 
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More recently, further developments were made to create fully 
immunocompetent humanised mouse models. In a study by Dorner et al (2011), 
it was demonstrated that expression of the two human genes, CD81 and 
occludin, in fully immunocompetent mice, was sufficient to render these mice 
susceptible to HCV infection (Dorner et al., 2011). Although, this model is 
limited to HCV entry it presents a useful alternative to the chimpanzee model 
for studies on virus neutralization, virus-receptor interaction and the 
development of novel therapeutics for blocking virus entry. More recently, 
Washburn et al (2011), developed the AFC8-hu HSC/Hep mice which represent 
the first mouse model with both human immune and liver cells. Infection of 
these mice with HCV appears to induce human immune responses (Washburn et 
al., 2011). Thus, major advances made with AFC8-hu HSC/Hep mice will allow 
further studies on HCV pathogenesis and in the development of improved 
therapeutics for HCV infection. 
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1.4 HCV life cycle 
HCV is a hepatotropic pathogen that reaches the liver through sinusoidal 
blood vessels to infect its primary target cells, which are hepatocytes. Infection 
occurs through a series of sequential stages: I) attachment to the cells; II) entry 
by receptor-mediated endocytosis; III) translation of incoming viral genome(s); 
IV) polyprotein processing and replication complex formation; V) RNA 
replication; VI) assembly of new virions and VII) release of virions from the cells. 
After binding and entry, the remainder of the HCV life cycle takes place in the 
cytoplasm of hepatocytes. Each of these steps is represented in (Figure 1.9) and 
described in the following paragraphs. 
1.4.1 Virus attachment and entry 
I. HCV liver uptake and attachment to hepatocytes 
HCV is transmitted predominantly through direct exposure to blood or 
blood products. Following exposure, HCV establishes a productive infection in 
hepatocytes. Hepatocytes are shielded from the bloodstream by Kupffer cells, 
liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells. HCV is 
thought to enter the liver through the sinusoidal blood and is captured by the 
LSECs to facilitate infection of hepatocytes. However, little is understood about 
these early events in infection. 
 
 
 
Figure 1.9 – Schematic representation of the HCV life cycle. Attachment of HCV to cell-
surface receptors leads to receptor-mediated endocytosis into a low-pH vesicles. Following 
membrane fusion, the viral genome is released into the cytoplasm. The incoming viral 
genome is a positive single-stranded RNA molecule and functions as a template for 
translation of the HCV-sense polyprotein, which is further processed to produce the mature 
viral proteins. Viral RNA replication occurs within membrane-associated replication 
complexes. Replicated RNA is used for further production of viral proteins or is 
encapsidated. The viral particles are thought to use the cellular secretory pathway for 
maturation and release of HCV virions. 
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As mentioned earlier, HCV particles exist in association with lipoproteins 
and thus circulate as lipoviroparticles (LVPs; section 1.2). HCV LVPs may cross 
from the liver endothelium through interaction with a set of capturing receptors 
called C-lectins (DC-SIGN and L-SIGN). DC-SIGN (dendritic-cell-specific ICAM-3 
grabbing non-integrin) and L-SIGN (liver/lymph node-specific ICAM-3 grabbing 
non-integrin) are highly expressed in Kupffer cells and LSECs, respectively, and 
have been suggested to mediate transcytosis of HCV particles from the blood to 
the underlying hepatocytes. Several reports support this hypothesis and revealed 
that HCV E2 protein can bind with high affinity to both DC-SIGN and L-SIGN 
(Gardner et al., 2003; Lai et al., 2006; Pohlmann et al., 2003). Loss of this 
interaction greatly inhibits virus uptake, suggesting that these lectins may be 
used for capturing HCV to the hepatocytes. 
Once HCV has transversed the endothelium, two receptors 
[glycosaminoglycans (GAGs) and low density lipoprotein receptor (LDL-R)] have 
been implicated in capturing and concentrating the virus at the basal surface of 
hepatocytes. GAGs are thought to represent, an initial, low affinity interaction 
between HCV particles and the cell surface (Barth et al., 2003; Koutsoudakis et 
al., 2006). GAGs such as heparin sulphate proteoglycan (HSPG) do bind 
recombinant E2 glycoprotein (Barth et al., 2003). Cells treated with heparinase, 
an enzyme responsible for cleaving heparin sulphate molecules, resulted in 
reduced binding of recombinant E2 and HCVcc entry into the cells (Barth et al., 
2003; Koutsoudakis et al., 2006). In addition to GAGs, many groups have 
suggested that the LDL-R is involved in HCV entry (Agnello et al., 1999; Germi et 
al., 2002; Molina et al., 2007). It has been shown that endocytosis of HCV 
correlates with the presence of LDL-R and this process is inhibited using anti-
LDL-R antibodies. Additional evidence for the role of LDL-R in HCV entry has also 
emerged from experiments in which knockdown of LDL-R in primary hepatocytes 
resulted in loss of HCV infectivity (Molina et al., 2007; Owen et al., 2009). 
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II. Entry 
Following attachment, internalisation of virus particles requires a series of 
interactions with at least four cell receptors. These include the scavenger 
receptor class B type I (SR-BI) (Scarselli et al., 2002), the tetraspanin CD81 
(Pileri et al., 1998) and two tight junction proteins, claudin-1 (CLDN1) (Evans et 
al., 2007) and occludin (OCLN) (Benedicto et al., 2009; Liu et al., 2009; Ploss et 
al., 2009). 
SR-BI is highly expressed in hepatic cells, where it functions as a 
lipoprotein receptor that mediates selective cholesterol ester uptake from high-
density lipoprotein (HDL) (Krieger, 2001; Reynolds et al., 2008). SR-BI is a 82KDa 
glycoprotein, consisting of a highly glycosylated large extracellular loop 
anchored to the plasma membrane at both the N- and C-termini by 
transmembrane domains with short extensions into the cell cytoplasm. SR-BI was 
initially identified as a receptor for HCV entry through its ability to bind to a 
soluble recombinant form of E2 glycoprotein (Scarselli et al., 2002). Receptor 
competition assays further demonstrated that anti-SR-BI antibodies that 
inhibited soluble recombinant E2, could prevent HCVpp infectivity (Bartosch et 
al., 2003b). Additionally, siRNA-mediated silencing of SR-BI in Huh-7 cells 
resulted in a reduction of HCVpp infectivity (Lavillette et al., 2005). Binding of 
E2 to SR-BI requires the HVR1 domain of E2 and deletion of this region results in 
loss of binding to the receptor (Scarselli et al., 2002). Consistently, HCV virions 
incubated with anti-HVR1 antibodies inhibited E2 binding to SR-BI, thereby 
reducing infectivity in cell culture. These studies demonstrate an important role 
for SR-BI in HCV entry (Bartosch et al., 2003b). 
CD81 was the first receptor, which was identified as mediating HCV entry 
(Pileri et al., 1998). It is a member of the tetraspanin family of transmembrane 
proteins. The protein has an apparent molecular weight of 26KDa and consists of 
four transmembrane domains, separated by two extracellular loops [small (SEL) 
and large (LEL)] and short cytoplasmic N- and C-terminal regions. Initial 
evidence that CD81 was a binding receptor for HCV come from studies 
demonstrating that solubilised forms of E2 protein could bind to CD81 (Pileri et 
al., 1998). In addition, the same group showed that this interaction was 
mediated through the LEL of CD81, as expression of the recombinant form of the 
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LEL bound to HCV (Pileri et al., 1998). Anti-CD81 antibodies or silencing of CD81 
using siRNAs inhibited HCVcc and HCVpp infection of primary human hepatocytes 
and hepatoma cell lines (Bartosch et al., 2003b; Molina et al., 2008; Wakita et 
al., 2005; Zhang et al., 2004). Further evidence supporting the role of CD81 in 
HCV entry was obtained from studies where human hepatoma cell lines (HepG2 
and HH29 cells), which were previously resistant to infection, became permissive 
to HCVpp upon ectopic expression of CD81 (Bartosch et al., 2003b; Lavillette et 
al., 2005; Zhang et al., 2004). 
Inhibition studies using anti-SR-BI and anti-CD81 antibodies have suggested 
that SR-BI may act concomitantly with CD81 (Zeisel et al., 2007). Since HCVcc 
could bind CHO cells expressing SR-BI but not CD81, it is suggested that HCVcc 
may attach to SR-BI before CD81 (Evans et al., 2007). Although CD81 can 
interact with a soluble form of E2, it does not appear to be able to interact 
directly with mature HCV virions, indicating that binding to other receptors may 
alter the virion conformation to reveal CD81 binding sites. Sharma et al (2011) 
reported that CD81 LEL induced changes in glycoprotein E1E2 conformation, as 
evidenced by an altered reactivity of the proteins with conformation-specific 
antibodies (Sharma et al., 2011). In support of this hypothesis, interaction of SR-
BI with E2 has been suggested to induce a conformational change in the HCV 
glycoproteins, which is essential for binding to the subsequent cell receptors. 
Indeed, deletion of HVR1 in E2 resulted in loss of SR-BI dependency and led to an 
increase in HCVcc binding to CD81 (Bankwitz et al., 2010). The authors 
hypothesised that HVR1 may mask conserved CD81 binding epitopes and shield 
them from neutralising antibodies. In addition, mutagenesis studies on E2-
specific N-linked glycan residues showed increased E2-CD81 association, 
suggesting that a conformational change in E2 may be required to promote high-
affinity association with CD81. 
After attachment to CD81, virions are directed to tight junctions, where 
interaction with CLDN1 and OCLN occurs, to facilitate cellular uptake. CLDN1 
and OCLN are expressed at the interface between basolateral and apical 
membranes, and are involved in regulating paracellular transport of solutes and 
generate apical-basal cell polarity (Shin et al., 2006). CLDN1 consists of four 
transmembrane domains and two extracellular loops. The first extracellular loop 
is required for HCVpp entry (Evans et al., 2007). Although no direct interaction 
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has been observed between HCV glycoproteins and CLDN1, several studies have 
revealed that CD81 interacts with CLDN1, suggesting that these factors can act 
in a cooperative manner during entry (Evans et al., 2007; Harris et al., 2008; 
Krieger et al., 2010). Furthermore, in nonpolarised or partially polarised cells 
this CD81-CLDN1 interaction occurs outside of cell junctions before infection and 
appears to influence the entry process (Harris et al., 2010; Harris et al., 2008). 
Disruption of CD81-CLDN1 association with anti-CLDN1 antibodies reduced E2 
association with the cell surface and resulted in loss of HCV infectivity (Krieger 
et al., 2010). Recently, two receptor tyrosine kinases, epidermal growth factor 
receptor (EGFR) and ephrin receptor A2, have been reported as cofactors for 
HCV cell entry (Lupberger et al., 2011). These receptors were suggested to 
mediate HCV entry by regulating CD81-CLDN1 association and viral glycoprotein-
dependent membrane fusion. Blocking the receptor kinase activity greatly 
reduced HCV infection both in vitro and in vivo (Lupberger et al., 2011). 
Another tight junction protein, OCLN, has been implicated in HCV entry 
(Benedicto et al., 2009; Liu et al., 2009; Ploss et al., 2009). Similar to CLDN1, 
OCLN has four transmembrane domains and two extracellular loops. Contrary to 
CLDN1, a direct interaction between OCLN and the E2 from HCVcc particles has 
been demonstrated (Liu et al., 2009b). This interaction is apparently essential 
for HCV entry since silencing of OCLN in cells permissive for HCV entry, resulted 
in a reduction of both HCVcc and HCVpp infectivity (Ploss et al., 2009). 
Furthermore, knockdown of OCLN in a cell-cell fusion assay, where fusion 
activity depended on cell surface expression of the E1E2 glycoprotein complex, 
diminished fusion activity, suggesting that OCLN may participate in the HCV 
fusion process (Benedicto et al., 2009). 
More recently, the Niemann-Pick C1-like 1 cholesterol absorption receptor 
(NPC1L1) has been suggested as an entry factor for HCV (Sainz et al., 2012). 
NPC1L1 is a cell surface cholesterol sensing receptor expressed on the apical 
surface of intestinal enterocytes and human hepatotyces, including Huh-7 cells. 
NPC1L1 is an entry factor used by HCV, that functions after binding, but at or 
before fusion (Sainz et al., 2012). However, the requirement of this receptor for 
HCV entry requires further confirmation, as expression of SR-BI, CD81, CLDN1 
and OCLN in murine and hamster cells rendered these cells permissive for HCV 
infection (Ploss et al., 2009). 
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Similar to other flaviviruses, HCV entry is thought to be mediated by 
clathrin-mediated endocytosis, with delivery of the viral nucleocapsid into the 
cytoplasm via early endosomes (Blanchard et al., 2006). Treatment of cells with 
agents that disrupt clathrin-coated pit formation or siRNA-mediated silencing of 
clathrin, reduced both HCVpp and HCVcc entry (Blanchard et al., 2006; Meertens 
et al., 2006). Once internalized, the virus glycoproteins are proposed to fuse 
with the membrane of early endosomes (Meertens et al., 2006). This mechanism 
is dependent on low pH, with an optimum at about 5.5 (Lavillette et al., 2006). 
Furthermore, experiments using drugs that inhibited acidification of endosomes 
have shown that low pH in endosomes is required for both HCVpp and HCVcc cell 
entry (Blanchard et al., 2006; Hsu et al., 2003; Koutsoudakis et al., 2006; 
Meertens et al., 2006). 
Investigation of fusion determinants indicated that three discrete regions of 
both E1 and E2 proteins participate in the intracellular membrane fusion process 
(Lavillette et al., 2007). The process of entry may also be dependent on an 
intact and dynamic microtubule network and for early post-fusion steps of 
infection (Roohvand et al., 2009). It is suggested that core protein may play a 
role in this process through its interaction with tubulin, which resulted in 
enhanced microtubule polymerization (Roohvand et al., 2009). This interaction 
could mediate the transport of the HCV nucleocapsid to sites where genome 
translation takes place and subsequently where the viral RNA would be released 
into the cytoplasm. 
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1.4.2 Translation and Replication 
III. Translation of incoming genomes 
Uncoating of viral nucleocapsids results in release of the viral genome into 
the cell cytoplasm. The viral genome serves as a template for synthesis of the 
HCV precursor polyprotein. In contrast to cellular mRNAs, which require a 5’-cap 
structure for recruitment of both eIF4F (eukaryotic initiation factor 4F) complex 
and the small (40S) subunit of the ribosome to initiate translation, HCV RNA 
lacks a 5’-cap and uses an IRES to mediate cap-independent translational 
initiation (Wang et al., 1993). IRES-mediated translation is initiated by direct 
binding of a vacant 40S ribosomal subunit to the IRES and positioning of the 
polyprotein start codon into the 40S P site (Kieft et al., 2001; Otto & Puglisi, 
2004). Compared to capped cellular mRNAs, the HCV IRES can capture the 40S 
ribosomal subunit in the absence of any known initiation factors previously 
identified as required for ribosome binding to an mRNA. However, integration of 
two eukaryotic initiation factors (eIF2 and eIF3) into the IRES-40S complex, is 
necessary for efficient protein synthesis of the viral RNA (Pestova et al., 1998). 
After interaction of the HCV IRES with the 40S ribosomal subunit, this complex 
binds to eIF3, followed by recruitment of the eIF-2:Met-tRNAi:GTP complex to 
generate a 48S-like complex (Ji et al., 2004). Upon hydrolysis of GTP, the 
initiation factors are released allowing attachment of the 60S ribosomal subunit 
to the 48S complex. This generates a functional IRES-80S complex, which can 
initiate viral protein synthesis. 
IV. Polyprotein processing and RC formation 
Translation of the HCV genome generates a large precursor polyprotein, 
which is targeted to the ER membrane and thereafter processed by cellular and 
viral proteases to generate the mature forms of structural and non-structural 
viral proteins (section 1.2.2). Host signal peptidase cleaves at the C-terminal 
end of the signal peptide between core and E1, releasing an immature form of 
core and creating the N-terminus for E1 (Hussy et al., 1996; Moradpour et al., 
1996; Santolini et al., 1994). Core is further processed within the signal 
sequence at its C-terminus by host signal peptide peptidase to yield the mature 
form of the protein (McLauchlan et al., 2002). Additional signal peptidase 
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cleavages occur at the boundaries between E1-E2, E2-p7, p7-NS2, yielding E1, 
E2, p7 and the N-terminus of NS2 (Dubuisson et al., 2002). E1 and E2 undergo 
further maturation through N-glycosylation and conformation of the 
glycoproteins. HCV NS proteins are processed by two viral proteases: the zinc-
dependent NS2/3 auto-protease that cleaves NS3 from NS2, and the NS3/4A 
protease which processes the polyprotein at the NS3-NS4A junction and 
subsequent downstream junctions, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B 
(section 1.2.2.2). 
Similar to many positive-sense RNA viruses, HCV induces dramatic 
remodelling of intracellular membranes to generate specialised compartments in 
which RNA replication takes place. For replication to occur, the viral genome, 
together with viral and host proteins is recruited to these specialised 
compartments in order to create the viral replication complex (RC). The HCV RC 
is thought to assemble on intracellular ER membranes through dynamic 
deformation of those membranes, which generate vesicles-like structures, 
known as the membranous web [MW; (Egger et al., 2002; Gosert et al., 2003)]. 
Membrane alterations induced by the expression of HCV proteins were 
systematically studied by inducibly expressing the entire HCV polyprotein and 
individual viral components (Egger et al., 2002). In this study, it was found that 
expression of the HCV polyprotein induces distinct membrane alterations. 
Formation of the MW was induced by NS4B alone and very similar in morphology 
to the “sponge-like inclusions” previously observed using electron microscopy in 
the liver of HCV-infected chimpamzees (Pfeifer et al., 1980). It is believed that 
membrane alterations provide 1) physical support and organisation of the RC, 2) 
compartmentalization and concentration of viral products essential for 
replication and 3) protection of the viral RNA from host defences. 
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As mentioned above, NS4B is sufficient to induce rearrangement of the ER 
membrane, by an as yet unknown mechanism (Egger et al., 2002; Gosert et al., 
2003). The precise composition of the HCV RC is not known, but it includes NS 
proteins (NS3-4A, NS4B, NS5A, and NS5B), cellular components and newly 
synthesized RNA molecules. Metabolic labelling of the nascent viral RNA with 
BrUTP in the presence of actinomycin D confirmed that the RC at the MW is the 
site of viral RNA synthesis (Gosert et al., 2003). By immunofluorescence 
microscopy, MWs appear as dot-like structures with diameters of up to several 
microns (Gosert et al., 2003). 
V. Mechanism of RNA replication 
The synthesis of new viral genomes is thought to occur in the MW and is 
catalysed by NS5B, the viral RdRp. Replication proceeds through the synthesis of 
a complementary negative-strand RNA by NS5B, using the positive-strand 
genome RNA as a template. Then, negative-strand RNA serves as a template to 
produce numerous strands of positive-sense RNA (Lohmann et al., 1999; 
Takehara et al., 1992). During this process, dsRNA intermediates are formed, 
which can be visualised at RC sites in actively replicating cells (Targett-Adams et 
al., 2008). The positive-strand RNA is produced in a 5-10 fold excess compared 
with negative-strand RNA, and is used as the template for further polyprotein 
translation, synthesis of new intermediates of replication and packaging into 
new virus particles (Quinkert et al., 2005). Several host and viral factors have 
been shown to modulate viral RNA synthesis. Some of these factors have been 
described previously in sections 1.2.1.1-I&II and 1.2.2.2-II to -V and are involved 
in regulating a range of cellular processes. These factors can directly influence 
the activity of RdRp [e.g., cyclophilin A (Kaul et al., 2009), and the protein 
kinase PRK2 (Kim et al., 2004)] or interfere with the activity of different 
components of the replication complex to modulate viral RNA replication. 
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1.4.3 Assembly and release 
The final stages of the HCV life cycle include the assembly of virions and 
their release from cells. As mentioned earlier, the HCV virion is thought to 
consist of a nucleocapsid, in which core encapsidates and protects the viral 
genome, and an outer envelope composed of a lipid membrane containing the 
E1E2 glycoproteins. In addition, the mature virion is thought to associate with 
VLDL/LDL, generating lipoviroparticles (LVP). Although little is known about the 
molecular mechanisms governing nucleocapsid formation and release of virions, 
much of what is known about these later steps of the HCV life cycle has been 
established through the development of the HCVcc model. 
VI. Nucleocapsid assembly 
Nucleocapsid assembly involves the formation of the capsid by 
oligomerization of the core protein and encapsidation of genomic RNA. Core 
protein has a central role in assembly as it is the constitutive unit of the 
nucleocapsid. After full maturation of core by SPP, the protein is targeted to 
lipid droplets (LDs; McLauchlan et al., 2002). This association is mediated by the 
D2 domain of core and is required for virus production (Boulant et al., 2007; 
Miyanari et al., 2007). Confocal microscopy analyses with fluorescent reporters 
identified crucial residues for core-LD association within D2 (Boulant et al., 
2006). Live cell imaging of virus-producing cells has been used to visualize core 
during the HCV assembly process (Counihan et al., 2011). Using this method, 
fluorescently labelled core was found to move to the surface of large, immotile 
LDs soon after translation. During the peak of virus assembly core formed 
polarized caps on these LDs that were frequently in close apposition to ER-
localized core, indicating that core may transfer between the ER and LDs at 
these sites (Counihan et al., 2011). Similarly, 3D reconstruction of confocal 
images during infection demonstrated that core gradually decorates the surface 
of LDs and the extent of LD coverage by core correlated with the production of 
infectious particles (Boulant et al., 2007). 
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In addition to being located around LDs, core protein also induces their 
redistribution from a dispersed distribution within the cytoplasm to the 
perinuclear region (Boulant et al., 2008). The loading of core onto LDs has been 
shown to displace adipocyte differentiation related protein (ADRP), an abundant 
protein on the LD surface. ADRP maintains the normal dispersed cytoplasmic 
distribution of LDs and its displacement by core protein during infection causes 
LDs to re-localise in aggregates at close to the microtubule organising centre 
(Boulant et al., 2008). Viral RNA is replicated at the ER, and the LD 
redistribution is believed to create the microenvironment that coordinates 
interaction between core and RCs during assembly (Boulant et al., 2008; 
Miyanari et al., 2007). Several studies have shown that core is also involved in 
the recruitment of NS proteins and RNA replication complexes to sites adjacent 
to LDs; for example, NS2, NS3, NS4AB, NS5A, NS5B localize around LDs in 
infected cells (Boulant et al., 2008; Jirasko et al., 2010; Ma et al., 2011; 
Miyanari et al., 2007; Popescu et al., 2011). Electron microscopy images showed 
that, although core is tightly associated with LDs, NS2, NS5A, E2 and E1 also 
colocalize in close proximity to LDs (Miyanari et al., 2007; Popescu et al., 2011). 
Furthermore, in situ hybridization analyses indicate that positive- and negative-
strand viral RNAs are found at the proximity of LDs (Miyanari et al., 2007). In 
contrast, viruses containing defective mutations in core-LD association do not 
show accumulation of the other viral elements around LDs (Miyanari et al., 2007; 
Popescu et al., 2011). The trafficking of core between LD and ER membranes 
and the consequent presence of other viral proteins around the LDs is essential 
to the assembly process. 
Mutational analyses have demonstrated important roles for p7 and the non-
structural proteins in assembly and release of infectious HCV. In addition to core 
protein, NS5A has been reported to associate with LDs and to co-localise with 
core on these organelles (Miyanari et al., 2007). Mutations within domain I of 
NS5A have established that this domain is required for its association with LDs, 
and this interaction is crucial for infectious virus production (Miyanari et al., 
2007). Also, deletions in domain III impaired virus production by disrupting the 
NS5A-core protein association on LDs but did not affect attachment of NS5A to 
LDs (Appel et al., 2008). Moreover, another study found that mutagenesis of a 
cluster of serine residues within domain III impaired NS5A basal phosphorylation, 
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resulting in a decrease in NS5A-core interactions, which disrupted virus 
production (Masaki et al., 2008). 
Several studies have identified regions or residues within the NS2 protein 
essential for infectious virus production (Jirasko et al., 2010; Jones et al., 2007; 
Ma et al., 2011; Popescu et al., 2011; Yi et al., 2009). NS2 directly interacts 
with multiple viral proteins including E1E2, p7, NS3 and NS5A, and 
immunofluorescence analysis have shown that NS2 co-localises with these 
proteins at the LD-ER interface, suggesting that it may provide an important link 
between replication complexes and the structural proteins during the assembly 
process (Jirasko et al., 2010; Popescu et al., 2011). Since no direct interaction 
has been identified between NS2 and core, it has been hypothesised that an 
interplay might exist between the core-NS5A and NS2-NS5A interactions during 
assembly (Jirasko et al., 2010; Ma et al., 2011; Stapleford & Lindenbach, 2011). 
In addition, p7 recruits both core and NS2 to sites adjacent to replication 
complexes (Boson et al., 2011; Tedbury et al., 2011). Mutagenesis studies on 
conserved residues of p7, which are important for ion channel activity, have 
shown that p7 is required for production of infectious virus (Jones et al., 2007; 
Steinmann et al., 2007). However, the exact function of p7 during virion 
assembly remains to be elucidated. In a recent study, p7 inhibited the 
acidification of intracellular compartments, presumably to protect intracellular 
virions during their maturation or secretion (Wozniak et al., 2010). Thus, HCV 
assembly is a complex process that requires multiple interactions between the 
structural and non-structural proteins, which are apparently orchestrated at LD-
associated ER-membrane structures. 
In addition to viral factors, a number of host proteins have been implicated 
in HCV morphogenesis, for example the heat shock cognate protein 70 (HSC70), 
annexin A2 (ANXA2) and the diacylglycerol acyl transferase 1 (DGAT1) enzyme 
(Backes et al., 2010; Herker et al., 2010; Parent et al., 2009). HSC70 was 
initially identified by mass spectrometric analysis as a host factor associated 
with HCVcc virions. HSC70 is thought to be required for an early step in infection 
given that HCVcc infection could be inhibited by anti-HSC70 antibodies (Parent 
et al., 2009). Furthermore, silencing of HSC70 using siRNAs revealed that HSC70 
is not required for viral RNA replication, but is important for production of 
infectious particles (Parent et al., 2009). Proteome analysis of HCV replication 
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complexes identified ANXA2 as an associated host factor presumably involved in 
viral replication (Backes et al., 2010). Although ANXA2 colocalized with viral 
non-structural proteins, silencing of the gene did not affect RNA replication. 
Instead, reduction of ANXA2 expression significantly impaired assembly of 
infectious virus (Backes et al., 2010). Moreover, although no interaction 
between NS5A and ANXA2 was observed, these two proteins did colocalize, 
suggesting that NS5A was responsible for the recruitment of ANXA2 to HCV 
replication sites and together contribute to virion morphogenesis, by an 
unknown mechanism. DGAT1, which catalyzes the final step of triglyceride 
synthesis and is crucial for LD biogenesis, has been shown to interact with core 
protein (Herker et al., 2010). This interaction appears to be essential for 
trafficking of core to LDs and disrupting this process by depletion of the DGAT1 
gene inhibits virion assembly (Herker et al., 2010). 
Although core is essential for formation of HCV virions, the mechanism of 
how virus particles are assembled is still not fully understood. An important step 
in this process is the multimerization of core, presumably followed by capsid 
construction and packaging of the RNA genome into viral particles. Recently 
Kushima et al (2010) suggested that the nucleocapsid-like particle of HCV is 
composed of a disulfide-bonded core protein complex (Kushima et al., 2010). 
Moreover, they identified that residue C128 is responsible for the formation of 
the disulfide bond between core monomers. Mutation of this residue led to loss 
of the disulfide-bonded core and consequently resulted in inhibition of HCV virus 
particle formation, indicating that disulfide-bonded core protein complex is 
required for the efficient virion assembly (Kushima et al., 2010). 
VII. Virus release 
It is suggested that the maturation and secretion of HCV particles is tightly 
linked to VLDL assembly. Initial observations were obtained from analysis of the 
composition of membrane vesicles containing HCV replication complexes (Huang 
et al., 2007a). This study revealed that, in addition to the non-structural 
proteins involved in virus replication, these membranes were highly enriched in 
proteins involved in the VLDL secretion pathway (apoB, apoE and microsomal 
triglyceride transfer protein [MTP]) (Huang et al., 2007a). Inhibition of MTP 
activity or silencing of apoB indicated that these factors which are involved in 
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the VLDL secretion pathway, also may facilitate the production of infectious HCV 
particles (Huang et al., 2007a). Furthermore, drug inhibition studies on the 
maturation of high-density intracellular HCV particles to secreted particles 
revealed that blocking transport between ER and Golgi compartments, led to the 
degradation of intracellular high-density HCV particles in a post-ER compartment 
and in a non-proteasomal manner (Gastaminza et al., 2008). In addition, these 
studies also demonstrated that inhibition of MTP activity and silencing of ApoB 
prevented the assembly of infectious particles at an early stage (Gastaminza et 
al., 2008). Several reports have demonstrated that apoE also associates with 
HCVcc particles and down-regulation of apoE using siRNAs suppresses infectious 
virus production (Benga et al., 2010; Chang et al., 2007; Jiang & Luo, 2009). In 
addition, HCV infectivity was also impaired by anti-apoE antibodies, suggesting 
that HCV virions are assembled as apoE-enriched lipoprotein particles (Chang et 
al., 2007). ApoE was found to interact with NS5A in HCV-infected cells, 
suggesting that apoE is required for an early step of virion assembly, and its 
recruitment by NS5A is important for viral assembly and release of infectious 
viral particles (Benga et al., 2010; Cun et al., 2010; Jiang & Luo, 2009). 
Compared to apoE, the importance of apoB and MTP activity in the assembly and 
secretion of infectious HCV is somewhat contradictory. Some studies 
demonstrated that siRNA-mediated depletion of apoB from infected cells 
resulted in inhibition of virus production, whereas treatment with MTP inhibitors 
reduced both HCV assembly and secretion (Gastaminza et al., 2008; Huang et 
al., 2007a). By contrast, other studies found that the levels of apoB and MTP 
activity had no influence on the assembly and release of HCVcc (Benga et al., 
2010; Chang et al., 2007; Jiang & Luo, 2009). The exact reasons for these 
differences are still not fully understood. Nonetheless, the VLDL assembly 
pathway is required for release of HCV infectious virus and apoE is believed to 
be a critical component of this pathway. 
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1.5 Immune responses and HCV infection 
The immune defences against invading pathogens are divided into two 
major arms: innate or non-specific immune responses and adaptive or specific 
immune responses. The innate immune system is the first line of defence and is 
composed of proteins (e.g. interferons) and cells (e.g. dendritic cells and natural 
killer cells). Although non-specific, innate immune responses have the advantage 
of being constitutively present and therefore, ready to mobilize following 
infection. The adaptive immune system acts as a secondary line of defence and 
is dependent on appropriate innate immune stimuli. This system is normally 
silent, but when activated is capable of mounting a targeted response to the 
infecting pathogens. The adaptive immune system is further divided into two 
types: humoral immunity, mediated by antibodies produced by B-cells and, 
cellular immunity, mediated by T-cells. The following sections present a brief 
overview of the immune responses during the course of HCV infection and 
describe some of the mechanisms used by the virus to evade such defences, 
which determine the outcome of infection. 
1.5.1 Innate immune responses 
1.5.1.1 Interferons and HCV infection 
More than 50 years ago, Lindenmann (1957) reported a phenomenon of viral 
interference to describe conditions which disrupted virus infectivity 
(Lindenmann et al., 1957). In their work, they found that infection of chicken 
embryo cells with influenza virus, whether active or inactive, produced and 
released a new factor into the surrounding fluid. This new factor, termed 
interferon (IFN), interfered with virus growth and conferred resistance to 
infection in non-infected cells. 
Since their discovery IFNs have been intensively studied, and now represent 
a large family of secreted proteins that exhibit strong antiviral activities and 
immunomodulatory properties. IFNs are classified, according to their cellular 
origin and to the types of receptors they bind, into three groups designated type 
I, II and III IFNs (Pestka et al., 2004; Stark et al., 1998). Type I IFNs in humans 
comprise 13 IFNα species and single species of IFNβ, IFNκ, IFNε and IFNω (Pestka 
et al., 2004). All type I IFNs bind to the same IFNα/β receptor (IFNAR) which 
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consists of two subunits, IFNAR1 and IFNAR2 (Figure 1.11). The function of type I 
IFNs, in particular IFNα and β is well characterized and they are essential for 
mounting a robust host response against viral infection. Indeed, mice deficient 
in IFNAR demonstrate increased susceptibility to infection with several viruses 
when compared with wild-type mice (Muller et al., 1994). In addition to their 
ability to inhibit viral infection, type I IFNs are also known to exert multiple 
immunoregulatory effects on NK and T cells (Gonzalez-Navajas et al., 2012). 
Type II IFNs comprise a single member, IFNγ, which also exhibits antiviral 
activities. Contrary to type I IFNs, IFNγ is not produced by virus-infected cells, 
but is expressed at high levels by activated T cells and NK cells. IFNγ binds to its 
own receptor (IFNGR), which is composed of two subunits (IFNGR1/2) (Figure 
1.11). The more recently described IFNs are type III IFNs and include three gene 
products IFNλ1, IFNλ2 and IFNλ3, also known as IL29, IL28A and IL28B, 
respectively (Kotenko et al., 2003; Sheppard et al., 2003). Similar to type I IFNs, 
these IFNs are induced upon viral infection and possess antiviral activities. Type 
III IFNs signal through the IFNλ receptor which is composed of IL-10R2 and 
IFNλR1 (Figure 1.11). Analysis of the crystal structure of type III IFNs, revealed 
that these IFNs are markedly different from type I or II IFNs and structurally 
related to members of the IL-10 family (Gad et al., 2009). 
I. Induction of type I IFNs during viral infection 
IFNα/β are produced by almost all cell types and are highly upregulated in 
response to viral infection. The signaling pathways that lead to the induction of 
these IFNs are dependent on the detection of viral signatures generated during 
infection [pathogen-associated molecular patterns (PAMPs)] by host-specialised 
receptors [pattern-recognition receptors (PRRs)]. In hepatocytes, three major 
classes of PRRs are recognised: 1) the Toll-like receptors (TLRs), that are mainly 
located in endosomes and the cell surface, and include TLR3, TLR7, TLR8 and 
TLR9; 2) the retinoic-acid-inducible gene I-like receptors (RLRs), that are 
located in the cytoplasm and include retinoic acid-inducible gene I (RIG-I), 
melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics 
and physiology 2 (LGP2), and 3) the nucleotide oligomerization domain [NOD]-
like receptors (NLRs), that are also present in the cytoplasm (Thompson et al., 
2011). Among these PRRs, TLR3 and RIG-I can recognise HCV genome signatures 
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and mediate downstream signalling which results in IFNα/β production (Saito et 
al., 2008b; Sumpter et al., 2005; Wang et al., 2009). TLR3 can recognise dsRNA 
and induce type I IFN expression in a manner that is dependent on “TIR-domain-
containing adaptor protein inducing IFNβ” (TRIF). Although TLR3 has been 
suggested to sense HCV infection, the role of this PRR is less well characterised 
than RIG-I, since in vitro studies on HCV infection are dependent on Huh-7 cells 
that are deficient in TLR3 signalling (Li et al., 2005a). However, activation of 
TLR3 signalling by HCV RNA has been demonstrated by ectopically expressed 
TLR3 (Wang et al., 2009). Induction of type I IFNs through RIG-I signalling is 
initiated by recognition of viral 5’triphosphate RNA as well as the poly-uridine 
motif at the viral 3’ UTR (Saito et al., 2007; Saito et al., 2008b). This binding 
leads to a conformational change of the sensor and results in interaction with 
IFNβ-promoter stimulator 1, IPS-1 (also called MAVS, Cardif or VISA), which 
mediates downstream signalling through recruitment of TBK1 and IKK1 kinases. 
Both TLR3 and RIG-I signalling pathways can then activate the transcription 
factors IRF-3/IRF-7 and NF-κB. After dimerization of IRF-3/IRF-7, these factors 
translocate into the nucleus, bind to the IFNα/β promoters and initiate 
transcription of the IFNα/β genes. Although viral infection is sensed in 
hepatocytes, HCV antagonises IFN production at multiple levels (Lau et al., 
2008; Loo et al., 2006). The viral protease NS3/4A has been reported to target 
and cleave IPS-1, blocking downstream signalling of IFNβ (Bellecave et al., 2010; 
Li et al., 2005c; Meylan et al., 2005). In addition, NS3/4A cleaves TRIF, which is 
essential for TLR3-dependent signalling (Li et al., 2005b). 
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Figure 1.10 - Activation of the interferon response triggered by the detection of viral 
pathogen-associated molecular patterns (PAMPs). All of the pattern-recognition receptors 
(PRRs) initiate signalling pathways that converge at the activation of the transcription 
factors interferon (IFN)-regulatory factor 3 (IRF3), IRF7 and/or nuclear factor-κB (NFκB); this 
leads to the expression of IFNβ. IFNβ then initiates an antiviral effector programme in the 
infected cell and neighbouring cells, which involves the expression of numerous IFN-
stimulated genes (ISGs). Some of the ISGs, such as RIG-I (retinoic-acid-inducible gene I), 
MDA5 (melanoma differentiation-associated gene 5), DAI (DNA-dependent activator of IRFs), 
some microRNAs and the TRIM (tripartite motif-containing) family of proteins, are involved 
in the amplification and regulation of the IFN response. Other ISGs, such as 2′5′-
oligoadenylate synthetase (OAS) and ribonuclease L (RNaseL), IFN-inducible dsRNA-
dependent protein kinase (PKR), myxovirus resistance (Mx) protein, adenosine deaminase 
RNA-specific (ADAR) and apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 3 
(APOBEC3), are involved in antiviral mechanisms that interfere with the life cycle of 
individual viruses. IFNAR1, interferon-α receptor; IPS1, IFNB-promoter stimulator 1; ISG15, 
IFN-stimulated protein of 15 kDa; MD2, myeloid differentiation protein 2; PPP, 5′ 
triphosphate; ssRNA, single-stranded RNA; STAT, signal transducer and activator of 
transcription; TLR, Toll-like receptor. Extracted from Bowie & Unterholzner, 2008. 
Patricia Domingues  Chapter 1 
61
II. IFN signalling pathways and their targeting by HCV infection 
IFNα/β signal through a common heterodimer receptor (IFNAR1 and IFNAR2) 
which is expressed in most tissues. The intracellular domains of these two 
receptors are associated with the Janus protein tyrosine kinases (Jak PTKs), Tyk2 
and Jak1, respectively (Figure 1.11). Activation of Jak1 and Tyk2 kinases 
phosphorylates IFNARs and leads to the recruitment and phosphorylation of 
“signal transducers and activators of transcription” (STATs) family members. 
Activation of STAT heterodimers (STAT1 and STAT2) by IFNα/β mediates 
recruitment of the IFN-regulatory factor 9 (IRF9) to form the IFN-stimulated 
gene factor 3 (ISGF3) complex (STAT1-STAT2-IRF9). This complex translocates 
into the nucleus and binds to IFN-stimulated response elements (ISREs) located 
in gene promoters to activate the transcription of hundreds of ISGs (IFN-
stimulated genes). Most of the type I ISGs encode proteins with antiviral 
activities, such as MxA guanosine triphosphatase, double-stranded RNA-activated 
protein kinase (PKR), 2’-5’ oligoadenylate synthetase (2’-5’OAS), RNase L, 
inducible nitric oxide synthase (iNOS/NOS-2), indoleamine 2,3-dioxygenase 
(IDO), IFN-stimulated gene 15 (ISG15), GTPase Mx1 (myxovirus resistance 1), and 
others. Additionally, ISG products can mediate immunomodulatory, metabolic 
and proapoptotic actions that suppress virus infection and stimulate the 
adaptive immune response (Pasare & Medzhitov, 2004; Stetson & Medzhitov, 
2006). During acute HCV infection, IFNβ is secreted by infected cells and leads 
to a strong induction of ISGs. Some of these gene products have been suggested 
to have direct anti-HCV activities, such as PKR, ISG56, ISG20, ADAR1 and viperin 
(Horner & Gale, 2009). 
While NS3/4A is involved in blocking IFN induction by cleaving signalling 
molecules, other viral proteins have been reported to antagonize IFN signalling 
by targeting the Jak/STAT pathway and blocking the expression of ISGs (Bode et 
al., 2007). In general, expression of HCV proteins seems to be associated with 
inhibition of STAT1 activities or degradation of STAT1 and disruption of ISG 
transcription (Blindenbacher et al., 2003; Heim et al., 1999; Lin et al., 2005). 
Other studies have demonstrated that core protein in particular is capable of 
interferering with STAT1 activation or with its ability to interact with the ISGF3 
complex (de Lucas et al., 2005). However, the exact mechanism by which core 
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interferes with STAT1 activities is still not understood. Expression of core has 
also been associated with increased expression of “suppressor of cytokine 
signalling-3” (SOCS3) (Bode et al., 2003). SOCS3 belongs to a family of proteins 
involved in negative regulation of Jak/STAT signalling. Induction of SOCS3 by 
core is thought to impair Jak-dependent activation of STATs and consequently 
antagonise IFN actions. HCV proteins have also been shown to directly 
antagonise expression or function of ISGs. Activation of the antiviral protein 
kinase PKR by dsRNA leads to the phosphorylation of the eukaryotic initiation 
factor 2α (eIF2α). This PKR-mediated phosporylation mediates inhibition of 
translation, cellular proliferation and induces apoptosis in infected cells (Gil et 
al., 2006). It has been suggested that HCV E2 and NS5A target activation and the 
downstream effects of PKR. Unglycosylated forms of E2 protein have been 
reported to interact with PKR and block PKR-mediated phosphorylation of eIF2α, 
preventing IFN-induced shut-down of translation (Pavio et al., 2002; Taylor et 
al., 1999). In addition, NS5A also confers suppression of PKR activation. NS5A is 
thought to directly interact with PKR through the IFN sensitivity-determining 
region (ISDR) at the C-terminus of the protein (Gale et al., 1997). Blocking PKR 
activity correlates with the degree of IFN-resistance in infected patients 
undergoing IFN-based treatment. However, this correlation in patients is 
apparently inconsistent and requires further in vivo validation. 
Patricia Domingues  Chapter 1 
63
 
Figure 1.11 - Interferon mediated signalling pathways. The action of the interferons is 
mediated through three receptor complexes. Type I IFNs bind to a heterodimer of IFNα 
receptor 1 (IFNAR1) and IFNAR2; IFNλ subtypes bind to the interleukin-10 receptor 2 (IL-
10R2) and IFNLR1 (IFNλ receptor heterodimer 1); and a tetramer consisting of two IFNGR2 
(IFNγ receptor 2) chains and two IFNGR1 chains recognises dimers of the type II IFNγ. 
Extracted from Sadler & Williams, 2008. 
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1.5.1.2 Natural Killer (NK) cells and HCV infection 
NK cells are unique lymphocytes of the innate immune system which are 
critical for controlling viral infection. They are enriched in human liver, have 
cytotoxic potential and can secrete several cytokines, such as tumour necrosis 
factor-α (TNFα) and IFNγ (Doherty et al., 1999; Ferlazzo et al., 2002). 
Additionally, NK cells can cross-talk with dendritic cells, which is essential for 
regulation of adaptive responses (Gerosa et al., 2002). NK cells express surface 
binding proteins (killer cell immunoglobulin-like receptors or KIRs) that can bind 
to ligands on the surface of most cells. Activation of NK cells and their functions 
in controlling infection are regulated by both activating and inhibitory KIRs and 
their corresponding HLA ligands. 
NK cells have been reported to play a role in innate immune responses 
during HCV infection (Cheent & Khakoo, 2011). However, the level of NK cell 
responsiveness is dependent on genetic factors and correlates with HCV 
clearance (Khakoo et al., 2004). HCV is able to interfere with NK antiviral 
functions through E2 interaction with the CD81 receptor on NK cells. This 
interaction inhibits NK function and results in decreased IFNγ production (Crotta 
et al., 2002; Tseng & Klimpel, 2002). However, in the context of infectious 
virions, efficient crosslinking of E2 with CD81 on NK cells has not been observed 
and in vitro exposure of NK cells to high concentrations of HCVcc did not impair 
their functions (Yoon et al., 2009). More recently, Amadei et al (2010), also 
demonstrated that NK cells are activated during the acute phase of HCV 
infection and can more strongly produce IFNγ and exert cytotoxicity, than in 
uninfected controls (Amadei et al., 2010). 
1.5.1.3 Dendritic cells and HCV infection 
Dendritic cells (DCs) are specialised, antigen-presenting cells of the innate 
immune system, that are able to link and regulate innate and adaptive immune 
systems. They are often regarded as sentinels that capture antigens on the 
periphery of different tissues. Processing of these antigens results in their 
presentation in the context of major histocompatibility complex molecules 
(MHC) to either T- or B-cells (Steinman, 2001). DCs comprise different forms and 
subsets, including plasmocytoid-DCs (pDCs) and myeloid-DCs (mDCs). DCs express 
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a variety of PRRs, such as TLRs, through which they sense and process viral 
antigens and become active (Creagh & O'Neill, 2006). Activation of mDCs leads 
to the production of interleukins -12 and -15 (IL-12 and IL-15), which can induce 
the expression of IFNγ in NK cells and promote CD4+ T-cell differentiation. By 
contrast, pDCs are important effectors of the innate responses to viral 
infections, as they are the major source of type I IFNs in the body and can 
produce large amounts of IFNα (Liu et al., 2009a). 
The frequency and number of DC subsets in the blood and their ability to 
produce IFNα is lower in patients infected with HCV, when compared with 
uninfected individuals (Longman et al., 2005; Ulsenheimer et al., 2005). By 
contrast, other studies have shown normal levels of IFNα expression by DCs in 
chronic HCV-infected patients (Decalf et al., 2007). The reasons for the 
discrepancy in these correlations are still not clear. IL-12 secretion by mDCs has 
been shown to be defective in cells obtained from HCV-infected patients (Della 
Bella et al., 2007; Dolganiuc et al., 2006; Kanto et al., 2004). Instead, these 
cells secrete enhanced levels of IL-10, which in turn results in suppression of IL-
12 and IFNα production in mDCs. Suppression of cytokines results in defective 
activation and proliferation of T-cells, allowing HCV to persist. Moreover, in 
vitro studies using the HCVcc system demonstrated that increased IL-10 
expression in infected DCs also resulted in loss of their ability to stimulate CD4+ 
or CD8+ T-cell responses (Saito et al., 2008a). 
1.5.2 Adaptive immune responses 
Elimination of viruses requires, in the majority of cases, coordination of 
multiple immune mechanisms and activation of strong adaptive immunity. 
Contrary to innate responses, adaptive immune responses take several weeks to 
develop in infected patients. These responses are divided into two major arms, 
humoral immunity (mediated by antigen-specific B-cells) and cellular immunity 
(mediated by T-cells). 
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1.5.2.1 Cellular immunity 
Cellular immune responses are mediated by helper or CD4+ T-cells and 
cytolytic or CD8+ T-cells. CD8+ cells are the main effector cells and eliminate 
viral infections through cytolytic (secretion of perforin and granzymes) and 
noncytolytic (secretion of cytokines such as IFNγ and TNFα) mechanisms. CD4+ or 
helper cells are so-called because their main function is to ensure optimal 
responses by other T-cells (such as CD8+ T-cells), B cells and other phagocytes to 
mount a strong response against infection (Swain et al., 2011). Activation of T-
cells is mediated through the recognition of virus-derived peptides, which are 
displayed by the major histocompatibility complexes I and II (MHC I and II; also 
known as HLA when referred to humans) on the surface of antigen presenting 
cells (Neefjes et al., 2011). MHC I molecules are present in most cells and are 
recognised, along with the antigens they present, by CD8+ T-cells. MHC II 
molecules are mainly found in specialised cells, such as dendritic cells, 
macrophages and B cells, and are mainly recognised by CD4+ T-cells. 
During acute HCV infection, T-cell-mediated responses are delayed and 
CD4+ and CD8+ T cells subsets only detected at 8-12 weeks after infection 
(Thimme et al., 2002; Thimme et al., 2001). However, these responses have 
been implicated in successful control of infection and clearance of virus. 
Immunisation of chimpanzees with viral proteins (non-structural proteins which 
are not normally targeted by neutralising antibodies) resulted in protection 
against infection (Folgori et al., 2006). Additionally, animal studies showed that 
depletion of CD4+ or CD8+ T-cells resulted in prolonged or persistent infection 
upon challenging the animals with HCV (Grakoui et al., 2003; Shoukry et al., 
2003). 
CD8+ T-cell responses target multiple epitopes in all viral proteins 
(structural and non-structural) (Cooper et al., 1999). Although the respective 
role of CD4+ and CD8+ subsets in viral clearance is not fully understood, 
cooperation between CD4+ and CD8+ T-cells is known to be required for 
clearance of infection. Several studies have suggested that self-limiting acute 
HCV infection is associated with strong and multispecific (8-12 epitopes) CD8+ T-
cell responses (Gruner et al., 2000; Lechner et al., 2000). Similarly, strong and 
multispecific CD4+ T-cell responses is a major determinant for resolution of 
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infection. Moreover, HCV-specific CD4+ T-cells are important for the outcome of 
infection, as loss of CD4+ helper activity has been associated with poor CD8+ T-
cell function (Kaplan et al., 2007; Urbani et al., 2006). Additionally, depletion of 
CD4+ T-cells from chimpanzees resulted in failure of CD8+ T-cell-mediated 
control of HCV infection (Grakoui et al., 2003). By contrast, progression of HCV 
infection into a chronic stage is associated with either weak or mono-specific 
CD4+ or CD8+ T-cell responses (Missale et al., 1996; Thimme et al., 2001). 
Despite the multispecificity of T cell-mediated responses, persistence of 
HCV infection and progression towards chronicity is common. Emergence of 
viruses with escape mutations has been proposed to be the main mechanism of 
evasion of CD4+ and CD8+ mediated responses (Petrovic et al., 2012). For 
instance, animal studies have demonstrated that amino acid substitutions in HCV 
epitopes inhibited CD4+ and CD8+ T-cell recognition and escaped T-cell-
mediated responses, whereas those with no substitutions, efficiently cleared 
infection (Erickson et al., 2001; Meyer-Olson et al., 2004). 
1.5.2.2 Humoral immunity 
Humoral immune responses are activated by the recognition of viral 
antigens and are mediated by antibodies. Acute HCV infection is accompanied by 
the production of virus-specific antibodies. Similar to cellular immune responses, 
appearance of virus-specific antibodies is delayed in acute infection, notably 8 
to 20 weeks after initiation of viral replication (Logvinoff et al., 2004). 
Antibodies generated during infection can target all viral proteins, however the 
majority of antibodies with virus-neutralising activities are mapped against the 
viral envelope proteins (E1 and E2) (Choo et al., 1994). 
Although initial studies in chimpanzees demonstrated that serum from HCV-
infected animals could neutralise virus infectivity in vitro and protect animals 
against challenge with HCV (Farci et al., 1994), direct evidence supporting the 
involvement of antibody-mediated clearance of infection is sparse. Resolution of 
HCV infection has been observed in both chimpanzees and humans without 
seroconversion (Christie et al., 1997; Cooper et al., 1999; Post et al., 2004). By 
contrast, in a single-source outbreak of HCV comprising young healthy females 
infected with the same HCV genotype, viral clearance was associated with rapid 
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induction of neutralizing antibodies in the early phase of infection (Pestka et al., 
2007). After resolution of infection, this antibody response was lost. Chronic HCV 
infection was accompanied by delayed induction of neutralizing antibodies and 
reduced or lack of capacity to neutralize the virus at early stages of infection 
(Pestka et al., 2007). However, from this study there were no data on cellular 
responses and it was not clear whether the neutralizing antibodies had a central 
role in resolving infection or it was associated with strong cellular immune 
responses. 
Despite the presence of neutralizing antibodies, persistent infection can be 
explained by several mechanisms, including the circulation of highly variable 
viral genomes (quasispecies) and continuous selection of escape variants, 
association of HCV glycoproteins with HDL proteins, direct cell-to-cell transfer of 
virus and glycosylation of E1/E2 proteins to shield neutralizing antibodies 
(Edwards et al., 2012). 
1.6 Interferon stimulated gene 15 
The biological response of IFNs against viral infections involves the 
upregulation of hundreds of interferon-stimulated genes (ISGs). One of the most 
strongly induced genes upon type I IFN stimulation is ISG15. ISG15 was identified 
more than 30 years ago by Farrell et al, (1979) as a 15KDa protein induced 
following IFN stimulation of Ehrlich ascites tumour cells (Farrell et al., 1979). In 
1986, the first human sequence of ISG15 was cloned from IFN-treated Daudi cells 
(Blomstrom et al., 1986). Further studies indicated that the full-length mRNA 
sequence encoded a polypeptide of 165 amino acids, generating a protein of 
about 18KDa (Reich et al., 1987). In the same year, Haas et al reported the 
induction of a low molecular weight protein following IFN treatment of A549 and 
murine L929 cells (Haas et al., 1987). They demonstrated that this protein 
reacted with antibodies against ubiquitin and named it ubiquitin cross-reactive 
protein (UCRP). Further analysis revealed, that the UCRP and ISG15 sequences 
were identical, thus identifying ISG15 as the first member of new family of 
ubiquitin-like proteins (Loeb & Haas, 1992). 
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1.6.1 ISG15, an ubiquitin-like protein 
ISG15 is expressed as an inactive precursor protein of 165 aa in length. The 
maturation process of ISG15 is mediated by proteolytic cleavage of the 8 C-
terminal amino acids (Potter et al., 1999). This cleavage exposes a C-terminal 
LRLRGG motif which is conserved in the mature form of ubiquitin (ub) protein 
and other ubiquitin-like proteins (ubls), such as SUMO and NEDD8 (Haas et al., 
1987). As with other members of this family of proteins, ISG15 is capable of 
conjugating to other proteins through the C-terminal LRLRGG motif (Loeb & 
Haas, 1992). The structure of ISG15 consists of two ubiquitin-like domains, each 
of which exhibit approximately 30% homology with ub (Loeb & Haas, 1992) 
(Figure 1.12). The crystal structure of ISG15 was solved by Narasimhan et al 
(2005), and demonstrated that each domain folds into a β-grasp structure, with 
5 β-sheets and 1 α-helix, connected by a 6 residue extended linker (hinge 
region) (Narasimhan et al., 2005). Each ISG15 domain also shares a similar 3-
dimensional structure with ub and two other ub-like modifiers, NEDD8 and SUMO 
(Narasimhan et al., 2005). The two ISG15 domains, although essential for ISG15 
conjugation, have different roles in this process. The N-terminal domain of ISG15 
is required for the efficient E3 ligase-mediated transfer of ISG15 from the E2 
enzyme UbCH8 to its substrates, but is dispensable for the activation and trans-
thiolation steps (Chang et al., 2008). On the other hand, the C-terminal domain 
of ISG15 is sufficient to link ISG15 to the E1 enzyme UbE1L and the E2 enzyme 
UbCH8 (Chang et al., 2008). 
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Figure 1.12 – ISG15 structure. [A] ISG15 is expressed as a precursor protein (17KDa) which 
is further processed by specific proteases to yield the mature, 15KDa protein. ISG15 
contains two ubiquitin-like (UBL) domains, each of which sharing 29% and 31% sequence 
homology with ubiquitin, respectively. The C-terminal UBL encodes the conserved di-Gly 
residues similar to ubiquitin and other ubiquitin-like proteins. [B] ISG15 secondary 
structure. Upper panel is represented a ribbon diagram of ISG15 showing two separate 
domains, with colour ramped from blue (N-terminus, N) to red (C-terminus, C) through green 
(Hinge). The two ubiquitin-like domains (each in β-grasp fold) are oriented differently and 
connected by a hinge. Lower panel shows an overlay of ribbon diagrams for ubiquitin (pink) 
with the N- (blue) and C-terminal (green) domains of ISG15 to emphasize the marked 
similarities in their respective β-grasp folds. Adapted from Narasimhan et al (2005). 
 
Similar to ubiquitination, ISG15 conjugation (ISGylation) is a 3-step process 
that requires a sequential action of multiple enzymes, involving activation, 
conjugation and ligation that are performed by E1, E2 and E3 enzymes 
respectively (Figure 1.13). The ISG15 activating enzyme is the Ub-activating E1-
like protein UbE1L (also known as UbA7) (Yuan & Krug, 2001). Cells or mice 
lacking UbE1L fail to form ISG15 conjugates upon stimulation, indicating that 
UbE1L is required for ISGylation (Kim et al., 2006; Malakhov et al., 2003; Yuan & 
Krug, 2001). UbE1L charges ISG15 by forming a high-energy thiolester 
intermediate and then transfers ISG15 and the thiolester linkage to the 
subsequent E2 enzymes. The E2 conjugating enzymes involved in ISGylation are 
UbcH8 and UbcH6 (Kim et al., 2004a; Takeuchi et al., 2005; Zhao et al., 2004). 
These enzymes also participate in Ub conjugation, indicating possible cross-talk 
between ISGylation and ubiquitination. E2 enzymes subsequently transfer ISG15 
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to specific E3 ligases, which in turn mediate the formation of an isopeptide bond 
between ISG15 and the ε-amino group of lysine residues of the target proteins. 
To date, three E3 ligases have been identified for ISG15: the HECT domain and 
RCC1-like domain containing protein 5 (HERC5) (Dastur et al., 2006), the 
estrogen-responsive finger protein EFP (also known as TRIM25) (Zou & Zhang, 
2006) and the human homolog of Drosophila ariadne (HHARI) (Okumura et al., 
2007). In contrast to EFP and HHARI, which target ISG15 to specific proteins (14-
3-3σ and 4EHP proteins, respectively), HERC5 does not have strong substrate 
specificity and mediates conjugation of ISG15 to the majority of substrates. 
siRNA-mediated knockdown of HERC5 abrogated the majority of ISG15 
conjugates, confirming its role as a major E3 ligase for ISG15 (Dastur et al., 
2006). 
As with ub, ISG15 can be removed from conjugated proteins through the 
action of deconjugating or deubiquitination enzymes (DUBs). In the case of ub, 
multiple proteins have deconjugation activity, but with ISG15 only one protein, 
UBP43 (or USP18), possesses deconjugation activity in vitro (Malakhov et al., 
2002). Other ubiquitin-specific DUBs have been suggested to possess de-
ISGylation activities (e.g. USP2, USP5, USP13, and USP14), although with lower 
affinity than UBP43 (Catic et al., 2007). The components of the ISGylation 
system identified so far, including UbE1L, UbcH6/8, HERC5, EFP and UBP43, are 
all inducible by IFN. 
Given the role of ub in protein degradation, it was initially thought that 
ISG15 could influence protein turnover. In a study reported by Liu et al, (2003), 
treatment with proteasome inhibitors (MG132 or lactacystin) resulted in 
increased levels of ISG15 conjugates (Liu et al., 2003). Using ATP-depleting 
agents in cells treated with proteasome inhibitors, they were able to show that 
the increase in ISG15 conjugates, but not ubiquitin conjugates, was dependent 
on the presence of ATP. Thus, the formation of ISG15 conjugates in the presence 
of proteasome inhibitors required de novo ISGylation, indicating that ISG15 does 
not mark proteins for degradation through the proteasome pathway (Liu et al., 
2003). Instead it is thought that ISG15 conjugation may alter subcellular 
localization, structure, stability or activity of target proteins (Yeh et al., 2000). 
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Figure 1.13 – Conjugation of ISG15 to target proteins (ISGylation). The expression of ISG15, 
the E1-activating enzyme UBE1L, multiple E2-conjugating enzymes (e.g. UBCH8) and E3-
ligase enzymes (e.g. HERC5) is coordinately induced by type I IFNs through IFN-stimulated 
response elements (ISREs). E1, E2 and E3 proteins sequentially catalyse the conjugation of 
ISG15 to numerous protein substrates to modulate pleiotropic cellular responses to inhibit 
virus production. ISGylation is reversibly regulated by ISG15 specific-proteases (USP18), 
which are also induced by IFNs. Extracted from Sadler & Williams, 2008. 
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1.6.2 ISG15 gene expression 
Induction of ISG15 expression is primarily triggered by type I IFNs. The 
ISG15 promoter region contains two IFN-stimulated response elements (ISREs), 
similar to all genes induced by type I interferons (Reich et al., 1987). ISG15 
expression is also triggered by different cell stress or stimuli, in particular those 
induced by viral or bacterial infections but also treatment with retinoic acid, 
campothecin and following irradiation. Some of these stresses activate 
transcription factors, such as IRF-3 and ISGF3, which can directly bind and 
activate the ISG15 promoter and upregulate expression of ISG15 (Mossman et al., 
2001; Nicholl et al., 2000). Given that IRF-3 can activate ISG15 transcription, 
ISG15 can also be produced in an IFN-independent manner following activation 
of cytoplasmic sensors with dsRNA (Memet et al., 1991). In addition, 
lipopolysccharide (LPS) has been demonstrated to strongly stimulate ISG15, via 
the IRF-3 or p38 MAP kinase and NF-kB activation pathways (Li et al., 2001; 
Malakhova et al., 2002; Manthey et al., 1998). 
The ISG15 promoter region contains also a PU.1 binding site. Therefore, 
ISG15 expression can also be induced by PU.1, a B- and myeloid-cell specific 
transcriptor factor, which overlaps with the ISG15 ISRE sequence (Meraro et al., 
2002). Shortening of telomere length also regulates ISG15 expression. Lou et al 
(2009) demonstrated that ISG15 expression, both mRNA and protein, is linked 
with telomere length and that expression increases with short telomeres (Lou et 
al., 2009). However, the mechanisms by which this activation is regulated and 
its functional consequences are not well understood. 
ISG15 and its conjugates are highly expressed in several tumor tissues and 
cell lines (Andersen et al., 2006; Desai et al., 2006). For example, ISG15 
expression is increased in bladder cancers compared with normal bladder tissue, 
and this expression positively correlates with the degree of tumor progression 
(Andersen et al., 2006). Interestingly, in breast cancer cell lines, the increased 
levels of ISG15 were found to be associated with decreased levels of 
polyubiquitinated proteins/degradation (Desai et al., 2006). Silencing of ISG15 in 
these cells increased the levels of polyubiquitinated proteins, suggesting an 
antagonistic role of ISG15 in regulating ubiquitin-mediated protein degradation 
(Desai et al., 2006). 
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1.6.3 Biological function of ISGylation 
The identification of the protein targets for ISGylation is fundamental to 
elucidate the biological role of ISG15 protein modification. Using a combination 
of affinity purification and mass spectrometry, several groups have identified 
some of the target proteins for ISGylation (Giannakopoulos et al., 2005; 
Malakhov et al., 2003; Zhao et al., 2005). A large number of those proteins 
function in diverse cellular pathways, including translation, glycolysis, cell 
motility, protein modification, intracellular protein trafficking, RNA splicing, 
chromatin remodelling, cytoskeletal organization, and stress responses 
(Giannakopoulos et al., 2005; Malakhov et al., 2003; Zhao et al., 2005). Other 
ISG15-modified proteins are involved in type I IFN signalling pathways, such PKR, 
MxA, RIG-I, PLCγ1, JAK1, ERK1 and STAT1 (Malakhov et al., 2003; Zhao et al., 
2005), suggesting a role of protein ISGylation in type I IFN-induced immune 
responses. 
1.6.3.1 Regulation of immune responses by ISG15 
Upon interferon treatment, ISG15 can be detected both in the free and 
conjugated forms. Several observations have indicated a role of ISG15 and 
ISGylation in regulating immune responses. For example, RIG-I was identified as 
a target protein for ISGylation (Kim et al., 2008; Zhao et al., 2005). ISGylation of 
RIG-I results in reduced levels of basal and virus-induced IFN production. In 
addition, cells lacking the ISG15 UbE1L enzyme showed higher levels of RIG-I 
protein than normal cells. Based on these observations, ISG15 conjugation of 
RIG-I is suggested to function as negative feedback loop which regulates RIG-I 
mediated signalling to maintain a balance between innate immune response and 
hypersensitivity during antiviral response. On the other hand, ISG15 can also 
positively regulate IFN signalling pathways through the ISGylation of IRF-3. 
ISGylation of this factor was shown to prevent its ubiquitination and 
degradation, indicating a positive feedback mechanism for the induction of the 
host antiviral response by ISGylation-dependent stabilization of IRF-3 (Lu et al., 
2006). 
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Additionally, free ISG15 is secreted from cells possibly to act as a cytokine 
or chemokine. This secreted form of ISG15 stimulates IFNγ production in cells 
expressing T-cell surface receptor-associated molecules, such as CD3, CD4, and 
CD8 (Recht et al., 1991). Moreover, secreted ISG15 stimulates neutrophil 
recruitment, maturation of dendritic cells and differentiation and proliferation 
of NK cells (D'Cunha et al., 1996a; Owhashi et al., 2003). 
1.6.3.2 Antiviral activities of ISG15 
The strong induction of ISG15 in response to IFN treatment or viral 
infection suggests a role for ISG15 in antiviral defence. Although initial studies in 
mice lacking ISG15 or UBE1L revealed no apparent defect in defence against 
vesicular stomatitis virus (VSV) and lymphocytic choriomeningitis virus (LCMV) 
(Kim et al., 2006; Osiak et al., 2005), a growing body of work strongly suggests a 
role for ISG15 in defence against other viral pathogens. 
I. Sindbis virus 
Evidence for the involvement of protein ISGylation in antiviral response 
came from studies using recombinant chimeric Sindbis virus systems. Mice 
lacking the IFNα/β receptor (IFNα/β R¯/¯) abrogated the expression of ISG15 and 
ISG15 conjugates and were more susceptible to Sindbis virus infection, when 
compared to normal mice (Lenschow et al., 2005). Moreover, this antiviral 
effect of ISG15 on virus infection was shown to be dependent on its ability to 
conjugate to target proteins. Overexpression of the ISG15-LRLRGG protein (i.e. 
the mature form of ISG15) attenuated viral infection in IFNα/β R¯/¯ mice, 
whereas expression of a mutant (LRLRAA) ISG15 form abrogated the antiviral 
effect of the protein (Lenschow et al., 2005). Later, the same group using ISG15 
knockout mice, showed that the gene is important for resistance to not only 
Sindbis virus infection, but also to infections with influenza A and B viruses, 
herpes simplex virus 1 and murine gamma herpesvirus 68 (Lenschow et al., 
2007). Consistent with these observations, another group showed that mice 
lacking UbE1L are more susceptible to infection with Sindbis virus 
(Giannakopoulos et al., 2009). In addition, mutation of a critical residue (Arg 
151) for the interaction of ISG15 with UbE1L, abrogated the antiviral effect of 
ISG15 (Giannakopoulos et al., 2009). Together, these studies suggest an 
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important role for protein ISGylation in antiviral defence against Sindbis virus 
infection and other viruses. 
II. Ebola virus and HIV-1 
As with many viruses, type I IFNs can inhibit viral replication. 
Overexpression of ISG15 and the activating enzyme UbE1L, can mimic the IFN-
mediated inhibition of human immunodeficiency virus 1 (HIV-1) assembly and 
release (Okumura et al., 2006). Overexpression of ISG15 alone without UbEL1 
was not inhibitory, indicating that ISG15 conjugation is required for its effects on 
HIV-1 release. Moreover, HIV-1 released from ISG15-expressing cells was rescued 
by expression of the ISG15 deconjugating enzyme, UBP43 (USP18) (Okumura et 
al., 2006). In addition, expression of UbEL1 or UbEL1 and ISG15 inhibits the 
ubiquitination of HIV-1-encoded Gag polypeptide and the cellular factor Tsg101, 
which results in disruption of the Gag-Tsg101 interaction and consequently 
prevention of assembly and release of HIV-1 virions from infected cells (Okumura 
et al., 2006). Furthermore, siRNA-mediated silencing of ISG15 during IFN 
treatment enabled HIV-1 release (Okumura et al., 2006). 
Similar to HIV-1, overexpression of ISG15 or UbE1L and UbcH8, also resulted 
in inhibition of budding of the Ebola virus VP40 virus-like particles (VLPs) 
(Okumura et al., 2008). Efficient release of VP40 VLPs requires interactions with 
host proteins such as Tsg101 and Nedd4, an E3 ubiquitin ligase. IFN treatment or 
expression of ISG15 were shown to significantly inhibit the release of virus 
particles via the VP40 pathway (Malakhova & Zhang, 2008; Okumura et al., 
2008). ISG15 covalently bound to and negatively regulated Nedd4 Ub-E3 ligase 
activity (Malakhova & Zhang, 2008; Okumura et al., 2008). This interaction 
between ISG15 and Nedd4 was shown to prevent ubiquitination of Ebola VP40 
protein and subsequent VP40-mediated virus production from the cells 
(Malakhova & Zhang, 2008; Okumura et al., 2008). Transfection of ISG15-specific 
siRNAs rescued budding of VP40 VLPs (Okumura et al., 2008). Together, these 
observations confirmed a direct inhibitory role of ISG15 on Ebola VP40 VLP 
budding. 
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III. Influenza viruses 
As mentioned above ISG15 knock-out mice are more susceptible to 
infection by several viruses, including influenza A and B viruses (Lenschow et al., 
2007). Inhibition of UbE1L and UbcH8, the ISG15 E1 and E2 enzymes, in A549 
cells resulted in inhibition of ISG15 conjugates, which significantly alleviated the 
IFN-induced antiviral activity against influenza A virus (Hsiang et al., 2009). 
Distinct from its effects on late stages of HIV-1 and Ebola virus replication, the 
antiviral effect of ISG15 on influenza A was evident predominantly at early times 
of infection (Hsiang et al., 2009). The antiviral mechanism of ISG15 against 
influenza A virus was suggested to result from its interaction and inhibition of 
one of the viral proteins, NS1 (Tang et al., 2010; Zhao et al., 2010). 
Similar to these observations on influenza A virus, mice lacking the ISG15 
UbE1L enzyme were more susceptible to influenza B virus infection, indicating 
that ISG15 antiviral activity to both influenza A and B viruses is mediated 
through its ability to form conjugates (Lai et al., 2009). The NS1 protein from 
influenza B virus (NS1B) was shown to bind ISG15, and NS1B-ISG15 interaction 
resulted in inhibition of ISG15 conjugation activities and alleviation of viral 
replication (Yuan & Krug, 2001). 
IV. HCV 
ISG15 has been proposed to have dual activities during HCV infection. 
Initial studies aimed at identifying predictors of host response to therapy 
revealed that expression of a subset of ISGs, including MxA, PKR, 2’5’-OAS, 
ISG15, and interleukin 8, were significantly upregulated in chronically infected 
HCV patients prior to starting therapy (MacQuillan et al., 2003). In addition, 
patients who fail to respond to therapy have higher levels of ISG15 gene 
expression as well as other genes involved in the ISGylation system, such as 
UPB43 (USP18), when compared with liver tissue from patients who do respond 
(Randall et al., 2006). In vitro studies demonstrated that siRNA-mediated 
silencing of USP18, which results in an increase in ISG15 conjugates, potentiated 
the ability of IFN to inhibit HCV RNA replication and virus production (Randall et 
al., 2006). Consistent with this idea, Kim & Yoo (2010), demonstrated that 
expression of ISG15 and the ISG15 conjugation machinery resulted in inhibition 
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of HCV replication in cells harbouring a genotype 1b replicon (Kim & Yoo, 2010). 
In addition, they showed that ISG15 was able to conjugate to the wild-type, but 
not a mutant form of NS5A protein. These data suggested that the antiviral 
activity of ISG15 during HCV replication was mediated by ISGylation of the NS5A 
protein. Furthermore, cotransfection of ISG15 and ISG15 conjugation enzymes 
enhanced the IFN-mediated decrease of HCV replication (Kim & Yoo, 2010). 
By contrast, other studies suggested a proviral activity of ISG15 during HCV 
replication (Chen et al., 2010; Chua et al., 2009). In these studies, depletion of 
ISG15 or UbE1L expression by siRNAs, followed by IFNα treatment resulted in a 
reduction in HCV RNA levels and virus production (Chen et al., 2010; Chua et al., 
2009). Broering et al, (2010) also showed that siRNA silencing of ISG15 
suppressed HCV replication in both murine and human cells harbouring a 
genotype 1b replicon (Broering et al., 2010). Moreover, both silencing and over-
expression of ISG15 significantly decreased and increased, respectively, HCV 
replication in infected Huh-7.5 cells. Silencing of ISG15 during IFN, Ribavirin or 
IFN/Ribavirin treatment enhanced their antiviral effects on HCV replication 
(Broering et al., 2010). Together, these observations suggest that ISG15 is 
required for HCV replication and suppression of ISG15 expression results in 
decreased viral replication. 
1.7 Aims 
The aims of the project were divided into two lines of investigation. The 
first aim was to expand the existing in vitro model systems for studying HCV 
replication and infection. To that end, studies were initiated to explore the 
feasibility of developing a subgenomic replicon that included sequences from a 
HCV genotype 3a isolate (Glasgow-3 strain) and to expand analysis of viral RNA 
synthesis in an alternative permissive cell line. For the first approach, sequences 
in the highly efficient genotype 2a JFH1 subgenomic replicon were replaced with 
those from the Glasgow-3 strain. In the second approach, HepaRG cells, which 
are liver-derived cells that retain features of mature hepatocytes, were used to 
examine their ability to support viral RNA synthesis. 
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From a previous siRNA library screen, the interferon-stimulated gene ISG15 
was identified as a modulator of HCV RNA replication. Hence, the second part of 
the project was to focus on determining the contribution of ISG15 to clearance 
of HCV. Two cells lines that support HCV replication, Huh-7 and U2OS cells, were 
employed to examine the role of ISG15 using both siRNA- and shRNA-mediated 
gene knockdown in SGR and HCVcc-infected cells. Finally, the mechanism 
through which ISG15 modulates HCV infection was analysed. In these studies, the 
importance of ISG15 conjugation to its antiviral activity was examined along with 
whether ISG15 affected the rates of synthesis or degradation of viral RNA during 
replication. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Bacteria 
Cells Source 
XL10-Gold 
Ultracompetent  
QuickChange Lightning Site-directed mutagenesis 
(Stratagene) 
DH5α Chemical 
competent  
NEB 
2.1.2 Cells 
Cells Description Source 
Huh-7 Human hepatoma cell line Nakabayashi et al, 1982 
Huh-7.5 Human hepatoma cell line Blight et al, 2002 
HepaRG Human hepatocyte cell line Gripon et al, 2002 
U2OS Human osteosarcoma cell line American Type Culture 
Collection 
Huh-7 (5-15) Human hepatoma genotype 1b 
replicon cell line 
Lohmann et al, 2003 
HEK-293T Human Embryonic Kidney cell 
line 
American Type Culture 
Collection 
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2.1.3 Vectors 
Plasmid Source 
pGEM-T Easy Promega 
pCMV-FLAG-UbcH7 Dr. Emilia Vanni (CVR) 
pOTB7-ISG15 Gene services 
pLKO.dCMV.TetO.mcs Prof. Roger Everett (CVR) 
pLKOneo.CMV.EGFPnls.TetR Prof. Roger Everett (CVR) 
pLKO-shPML1 Prof. Roger Everett (CVR) 
2.1.4 Clones 
Plasmid Source 
pSGR-JFH1 Prof. Takaji Wakita (National Institute of Infectious 
Diseases, Japan) 
pSGR-Blast-JFH1 Dr. Arvind Patel (CVR) 
pSGR-luc-JFH1 Dr. John McLauchlan (CVR) 
pSGR-neo-luc-JFH1 Dr. John McLauchlan (CVR) 
pJFH1 Prof. Takaji Wakita (National Institute of Infectious 
Diseases, Japan) 
pJ6-JFH1 (JC-1) Dr. Arvind Patel (CVR) 
2.1.5 Cell culture growth media 
Huh-7, Huh-7.5, U2OS and HEK-293T cell lines were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Invitrogen Life Technologies), supplemented with 
10% foetal bovine serum (FBS), 100U/ml of penicillin and 100μg/ml of 
streptomycin. 
HepaRG cells were cultured in William’s E medium (WEM, Invitrogen Life 
Technologies), supplemented with 10% foetal bovine serum gold (PAA), 2mM L-
glutamine, 100U/ml of penicillin, 100μg/ml of streptomycin, 5μg/ml of insulin 
and 0.5μM hydrocortisone. 
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2.1.6 Antisera 
I. Primary Antibodies 
Dilution 
Antibody Type 
IF WB 
Source 
Anti-NS5A Sheep polyclonal 1:5000 1:1000 
Prof. Mark Harris 
(University of Leeds) 
Anti-dsRNA Mouse monoclonal N/A 1:200 Scicons (Hungary) 
Anti-ISG15 Mouse monoclonal N/A 1:100 
Dr. Ernest Borden 
(Cleveland Clinic 
Foundation, Ohio) 
Anti-ISG15 Rabbit polyclonal 1:50 1:50 Santa Cruz 
Anti-Phospho-
Stat1 (Tyr701) 
Rabbit 
monoclonal N/A 1:1000 Cell Signalling 
Anti-HERC5 Rabbit polyclonal N/A 1:1000 Enzo Life sciences 
Anti-Actin Mouse monoclonal N/A 1:1000 Sigma 
II. Secondary Antibodies 
Dilution 
Antibody Type 
IF WB 
Source 
Anti-mouse IgG-HRP Goat polyclonal 
N/A 1:2000 Sigma 
Anti-sheep IgG-HRP Goat polyclonal 
N/A 1:2000 Sigma 
Anti-rabbit IgG-HRP Goat polyclonal 
N/A 1:2000 Sigma 
Anti-rabbit-Alexa 
488 
Donkey 
polyclonal 
1:2000 N/A Invitrogen Life 
Technologies 
Anti-rabbit-Alexa- Donkey 1:2000 N/A Invitrogen Life 
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594 polyclonal Technologies 
Anti-sheep-Alexa-
488 
Donkey 
polyclonal 
1:2000 N/A Invitrogen Life 
Technologies 
Anti-sheep-Alexa-
594 
Donkey 
polyclonal 
1:2000 N/A Invitrogen Life 
Technologies 
2.1.7 Synthetic oligonucleotides 
The oligonucleotides represented in the following table, used for PCR 
amplification, SDM (site-directed mutagenesis) or Seqn (sequencing) analysis, 
were ordered from Sigma. 
Oligo name Use Forward/ Reverse Sequence (5’→3’) 
EcoRI-4B PCR Fwd ACCGAATTCGCCTCTAGGGCGGC
TCTCATC 
4B/5A-SacI PCR Rev GGTGAGCTCCTGTCAAGATGGTG
CAAACCC 
4B-M1 (SDM1) SDM Fwd CCAGAGGAAACCACGTCTCCCCTA
CTCACTACG 
4B-M1 (SDM1) SDM Rev CGTAGTGAGTAGGGGAGACGTGG
TTTCCTCTGG 
4B-M2 (SDM2) SDM Fwd CCTACTCACTACGTGCCGGAGTC
GGATGCG 
4B-M2 (SDM2) SDM Rev CGCATCCGACTCCGGCACGTAGT
GAGTAGG 
4B-M3 (SDM3) SDM Fwd CGGAGTCGGATGCGGCGGCGCG
TGTGACC 
4B-M3 (SDM3) SDM Rev GGTCACACGCGCCGCCGCATCCG
ACTCCG 
4B-M5 (SDM5) SDM Fwd CGTGTGACCCAACTACTTAGCTCT
CTTACTATAACC 
4B-M5 (SDM5) SDM Rev GGTTATAGTAAGAGAGCTAAGTA
GTTGGGTCACACG 
4B-M6 (SDM6) SDM Fwd GCCTACTCAGAAGACTCCACCAAT
GGATAACTGAGGACTGCCC 
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4B-M6 (SDM6) SDM Rev GGGCAGTCCTCAGTTATCCATTG
GTGGAGTCTTCTGAGTAGGC 
4B-M7 (SDM7) SDM Fwd CTCCACCAATGGATAAATGAGGA
CTGCCCCATC 
4B-M7 (SDM7) SDM Rev GATGGGGCAGTCCTCATTTATCC
ATTGGTGGAG 
4B-M8 (SDM8) SDM Fwd GGATAAATGAGGACTGCCCCTCC
CCATGCTCCGGATCCTGGC 
4B-M8 (SDM8) SDM Rev GCCAGGATCCGGAGCATGGGGAG
GGGCAGTCCTCATTTATCC 
4B-M9 (SDM9) SDM Fwd GCGGCGGCGCGTGTGACCGCACT
ACTTAGCTCTCTTAC 
4B-M9 (SDM9) SDM Rev GTAAGAGAGCTAAGTAGTGCGGT
CACACGCGCCGCCGC 
4B-M10 (SDM10) SDM Fwd CTACTTAGCTCTCTTACTGTAACC
AGCCTACTCAGAAGAC 
4B-M10 (SDM10) SDM Rev GTCTTCTGAGTAGGCTGGTTACA
GTAAGAGAGCTAAGTAG 
4B-M11 (SDM11) SDM Fwd CAATGGATAAATGAGGACTACCC
CTCCCCATGCTCCGG 
4B-M11 (SDM11) SDM Rev CCGGAGCATGGGGAGGGGTAGT
CCTCATTTATCCATTG 
4B-M8 (SDM8) SDM Fwd GGATAACTGAGGACTGCCCCTCC
CCATGCTCCGGATCCTGGC 
4B-M8 (SDM8) SDM Rev GCCAGGATCCGGAGCATGGGGAG
GGGCAGTCCTCAGTTATCC 
4B-M8 & M11 (only) SDM Fwd AATTGGATAACTGAGGACTACCC
CTCCCCATGCTCCGG 
4B-M8 & M11 (only) SMD Rev CCGGAGCATGGGGAGGGGTAGT
CCTCAGTTATCCAATT 
4B-M11/Δ8 SDM Fwd CAATGGATAAATGAGGACTACCC
CATCCCATGCTCCGG 
4B-M11/Δ8 SDM Rev CCGGAGCATGGGATGGGGTAGTC
CTCATTTATCCATTG 
PmeI/NcoI-NS3 PCR Fwd GTTTAAACCATGGCTCCGATCACA
GCATAC 
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NS3-SanDI PCR Rev GGGACCCAGTTGGAGCATGCAAG
TAC 
NS3_Mut/NcoI SDM Fwd GTTATGTGGACTGTCTATCATGG
TGCAGGCTCAAG 
NS3_Mut/NcoI SDM Rev CTTGAGCCTGCACCATGATAGAC
AGTCCACATAAC 
ISG15_HindIII PCR Fwd ACCAAGCTTATGGGCTGGGACCT
GAC 
ISG15/WT_XbaI/BamHI PCR Rev GGTGGATCCTCTAGATTAGCCTC
CCCGCAGGCGCAG 
ISG15/dN_XbaI/BamHI PCR Rev GGTGGATCCTCTAGATTAGGCTG
CCCGCAGGCGCAG 
Kozak-Flag PCR Fwd AAAAAGCTAGCTCTACCATGGACT
ACAAAGACG 
ISG15-seqn Seqn Fwd TGAAGCAGCAAGTGAGCGGG 
ISG15_His-HindIII1 PCR Fwd CACCATCACCACAAGCTTATGGGC
TGGGACCTGACG 
ISG15_NheI-Kozak-His2 PCR Fwd ACCGCTAGCTCTACCATGCATCAT
CACCATCACCAC 
HCV JFH1 probe qPCR probe AAAGGCCTTGTGGTACTG 
JFH1 qPCR Fwd qPCR Fwd TCTGCGGAACCGGTGAGTAC 
JFH1 qPCR Rev qPCR Rev GCACTCGCAAGCGCCCTATC 
2.1.8 siRNAs and shRNAs 
Scrambled negative control (siCtrl), human ISG15 (siISG15) and human 
HERC5 (siHERC5) siRNAs were supplied by Ambion (Applied Biosystems). 1nM of 
each siRNA was supplied by the manufacturer and resuspended in dH2O to yield a 
stock concentration of 100μM (siCtrl) or 50μM (ISG15 and HERC5 siRNAs). Each 
cellular gene was targeted by 3 siRNAs directed against different regions of the 
mRNA sequence. 
The designed shRNAs targeting different regions of the ISG15 mRNA were 
ordered from Sigma. The respective shRNA control was provided by Prof. Roger 
Everett. 
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Name Sequence 
siRNA Negative 
Control (siCtrl) Supplied by Applied Biosystems 
ISG15 siRNA 1 Supplied by Applied Biosystems 
ISG15 siRNA 2 Supplied by Applied Biosystems 
ISG15 siRNA 3 Supplied by Applied Biosystems 
HERC5 siRNA 1 Supplied by Applied Biosystems 
HERC5 siRNA 2 Supplied by Applied Biosystems 
HERC5 siRNA 3 Supplied by Applied Biosystems 
ISG15 shRNA 1 (sh1) 
gatccGCGCAGATCACCCAGAAGATTCAAGAGATCTTCTGGGTG
ATCTGCGCTTTTTTACGCGTg (5’→3’) 
gCGCGTCTAGTGGGTCTTCTAAGTTCTCTAGAAGACCCACTAG
ACGCGAAAAAATGCGCActtaa (3’→5’) 
ISG15 shRNA 2 (sh2) 
gatccGGCGCAGATCACCCAGAAGTTCAAGAGACTTCTGGGTG
ATCTGCGCCTTTTTTACGCGTg (5’→3’) 
gCCGCGTCTAGTGGGTCTTCAAGTTCTCTGAAGACCCACTAGA
CGCGGAAAAAATGCGCActtaa (3’→5’) 
ISG15 shRNA 3 (sh3) 
gatccGCGACGAACCTCTGAACATTTCAAGAGAATGTTCAGAGG
TTCGTCGCTTTTTTACGCGTg (5’→3’) 
gCGCTGCTTGGAGACTTGTAAAGTTCTCTTACAAGTCTCCAAG
CAGCGAAAAAATGCGCActtaa (3’→5’) 
ISG15 shRNA 4 (sh4) 
gatccGAACATCCTGGTGAGGAATTTCAAGAGAATTCCTCACCA
GGATGTTCTTTTTTACGCGTg (5’→3’) 
gCTTGTAGGACCACTCCTTAAAGTTCTCTTAAGGAGTGGTCCT
ACAAGAAAAAATGCGCActtaa (3’→5’) 
ISG15 shRNA 5 (sh5) 
gatccGCGGGCTGGAGGGTGTGCATTCAAGAGATGCACACCCT
CCAGCCCGCTTTTTTACGCGTg (5’→3’) 
gCGCCCGACCTCCCACACGTAAGTTCTCTACGTGTGGGAGGTC
GGGCGAAAAAATGCGCActtaa (3’→5’) 
ISG15 shRNA 6 (sh6) 
gatccGCACCGTGTTCATGAATCTTTCAAGAGAAGATTCATGAA
CACGGTGCTTTTTTACGCGTg (5’→3’) 
gCGTGGCACAAGTACTTAGAAAGTTCTCTTCTAAGTACTTGTG
CCACGAAAAAATGCGCActtaa (3’→5’) 
Ctrl shRNA (shCtrl) accgTTATCGCGCATATCACGCGTTCAAGAGACGCGTGATATGCGCGATAACTTTTTc (5’→3’) 
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2.1.9 Kits 
Kit Source 
KOD Hot Start DNA Polymerase kit Novagen 
TaqMan Reverse Transcription reagents Applied Biosystems 
QuickChange Lightning Site-directed 
mutagenesis kit Stratagene 
T7 RiboMax Express Large Scale RNA production 
system Promega 
PureLink HiPure plasmid Midi prep kit Invitrogen Life Technologies 
QIAquick gel extraction kit Qiagen 
RNeasy Mini Kit Qiagen 
RNeasy Midi Kit Qiagen 
RNeasy MinElute Cleanup Kit Qiagen 
uMACS Streptavidin Kit Miltenyi Biotech 
MaXtract 2ml Phase Lock High-density tubes Qiagen 
Luciferase assay system Promega 
Enhanced Chemiluminescence Plus Western 
Blotting Detection system Amersham Biosciences 
2.1.10 Transfection reagents 
Reagent Source 
Opti-MEM I Gibco 
Lipofectamine 
RNAiMAX Invitrogen Life Technologies 
Lipofectamine 2000 Invitrogen Life Technologies 
PLUS reagent Invitrogen Life Technologies 
Polybrene Sigma 
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2.1.11 Interferons and related reagents 
Reagent Description Source 
hIFNα α-Interferon, Human, recombinant, E.coli Merck 
hIFNβ β-Interferon, Human, recombinant, CHO cells Calbiochem 
hIFNγ Interferon-γ, Human, recombinant, E.coli Roche 
Poly-I:C - Invivogen 
2.1.12 Commonly used chemical 
Chemical Abbreviation Source 
2-Mercaptoethanol β-ME Sigma 
37.5:1 acrylamide/bis solution - Bio-RAD 
4’,6-diamidino-2-phenylindole DAPI Promega 
Agarose - Melford 
Ammonium persulphate APS Bio-RAD 
Ampicillin Amp Melford 
Bromophenol blue BPB BDH 
Chloroform - Sigma 
Ethanol EtOH Fisher Scientific 
Ethidium Bromide EtBr Sigma 
Glucose - BDH 
Glycine - BDH 
Methanol MeOH BDH 
N,N,N’,N’-Tetramethylethylene-diamine TEMED Sigma 
Neomycin phosphotransferase G418 Melford 
Phenol - Sigma 
Propan-2-ol - BDH 
Sodium chloride NaCl BDH/ ABI 
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Sodium dodecyl sulphate SDS BDH 
Sodium hydroxide NaOH BDH 
Sucrose - BDH 
Tween 20 - Sigma 
N,N-Dimethylformamide DMF Sigma 
EZ-link Biotin-HPDP - Pierce 
Chloroform/Isoamylalcohol(24:1) - Fluka 
Tris-EDTA TE Sigma 
Tris NaCl EDTA buffer solution STE Fluka 
Dithiothreitol DTT BioUltra 
2.1.13 Composition of buffers and solutions 
2.1.13.1 Bacteria growth media 
Solution Composition 
Luria-Bertani (LB) -
broth 
170mM NaCl, 10g/l Bactopeptone, 5g/l yeast extract 
2YT-Broth (Yeast 
tryptose Broth) 
85mM NaCl, 16g/l Bactopeptone, 10g/l yeast extract 
LB-agar LB-broth plus 1.5% (w/v) agar 
2.1.13.2 Tissue culture 
Solution Composition 
Trypsin 0.25% (w/v) Difco trypsin dissolved in PBS(A), 0.0005% 
(w/v) phenol red 
Versene 0.6mM EDTA in PBS(A), 0.002% (w/v) phenol red 
PBS(A) 170mM NaCl, 3.4mM KCl, 10mM Na2HPO4, 1.8mM 
KH2PO4, Tris-HCl (pH 7.2) 
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2.1.13.3 DNA manipulation and luciferase assay buffers 
Solution Composition 
Gel loading buffer 5x TBE, 50% sucrose, 1 µg/ml BPB 
TBE (10x) 0.9M Tris-HCl, 0.9M boric acid, 0.02M EDTA 
Equilibration buffer 
(EQ1) 
0.1M sodium acetate (pH 5.0), 0.6M NaCl, 0.15% (v/v) 
Triton X-100 
Resuspension buffer 
(R3) 50mM Tris-HCl (pH 8.0), 10mM EDTA, 100μg/ml RNase A 
Lysis buffer (L7) 0.2M NaOH, 1% (w/v) SDS 
Precipitation buffer 
(N3) 3.1M potassium acetate (pH 5.5) 
Wash buffer (W8) 0.1M sodium acetate (pH 5.0), 825mM NaCl 
Elution buffer (E4) 100mM Tris-HCl (pH 8.5), 1.25M NaCl 
Luciferase lysis buffer 
25mM Tris-phosphate (pH 7.8), 2mM DTT, 2mM 1,2-
diaminocyclohexane-N,N,N’,N’-tetraacetic acid, 10% 
glycerol, 1% Triton X-100 
2.1.13.4 SDS-PAGE and Western Blot analysis 
Solution Composition 
Sample loading buffer 31% stacking gel buffer, 31% glycerol, 21% SDS (25%), 9% 2-mercaptoethanol, 1µg/ml BPB, 8% H2O 
Gel running buffer 25mM Tris-HCl, 200mM glycine, 0.1% (w/v) SDS 
Resolving buffer 1.5M Tris-HCl (pH 8.9), 0.4% SDS 
Stacking buffer 0.5M Tris-HCl (pH 6.8), 0.4% SDS 
Towbin buffer 25mM Tris-HCl (pH 8.0), 200mM glycine, 20% (v/v) methanol 
PBS(A) 170mM NaCl, 3.4mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, Tris-HCl (pH 7.2) 
PBS-T PBS(A) plus 0,05% (v/v) Tween 20 
Blocking buffer  5% (w/v) Marvel milk in PBS-T 
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2.2 Methods 
2.2.1 Bacteria cultures 
Depending on the application, different strains of E. coli were used. Once 
transformed, the bacteria were recovered in 2YT-broth media and then grown in 
LB agar plates or in LB-broth medium, supplemented with appropriate 
antibiotics (100μg/ml Amp or 25μg/ml Chloramphenicol). The LB-agar was 
poured into 90mm dishes and allowed to set at room temperature. The bacterial 
cultures were plated onto the LB-agar plates using a glass spreader, inverted and 
incubated at 30°C or 37°C for approximately 20 or 16h, respectively. 
For growing bacteria cultures from LB-agar plates to minipreps (Section 
2.2.2.9) or midipreps (Section 2.2.2.10), single colonies were picked using a 
pipette tip and used to inoculate 2ml (minipreps) or 150-500ml LB-broth medium 
(midipreps), supplemented with appropriate antibiotics. The cultures were 
incubated with rotation (180rpm) at 30°C or 37°C. 
To ensure that a single bacterial colony was expanded from miniprep to 
midiprep culture, the streak plate procedure was used. Briefly, bacteria were 
picked from the miniprep culture using a sterile wire loop and spread over the 
surface of a fresh LB-agar plate (supplemented with appropriate antibiotic). The 
agar plates were incubated as before and single colonies grown into midiprep 
cultures. 
2.2.2 Manipulation of DNA 
2.2.2.1 Polymerase Chain Reaction (PCR) 
For amplification of viral or human gene (ISG15) cDNAs, the KOD Hot Start 
DNA Polymerase PCR kit (Novagen) was used. The product of these reactions was 
utilised for cloning into appropriate vectors and site-directed mutagenesis 
(Section 2.2.2.2). The reactions were performed in a ThermoHybaid PX2 Thermal 
Cycler as follows: 
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Reaction components 
Components Volume (μl) 
10x KOD buffer 5 
Template DNA 1 
Fwd primer (10uM) 1 
Rev primer (10uM) 1 
dNTPs (2mM) 5 
MgSO4 2 
KOD polymerase 1 
dH2O 34 
Cycling conditions (viral cDNAs) 
Stage Temperature Time Number of cycles 
Initial denaturation 94°C 2min 1 
Denaturation 94°C 15sec 
Primer annealing 63°C 30seconds 
Extension* 72°C 20sec 
30 
Hold 4°C ∞ 1 
*typically, 1minute/Kbp 
Cycling conditions (ISG15 cDNA) 
Stage Temperature Time Number of cycles 
Initial denaturation 94°C 2min 1 
Denaturation 94°C 20sec 
Primer annealing 63°C 30sec 
Extension* 72°C 1 or 2min 
30 
Hold 4°C ∞ 1 
*typically, 1minute/Kbp 
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Products of the entire PCR reaction were separated by agarose gel 
electrophoresis (Section 2.2.2.11-I) and the band of interest was purified by 
QIAquick spin column methodology (Section 2.2.2.11-II). 
2.2.2.2 Site-directed mutagenesis 
Mutagenesis reactions were performed using the QuikChange® Lightning 
Site-Directed Mutagenesis kit (Stratagene). Forward and reverse primers for 
mutagenesis (Section 2.1.7) were designed to incorporate the desired 
mutation(s) in the middle of the primer sequence and were between 25 and 45 
bases in length. PCR reactions were performed in a ThermoHybaid PX2 Thermal 
Cycler as follows: 
Reaction components 
Components Volume (μl) 
10x reaction buffer 5 
dsDNA template 1 
Fwd primer (125ng) 1 
Rev primer (125ng) 1 
dNTP mix 1 
QuickSolution reagent 1.5 
QuickChange Lightning Enzyme 1 
dH2O 38.5 
 
Cycling conditions 
Stage Temperature Time Number of cycles 
Initial denaturation 95°C 2min 1 
Denaturation 95°C 1min 
Primer annealing 60°C 30sec 
Extension 68°C 5min 
18 
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Final extension 68°C 5min 1 
Hold 4°C ∞ 1 
 
Following PCR, 10U of DpnI was added to digest the non-mutated dam-
methylated parental DNA. The reactions were mixed by pipetting, centrifuged at 
8000g for 15sec, followed by incubation at 37ºC for 1h. DpnI-treated DNA was 
then transformed into 50μl XL10-Gold Ultracompetent cells (Section 2.2.2.8). 
2.2.2.3 Cloning of PCR products 
I. pGEM-T Easy cloning system (Promega) 
Amplification of DNA using a non-proofreading polymerase such as Taq DNA 
polymerase (which lacks 3’→5’ exonuclease activity) yields products that 
contain a single 3’ terminal nucleotide overhang (commonly an A residue). The 
T-vectors, such as pGEM-T Easy vector, contain a complementary 3’ single T 
overhang and are used for cloning of products with A-residue overhangs. 
II. dA tailling 
PCR products generated from proofreading DNA polymerases such as KOD 
polymerase have blunt ends and usually have to be introduced into blunt-ended 
vectors. For cloning of such blunt-ended PCR fragments into T-vectors it is 
necessary to introduce A overhangs at the 3’ end termini. To that end, 2μl of 10x 
Taq buffer, 2μl of 2mM dATP and 1μl of Taq polymerase were added to the PCR 
product (15μl final volume). The reaction was incubated at 70°C for 20min, 
followed by purification of the PCR product by QIAquick spin column 
methodology (Section 2.2.2.11-II). 
III. Ligation reactions 
In a standard ligation reaction, DNA vectors (usually pGEM-T Easy vector) 
and purified PCR product were combined at 1:3 molar ratio. Typically, 1μl of 
pGEM-T Easy vector, 3μl of DNA fragment, 5μl of 2x ligase buffer were mixed 
with 1U T4 DNA ligase and water added to a final volume of 10μl. The ligation 
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mix was mixed briefly and incubated overnight at 4ºC. The ligated DNA was then 
used for transforming bacteria (Section 2.2.2.7). 
2.2.2.4 Restriction enzyme digestion 
Restriction digestions were prepared by adding 10U enzyme per 0.5-1μg of 
DNA and using the appropriate buffer (according to the supplier specifications, 
NEB or Roche). All the reactions were performed at 37ºC (unless otherwise 
specified) for 2h. Following the restriction reaction, DNA was purified by 
QIAquick spin column methodology (Section 2.2.2.11-II). 
2.2.2.5 Dephosphorylation of linearised plasmid DNA 
In a ligation reaction, the DNA ligase catalysis the formation of 
phosphodiester bonds between the 5’ phosphate and the 3’- hydroxyl groups. To 
prevent recirculation of digested DNA vector, the 5’ phosphate is usually 
removed from the vector using calf intestinal phosphatase (CIP). Following 
restriction digestion of DNA vectors, 4U of CIP was added and the mixture was 
incubated for 30min at 37ºC. The digested DNA was then purified using QIAquick 
spin column methodology (Section 2.2.2.11-II). 
2.2.2.6 Mung Bean nuclease treatment 
Prior to in vitro transcription (Section 2.2.3.1) of viral RNAs, the SGR or 
full-length HCV cDNA plasmids were linearised using XbaI endonuclease. 
Restriction enzymes like XbaI produce 3’ end overhangs, which have been 
reported to interfere with the T7 and SP6 mediated transcription (Schenborn & 
Mierendorf, 1985). DNA templates containing 3’ end overhangs were shown to 
synthesised extraneous RNA transcripts, which were complementary to the 
expected RNA transcripts. This is thought to be caused by self-annealing of the 
3’ overhang end of the DNA template and consequently lead the initiation of 
transcription by T7 or SP6 polymerases at additional sites other than the 
promoter region. Thus to avoid this synthesis of extraneous RNA transcripts, the 
ends of the linearised plasmid were removed prior to transcription. Therefore, 
after phenol/chloroform purification and ethanol precipitation of linearised DNA 
(Section 2.2.2.11-III & IV), the DNA was treated with 2U of Mung Bean Nuclease 
(Promega) in 1x reaction buffer for 30min at 30ºC. 
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2.2.2.7 Transformation of competent DH5α cells 
Competent E. coli DH5α cells were used for cloning plasmid DNA or ligation 
reactions. Typically, 1μg of plasmid DNA, or 7-15μl of ligation reaction were 
used per transformation reaction (50μl of bacteria). The DNA was added to pre-
chilled bacteria (30min on ice) and then heat-pulsed at 42°C for 2min. 
Subsequently, the transformation mix was immediately placed on ice for 1min 
and then transferred into 300μl 2YT-broth media (pre-heated at 37°C). The cells 
were incubated at 37°C with rotation (180rpm) for 45min and then plated on LB-
agar plates, supplemented with appropriate antibiotic. The plates were inverted 
and incubated at 30°C or 37°C for approximately 20 or 16h, respectively. 
2.2.2.8 Transformation of XL10-Gold Ultracompetent Cells 
For transformation of DpnI-treated DNA (Section 2.2.2.2), XL10-Gold 
Ultracompetent cells were used. 45μl of cells (gently thawed on ice) were 
utilised for each transformation, to which 2μl β-ME was added. After 2min 
incubation on ice, 4μl of DpnI-treated DNA was added to the competent bacteria 
and incubated on ice for further 30min. The transformation mix was then heat-
pulsed at 42°C for 50sec, followed by 2min incubation on ice. Pre-heated 2YT-
Broth (42°C, 500μl) was added to the mix, followed by incubation at 37°C for 1h 
with rotation (180rpm). 250μl of the transformation mix was plated on LB-agar 
plates, supplemented with appropriate antibiotic, and then incubated at 37°C 
for approximately 16h. 
2.2.2.9 Small-scale preparation of DNA (Minipreps) 
Single colonies of transformed bacteria were grown in 2ml of LB-broth 
media. To prepare DNA, 200μl of each bacterial culture was transferred to a 
centrifuge tube, 200μl of lysis buffer was added and the mixture vortexed 
briefly. 200μl of precipitation buffer (section 2.1.13.3) was added to the 
mixture, mixed by vortexing and the cellular debris pelleted by centrifugation at 
10000g for 2min. The supernatant was transferred to a new centrifuge tube 
containing 600μl of 100% isopropanol to precipitate the DNA. The samples were 
centrifuged at 10000g for 5min. The DNA pellet was washed once with 500µl of 
70% ethanol, allowed to dry at room temperature, and resuspended in 20µl of 
water. The purified DNA was then analysed by restriction enzyme digestion. 
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2.2.2.10 Large-scale preparation of DNA (Midipreps) 
Large scale preparation of plasmid DNA was performed by using a 
PureLinkTM HiPure Plasmid DNA Purification Kit (Invitrogen) according to the 
manufacturer’s protocol. 
Bacteria (typically in 150-500ml cultures) were pelleted by centrifugation 
at 4000g for 10min and resuspended in 4ml of R3 buffer (resuspension buffer). 
Cells were lysed by addition of 4ml of L7 buffer (lysis buffer), mixed 
immediately by inversion and incubated for 5min at room temperature. 4ml of 
N3 buffer (precipitation buffer) was added, mixed by inversion and the solution 
incubated for 10min at room temperature. The solution was then filtered, and 
the filtrate transferred to HiPure Midi columns (previously equilibrated with 
10ml of EQ1 – equilibration buffer). The solution passed through the column by 
gravity flow and the DNA was retained on the filtration cartridge inserted into 
the column. The columns were washed 2x with 10ml of W8 buffer (wash buffer) 
and then transferred to polypropylene tubes to elute the DNA by adding 5ml of 
E4 buffer (elution buffer). The DNA was precipitated by adding 3.5mL of 100% 
isopropanol, mixed by vortexing and incubated for 10min at room temperature. 
The DNA was pelleted by centrifugation at 6500g for 30min. The pellet was 
washed with 3ml of 70% ethanol followed by centrifugation at 6500g for 5min. 
The pellet was resuspended in 50-200µl of water and stored at -20ºC. 
2.2.2.11 Separation and purification of DNA fragments 
I. Agarose gel electrophoresis 
The DNA fragments yielded by PCR or from restriction enzyme digestions 
were separated according to their molecular length by agarose gel 
electrophoresis. Agarose gels were prepared containing 1-2% agarose melted in 
0.5% TBE buffer. Ethidium bromide was added to the gel mix at a final 
concentration of 0.05μg/ml. The DNA samples were mixed with loading buffer 
and then loaded onto the gel. Molecular weight markers (100bp or 1Kbp, NEB) 
were used for identification of the sizes of DNA fragments. For visualization of 
the DNA, the gels were exposed to UV-light (long or short-wave depending on 
the application) and photographed using a BioRad gel documentation system. 
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II. Purification of DNA fragments from agarose gels 
Purification of DNA fragments from agarose gels was performed using a 
QIAquick Spin Kit (Qiagen). The appropriate DNA fragments were excised from 
the gel using a scalpel blade and then transferred into a 1.5ml centrifuge tube. 3 
volumes of QG buffer were added per 1 volume of gel and the tubes were placed 
at 60°C to dissolve the gel. The sample was added to a QIAquick Spin Column 
and centrifuged at 10000g for 1min. The DNA that bound to the column was 
washed with 700µl PE buffer and centrifuged at 10000g for 1min. The PE buffer 
was discarded, the columns placed in a fresh tube and centrifuged as before to 
completely remove any residual PE buffer. The columns were transferred into a 
clean centrifuge tube and, to elute the DNA, 30µl of elution buffer was added to 
each column. After 1min incubation at room temperature columns were 
centrifuged at 10000g for 1min. The recovered DNA was immediately used for 
further cloning steps or stored at -20°C. 
III. Phenol-chloroform purification 
Digested DNA was purified by adding an equal volume of 1:1 
phenol/chloroform solution to the sample. After vigorous mixing by vortexing, 
the solution was centrifuged at 10000g for 1min to separate the organic 
(containing proteins) and aqueous layers (containing nucleic acids). The aqueous 
layer (upper part) was transferred to a fresh centrifuge tube and an equal 
amount of 100% chloroform was added. The solution was vortexed as before and 
centrifuged at 10000g for 1min to separate organic and aqueous layers. The 
aqueous layer was transferred into a fresh tube and DNA was precipitated by 
ethanol precipitation (Section 2.2.2.11-IV). 
IV. Ethanol precipitation 
DNA was precipitated by adding 2.5 volumes of 100% ethanol and 1/20 
volume of NaCl (5M). The solution was mixed by vortexing and incubated at 4ºC 
for 5-10min. DNA was pelleted by centrifugation at 10000g for 5min. The pellet 
was washed once with 75% ethanol and centrifuged at 10000g for 2min. The 
supernatant was removed and the pellet resuspended in an appropriate volume 
of water after drying. 
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2.2.2.12 Sequencing analysis of DNA 
Nucleotide sequences were determined by automated nucleotide 
sequencing performed by The Sequencing Service (School of Life Sciences, 
University of Dundee, Scotland). Analysis of the resulting sequences was 
performed using Vector NTI (Invitrogen) or CLC Genomics Workbench 4. 
2.2.3 Manipulation of RNA 
2.2.3.1 In vitro transcription of linearised DNA 
In vitro transcripts were generated from previously linearised HCV SGR or 
full-length cDNA (section 2.2.2.6) using the T7 RiboMAXTM Express Large Scale 
RNA Production System (Promega). Each reaction mixture typically contained 2x 
T7 RiboMax buffer, 1µg of linearised/MB-treated DNA, 2µl of T7 RNA polymerase 
and RNase-free water made up to a 20ul total reaction volume. The reactions 
were incubated at 37°C for 1-2h. To remove the DNA template from the 
transcription reactions, 1U of RNase-free DNase was added per µg of DNA and 
incubated at 37°C for 15min. For purification and precipitation of the 
transcribed RNA, the RNeasy Mini Kit (Qiagen) was used. 
2.2.3.2 RNA cleanup (RNeasy Mini Kit, Qiagen) 
Firstly, RNase-free water was added to the in vitro transcribed reaction to 
adjust the volume to 100μl. 350μl of RLT buffer was then added and the solution 
was mixed by pipetting. Subsequently, 250μl of 100% ethanol was added, the 
solution mixed again before transfer to a RNeasy mini spin column. After 
centrifugation at 10000g for 15sec, the flow-through was discarded. 500μl of RPE 
was added to the column and then centrifuged as before. A second wash with 
500μl of RPE was performed by centrifuging the columns at 10000g for 2min. The 
flow-through was discarded and the columns were centrifuged again at 10000g 
for 1min to remove any residual flow-through or RPE buffer. The collection tube 
and the flow-through were discarded and the column transferred to a new tube. 
To elute the RNA, 25-50μl of RNase-free water was added to the column and 
incubated for 1min at room temperature. Then, the columns were centrifuged 
for 1min at 10000g and the eluted RNA collected and stored at -70°C. 
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2.2.3.3 Extraction of RNA from mammalian cells (small-scale) 
Extraction of RNA from up to 107 cells was performed using the RNeasy Mini 
Kit (Qiagen); such extractions produced up to 100μg of RNA. Before lysis, the 
culture media was removed and cells were washed once with PBS(A). The cells 
were lysed by adding 300-600μl RLT buffer directly to the wells and incubated 
for 2min at room temperature. The lysate was homogenized by pipetting and 
then transferred into a fresh tube. 1 volume of 70% ethanol (typically 300-600μl) 
was added to each homogenised sample and mixed well by pipetting. The 
samples were transferred into a RNeasy spin column and centrifuged at 10000g 
for 15sec. The flow-through was discarded and 700μl of RW1 buffer (wash 
buffer) was added to the column. After centrifugation at 10000g for 15sec, the 
flow-through was discarded and the columns transferred into new tubes. 500μl 
of RPE buffer was added to the column and centrifuged at 10000g for 15sec. A 
second wash with 500μl of RPE buffer was performed followed by centrifugation 
for a longer time, 2min at 10000g. The flow-through was discarded and the 
columns were centrifuged again at 10000g for 1min to remove any residual flow-
through or RPE buffer. The collection tube and the flow-through were discarded 
and the column transferred to a new tube. To elute the RNA, 50μl of RNase-free 
water was added to the column and incubated for 1min at room temperature. 
Then, the columns were centrifuged for 1min at 10000g and the eluted RNA 
collected and stored at -70°C. 
2.2.3.4 Extraction of RNA from mammalian cells (large scale) 
Extraction of up to 1mg of RNA from up to 108 cells was performed using 
the RNeasy Midi Kit (Qiagen). Before lysis, the culture media was removed and 
cells were washed once with PBS(A). The cells were lysed by adding 3ml RLT 
buffer directly to the dishes and incubated for 2min at room temperature. The 
lysate was homogenized by pipetting and the samples then transferred into a 
fresh 15ml tube. 1 volume of 70% ethanol (typically 3ml) was added to each 
homogenised sample and mixed thoroughly by shaking vigorously. The samples 
were transferred into an RNeasy Midi column and centrifuged at 4500g for 5min. 
The flow-through was discarded and 4ml of RW1 buffer (wash buffer) was added 
to the column. After centrifugation at 4500g for 5min, the flow-through was 
discarded and 2.5ml of RPE buffer (wash buffer containing ethanol) was added to 
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the column and centrifuged at 4500g for 2min. A second wash with 2.5ml of RPE 
buffer was performed at 4500g for 5min. The flow-through and the tubes were 
discarded and the columns transferred into new 15ml RNase-free tubes. To elute 
the RNA, 150μl of RNase-free water was added to the column and incubated for 
5min at room temperature. The columns were centrifuged for 3min at 4500g. A 
second elution step was performed by adding 200μl of RNase-free water to the 
columns. The columns were centrifuged as before and the eluted RNA 
transferred into new RNase-free centrifuge tubes and stored at -70°C. 
2.2.4 Transfection of DNA/RNA into mammalian cells 
2.2.4.1 Transfection of DNA/RNA into mammalian cells using 
lipofectamine 
Prior to DNA/RNA transfection (e.g. expression plasmids or poly-I:C), cells 
were seeded on the appropriate culture plates and allowed to settle for 24h at 
37ºC. Depending on the culture plates used, 0.5-1μg DNA/RNA and 2-10μl of 
Lipofectamine 2000 (Invitrogen) were diluted separately in 250μl of Opti-MEM I 
(Gibco) and incubated at room temperature for 5min. The diluted DNA and 
Lipofectamine 2000 were combined and incubated at room temperature for 
further 20min. The DNA-Lipofectamine 2000 mixture was added to the plated 
cells and incubated at 37ºC for the appropriate length of time. 
2.2.4.2 Electroporation of viral RNA into mammalian cells 
Trypsinized cells, typically grown in 175cm2 culture flasks, were counted 
using a haemocytometer. The appropriate volume of cells (containing 3.5x106 
cells) was transferred into 15ml centrifuge tubes and centrifuged at 200g for 
5min at room temperature. The media was decanted and the cells washed by 
resuspension in 10ml of PBS(A). The cells were centrifuged as before and the 
PBS(A) decanted. The pelleted cells were resuspended in 400ul PBS(A) and 
transferred into 4mm electroporation cuvettes along with 5-10µg of in vitro 
transcribed viral RNA. Cells were electroporated (250V and 950uF) using a 
BioRad GenePulser Xcell. The contents of each cuvette were resuspended in 
appropriate media (complete DMEM or WEM media) and seeded onto culture 
flasks or plates. 
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2.2.5 Protein methods 
2.2.5.1 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were resolved by SDS-PAGE electrophoresis, based on the method 
described by Laemmli (1970). Resolving gels were prepared using acrylamide 
solution at a final concentration of 8-12.5% in 1x resolving gel buffer. Addition of 
APS (0.1%) and TEMED (0.08%) initiated polymerisation and the solution was 
immediately poured into the gel assembly apparatus (using Bio-Rad Miniprotein II 
Apparatus), leaving a gap of ~2 cm from the top. The solution was then overlaid 
with H2O. When polymerisation was complete, the water was discarded and 
excess water at the gel surface was absorbed carefully with filter paper. 
Stacking gel was prepared using acrylamide at a final concentration of 5% in 1x 
stacking gel buffer. Polymerisation was initiated upon the addition of APS (0.1%) 
and TEMED (0.08%), and the solution immediately overlaid onto the resolving 
gel. A 10-15 tooth Teflon comb was used to form wells in the stacking gel. The 
gel was allowed to polymerise before removal of the comb. The gels were placed 
in holders, transferred to an electrophoresis tank and submerged in 1x gel 
running buffer. 
Before loading the protein samples on the gel, they were boiled for 10min 
at 100ºC. The wells in the gels were washed 2x with a syringe and 10-20µl 
(depending on the combs used) of each sample was loaded. High range protein 
markers (Amersham) were also included for protein size determination and 
empty wells were filled with an equal volume of boiling mix. Electrophoresis was 
performed at 120V until the required separation of protein markers and samples 
was achieved. Gels were then removed from the apparatus for Western blot 
analysis. 
2.2.5.2 Western blot analysis 
After SDS-PAGE electrophoresis, the resolved proteins were transferred to 
HybondTM-ECLTM nitrocellulose membranes using a Bio-Rad mini-transblot 
apparatus. The gel containing cassette, together with an ice container, were 
placed in the transblot apparatus and filled with Towbin buffer. Transfer was 
performed at 60V for approximately 2h. 
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2.2.5.3 Immunodetection 
Following transfer, the nitrocellulose membrane was incubated with 
blocking buffer for 1h at room temperature. After three washes with PBS-T the 
membranes were probed with appropriate antibody (diluted in 5% milk/PBS-T), 
by overnight incubation at 4ºC. The membranes were washed again six times 
with PBS-T (20min per wash) and then probed with appropriate secondary 
antibody (diluted in 2% milk/PBS-T) for 1h at room temperature. Finally the 
membrane was washed again six times with PBS-T (20min per wash; the last two 
washes with only PBS(A)). 
Proteins were detected using Enhanced Chemiluminescence Plus Western 
Blotting Detection System (Amersham Biosciences). Following 2-5min incubation 
with ECL Plus reagent solution, the membranes were placed between mellanine 
sheets and the proteins visualised by exposure to Kodak X-OMAT S films which 
were developed using a Konica film-processing unit SRX-101a. 
2.2.5.4 Stripping of antibodies from nitrocellulose membranes 
In order to re-probe nitrocellulose membranes, they were incubated in 
stripping buffer (1% SDS, 0.2M glycine, pH 2.5) for 30min at room temperature 
with agitation. Membranes were then washed three time with PBS-T (10min per 
wash) and blocked with 5% milk/PBS-T. Membranes were re-probed as described 
above. Only one stripping step was performed per membrane. 
2.2.6 Microscopy Methods 
2.2.6.1 Indirect Immunofluorescence 
Naive, replicon or infected cells seeded on 13mm glass coverslips were 
fixed for 10min with 100% methanol at -20ºC. The methanol was removed and 
the cells washed three times with PBS(A). The cells were incubated with primary 
antibody, at an appropriate dilution in PBS(A), for 2h at room temperature. The 
cells were washed with PBS(A), and stained with secondary antibody (diluted at 
1:1000) conjugated with either FITC, TRITC or Cy5 for 1h at room temperature. 
The nuclei were stained by the addition of DAPI (diluted 1:2000 in PBS(A)). 
Finally, the cells were washed with PBS(A) three times, followed by two washes 
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with water. The coverslips were mounted on a glass slide (in Citifluor 
glycerol/PBS) and sealed with nail varnish prior to examination with a Zeiss 
Laser Scanning LSM510 META inverted confocal microscope (Carl Zeiss Ltd., UK). 
The images were analyzed using LSM510 software. 
2.2.7 Cell culture methods 
2.2.7.1 Propagation of cell lines 
Huh-7, Huh-7.5, U2OS and HEK-293T cells were cultured in complete DMEM 
media and incubated at 37ºC with 5% CO2. HepaRG cells were cultured in 
complete WEM media under the same temperature and CO2 conditions. Cells 
harbouring SGR containing the neomycin/blasticidin resistance genes were 
cultured in the presence of 0.5mg/ml to 1mg/ml of G418 or 0.5µg/ml of 
Blasticidin. Cells were grown in tissue culture flasks (80cm2 and 175cm2), and 
the media was changed every 3-4 days. When the cells reached confluence, they 
were trypsinised for detachment, resuspended in 10ml media and a proportion 
(1:5 to 1:10) was used to seed a new flask or used for experiments. 
2.2.7.2 Freezing cells 
Cryogenic preservation of cell cultures was used to preserve stocks of cell 
lines. A culture flask of confluent cells was trypsinised and resuspended in the 
appropriate medium (DMEM or WEM depending on the cell line). Cryoprotection 
of cells was achieved by adding DMSO (to a final concentration of 10% (v/v)) and 
foetal calf serum (to 50% (v/v)). The cell suspension was then aliquoted in 
cryogenic vials (1ml/each), and kept at -70ºC overnight. The following day, cell 
aliquots were transferred to liquid nitrogen (-180ºC) for long term storage. 
2.2.7.3 Lentivirus transduction of cell lines 
Generation of lentiviruses and transduction of Huh-7 cells was used for 
either the production of cell lines with stable knockdown of protein expression 
or for expression of tagged proteins. Depletion of endogenous protein expression 
was based on RNAi-mediated gene silencing, which used lentiviral plasmids to 
express short hairpin RNA (shRNA) molecules. 
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On the day preceding transfection, HEK-293T cells were seeded in 60mm 
tissue culture dishes, in growth media containing 10% heat-inactivated serum 
(30min at 56°C) and 0.1% penicillin/streptomycin (P/S), at a density of 
approximately 1.5×106 cells per dish. For each transfection, 4.5μg of each 
plasmid DNA (the plasmid DNA of interest and two helper plasmids for 
production of lentiviral particles, pCMV.DR8.91 and pVSV-G) were mixed with 
300μl of serum-free DMEM and 10μl of PLUS reagent. The DNA-PLUS mixtures 
were incubated for 15min at room temperature. 300μl of serum-free DMEM and 
14μl of Lipofectamine2000 reagent were then added to the DNA-PLUS mixture 
and the whole mixture was incubated at room temperature for a further 15min. 
The media from HEK-293T cells was removed and kept at 37°C (conditioned 
media) and the cells washed once with serum-free DMEM. 1ml of serum-free 
media was added to the transfection mixture, before transferring to the cells, 
which were then incubated for 3h at 37°C. Following the incubation period, the 
cells were overlaid with 3ml of conditioned media. The cells were allowed to 
recover for 4-6h and media was changed to fresh DMEM (containing 30% FBS and 
1% P/S). The lentiviral particles were produced from the cells over a period of 
40 to 60h, before supernatants were harvested. 
2.2.7.4 Transduction of cell lines with lentivirus 
On the day before transduction with lentivirus stocks, 6×105 Huh-7 cells 
were seeded onto 60mm dishes. At 60h post-transfection, the supernatants from 
HEK-293T cells containing lentiviral particles were harvested and centrifuged at 
200g for 5min to remove cell debris. The supernatants were then filtered using a 
0.45μm filter. 1ml of the supernatant, together with 5μg of polybrene, was 
added to Huh-7 cells, which were then incubated for 1h at 37°C, with gentle 
agitation every 10-15min. This procedure was repeated by adding a further 3ml 
of lentivirus supernatant containing polybrene to Huh-7 cells and incubated 
overnight. Finally, Huh-7 cells were overlaid with fresh media supplemented 
with 5μg/ml polybrene. Transduced cells were selected using the appropriate 
antibiotics (initially 1μg/ml puromycin, and subsequently increased to 10ug/ml, 
or 1mg/ml G418, depending on the plasmid). The resulting cell lines produced 
are detailed in the following table: 
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Name Description Selection 
shCtrl Huh-7+pLKO.dCMV.Control-shRNA Puromycin 
sh1 Huh-7+pLKO.dCMV.ISG15-shRNA1 Puromycin 
sh2 Huh-7+pLKO.dCMV.ISG15-shRNA2 Puromycin 
sh3 Huh-7+pLKO.dCMV.ISG15-shRNA3 Puromycin 
sh4 Huh-7+pLKO.dCMV.ISG15-shRNA4 Puromycin 
sh5 Huh-7+pLKO.dCMV.ISG15-shRNA5 Puromycin 
sh6 Huh-7+pLKO.dCMV.ISG15-shRNA6 Puromycin 
ISG15-FLAG-GG Huh-7+pLKO.dCMV.TetR.eGFP+ 
pLKO.dCMV.TetO.FLAG-ISG15-GG 
Neomycin/ 
puromycin 
ISG15-Flag-AA Huh-7+pLKO.dCMV.TetR.eGFP+ 
pLKO.dCMV.TetO.FLAG-ISG15-AA 
Neomycin/ 
puromycin 
 
2.2.8 Assessment of HCV infection, replication and infectious 
virus production 
2.2.8.1 Analysis of HCV RNA replication (SGR) 
I. Luciferase assays 
Transient replication assays were performed by electroporation of in vitro 
transcribed replicon RNA expressing the luciferase reporter into mammalian cells 
(Section 2.2.4.2). Linearized DNA was used to direct in vitro transcription of 
replicon RNA, and 5-10μg of the transcription reaction was electroporated into 
cells. Typically, 8x104 or 1x105 cells were seeded into each well after 
electroporation (depending on the cell line), in a 24-well plate format. 
Luciferase assays were performed at 4, 24, 48 and 72h post-electroporation. 
For determination of luciferase activity, cells were washed once with 
PBS(A) and lysed with 100μl cold 1x cell lysis buffer (Promega). After 2min 
incubation, 50μl of lysate was mixed with 100μl of luciferase assay reagent in a 
1.5ml microcentrifuge tube. The solutions were mixed briefly and the luciferase 
activity measured using a GlomaxTM 20/20 Luminometer. 
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II. Colony forming assays 
Colony forming assays were performed by electroporation of neomycin- or 
blasticidin-selective replicon RNA into mammalian cells. In vitro transcribed Neo 
or Blast replicon RNAs were used to electroporated 3.5x106 cells (Section 
2.2.4.2). 24-48h after electroporation, media was replaced with fresh media 
supplemented with 0.5 to 1mg/ml of G418 or 0.5µg/ml of Blasticidin (depending 
on the HCV replicon used). 3 to 4 weeks after electroporation, drug-resistant 
colonies were stained with Coomassie Brillant blue (CBB). The medium was 
removed from the culture dish and the cells washed once with PBS(A). Colonies 
were stained with 10ml of CBB for 20min. The CBB was removed and the colonies 
washed well with water and allowed to dry. 
2.2.8.2 Analysis of HCV Infectivity (HCVcc) 
I. Preparation of virus 
In vitro transcribed full-length genomic viral RNA (10µg) was used to 
electroporate Huh-7 cells (Section 2.2.4.2). The transfected cells were seeded 
on 90mm tissue culture dishes and incubated at 37°C for the required time 
period (72h for JFH1 or 48h for JC-1 virus). The medium containing infectious 
virions was harvested and centrifuged at 200g for 5min to sediment any residual 
cell debris, before infectivity was determined (Section 2.2.8.2-II). 
II. 50% tissue culture infectivity dose (TCID50) 
For quantification of virus infectivity, limiting dilution assays using the 
TCID50 assay as described by Lindenbach (2005) were employed. The TCID50 assay 
measures the dilution of virus that will infect 50% of replicate cell cultures. To 
determine the virus titre by TCID50 assay, Huh-7 cells were seeded at a density 
of 3x103 (in 100μl complete DMEM) per well in flat-bottomed 96-well plates 
(Nunc). 48 or 72h later, serial 3-fold dilutions of cell medium were added, with 8 
wells per dilution. Up to 72h later, the medium was removed, the cells were 
fixed with ice-cold methanol and incubated at -20°C for 20min. The cells were 
then washed 3x with PBS(A) and probed with anti-NS5A antibody (1:5000 
dilution) in PBS(A) for 1h at room temperature. The cells were washed again 3x 
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with PBS(A) and incubated with the appropriate FITC-conjugated secondary 
antibody (1:2000 dilution) in PBS(A) for 1h at room temperature. After three 
washes in PBS(A) and two washes with water, the cells were overlaid with 100μl 
of dH2O before visualization under a fluorescent microscope to determine the 
number of positive wells at each dilution. The wells containing at least one 
NS5A-expressing cell were counted as positive, and the TCID50 was calculated 
according to the Reed & Muench formula (Lindenbach, 2005). 
2.2.8.3 RNA interference 
I. Reverse transfection of mammalian cells with siRNA 
To verify the effect of cellular genes (e.g. ISG15, HERC5) on virus 
replication, target siRNAs were transfected into Huh-7/SGR and U2OS/SGR cells 
using lipofectamine RNAiMAX reagent. Transfections were performed in 24- or 
12-well plates (depending on the experiment). For each well (e.g. 24-well 
plate), 100µl Opti-MEM I was mixed with 1µl lipofectamine RNAiMAX and the 
siRNAs were added to the transfection mixture. For transfection of negative 
control (scrambled) siRNA, 1µl of siCtrl mix (final concentration 50 nM) was 
added to the wells. For the target siRNAs, 0.5µl of a mixture of 3 siRNAs, 
targeting the same gene (final concentration 75nM), was used. The transfection 
mixture was gently mixed by pipetting, added to the wells and incubated for 
20min at room temperature. Wells were then seeded with 8x104 cells in 900µl of 
DMEM, giving a total volume of 1ml in each well. At appropriate times after 
transfection (24 or 48h, depending on the experiment), the supernatant was 
removed and the cells washed once with PBS(A) before: i) lysis in RLT buffer 
(Section 2.2.3.3) for RT-qPCR assays (Section 2.2.8.5); ii) lysis with BM for 
Western blotting analysis (Section 2.2.5) or iii) fixed with methanol for indirect 
immunofluorescence analysis (Section 2.2.6.1). 
II. Mammalian cell lines constitutively expressing shRNAs 
The lentiviral cell lines developed in sections 2.2.7.3 & 2.2.7.4 were used 
to assess the effect of ISG15 depletion, using short hairpin RNAs. These cells 
were used for electroporation with viral subgenomic RNA or infection with virus. 
Depending on the experiment (specified where appropriate in Chapter 5), these 
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cells were used for: i) transient HCV replication assays (Section 2.2.8.1-I); ii) 
measuring HCV and ISG15 expression levels in the presence or absence of 
exogenous IFN treatment by RT-qPCR assay (Section 2.2.8.5) and Western 
blotting analysis (Section 2.2.5) or iii) assessing the rates of viral RNA synthesis 
and degradation (Section 2.2.8.4). 
2.2.8.4 4sU labelling and purification of nascent viral RNA 
Metabolic labelling of newly transcribed viral RNA was performed using the 
method previously described by (Dolken et al., 2008). The protocols for labelling 
and purification are described below in 3 stages. 
I. 4sU labelling of nascent viral RNA 
Cells were cultured in 90mm tissue culture dishes (2 plates per sample) in 
order to guarantee sufficient material for subsequent pull-down of labelled RNA 
(ideally 50 to 150μg of total RNA). Cells were seeded at a density of 5.5x105 or 
8x105 per 90mm culture dish (depending on whether the cells were cultured for 
72 or 48h, respectively) 24h prior to infection with JC-1 (moi=0.8). After plating, 
the cells were either: i) infected and labelled with 100μM 4sU for 24h; ii) 
infected for 24h and labelled with 100μM 4sU for a further 24h; or iii) infected 
for 24h, then pulse-labelled with 200μM 4sU for 6h followed by monitoring for 
loss of labelled RNA for 48h. To start labelling, 4sU was prepared in cell culture 
medium at the required concentration (100μM for up to 24h labelling; 200μM for 
up to 12h labelling) and the mixture added immediately to the cells, following 
by incubation at 37°C for the appropriate time. The medium was then removed 
from the cells, washed once with PBS(A) and the cells were immediately lysed by 
adding 3ml of RLT buffer. Total RNA was isolated and purified following the 
method described in Section 2.2.3.4. 
II. Biotinylation of newly transcribed RNA 
For isolation of labelled transcripts, the total RNA extracted from the cells 
was biotinylated, using a modified form of biotin (EZ-link Biotin-HPDP, Pierce) 
which has affinity for thiol groups (4sU). To biotinylate labelled transcripts, the 
following components were added per μg of RNA, 2μl of Biotin-HPDP (1mg/ml 
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dissolved in DMF), 1μl of 10x Biotinylation Buffer (100mM Tris pH 7.4, 10mM 
EDTA) and up to 6μl of RNase–free water; typically, 60μg of total RNA was used 
for biotinylation reactions. Reactions were incubated for 1.5h at room 
temperature with rotation. To remove unincorporated biotin-HPDP, two rounds 
of chloroform extraction were performed, using Qiagen MaXtract 2ml Phase Lock 
gel kit, according to manufacturer’s instructions. Prior to use, the Qiagen 
MaXtract 2ml Phase Lock tubes (hereafter referred to as Phase lock tubes) were 
centrifuged at 10000g for 1min to pellet the gel matrix. The biotinylation 
reaction was added to the Phase lock tubes (600μl total volume for 60μg RNA 
reaction), then an equal volume of chloroform/isoamyl acohol (24:1) was added 
to each tube and shaken vigorously. After incubation for 2-3min, the Phase lock 
tubes were centrifuged at 10000g for 5min. The upper phase was transferred 
into a new Phase lock tube and a second round of chloroform extraction was 
performed as before. The upper phase from the second chloroform extraction 
was transferred into a new tube and the RNA precipitated by adding 1/10 
volume of NaCl (5M) and an equal volume of 100% isopropanol (due to some loss 
during the extraction procedure, the sample volume was approximately 500μl). 
After centrifugation at 20000g for 30min at 4°C, the supernatant was removed, 
the pellet washed with an equal volume of 75% ethanol and centrifuged at 
20000g for 10min. Finally, the supernatant was carefully removed and the RNA 
resuspended in 100µl of 1x TE. 
III. Streptavidin isolation of biotinylated RNA 
Following biotinylation, the RNA samples (in a volume of 100µl) were 
denatured at 65°C for 10min and immediately placed on ice for a further 5min. 
100µl of streptavidin beads were then added to the RNA samples and incubated 
with rotation for 15min at room temperature. For separation of 
RNA/streptavidin complexes, the samples were applied to the μMacs columns 
and placed into a magnetic stand. The columns were then washed 3x with 0.9ml 
of washing buffer (100mM Tris-HCl, pH7.5, 10mM EDTA, 1M NaCl, 0.1% Tween20) 
at 65°C and the flow-through (which contained >90% unbound RNA) was retained 
on ice. The columns were washed again 3x with 0.9ml washing buffer at room 
temperature and the eluates discarded. To elute the RNA which was bound to 
the columns, two separate quantities of 100µl Elution Buffer (100mM DTT) were 
added to the columns. To purify the bound and eluted RNA as well as RNA in the 
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flow-through, the RNeasy MiniElute Kit (Qiagen) was used. 700µl of RLT buffer 
was added to each sample and mixed by pipetting. 500µl of 100% ethanol was 
added to the diluted RNA, mixed thoroughly by pipetting and the mixture 
transferred to a RNeasy MiniElute spin column. After centrifugation for 15sec at 
8000g, the flow-through, together with the collection tube, was discarded. The 
spin columns were transferred to new tubes and 500µl of RPE buffer (wash 
buffer containing ethanol) was added to each column. The columns were 
centrifuged at 8000g for 15sec and flow-through discarded. Another wash was 
performed by adding 80% ethanol to the columns followed by centrifugation at 
8000g for 2min. The flow-through and the collection tubes were discarded, the 
columns were transferred to a new collection tube and centrifuged again at 
10000g for 1min to remove any residual flow-through or ethanol. The collection 
tube and the flow-through were discarded and the column transferred to a new 
tube. To elute the RNA, 30ul (bound and eluted RNA samples) or 18ul (flow-
through RNA samples) of RNase-free water was added to the column and 
incubated for 1min at room temperature. The columns were centrifuged for 
1min at 10000g and the eluted RNA collected and stored at -70°C. All the RNA 
fractions (total, newly transcribed and pre-existing/flow-through) were then 
analysed by RT-qPCR (Section 2.2.8.5). 
2.2.8.5 Reverse Transcription-Quantitative PCR (RT-qPCR) 
RT-qPCR was a two-step process involving the reverse transcription of RNA 
followed by a real-time PCR amplification using either relative or absolute 
quantification procedures. 
I. cDNA synthesis 
Reverse transcription of viral and cellular RNAs was performed using the 
TaqMan Reverse Transcription Reagents Kit (Applied Biosystems). For each 
reaction 1μl of RNA was reverse transcribed in a ThermoHybaid PX2 Thermal 
Cycler as follows: 
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Reaction components (final volume of 20µl) 
Components Volume (µl) 
10x RT buffer 2 
MgCl2 (25mM) 4.4 
dNTPs (10mM) 4 
Random Hexamers (50μM) 1 
RNase inhibitor (20U/μl) 0.4 
Multiscribe Reverse Transcriptase (50U/μl) 0.5 
dH2O 6.7 
RNA 1 
Cycling conditions 
Stage Temperature Time Number of cycles 
Primer annealing 25°C 10min 1 
Extension 37°C 60min 1 
RT inactivation 95°C 5min 1 
Hold 4°C ∞ 1 
 
II. Real-Time PCR 
Relative Quantification (RQ) 
The relative quantity of viral or cellular RNA from electroporated or 
infected cells was determined by a RQ reaction. The cDNA obtained from the 
reverse transcription of total intracellular RNA (Section 2.2.3.3 and 2.2.3.4) was 
amplified using target HCV-, ISG15-, USP18-, HERC5-specific and control GAPDH-
specific primers (Applied Biosystems) in the presence of FAMTM (target-specific) 
and VIC® (control-specific) labelled MGB probes. The JFH1 probe and primer 
sequences were located in the 5’ UTR of the viral genome. Each sample was run 
in triplicate as a singleplex reaction. The reaction mixes are described below 
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along with the reaction cycle conditions performed on an Applied Biosystems 
7500 Fast Real-Time PCR System using Fast Universal PCR conditions: 
Real-Time PCR Reaction Mix for JFH1 RNA 
Components Volume (µl) 
18μm Forward Primer (Final 900nm) 1 
18μm Reverse Primer (Final 900nm) 1 
5μm FAM JFH1 Probe (250nm) 1 
TaqMan Fast Universal Mix (2x) 10 
dH2O 5 
cDNA 2 
Real-Time PCR Reaction Mix for ISG15, USP18, HERC5 and GAPDH RNA: 
Components Volume (µl) 
Probe 1 
TaqMan Fast Universal Mix (2x) 10 
dH2O 7 
cDNA 2 
Cycling conditions 
Stage Temperature Time Number of cycles 
Denaturation 95°C 20sec 1 
Primer annealing 95°C 3sec 
Extension 60°C 30sec 
40 
 
The HCV or cellular target signals were normalised to the endogenous 
GAPDH control and the data was analysed using Applied Biosystems software 
(SDS version 1.3.1), according to the manufacturer’s instructions. 
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Absolute Quantification (AQ) 
The absolute quantity of viral transcripts from the RNA fractions obtained 
from the 4sU experiments was determined by an AQ reaction. The cDNA 
obtained from the reverse transcription (Section 2.2.8.5-I) of viral RNA was 
amplified using the HCV-specific primer/FAM probe combination described for 
RQ (Section 2.2.8.5-II). In vitro transcribed JFH1 genomic RNA of known 
concentration was used as a standard. Serially-diluted standard cDNAs and 
undiluted sample cDNAs were analysed in triplicate and real-time reactions were 
amplified and analysed using the same Fast Universal PCR conditions as for RQ 
reactions (Section 2.2.8.5.II). 
2.2.8.6 Resazurin assay 
For measuring the impact of labelling Huh-7 cells with 4sU nucleoside on 
cell viability, the resazurin assay was used. Resazurin is a redox dye with both 
colorimetric and fluorimetric properties, which changes relative to cellular 
metabolic activity. This assay is based on the ability of viable or metabolically 
active cells to convert the non-fluorescent redox dye (resazurin, blue) into a 
fluorescent reduced product (resorufin, red). This conversion occurs 
intracellularly and is undertaken by the activity of mitochondrial enzymes. 
The resazurin assay was performed at 2, 16, 24, 48h after 4sU labelling. At 
each time-point, the media was replaced with 500ul of fresh media containing 
resazurin (1:50 from a 1mg/ml stock) and the cells incubated at 37°C for 6h. 
After the incubation period, 100ul of resazurin-containing media was transferred 
into a black 96 well plate. The fluorescence was measured in a Varioskan Flash 
(Thermo Scientific) using the following settings: 544nm excitation wavelength 
(typically between 530 and 560nm) and 590nm absorbance wavelength. 
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3 Expanding HCV in vitro model systems 
3.1 Introduction 
With the advent of subgenomic replicons (SGRs), it became possible to 
study HCV RNA synthesis in cell culture (Lohmann et al., 1999). The first 
generation of functional HCV replicons was derived from a consensus Con1 cDNA 
clone which was able to replicate under selective pressure in Huh-7 human 
hepatoma cells (Lohmann et al., 1999). Subsequently, other viable replicons 
were constructed from both genotype 1a (Blight et al., 2000) and 2a strains of 
the virus (Kato et al., 2003). The genotype 2a replicons were established from a 
consensus sequence of strain JFH1, which was isolated from a 32-year-old 
Japanese patient with fulminant hepatitis (Kato et al., 2003). These JFH1 
replicons could replicate more efficiently in Huh-7 cells than the Con1 replicons 
and did not require cell culture adaptive mutations to achieve high replication 
levels. 
The SGR system represents a powerful tool to study RNA replication in cell 
culture, although there is a remaining need to develop systems that include 
other HCV genotypes and to expand viral RNA synthesis in alternative permissive 
cell lines with natural host-like environments. These systems would provide 
improved models to 1) understand the underlying mechanisms and the role of 
host and viral factors required for viral replication of different HCV genotypes 
and 2) screen for novel anti-viral drugs and provide a platform for testing of 
resistance variants from patients. 
3.1.1 Expanding the SGR systems to include other HCV 
genotypes 
Although the development of the SGR system was a major breakthrough to 
study HCV RNA replication, it is limited by the availability of HCV isolates that 
can replicate viral RNA in tissue culture cells (namely genotypes 1a, 1b and 2a). 
In an attempt to expand the repertoire of HCV SGR systems, we aimed to 
construct a SGR with sequences from genotype 3 (gt3). 
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Currently, gt3 strains account for 44% of HCV infections in the UK (Brant et 
al., 2010) and thus have a similar prevalence to gt1 strains (45%). Chronic HCV 
infection has been associated with liver steatosis (virally- or metabolically-
induced) and this has been suggested to be an important risk factor for 
progression to other liver diseases. Virus-induced steatosis is more frequent and 
more severe in patients infected with HCV gt3 (Adinolfi et al., 2001) and reduces 
the response to antiviral therapies (Shah et al., 2011). In addition, gt3 infection 
also carries a greater chance of developing accelerated liver fibrosis (Bochud et 
al., 2009). The correlations and consequences of HCV-induced steatosis in 
patients infected with gt3 on viral replication, disease progression and lower 
response to antiviral therapies have not been fully addressed. An in vitro system 
that enabled replication of gt3 strains would aid development of an 
understanding of the characteristics of gt3 infections. However, previous 
attempts to construct subgenomic replicons entirely from gt3 sequences have 
failed (Hubb, 2008). Therefore, we sought to explore the feasibility of replacing 
sequences in the highly efficient JFH1 SGRs, with those from an isolate from 
Glasgow, as a first step in strategically designing a gt3 replicon. 
3.1.2 Hepatocyte-like permissive cell lines for HCV replication 
For many years, researchers have sought to improve HCV cell culture 
models to try to recapitulate the events which occur during natural HCV 
infection in vivo. Primary human hepatocytes potentially represent the best 
model for studying HCV in culture. However, primary cell lines are limited by 
their availability, growth potential and survival time. Moreover, they require 
elaborate isolation procedures and can exhibit considerable donor variability. 
Thus, the focus of the second part of the studies presented in this chapter 
was to test the ability of HCV JFH1-SGRs to replicate in HepaRG, a human 
hepatocyte cell line. This cell line was originally isolated from a female HCV-
infected patient with hepatocellular carcinoma (Gripon et al., 2002). The cells 
exhibit hepatocyte-like morphology and support HBV infection in a similar 
fashion to primary human hepatocytes. In addition, HepaRG cells have the 
ability to differentiate into both hepatocyte-like and billiary-like epithelial cells 
when cultured under appropriate conditions (Parent et al., 2004). HepaRG cells 
also express several liver-specific factors and have a similar gene expression 
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pattern to primary human hepatocytes (Hart et al., 2010). In this context, 
HepaRG cells could provide a useful alternative to primary cells for studying HCV 
due to better availability and unlimited proliferation. 
3.2 Construction of JFH1 SGRs containing genotype 3 
sequences 
As mentioned above, the use of SGR systems is limited by the availability of 
HCV isolates that replicate viral RNA in tissue culture cells. Previous attempts to 
construct replicons entirely from gt3 sequences have failed (Hubb, 2008). 
Hence, we aimed to examine the feasibility of replacing sequences in the highly 
efficient JFH1 SGR (gt2a), with those from a gt3 isolate from Glasgow (Shaw et 
al., 2003). Attention was focused on the C-terminal end of NS4B and the NS3/4A 
protease complex. The NS4B C-terminus was selected as a recent study had been 
published from our group (Jones et al., 2009) that had identified mutations in 
this region with varying effects on HCV RNA replication. In the case of NS3/4A, 
Imhof and Simmonds (2010) had shown that virus production was not blocked by 
introducing gt3 sequences into the full-length infectious JFH1 chimeric clone 
(JC-1). To examine whether gt3 sequences were functional in replication, a SGR 
expressing luciferase as a reporter (Luc-JFH1, hereafter referred as Luc-WT), 
was used since it allows rapid and transient assessment of viral RNA synthesis. 
The Luc-WT SGR is a bicistronic construct which contains a firefly luciferase 
reporter gene in the first cistron under the control of the HCV IRES and the JFH1 
NS3 to NS5B region in the second cistron under the control of a heterologous 
IRES from EMCV (Targett-Adams & McLauchlan, 2005). Assaying for luciferase 
activity is based on the assumption that enzyme levels directly correlate with 
the replication levels of replicon RNAs (Targett-Adams & McLauchlan, 2005). 
3.2.1 The NS4B C-terminal region is essential for HCV RNA 
replication 
Previous work from our group (Jones et al., 2009) demonstrated that the C-
terminal region of NS4B can tolerate several mutations without affecting 
replication. Hence, the capacity to replace residues in the C-terminal region of 
JFH1 NS4B with corresponding gt3 amino acids without abrogating replication 
was assessed. 
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NS4B is a hydrophobic protein which is able to interact with and rearrange 
the ER membrane to form sites where replication complex (RC) assembly takes 
place (called the membranous web, MW) (Egger et al., 2002; Gosert et al., 2003; 
Hugle et al., 2001). NS4B is predicted to comprise four transmembrane domains 
(TMDs) in the central region of the protein (aa ~70 to 190), flanked by N- and C-
terminal regions located at the cytosolic side of the ER membrane (Figure 3.1-A) 
(Elazar et al., 2004; Lundin et al., 2003). The N-terminal region (aa 1 to ~69) of 
NS4B is less conserved among HCV genotypes than the rest of the protein. This 
region is predicted to contain an amphipathic α-helix (aa 6 to 29), and a fifth 
TMD (termed TMX) which has been suggested to translocate into the ER 
membrane by a post-translational mechanism (Gouttenoire et al., 2009a; Lundin 
et al., 2003). 
The C-terminal region of NS4B (aa 191 to 261) is relatively well conserved 
between HCV genotypes and is predicted to possess two α-helical segments, H1 
(aa192 to 227) and H2 (aa228 to 253) (Figure 3.1). Recent studies on this region 
have suggested that H2 has an amphipathic α-helix which can mediate 
membrane association, suggesting that NS4B membrane association is mediated 
not only by the TMD but also by the amphipathic α-helices at the N- and C-
terminal domains (Elazar et al., 2004; Gouttenoire et al., 2009b; Liefhebber et 
al., 2009; Lindstrom et al., 2006). 
 
 
Figure 3.1- Predicted secondary structure of the NS4B C-terminus and sequence 
conservation between gt2a and gt3a variants. [A] A schematic representation of the 
predicted secondary structure of NS4B at the ER membrane. NS4B is predicted to contain 
four transmembrane domains (1-4), flanked by N- (aa 1 to ~69) and C- terminal (aa 191 to 
261) regions oriented to the cytosolic side of the ER. Represented are the amphipathic α-
helix (aa 6 to 29), a fifth TMX at the N-terminal region, as well as the NBM (nucleotide 
binding motif) (aa 129 to 135). The two predicted helices H1 (aa 201 to 213) and H2 (aa 228 to 
253) at the C-terminal region are also shown. [B] Sequences from the C-terminal region of 
NS4B, derived from strain JFH1 (GeneBank AB047639) and from Glasgow-3 strain (Shaw et 
al., 2003) were aligned using CLC workbench 4. Regions 1 and 2 represent conserved and 
less well conserved sequences between the two genotypes, respectively. Grey boxes within 
Regions 1 and 2 indicate helices H1 and H2, respectively. 
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Figure 3.2 – Representation of the gt3 mutants at the C-terminus of NS4B. Schematic 
representation of the amino acid sequence of the NS4B C-terminal region of gt2a and gt3a 
(Glasgow-3 strain). Amino acids substituted with gt3a variants are underlined and 
numbered M1-M11. 
 
3.2.2 Construction of SGRs containing gt3a sequences at the 
C-terminal region of NS4B (2a3a-NS4B-SGR) 
Alignment of the C-terminal region of NS4B from strain JFH1 (gt2a, 
GenBank AB047639) and HCV-strain Glasgow-3 (gt3a, (Shaw et al., 2003)) 
revealed that it can be separated into two segments Region 1 and Region 2, 
which contain α-helices H1 and H2 respectively. Region 1 was completely 
conserved (comprising aa 191 to 218) whereas region 2 (comprising aa 219 to 
261) differed at 11 amino acid positions (Figure 3.1-B). Using this information, 
the variable amino acids in Region 2 in strain JFH1 NS4B were converted to 
encode the corresponding Glasgow-3 residues (Figure 3.2). These mutations were 
introduced into a 266bp BamHI-BamHI DNA fragment spanning NS4B and NS5A 
sequences by site-directed mutagenesis (SDM), before introduction into a 
replicon called Luc-SGR-JFH1/M4. Luc-SGR-JFH1/M4 was generated in a previous 
study from our group (referred to as M9 in Jones et al., 2009). This construct 
contained a Gln to Ala mutation at position 231, which corresponds to the 
Glasgow-3 sequence at this position (Figure 3.1-B and Figure 3.2). Substitution 
from Gln to Ala had no impact on viral replication and thus Luc-SGR-JFH1/M4 
was used as the parent plasmid into which the remaining gt3a mutations were 
introduced. 
Patricia Domingues  Chapter 3 
 
121 
The overall strategy used to construct the Luc-2a3a-NS4B replicons from 
Luc-SGR-JFH1/M4 is represented in Figure 3.3 and is described as follows: 
 PCR amplification of the complete NS4B (783bp) and the first 31bp of 
NS5A coding regions from Luc-SGR-JFH1/M4, using the EcoRI-4B_Fwd 
and 4B/5A-SacI_Rev primers, which inserted EcoRI and SacI restriction 
sites at the 5’ and 3’ ends respectively of the amplified fragment 
(EcoRI-NS4B-SacI; Figure 3.3-A). 
 Insertion of EcoRI-NS4B-SacI into the pGEM-T Easy vector using EcoRI 
and SacI restriction sites to generate pGEM-NS4B/M4 (Figure 3.3-B). 
 The NS4B gt3a mutants were inserted into pGEM-NS4B/M4 by SDM using 
the primers shown in Figure 3.3-D and the strategy is described as 
follows (the numbers below correspond to the circled numbers in Figure 
3.3-C): 
1. Insertion of M1, M2 and M3 into pGEM-NS4B/M4 within the BamHI-
BstXI region to yield pGEM-NS4B-M1-4. 
2. Insertion of M6, M7 and M8 into pGEM-NS4B/M4 within the BstXI-
BamHI region to yield pGEM-NS4B-M4/6-8. 
3,4,5. Using BstXI and SacI restriction sites (Figure 3.3-C, upper panel), 
BstXI-M6-8-SacI was excised from pGEM-NS4B-M4/6-8 and inserted 
into the pGEM-NS4B-M1-4 backbone, generating pGEM-NS4B-M1-
8/Δ5. 
6. Insertion of M5 into the pGEM-NS4B-M1-8/Δ5 construct. This 
insertion resulted also in loss of the BstXI restriction site. 
7,8,9. Sequential insertion of M9, M10 and M11 into pGEM-NS4B-M1-8, 
resulting in the final pGEM-NS4B-M1-11 construct. 
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 Finally, using the BamHI restriction sites, the NS4B mutants were 
excised from pGEM-NS4B-M1-11 and inserted into Luc-JFH1 to yield Luc-
M1-11 (Figure 3.3-E). 
 In addition to the final Luc-M1-11 construct, mutants generated at 
intermediate SDM stages were also inserted into the Luc-SGR replicon 
(Figure 3.3-F) following the same cloning strategy (Figure 3.3-E). 
 
 
 
 
 
 
 
 
 
Figure 3.3- Construction of NS4B C-terminal mutants by site-directed mutagenesis. [A] PCR 
amplification of NS4B and the first 31bp of the NS5A coding region from Luc-SGR-JFH1/M4 
using the forward “EcoRI-4B_Fwd” and reverse “4B/5A-SacI_Rev” oligonucleotide primers. 
[B] Insertion of the amplified fragment, EcoRI-NS4B-SacI, into the pGEM-T Easy vector. [C] 
Representation of the restriction sites and locations of mutations at the 266bp BamHI-
BamHI fragment within the EcoRI-NS4B-SacI region (upper panel). NS4B nt sequence 
numbered 1 to 783: BamHI (position 521), BstXI (position 709) and BamHI (position 4, within 
the NS5A coding region). Insertion of M1 to 11 by SDM into pGEM-NS4B vector (lower 
panel): 1) Insertion of M1-3; 2) Insertion of M6-8; 3,4,5) Cloning of M6-8 into pGEM-M1-4 
vector using the BstXI and SacI restriction sites; 6) Insertion of M5 into pGEM-M1-8/Δ5; 
7,8,9) Insertion of M9, 10 and 11 into pGEM-M1-8 construct. [D]) Sequence and position of 
the SDM oligos used to generate M1 to M11 in the NS4B coding region. [E] Cloning of the 3’ 
terminal region of NS4B containing the gt3a mutants into Luc-SGR using BamHI-BamHI 
restriction sites. [F] Table representing all final Luc-SGRs generated at final or intermediate 
SDM stages. SDM, site-directed mutagenesis; nt, nucleotides; aa, amino acids. 
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SDM 1
SDM 2
TCC  AGA  GGA  AAC  CAC  GTC  GCC  CCT  ACT  CAC  TAC  GTG  ACG GAG
S       R       G       N       H        V       A       P      T       H       Y       V       T        E
TCG  GAT  GCG  TCG  CAG  CGT  GTG  ACC  CAA  CTA  CTT  GGC  TCT CTT
S       D       A       S       Q       R        V       T      Q       L       L       G       S       L
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3.2.3 Analysis of the replication competence of 2a3a-NS4B-
SGRs 
I. Luc-SGR containing all NS4B gt3a mutants does not replicate 
efficiently 
To determine whether introduction of gt3a sequences into the C-terminus 
of NS4B was tolerated in the context of the JFH1 replicon, transcribed RNA from 
Luc-M1-11 was electroporated into Huh-7 cells and the luciferase activity was 
measured for up to 72h (Figure 3.4), as an indirect assessment of replication 
efficiency. RNAs encoding Luc-WT and Luc-GND (a replication defective replicon 
encoding a GDD to GND mutation in the NS5B sequence (Kato et al., 2003) were 
also electroporated into cells and used as positive and negative controls 
respectively. The luciferase values indicated that replication of Luc-WT 
increased at all time points after electroporation (Figure 3.4-A). By contrast, the 
luciferase values decreased for Luc-GND, indicating the inability of this 
construct to replicate. For Luc-M1-11 the luciferase values declined between 4 
to 48h, similar to the pattern for Luc-GND (Figure 3.4-A). Between 48 and 72h 
there was a small recovery in luciferase activity (~2 fold), suggesting perhaps 
some ability of this construct to replicate, although enzyme levels were very 
low. 
Since M1-11 gave such low levels of replication, intermediate Luc-SGRs 
constructed during SDM (Figure 3.3-C & F) were examined to determine whether 
single mutations or a combination of mutations could account for the lack of 
replication. Starting from the constructs with a higher to lower number of gt3 
changes, Luc-M1-10, Luc-M1-9 and Luc-M1-8 constructs (which excluded M11, 
M10-11 and M9-11, respectively) were tested. As shown in Figure 3.4-A, removal 
of M11, M10 or M9 from Luc-M1-11 still gave decreased luciferase activity over 
72h similar to Luc-GND. In addition, the small recovery detected previously with 
the Luc-M1-11 replicon between 48 and 72h was now lost with all of the 
constructs (Luc-M1-10, Luc-M1-9 and Luc-M1-8) (Figure 3.4-A). Therefore, 
removal of M11, M10 or M9 from Luc-M1-11 did not restore replication. 
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II. M8 negatively affects replication in the context of the remaining gt3 
mutations 
To examine the other mutations that may impair replication, constructs 
containing mutants M1-4 and M4/6-8 (located at the N- and C-terminus of region 
2 of NS4B, respectively (Figure 3.3-C)) were tested. M5 was not present in these 
constructs as it was only introduced after combining M1-4 and M6-8 in the same 
vector (see SDM strategy Figure 3.3-C). RNA transcripts from Luc-M1-4 and Luc-
M4/6-8 were electroporated into Huh-7 cells and the activity of luciferase was 
measured as described before. The luciferase values indicated that M1-4 could 
replicate efficiently over 72h, in a similar manner to the WT replicon (Figure 
3.4-B). On the other hand, luciferase activity declined in the first 24h after 
electroporation for Luc-M4/6-8 and between 24 and 72h a small recovery in 
activity (~2 fold) was detected. Thus, separating the mutations in Luc-M1-8 
roughly in half was able to at least partially overcome the negative impact on 
replication. In addition, these results suggested that the mutation(s) responsible 
for the reduced replication competence of Luc-M1-11 were located most 
probably between M5-8 (i.e., M5, M6, M7 or M8, or a combination of these 
mutations). From among these mutants, attention was focused on M8 as it is 
located in close proximity to the NS4B/NS5A cleavage site and thus could affect 
proteolysis at this site by NS3/4A (Figure 3.3-C & D). Substitution of Ile with Ser 
is also a significant change in the physicochemical characteristics at position 259 
(hydrophibic to polar residue) (Figure 3.5-A) and this could have a detrimental 
effect on NS4B function. 
Similarly, M5 was another candidate because absence of this mutation in 
Luc-M1-4 and Luc-M4/6-8 constructs either completely or partially restored 
replication to WT-like levels (Figure 3.4-B). Moreover, substitution of Gly to Ser 
added another hydrophilic amino acid (aa) in the central region of H2 (Figure 
3.5-A). Although this change did not result in a change to the hydropathy pattern 
within the H2 (Figure 3.5-B), it could possibly negatively impact on H2 
interactions with other aa within NS4B or other viral proteins. 
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Figure 3.4 – Assessment of replication efficiency of NS4B gt3a mutants. Huh-7 cells were 
electroporated with Luc-SGR RNAs containing all or different combinations of gt3 mutants. 
The cells were lysed at 4, 24, 48 and 72h after electroporation and the extracts used for 
measuring luciferase activity. [A] M1-8, M1-9, M1-10 and M1-11; [B] M1-8, M1-4 and M6-8; [C] 
M1-8, M6-8, M1-8/Δ5 and M1-7/Δ5; [D] M1-8, M5, M8 and M5,8; [E] M1-8, M1-9/Δ8, M1-10/Δ8 
and M1-11/Δ8. RLU, relative light units. 
 
 
 
 
 
 
 
 
Figure 3.5 – Properties of the amino acids at the C-terminus of NS4B. [A] Analysis of aa 
residues within gt2 and gt3 sequences. Represented are aa 228 to 261 spanning M3 to M11. 
[B] Hydrophobicity plot of gt2a (upper panel) and gt3a M1-8 (lower panel) at the C-terminus 
of NS4B, using CLC Genomics Workbench 4 (based on Kyle-Doolittle algorithm). Positive 
values represent hydrophobic regions. 
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To examine both possibilities, Luc replicons containing M1-8 including or 
excluding M5 (Luc-M1-8 and Luc-M1-8/Δ5 respectively) and M1-7, excluding M5 
and M8 (Luc-M1-7/Δ5), were constructed (following the same strategy described 
in Figure 3.3-C). RNA transcripts from Luc-M1-8/Δ5 and Luc-M1-7/Δ5 were 
electroporated into Huh-7 cells and the activity of luciferase was measured for 
up to 72h as before. For comparative purposes Luc-M1-8 was tested in addition 
to the Luc-WT and –GND controls. As shown in Figure 3.4-C, luciferase values 
declined over the 72h period for Luc-M1-8/Δ5, following the same pattern as 
Luc-GND and Luc-M1-8, suggesting that M5 did not impair replication. However 
removal of M5 and M8 (Luc-M1-7/Δ5) restored luciferase activity to levels similar 
to Luc-WT over the 72h period (Figure 3.4-C). Furthermore, the effect of M5 and 
M8 individually (Luc-M5 and Luc-M8 respectively) or a combination of both 
mutants (Luc-M5,8) on replication was assessed. As shown in Figure 3.4-D, 
luciferase values for Luc-M5 increased over 72h similar to the levels for Luc-WT. 
By contrast, luciferase activity declined in the first 24h after electroporation for 
Luc-M8 and Luc-M5,8, and then recovered between 24 and 72h, although activity 
did not reach the same levels as for Luc-WT (~15 to 23 fold lower). Thus, M5 
alone did not apparently account for the lack of replication by M1-8. However, 
deletion of M5 and M8 in the context of the remaining NS4B mutations (Luc-M1-
7/Δ5) restored WT-like replication, suggesting that M8 was the mutation 
responsible for reduced replication competence of Luc-M1-8. 
To further confirm these results, a Luc replicon Luc-M1-7, containing M5 
and excluding M8 was constructed and its ability to replicate assessed as before. 
As shown in Figure 3.6-A, the luciferase levels increased throughout the 72h 
period for Luc-M1-7 in a similar fashion as observed for Luc-WT. In addition, 
examination of viral protein synthesis at 72h after electroporation by Western 
blot analysis, revealed high levels of NS5A protein in M1-7 (Figure 3.6-B), close 
to levels produced by Luc-WT. Thus, the C-terminal region of NS4B could 
tolerate mutations M1 to M7 without significantly affecting HCV RNA replication 
but inclusion of M8 into the NS4B sequences led to either no or very little RNA 
synthesis (Figure 3.6). 
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Since removal of M8 (Luc-M1-7) restored replication, the remaining 
mutations M9, M10 and M11 were added back to this construct (Luc-M1-9/Δ8, 
Luc-M1-10/Δ8 and Luc-M1-11/Δ8) and their ability to replicate was assessed. As 
shown in Figure 3.4-E, luciferase activity still decreased in the first 24h for Luc-
M1-9/Δ8 or in the first 48h for Luc-M1-10/Δ8 and Luc-M1-11/Δ8. Following those 
times, luciferase activity increased up to 72h for all of the constructs (Figure 
3.7), although did not achieve similar luciferase activity as for Luc-WT (~670, 
~300 and ~17 fold lower than WT in Luc-M1-11, Luc-M1-10 and Luc-M1-9, 
respectively). Nonetheless, the data indicate that as many as 10 gt3a-specific 
mutations could be introduced into the C-terminal region of NS4B and some HCV 
RNA replication could be retained. 
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Figure 3.6 – Luc-M1-7 replicates efficiently in Huh-7 cells. Huh-7 cells were electroporated 
with Luc-SGR RNAs containing Luc-WT, Luc-GND or M1-7. The cells were lysed at 4, 24, 48 
and 72h after electroporation and the extracts used for measuring the luciferase activity [A]; 
[B] Extracts from cells electroporated with Luc-WT, GND or M1-7 were prepared at 72 h 
post-electroporation and examined for NS5A expression using anti-NS5A and anti-catalase 
antisera RLU, relative light units. 
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Figure 3.7 – Replication efficiency of NS4B gt3a mutants. Huh-7 cells were electroporated 
with Luc-SGR RNAs containing M1-8, M1-9/Δ8, M1-10/Δ8 and M1-11/Δ8. The cells were lysed 
at 4, 24, 48 and 72h after electroporation and the extracts used for measuring luciferase 
activity. RLU, relative light units 
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3.2.4 Construction of 2a3a-NS3-4A-SGR 
As mentioned at the beginning of this section, in parallel with the gt3 
substitutions at the C-terminus of NS4B, the study also examined the impact of 
inserting gt3 sequences for the NS3/4A protease complex into the sub-genomic 
replicon. In a recent study, it was shown that virion production could be 
achieved by inserting the NS3 protease and the NS4A cofactor from the six major 
genotypes into the JC-1 chimeric version of JFH1, which produces high levels of 
infectious virus in Huh-7.5 cells (Imhof & Simmonds, 2010). Thus, in the second 
part of this study, we aimed to clone the NS3 protease and NS4A cofactor 
regions from J3a3a [JC-1 chimera containing NS3/4A sequences from HCV-strain 
Glasgow-3 (Imhof & Simmonds, 2010), Figure 3.9] into the Luc-JFH1 replicon and 
assess its ability to replicate. 
NS3 is composed of two functional and discrete units, an N-terminal 
chymotrypsin-like serine protease domain and a C-terminal RNA helicase/NTPase 
domain (Bartenschlager et al., 1993; Kim et al., 1997). NS4A is a small 
hydrophobic protein (6KDa) that forms a stable complex with the NS3 protease 
domain to promote anchoring to cellular membranes through an N-terminal 
hydrophobic peptide, thereby facilitating cleavage of the HCV polyprotein at the 
NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B junctions (Bartenschlager et 
al., 1993; Grakoui et al., 1993). In addition, the NS3/4A protease can antagonise 
antiviral mechanisms during HCV infection. NS3/4A cleaves IPS-1, the interferon 
β (IFNβ) promoter stimulator-1, and TRIF, a TLR3 adaptor protein (Li et al., 
2005b; Li et al., 2005c; Loo et al., 2006). Cleavage of these molecules prevents 
IPS-1- and TRIF-dependent signal transduction which is essential to stimulate 
IFNα and β expression. 
3.2.5 J3a3a replicates efficiently in Huh-7 and Huh-7.5 
The NS3-4A intergenotypic chimeric constructs developed by Imhof and 
Simmonds (2010) were characterised in Huh7.5 cells. These cells have been 
previously reported to give higher levels of replication as well as generate a 
higher titre of infectious virus when compared with parental Huh-7 cells 
(Pietschmann et al., 2006), which were the cells used in the current study. 
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Figure 3.8 – Schematic diagram of the JC-1 chimera genome. In the upper and lower panels 
are represented the JFH1 and JC-1 genome respectively. JC-1 chimera contains sequences 
from strain J6, spanning core to part of the NS2 coding regions, and from JFH1 strain for 
the remaining coding regions. 
 
To rule out the possibility that Huh-7 and Huh-7.5 cells give different 
replication efficiencies for J3a3a and any Luc-SGR derived constructs, RNA 
transcripts from J3a3a and JC-1 (used as control, Figure 3.8) were 
electroporated into the two cell lines. At 48h post-electroporation, levels of 
viral RNA were examined by RT-qPCR analysis. As shown in Figure 3.9-B, the 
levels of JC-1 RNA were about 6-fold higher in Huh-7.5 cells, when compared 
with the parental Huh-7 cells, as previously reported (Pietschmann et al., 2006). 
This suggested that J3a3a could replicate in Huh-7 cells, although less efficiently 
than in Huh-7.5 cells. Nonetheless, these data indicate that J3a3a can synthesise 
viral RNA in Huh-7 cells. 
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Figure 3.9 – J3a3a recombinant chimera and its ability to replicate in Huh-7 and Huh-7.5 
cells. [A] Schematic representation of the genomic map of the J3a3a chimera. Represented 
are the naturally occurring (BstBI, BglII, BlpI and SapI) or mutated (MluI) restriction sites 
used to clone the gt3a NS3 protease and NS4A cofactor coding regions in the JC-1 
backbone construct (adapted from (Imhof & Simmonds, 2010)). [B] RT-qPCR analysis of 
J3a3a and JC-1 RNA levels in Huh-7 and Huh-7.5 cells. HCV RNA levels were normalised 
against endogenous levels of GAPDH mRNA expression. 
3.2.6 Construction of JFH1 SGR containing genotype 3a NS3-
4A protease variants 
To construct a SGR containing the gt3a NS3 protease and NS4A coding 
sequences (Figure 3.10, A-D), the NS3 protease region was amplified from the 
J3a3a chimera, using the oligonucleotide primers “PmeI/NcoI-NS3_Fwd” (which 
inserted two new restriction sites, PmeI and NcoI, at the 5’ end of the fragment) 
and “NS3-SanDI_Rev” (which inserted a SanDI restriction site at the 3’ end of the 
fragment) (Figure 3.10-A). This fragment, PmeI/NcoI-NS3-SanDI, was then 
inserted into pGEM-T Easy to yield pGEM-PmeI/NcoI-NS3-SanDI. Subsequently, a 
second NcoI restriction site in the NS3 coding region was mutated in pGEM-
PmeI/NcoI-NS3-SanDI by SDM (Figure 3.10-B), to allow the use of the newly 
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inserted NcoI site in later cloning steps. Using BglII and SanDI restriction sites, 
the region encoding the NS4A cofactor was excised from the J3a3a chimera 
(BglII-NS3-NS5A-SanDI) and inserted into pGEM-PmeI/NcoI-NS3-SanDI vector to 
yield pGEM-PmeI/NcoI-NS3-NS5A-SanDI (Figure 3.10-C). 
Having generated a plasmid containing the relevant NS3 protease and NS4A 
coding sequences from gt3a, the strategy for constructing a SGR encoding these 
sequences is outlined in Figure 3.10-D. The process was as follows: 
1) pGEM-PmeI_EMCV-NS3-NS5A_SanDI was produced by combining 3 DNA 
fragments: PmeI-NcoI fragment containing the EMCV IRES generated 
from pLuc-SGR (numbered 1 in Figure 3.10-D); XmnI-PmeI and XmnI-
NcoI fragments from pGEM-PmeI/NcoI-NS3-NS5A-SanDI (numbered 2 
and 3 in Figure 3.10-D). Ligation of these 3 DNA fragments produced 
plasmid pGEM-PmeI-EMCV-NS3-NS5A-SanDI (Figure 3.10-D). 
2) Using the PmeI and SanDI restriction sites, a DNA fragment containing 
the EMCV-NS3-NS5A segment was excised from pGEM-PmeI-EMCV-NS3-
NS5A-SanDI and inserted into the Luc-SGR, to generate Luc-SGR-2a3a-
NS3/4A (Figure 3.10-D). 
 
 
 
Figure 3.10 – Cloning of the NS3-4A protease region from gt3a into Luc-SGR. [A] PCR 
amplification of NS3 protease coding region from J3a3a and insertion of PmeI/NcoI (3’ end) 
and SanDI (5’ end) restriction sites using the forward “PmeI/NcoI-NS3_Fwd” and reverse 
“NS3-SanDI_Rev” oligos. [B] 1) Insertion of PmeI/NcoI-NS3-SanDI into the pGEM-T Easy 
vector; 2) deletion of a second NcoI restriction site by SDM. [C] Cloning of NS4A region: 1) 
digestion of J3a3a vector with BglII and SanDI and 2) insertion of BglII-NS3-NS5A-SanDI 
fragment into pGEM-PmeI/NcoI-NS3-SanDI. [D] Cloning of NS3-4A region from pGEM-T Easy 
vector into Luc-SGR: 1) Excision of EMCV IRES from Luc-SGR using PmeI and NcoI 
restriction sites; 2) Digestion of pGEM-PmeI/NcoI-NS3-NS5A-SanDI vector with XmnI, PmeI 
and NcoI; 3) Ligation of PmeI-EMCV IRES-NcoI, XmnI-PmeI and NcoI-XmnI fragments; 4) 
Using PmeI and SanDI, gt3a NS3-4A region was excised from pGEM-PmeI-EMCV-NS3-NS5A-
SanDI and inserted into Luc-SGR. SDM, site-directed mutagenesis. 
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3.2.7 Analysis of Luc-2a3a-NS3-4A-SGR replication 
To determine whether the introduction of NS3 and NS4A gt3a sequences 
affected transient replication of the JFH1 SGR, RNA from Luc-2a3a-NS3-4A was 
electroporated into Huh-7 cells and the activity of luciferase was measured for 
up to 72h (Figure 3.11). RNAs from Luc-WT and Luc-GND were also 
electroporated into cells and used as positive and negative controls respectively. 
Luciferase activity from Luc-WT and Luc-GND followed the same pattern as 
seen previously. Thus, enzyme activity increased between 4 and 72h for Luc-WT 
whereas luciferase values from Luc-GND decreased over the corresponding 
period. Luc-2a3a-NS3-4A gave the same pattern of luciferase activity as Luc-
GND, indicating that replacement of the JFH1 NS3 protease and NS4A cofactor 
with gt3a sequences in Luc-WT was not tolerated in short-term transient assays 
in Huh-7 cells. 
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Figure 3.11 – Luc-2a3a-NS3-4A cannot replicate in Huh-7 cells. Huh-7 cells were 
electroporated with WT, GND and 2a3a-NS3-4A Luc-SGRs. The cells were lysed at 4, 24, 48 
and 72h after electroporation and the extracts used for measuring the luciferase activity. 
RLU, relative light units. 
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Given that Huh-7.5 cells generally support higher levels of HCV replication 
than Huh-7 cells, it was thought that Luc-2a3a-NS3-4A might also replicate 
better in Huh-7.5 cells. To that end, RNA transcripts from Luc-WT, Luc-GND and 
Luc-2a3a-NS3-4A were electroporated into both cell lines and luciferase activity 
assessed at 4, 24, 48 and 72h after electroporation. As shown in Figure 3.12, the 
luciferase activity in both Huh-7/WT and Huh-7.5/WT cells increased from 4 to 
72h after electroporation. By contrast for Luc-GND, the luciferase values 
decreased throughout all time points in both cells lines. As before, luciferase 
activity from Luc-2a3a-NS3-4A gave similar levels to Luc-GND in Huh-7 cells, 
indicating its inability to replicate. When electroporated into Huh-7.5 cells, Luc-
2a3a-NS3-4A activity decreased between 4 and 48h. However, a 5- to 6-fold 
increase in luciferase activity was detected between 48 and 72h, suggesting that 
Luc-2a3a-NS3-4A could replicate in Huh-7.5, although with much lower 
efficiency than the WT replicon. These data were reproducible in further 
experiments (J. Liefhebber, pers. comm.). 
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Figure 3.12 – Transient replication assay of Luc-WT, Luc-GND and Luc-2a3a-NS3-4A 
electroporated in Huh-7 and Huh-7.5 cells; the cells were lysed at 4, 24, 48 and 72h after 
electroporation and the extracts used for measuring the luciferase activity. RLU, relative 
light units. 
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3.3 Characterisation of ability of HepaRG cells to 
replicate HCV genomes 
As mentioned previously, in vitro studies on HCV infection and replication 
have been possible due to the use of permissive Huh-7 and Huh-7-derived cell 
lines that support the virus life cycle. Despite the advantages of these cells, 
they do not fully recapitulate all aspects of HCV replication in naturally infected 
hepatocytes. To gain a better understanding of HCV-host interactions, 
alternative cellular models which exhibit more hepatocyte-like characteristics 
than Huh-7 cells are needed. In this context, we sought to investigate the 
feasibility of replicating HCV RNAs in HepaRG cells, which have a similar gene 
expression pattern to primary human hepatocytes and human liver tissue (Hart 
et al., 2010). 
3.3.1 HepaRG cells are not permissive for transient HCV 
replication 
To investigate whether HepaRG cells could support HCV replication, Luc-
WT was used since it allows rapid and transient assessment of viral RNA 
synthesis. RNA transcripts from Luc-WT and Luc-GND were introduced into Huh-7 
and HepaRG cells and luciferase activity in cell extracts was assayed at time 
intervals up to 72h after electroporation (Figure 3.13-A). Luciferase values 
generated by Luc-WT in Huh-7 cells (Huh-7-WT) decreased slightly between 4 
and 24 h and then increased (about 6 fold) until 72h after electroporation. By 
contrast, luciferase values decreased throughout all the time points for Luc-GND 
(Huh-7-GND), as shown in previous experimental data. In HepaRG cells, the 
luciferase values produced by both the Luc-WT and Luc-GND replicons (HepaRG-
WT and -GND, respectively) followed a similar pattern to Huh-7-GND between 4 
and 72h (Figure 3.13-A). 
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Figure 3.13 – HCV SGR replicons cannot replicate in HepaRG cells. [A] Huh-7 and HepaRG 
cells were electroporated with in vitro transcribed Luc-WT and Luc-GND RNAs. Cell extracts 
were assayed for luciferase activity at 4, 24, 48 and 72h after electroporation. RLU, relative 
light units. [B] Intracellular localization of NS5A protein: Huh-7 and HepaRG cells containing 
Luc-WT replicons were fixed at 4, 24, 48 and 72h after electroporation and the cells stained 
for NS5A protein using anti-NS5A antisera. White arrows indicate NS5A expressing cells. [C] 
Extracts from Huh-7 and HepaRG cells electroporated with Luc-WT and Luc-GND were 
prepared at 72h post-electroporation and examined by Western blot analysis with anti-NS5A 
and anti-actin antisera. 
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The correlation between luciferase activity and viral protein synthesis in 
both Huh-7 and HepaRG cells with Luc-WT was examined by indirect 
immunofluorescence and Western blot analysis. Immunofluorescence analysis 
revealed that NS5A expression could be detected in Huh-7 cells electroporated 
with Luc-WT RNA as early as 4h and 24h, and the abundance of intracellular 
protein increased by 48h and 72h (Figure 3.13-B). By contrast, NS5A expression 
was barely detectable at early time-points (Figure 3.13-B, white arrows indicate 
NS5A expressing cells) in HepaRG cells and by 48h and 72h expression of the 
protein was not observed. 
Detection of NS5A protein by Western blot analysis was only examined at 
72h post-electroporation (Figure 3.13-C). Analysis of cell extracts revealed that 
expression of NS5A was readily observed in Huh-7-WT, however in Huh-7-GND, 
NS5A was not detected. NS5A expression from either the Luc-WT or -GND 
replicons was not found in HepaRG cells. Analysis of the abundance of actin in 
each sample revealed that approximately equivalent amounts of cell protein 
were present in the extracts. These results are in agreement with the data from 
the luciferase assays and together indicate that HepaRG cells cannot support 
HCV RNA synthesis during transient assays. 
3.3.2 HepaRG cells can efficiently translate HCV SGR RNAs 
To determine whether the lack of HCV replication in HepaRG cells could be 
linked to low efficiency in the translation of input replicon RNAs, Luc-WT RNA 
was electroporated into Huh-7 and HepaRG cells and the extent of translation 
was determined between 1 and 8h, which is prior to the onset of detectable 
replication (typically 12-14h in Huh-7 cells (Jones et al., 2007)). As shown in 
Figure 3.14, luciferase values in Huh-7 cells increased about 25-fold between 1 
and 4h after electroporation. After 4h, luciferase activity decreased slightly and 
reached a plateau by 8h. In HepaRG cells, the luciferase values closely followed 
the same pattern as in Huh-7 cells during the first 4h after electroporation, but 
the enzyme levels were about 5-fold lower. In the following 4h (between 4 and 
8h after electroporation) luciferase activity continued to rise, reaching levels at 
8h which were almost identical to those in Huh-7 cells. These results suggest 
that the inability of HepaRG cells to support transient HCV replication is not 
linked to an inability to translate input viral RNA. 
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Figure 3.14 - Translation of Luc-SGRs in Huh-7 and HepaRG cells. Huh-7 and HepaRG cells 
were electroporated with in vitro transcribed Luc-WT RNA and assayed for luciferase 
activity at 1, 2, 4, 6 and 8h after electroporation. RLU, relative light units. 
3.3.3 HCV can replicate in HepaRG cells in stable replication 
assays 
To further investigate whether HepaRG cells could support HCV replication, 
RNA transcripts from subgenomic replicons carrying the neomycin resistance 
gene were electroporated into cells and their ability to form drug-resistant 
colonies was assessed by 3–4 weeks after electroporation. In these experiments, 
RNA was made from SGR constructs in which the neomycin selectable marker 
gene (neo) replaced the Luc reporter gene (Neo-SGR-WT and –GND), thereby 
permitting selection of drug-resistant colonies in the presence of G418. 
To determine whether HepaRG cells could form drug-resistant colonies, 
Neo-SGR-WT and -GND RNA transcripts (hereafter referred as Neo-WT and Neo-
GND respectively) were electroporated into Huh-7 and HepaRG cells and 
incubated for 3-4 weeks in the continuous presence of G418 to select for cells 
that were neomycin resistant. After 3-4 weeks, the drug-resistant colonies were 
stained with Coomassie Brilliant blue. From the results shown in Figure 3.15, the 
colony-forming capacity in both cell lines was visibly different and by 
comparison with Huh-7 cells, HepaRG cells had a lower capacity to form 
neomycin resistant colonies. Nevertheless, the ability to recover drug-resistant 
colonies with HepaRG cells suggested that the Neo-WT replicon could 
constitutively replicate, albeit at a much lower efficiency compared to Huh-7 
cells. Thus, contrary to the data from the experiments with transient assays, 
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HepaRG cells could support HCV replication in an assay that relied on 
constitutive replication. 
Following the above results, it was possible to select a population of drug-
resistant HepaRG cells containing HCV replicons. To expand the range of 
antibiotics that could be used for selection, another replicon was used that 
replaced the neo gene with the blasticidin resistance gene (blast). In parallel 
experiments, growth of HepaRG cells in the presence of blasticidin gave more 
rapid cell killing as compared to G418 (data not shown). Preliminary data with 
populations of cells harbouring the blasticidin-resistant replicon (Blast-SGR-WT) 
also revealed detection of NS5A while the protein was rarely found in cells with 
the neo replicon (data not shown). As a consequence, further experiments were 
performed on blasticidin-resistant HepaRG replicon cells. 
WT GND
HepaRG
Huh-7
 
Figure 3.15 – Colony-forming capacity in Huh-7 and HepaRG cells. Huh-7 and HepaRG cells 
were electroporated with G418-selectable replicons (Neo-WT and Neo-GND). After 3-4 weeks 
of incubation with the antibiotic, drug-resistant colonies were stained with Coomassie 
Brilliant blue. 
Patricia Domingues  Chapter 3 
 
150 
To characterize the HCV subgenomic replicon in HepaRG cells, a population 
of blasticidin-resistant cells (hereafter referred to as HepaRG-SGR) was 
examined for the presence of NS5A protein and dsRNA by indirect 
immunofluorescence (Figure 3.16-A). The presence of viral dsRNA was analysed 
using the J2 antibody, previously described as an indicator of putative sites of 
RNA replication (Targett-Adams et al., 2008). For comparative purposes, Huh-7 
replicon cells (Huh-7-SGR) were used as control. Huh-7-SGR and HepaRG-SGR 
cells were fixed and probed with anti-NS5A antisera and monoclonal J2 antibody. 
In Huh-7-SGR cells, immunofluorescence analysis revealed that most of the cells 
were positive for NS5A expression (~99% of the cells) and the viral protein was 
widely distributed throughout the cell cytoplasm. The distribution of dsRNA in 
these cells was punctate and in some areas colocalization of J2 and NS5A was 
evident (Figure 3.16-A-i). By contrast, in HepaRG-SGR cells, only 5 to 10% of the 
cell population expressed NS5A protein. In these cells, NS5A was also distributed 
throughout the cell cytoplasm, but exhibited a more punctuate localization than 
in Huh-7 cells. The distribution of dsRNA in most of the HepaRG-SGR cells 
followed the distribution of NS5A, and contrary to Huh-7-SGR cells, J2 and NS5A 
colocalized to a greater extent in these cells (Figure 3.16-A-ii). 
Expression of NS5A protein was also examined by Western blot analysis. 
Extracts from Huh-7-SGR cells revealed the presence of high levels of NS5A 
protein. By contrast, much lower, but detectable amounts of NS5A were 
observed in HepaRG-SGR cells (Figure 3.16-B). In addition, NS5A in the HepaRG-
SGR cells was present as two species, representing the hypo- (56 kDa) and 
hyperphosphorylated (58 kDa) forms of the protein, which are typically found in 
cells containing the replicon. In Huh-7-SGR cells, it was not possible to identify 
two species due to the excessive amount of protein detected. 
In addition to these results, steady-state levels of replicon RNA were 
monitored for up to 14 passages during establishment of the respective Huh-7-
SGR and HepaRG-SGR cell lines by RT-qPCR analysis. As shown in Figure 3.16-C, 
the range in viral RNA levels in Huh-7 cells were 7- to 33-fold greater than those 
in HepaRG cells. Nonetheless, replicon RNA could be detected in HepaRG-SGR 
cells during the establishment of the replicon cell line and together with the 
results from the colony-forming experiments, suggest that HepaRG cells can 
support HCV replication in long-term replication assays. 
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Figure 3.16 – Stable HCV replication in HepaRG cells. [A] Immunofluorescence analysis of 
NS5A and dsRNA localisation in Huh-7 and HepaRG replicon cells. For visualization of 
nuclei, the cells were stained with DAPI. Boxed regions are shown enlarged in panels i and 
ii (right side of respective cells). Arrows indicate colocalization of dsRNA and NS5A in 
replicon-containing cells. [B] Cell extracts from Huh-7 and HepaRG replicon cells were 
probed with NS5A and actin antisera. Upper NS5A blot represents a lower exposure time, 
and the lower NS5A blot represents a higher exposure time. [C] RT-qPCR analysis of 
steady-state levels of replicon RNA in Huh-7 and HepaRG replicon-containing cells during 
early passages. HCV RNA levels were normalised against endogenous levels of GAPDH 
mRNA. 
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3.3.4 HepaRG cells are not permissive for HCVcc infection 
To determine the permissiveness of HepaRG cells to HCV infection, JC-1 
virus was used (Figure 3.8). To generate a stock of infectious virus, Huh-7 cells 
were electroporated with JC-1 RNA and the supernatant was removed at 48h. 
The virus titre was estimated as 6.5x104virus/ml by TCID50 analysis and then used 
as the inoculum to infect Huh-7 and HepaRG cells. In order to include a negative 
control for virus production, the inoculum was exposed to UV light to inactivate 
the virus. As shown in Figure 3.17-A, the UV-inactivated inocula lost the ability 
to establish infection in Huh-7 cells, when compared with non-inactivated stock. 
Quantitative analysis of intracellular viral RNA further confirmed that only the 
non-inactivated inoculum retained the ability to replicate in Huh-7 cells (Figure 
3.17-B). 
Using this information, JC-1 and JC-1/UV (virus exposed to UV light for 2 
minutes) were used to infect Huh-7 and HepaRG cells at a moi of 0.4. At 6, 24 
and 48h after infection, RNA was extracted from cells and viral RNA levels were 
assessed by RT-qPCR. As shown in Figure 3.18, JC-1 replicated efficiently in Huh-
7 cells, as the RNA levels increased throughout the infection period. By contrast, 
the UV-inactivated virus did not produce detectable levels of viral RNA over the 
same time period. In HepaRG cells, viral RNA was only detected at 6h after 
infection and in the following 24 and 48h these levels decreased, similar to the 
JC-1/UV virus, indicating that HepaRG cells could not support infection and 
replication of JC-1. 
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Figure 3.17 - Infection of Huh-7 cells with UV-inactivated virus. Huh-7 cells were infected 
with JC-1 or JC-1/UV for up to 48h. [A] TCID50/ml of JC-1 inocula exposed to 0, 1, 2 and 
5min of UV light. [B] Levels of HCV RNA were determined by RT-qPCR analysis normalised 
against abundance of GAPDH mRNA. 
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Figure 3.18 – HepaRGs are not permissive to HCV infection. Huh-7 and HepaRG cells were 
infected with JC-1 or JC-1/UV for up to 48h. Levels of HCV RNA were determined by RT-
qPCR analysis and normalised against abundance of GAPDH mRNA. 
 
3.3.5 Innate immune responses may dictate the 
permissiveness of HepaRG cells to viral replication 
The permissiveness of Huh-7 cells to HCV infection and replication in vitro 
is thought to be linked with an impaired antiviral response (Keskinen et al., 
1999; Li et al., 2005a). By contrast, HepaRG cells may retain the ability to 
mount a robust antiviral response upon HCV replication. To investigate whether 
the reduced permissiveness of HepaRG cells to HCV infection and replication 
could be linked with an intact innate response, IFN-regulated pathways were 
examined in these cells. 
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The innate immune system represents the first line of defence against 
invading viral pathogens. Following infection, recognition of conserved 
molecular signatures expressed by the virus (pathogen associated molecular 
patterns, PAMPs) are recognised by specialised pattern recognition receptor 
molecules (PRR), such has TLR3 and RIG-I. This interaction initiates TLR3- and 
RIG-I-dependent signalling pathways leading to induction and release of type I 
IFNs (Figure 3.19). Binding of type I IFNs to IFNα/β receptors (IFNR1/2) on the 
cell surface activates Jak/STAT signalling pathways and stimulation of a wide 
array of IFN-stimulated genes (ISGs) (Figure 3.19). Most of these genes encode 
antiviral proteins which can mediate antiviral activities and are likely to 
influence the outcome of infection. 
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Figure 3.19– dsRNA signalling and activation of type I IFN pathways. Upon infection, viral 
RNA can signal through RIG-I/TLR3-dependent pathways and induce the production of 
IFNα/β. IFNα/β bind to type I IFN receptors at the cell surface and activate Jak/STAT 
signalling cascade, which induces the synthesis of hundreds of IFN-stimulated genes 
(ISGs). 
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3.3.5.1 IFN signalling through the JAK/STAT pathway is functional in 
HepaRG cells 
To analyse the kinetics of type I and type II IFN-inducible gene expression, 
HepaRG and Huh-7 cells were treated with increasing doses of IFNα, β and γ. At 
48h after treatment, ISG induction was assessed my measuring ISG15 RNA and 
protein expression levels. As shown in Figure 3.20-A, ISG15 mRNA increased in a 
dose-dependent manner in response to IFNα and β in Huh-7 cells, but was less 
efficiently induced by IFNγ. Similarly ISG15 mRNA expression increased in 
HepaRG cells following treatment with IFNα and β, but to a lesser extent with 
IFNγ. However, the ISG15 levels detected in HepaRG cells were ~4-fold (IFNα 
treated) and ~2-fold lower (IFNβ treated) than in Huh-7 cells (Figure 3.20-C). 
Analysis of protein synthesis revealed that following IFNα and β treatment, high 
levels of both conjugated and free ISG15 protein were detected in both Huh-7 
and HepaRG cells (Figure 3.20-B & D). Similar to the RNA data, IFNγ proved to be 
a poor inducer of ISG15 protein. Thus, these data indicate that IFN signalling 
through Jak/STAT pathway is intact in both Huh-7 and HepaRG cells. 
 
 
 
 
 
 
 
Figure 3.20- Type I IFNs are strong inducers of ISG15. HepaRG and Huh-7 cells were treated 
with increased doses (0, 50, 100 and 200U/ml) of IFNα, β and γ. At 48h after treatment cells 
extracts were used for RT-qPCR analysis of ISG15 mRNA expression (A – Huh-7 and C – 
HepaRG cells) and Western blot analysis (B – Huh-7 and D – HepaRG cells) of ISG15 free 
and conjugated forms using anti-ISG15 antisera. 
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3.3.5.2 HepaRG cells sense extracellular and intracellular poly-I:C and 
induce the expression of ISG15 
To further characterise the responsiveness of HepaRGs cells, they were 
treated with poly-I:C. Poly-I:C is a synthetic analogue of dsRNA which is 
recognised by TLR3 (extracellular) or RIG-I/MDA5 (intracellular) receptors. 
Activation of these receptors promotes the induction of type I IFNs and 
consequently the expression of ISGs. For comparative purposes, Huh-7 cells were 
used in these experiments, as they have been previously shown to be defective 
for poly-I:C signalling through TLR3 (Li et al., 2005a). 
Poly-I:C was added to monolayers of HepaRG and Huh-7 cells and at 6, 24 
and 48h, ISG15 expression was analysed by RT-qPCR. As shown in Figure 3.21, 
poly-I:C failed to induce ISG15 at any time-point in Huh-7 cells. By contrast, 
ISG15 expression increased about 20-fold by 6h after poly-I:C treatment in 
HepaRG cells, when compared with mock-treated cells (Figure 3.21); by 24 and 
48h ISG15 expression decreased. Thus, contrary to Huh-7 cells in which TLR3 is 
defective, HepaRG cells retained the ability to sense extracellular poly-I:C, 
suggesting that TLR3 signalling is intact in these cells. 
To examine whether cytoplasmic signalling responses were intact in 
HepaRG cells, poly-I:C was transfected into the cells, to mimic intracellular 
dsRNA generated during viral replication. For comparative purposes, in addition 
to HepaRG and Huh-7 cells, Huh-7.5 cells were also used in these experiments. 
Huh-7 cells contain a functionally intact RIG-I signalling pathways whereas Huh-
7.5 cells are defective in this pathway as a result of a point mutation within RIG-
I CARD-like homology domain (Sumpter et al., 2005). HepaRG, Huh-7 and Huh-
7.5 cells were transfected with 5ug/ml of poly-I:C and the ability to induce 
ISG15 expression was analysed at 24h by RT-qPCR. As shown in Figure 3.22, 
ISG15 levels increased ~160 fold in response to poly-I:C in HepaRG cells, when 
compared to the levels in mock-treated cells. Interestingly, high levels of ISG15 
were induced in response to poly-I:C transfection in Huh-7 cells, indicating that 
TLR3-independent signalling was used for sensing dsRNA in these cells, such as 
the RIG-I pathway. As expected, Huh-7.5 cells which are defective in both TLR3 
and RIG-I signalling, did not respond to intracellular poly-I:C (Figure 3.21). Thus, 
in contrast to Huh-7 cells, HepaRG cells can sense and respond to both 
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extracellular and intracellular poly-I:C, indicating that innate signalling 
pathways are intact in these cells. 
 
Figure 3.21– Extracellular responses to poly-I:C in HepaRG cells. Huh-7 and HepaRG cells 
were treated with poly-I:C (100ug/ml) and IFNα (10U/ml) and at 6, 24 and 48h after treatment 
cells extracts were used for RT-qPCR analysis of ISG15 mRNA expression. 
 
 
Figure 3.22 – Intracellular responses to poly-I:C in HepaRG cells. HepaRG, Huh-7 and Huh-
7.5 were electroporated with 5ug/ml poly-I:C and 24h after, ISG15 expression was analysed 
by RT-qPCR. 
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3.3.5.3 HepaRG cells induce ISG15 expression in response to viral RNA 
To examine whether HCV RNA could elicit an induction in the IFN signalling 
cascade, Luc-WT and –GND RNAs were electroporated into Huh-7 and HepaRG 
cells and ISG15 RNA levels were monitored by RT-qPCR. To assess HCV RNA 
replication, luciferase activity was measured between 4 and 48h. As shown in 
Figure 3.23, luciferase activity decreased slightly between 4 and 12h in Huh-7 
for Luc-WT (Huh-7 WT) and between 12h and 48h increased about 6-fold. By 
contrast, luciferase values decreased throughout all the time points for Luc-GND 
(Huh-7 GND). In HepaRG cells, luciferase activity for both the Luc-WT and Luc-
GND replicons (HepaRG WT or GND, respectively) was lower than in Huh-7 cells 
and followed a similar pattern to Huh-7 GND between 4 and 48h, consistent with 
previous results (Figure 3.13-A). Analysis of ISG15 RNA by RT-qPCR, revealed that 
basal levels did not change throughout the 48h period in Huh-7-WT or Huh-7-
GND, when compared with mock-electroporated cells (Figure 3.23). By contrast, 
in HepaRG cells the basal levels of ISG15 in mock-electroporated cells were 6- to 
10-fold higher than the respective Huh-7 cells. Moreover, ISG15 RNA increased 
between 2- to 3-fold between 4 and 12h in HepaRG cells; by 24 and 48h those 
levels had decreased to levels similar to mock-electroporated cells. Taken 
together, in contrast to Huh-7 cells, HepaRGs had the ability to sense and 
respond to HCV RNA. Hence, the low permissiveness to replicate HCV RNAs in 
HepaRG cells may be partially explained by innate immune responses in these 
cells. 
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Figure 3.23– ISG15 is upregulated during transient HCV replication in HepaRG cells. [A] 
Huh-7 and HepaRG cells were electroporated with in vitro transcribed Luc-WT and Luc-GND 
RNA; Cell extracts were assayed for luciferase activity at 4, 8, 12, 24 and 48h after 
electroporation. RLU, relative light units. [B] Levels of ISG15 and IFNβ mRNA were 
determined by RT-qPCR analysis normalised against abundance of GAPDH mRNA. 
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3.4 Discussion 
The advent of replicons based on natural HCV isolates and cell lines that 
could support viral RNA replication has made it possible to study the factors 
governing the mechanisms required for synthesis of the HCV genome as well as 
providing a tool for screening and identification of lead compounds for antiviral 
therapeutics. Currently, replicon systems are available for gt 1a, 1b and 2a 
isolates, which are able to replicate viral RNA both transiently and continuously 
in Huh-7 cells. Out of the predicted 170 million individuals infected with HCV, 
estimates for those carrying gt3 strains are uncertain although it is the second 
most predominant genotype after gt1. Moreover, it is widely distributed across 
the globe. In the UK, infection with gt3 accounts for about 44% of cases and has 
a similar prevalence to gt1. The lack of cell culture systems for gt3 has 
hampered studies on its pathogenesis and responsiveness to novel anti-HCV 
therapeutics. Previous attempts to construct a gt3 replicon using sequences from 
a Glasgow gt3a isolate failed to replicate in cells in vitro (Hubb, 2008). Our 
approach focused on replacing amino acid sequences from the C-terminus of 
NS4B and NS3/4A protease from the JFH1 SGR with those from the Glasgow-3 
gt3a isolate. In addition, we also sought to expand the cell lines permissive for 
HCV RNA replication. Thus far, only Huh-7 cells are highly permissive for viral 
replication and virus production in culture. As stated earlier, although these 
cells are derived from the liver, they are also hepatoma cells and thus may not 
fully recapitulate the features of hepatocytes during normal infection by HCV. In 
the second part of the studies presented in this chapter, the key objective was 
to determine the permissiveness of HepaRG cells, a cell line which retains many 
features of fully functional hepatocytes, to HCV replication. 
3.4.1 Chimeric gt2a/gt3a SGR 
Eleven amino acid changes were required to convert the C-terminus of 
NS4B from a JFH1 sequence into gt3. Introduction of these changes into the JFH1 
luciferase replicon (Luc-M1-11) effectively abolished replication, with only a 
slight rise in luciferase activity by 72h after electroporation (Figure 3.4-A). All of 
these changes lay in Region 2 at the C-terminus of NS4B; by contrast, the 
sequences in Region 1 were fully conserved (Figure 3.24-A). This suggests two 
functionally distinct regions at the C-terminus of NS4B. Interestingly, 7 out of 
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the 11 amino acid differences reside in predicted Helix 2 (Figure 3.24-A). 
Analysis of helical wheel projections of Helix 2 containing the gt3a substitutions 
(Figure 3.25) indicated that the variable sequences are not strictly located to a 
particular face of the helix. Perhaps the most interesting feature in this analysis 
is the positions of M9 and M10, which do slightly impair replication. The amino 
acids at these positions are located about 2 helical turns from each other. 
Therefore, substitution at these sites may impede genotype-specific interactions 
of H2 with either viral or host factors. There is evidence that palmitoylation 
occurs at cysteine residues at positions 257 and 261 (Yu et al., 2006). M11 is 
located at position 257 and is a Tyr residue in the gt3a sequence, which would 
block palmitoylation at this site. Yu et al demonstrated that palmitoylation at 
residue Cys 261 affects oligomerisation of NS4B, which might be linked to 
membranous web formation. It is possible that, in our study, substitution at 
position 257 impairs replication also through affecting oligomerisation of the 
protein. 
The most deleterious variant amino acid was found at position 259 (M8; Ile 
to Ser). This substitution is located at the P3 position at the boundary sequence 
for cleavage of NS4B/NS5A (Figure 3.26). NS3-dependent cleavage sites consist 
of an acidic amino acid at P6 position, a Cys or Thr at the P1 position and a Ser 
or Ala at the P1’ position (Bartenschlager et al., 1995). However, changes in 
amino acid residues located at the P3 and P4 positions within the NS4B/NS5A 
boundary sequence also affect efficient proteolysis at this site (Kim et al., 
2000). Moreover, Herod et al, (2012) demonstrated that increased rate of 
cleavage at the NS4B/NS5A boundary can be achieved by mutations at the P3 
and P4 sites (Herod et al., 2012). This increase in cleavage efficiency at the 
NS4B/NS5A boundary also resulted in a lethal effect on viral replication. Thus, it 
is possible that the negative impact of mutation I259S at P3 is a result of 
changes in the rate of cleavage between NS4B and NS5A segments in the viral 
polyprotein. Interestingly, introduction of compensatory mutations at P1’-P3’ 
slowed the rate of cleavage at this boundary and also restored replication 
(Herod et al., 2012). Analysis of the gt3a sequence at the N-terminus of NS5A, 
revealed that a change at the P3’ position is required to convert gt2a to a gt3a 
sequence (Figure 3.26, Ser to Asp). Future studies that substituted Asp for Ser at 
position P3’ would help to address this question. 
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-M1, M2, M3, M4, M5, M6, M7, M8, M9, M10Luc-M1-10
+M1, M2, M3, M4, M5, M6, M7, M9, M10, M11Luc-M1-11/Δ8
-M1, M2, M3, M4, M5, M6, M7, M8Luc-M1-8
Luc-SGR constructs NS4B mutants Replication
Luc-M1-11 M1, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11 +/-
Luc-M1-9 M1, M2, M3, M4, M5, M6, M7, M8, M9 -
Luc-M1-7 M1, M2, M3, M4, M5, M6, M7 +++
Luc-M8 M8 ++
Luc-M1-10 /Δ8 M1, M2, M3, M4, M5, M6, M7, M9, M10 ++
Luc-M1-9 /Δ8 M1, M2, M3, M4, M5, M6, M7, M9 ++
WT GND
[A]
[B]
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Figure 3.24 – Replication efficiency of genotype 3 NS4B mutants. [A] Schematic 
representation of the amino acid sequence of the NS4B C-terminal region of gt2a and gt3a. 
Amino acids substituted with gt3a variants are underlined and numbered M1-M11. [B] 
Summary of effect of mutations on viral replication using green or “++++” as WT-like 
replication and red or “-“ as GND replication deficient. Intermediate colours represent 
different degrees of replication in relation to both WT and GND. 
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Helix 2 - JFH1 sequence Helix 2 – gt3 sequence  
Figure 3.25 – Helical wheel projections of JFH1 (left panel) and Glasgow-3 (right panel) 
NS4B Helix 2. Grey dashed arrows represent the positions on the helix of the gt3a changes. 
Physicochemical properties of amino acids are represented: circles - hydrophilic residues; 
diamonds - hydrophobic residues; triangles - potentially negatively charged; pentagons - 
potentially positively charged. The most hydrophobic residues are shown in green. The 
amount of green decreases proportionally to the hydrophobicity, with zero hydrophobicity 
coded as yellow. Hydrophilic residues are represented in red and the amount of red 
decreases proportionally to the hydrophilicity. The helical wheel projections of Helix 2 of 
NS4B were generated using a program available online 
http://rzlab.ucr.edu/scripts/wheel/wheel.cgi. 
 
Although expression of NS4B alone is able to modify membranes, it also 
engages in protein-protein interactions with other HCV proteins and host factors 
as well as protein-RNA interactions. While it is not yet known whether these or 
additional interactions with the C-terminus are important for efficient RNA 
replication, it is possible that the lack of RNA replication by Luc-M1-11 is the 
result of suboptimal protein-protein interactions mediated by the C-terminus of 
NS4B. The mechanisms involved in membrane changing by NS4B to create sites 
for RC assembly are not understood, but are likely to be dependent on 
multimerization and complex interactions between viral and host proteins. For 
example, interactions between NS5A and NS4B have been demonstrated to be 
essential to maintain the membranous web and the efficiency of replication 
(Paul et al., 2011). Recent studies demonstrated that membranous web integrity 
was maintained by the activity of an ER-localised lipid kinase, PI4KIIIα (Berger et 
al., 2009; Reiss et al., 2011). Moreover, NS5A was shown to recruit and activate 
PI4KIIIα, which leads to an accumulation of PI4P at sites of HCV replication 
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(Reiss et al., 2011). Silencing of PI4KIIIα significantly reduced HCV replication in 
both replicon-bearing cells and in cells infected with HCVcc, confirming that 
PI4KIIIα is essential for HCV replication (Lim & Hwang, 2011). The region 
encoding the last 67 amino acids of NS4B and first 91 amino acids of NS5A was 
shown to be the minimal functional segment able to restore a low level of 
replication in cells depleted for PI4KIIIα (Vaillancourt et al., 2012). Moreover, 
NS4B S258P and NS5A R70S substitutions were required to rescue a low level of 
replication in PI4KIIIα-deficient cells (Vaillancourt et al., 2012). It is interesting 
to speculate that changes which may modulate NS4B-NS5A interactions may also 
affect the ability of NS5A to recruit and activate PI4KIIIα, thereby resulting in a 
lethal defect on replication. Thus, it would be interesting to investigate whether 
the deleterious changes at the C-terminus of NS4B in this study could result from 
such a mechanism. 
Changes at the C-terminus of NS4B have also been demonstrated to 
influence mobility and post-translational modification of NS5A (Jones et al., 
2009). As stated earlier, NS5A exists as hypo- and hyperphosphorylated forms, 
and hyperphosphorylation has been suggested to act as a modulating switch 
between RNA synthesis and assembly of virus particles. NS4B may play a critical 
role in this process and its ability to generate membrane rearrangements is 
linked with hyperphosphorylation status of NS5A. Amino acid changes at the C-
terminus of NS4B that disrupted foci formation, also increased mobility of NS5A 
(Jones et al., 2009). The Jones et al. (2009) study emphasises the importance of 
the integrity of NS4B-NS5A interactions for virus replication and presumably for 
optimal interactions between NS5A and other viral/host proteins. Although 
mutation of Cys257 to Ala (referred to as M15 in Jones et al., 2009) did not 
affect viral replication, it is possible that in our study this change, together with 
the remaining substitutions, affected the optimal interaction of NS4B with NS5A, 
and consequently protein-protein interactions of NS4B with other viral or host 
proteins. 
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In conclusion, the approach adopted in these studies identified amino acids 
that vary between gt2a and gt3a at the C-terminus of NS4B that can be tolerated 
without impairing HCV RNA replication. Deleterious amino acid changes were 
also found, which would form the basis for further analysis to determine 
whether compensatory mutations outside of this region could restore 
replication. This approach has been successful in other mutagenesis studies (Paul 
et al., 2011) and is therefore feasible. Given the data reported by Paul et al, it 
would seem appropriate to perhaps examine firstly the gt3a sequences in NS5A 
that differ from gt2a. This could help build a map of genetic interactions for 
specific genotypes and thus aid our understanding of the spectrum of 
interactions that occur in the replication complex. 
 
S G S W
NS4B NS5A
P I P CD C
S G D WP S P CD Y
P1 P1’P3 P3’
gt 2a
gt 3a
 
Figure 3.26 – Schematic representation of the amino acid sequence found at the NS4B/NS5A 
boundary. The upper and lower sequences are those found in gt2a (JFH1 strain) and gt3a 
(Glasgow-3 strain). The amino acid variations between the two genotypes are shown in red 
and in bold are represented conserved amino acids between all HCV genotypes. 
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The approach used in the current study to construct a gt3 SGR was 
extended to include the gt3 sequences encoding the NS3/4A viral protease. Our 
results with the Luc-2a3a-NS3-4A-SGR provided further valuable information on 
the effect of gt3a sequences in the non-structural region on genome synthesis. 
We found that, cloning of these sequences into the JFH1-SGR (Luc-2a3a-NS3-4A) 
abolished any detectable transient replication by 72h in Huh-7 cells. However, 
delayed replication was evident between 48 and 72h in Huh-7.5 cells. These 
findings are similar to those reported by (Imhof & Simmonds, 2010). They found 
that the J3a3a chimera (construct JC-1 containing NS3-4A sequences from gt3a) 
yielded very low levels of replication in Huh-7 cells as detected by cells positive 
for NS5A expression. Indeed, NS5A-positive cells were not found prior to day 5 
after electroporation of RNA. In Huh-7.5 cells, there was an eclipse phase of 6 
days before NS5A was detected in 80% of the cells. Hence, in both Huh-7 and 
Huh-7.5 cells, any replication is apparently delayed but eventually more robust 
in Huh-7.5. In the case of Huh-7.5 cells, J3a3a required an adaptive mutation 
(L1663A) in the NS4A membrane segment to permit continuous spread in culture. 
Time constraints did not allow introduction of this mutation into Luc-2a3a-NS3-
4A to determine whether it would direct higher or earlier RNA replication in 
Huh-7.5 cells or indeed enable detection of replication in Huh-7 cells. Clearly, 
such an approach would address whether the mutation is able to influence either 
replication (as detected in the SGR system) or virus assembly (as detected with 
J3a3a in the infectious virus system). 
A separate topic is the question as to why Huh-7 cells show either no or 
very low replication of Luc-2a3a-NS3-4A whereas Huh-7.5 cells do apparently 
support some replication. Huh-7 cells and their derivatives are the most 
permissive cells for HCV replication and some studies have linked such an ability 
to the lack of dsRNA sensing through TLR3 (Li et al., 2005a). In the case of Huh-
7.5 cells, which are derived from Huh-7 cells, they lack not only TLR3 but also 
activation of IRF-3 through RIG-I signalling. A point mutation within RIG-I CARD-
like homology domain was found in Huh-7.5 cells, resulting in defective RIG-I-
mediated activation of IRF-3 (Sumpter et al., 2005). As stated previously 
(section 3.2.4), the HCV NS3/4A protease can antagonise antiviral mechanisms 
during HCV infection by cleavage of the adaptor molecules MAVS (RIG-I 
signalling) and TRIF (TLR3 signalling). Cleavage of these molecules prevents 
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stimulation of type I IFNs and therefore prevents IFN-mediated control of HCV 
replication. It is possible that in the context of a gt2a backbone, gt3a NS3-4A 
kinetics of cleavage of MAVS is reduced, which renders this antiviral pathway 
sufficiently active to inhibit RNA replication. If that would be the case, it is 
interesting to hypothesize that blocking IFN activation, by means of lack of 
signalling through both RIG-I and TLR3 (as in the case in Huh-7.5 cells), may 
allow Luc-2a3a-NS3-4A-SGR to replicate. Further studies that are directed at 
determining whether replication of Luc-2a3a-NS3-4A in Huh-7.5 cells is ablated 
under conditions where the RIG-I and TLR3 pathways are restored would help to 
address this question. 
Having demonstrated that converting separately the C-terminus of NS4B 
and the NS3/4A complex to gt3a in the JFH1 SGR could enable replication, it 
would have been interesting to combine the chimeras and examine whether 
replication was either increased or decreased. The possible interactions between 
NS4B and NS5A are described above. It is also known that functional NS3/4A 
interacts with other viral proteins. For example, Paredes & Blight (2008) have 
previously demonstrated a genetic interaction between the NS3 protease and the 
C-terminal region of NS4B, and that this interaction is important for viral 
replication. Moreover, this interaction was abolished with amino acid changes 
residing between aa 254 and 258, which abolished replication. It is possible that 
other amino acids outside of this small segment but within the C-terminal 
domain of NS4B also are involved in interactions with the NS3 protease. The 
constructs and data from the studies presented here would provide a platform 
for such analysis. 
3.4.2 Permissiveness of HepaRG cells to HCV replication 
Several cell lines, including primary and human hepatoma cells, have been 
evaluated for their ability to support HCV replication in cell culture (Lindenbach 
et al., 2005; Wakita et al., 2005). Despite such efforts, thus far only Huh-7 cells 
have proven to be optimal for both replication and virion production. Other 
hepatoma cell lines, such as Huh-6 and HepG2 cells, are also permissive for HCV 
replication, however the efficiency in replicating viral RNA and production of 
infectious virus is lower than in Huh-7 cells (Date et al., 2004). Huh-7 cells are 
liver-derived and, at least, appear capable of mimicking the environment in 
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hepatocytes that permits productive infection. However, they are also derived 
from tumour cells and therefore their differentiation status is likely to differ 
substantially from human hepatocytes. For example, some studies have 
demonstrated that Huh-7 cells and derived cells differ substantially, at the level 
of cellular miRNA expression profiles and allelic variations within the IL28B gene 
(Bensadoun et al., 2011; Ehrhardt et al., 2011). The IL28B polymorphism is a 
predictive marker for outcome of HCV infection. Therefore, variations within 
this genotype between hepatoma cell lines used for in vitro studies and human 
hepatocytes may lead to different observations regarding the biology of HCV 
infection and antiviral compound efficiencies. In an attempt to examine HCV 
replication in cells that more closely reflect events in mature hepatocytes, we 
investigated HepaRG cells since they are derived from hepatic progenitor cells 
and exhibit features of fully functional mature hepatocytes (Cerec et al., 2007). 
Gene expression profiles revealed that the mRNA content in HepaRG cells more 
closely reflects primary hepatocytes and human liver tissues than HepG2 cells, 
the most frequently used liver cell line (Hart et al., 2010). Given that HepaRG 
cells are derived from hepatocellularcarcinoma liver tissue, their karyotype 
presents a few abnormalities, more specifically in chromosome 7 and a 
translocation from chromosome 22 to 12 (Gripon et al., 2002). However, the 
remainder of the chromosomes do not shown significant differences with primary 
hepatocytes (Hart et al., 2010). 
Despite being able to translate viral RNA, HepaRG cells were unable to 
initiate HCV RNA replication following transfection of SGR RNA. Nevertheless, 
assessment of replication using colony forming assays did reveal some stable 
replication of SGR RNAs in HepaRG cells, under selective pressure with an 
antibiotic. Such results suggest adaptation of JFH1 SGR to the HepaRG cell 
environment may be required for efficient genome synthesis. However, 
replication was at least 10-fold less than in Huh-7 cells and eventually the 
HepaRG-SGR cells did not prove capable of long-term maintenance beyond a few 
weeks. Therefore, it did not prove possible to determine any adaptive changes 
in the JFH1-SGR that permitted continuous replication in HepaRG cells. 
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Similar to the results from transient replication assays, HepaRG cells were 
not susceptible to infection with JC-1 virus, since no replication was detected up 
to 48h after infection, when compared with Huh-7 cells. HepaRG cells have been 
reported to be permissive for infection with HCV particles derived from serum 
(HCVsp) of infected patients (Ndongo-Thiam et al., 2011). However, the authors 
observed that HepaRG cells were susceptible to HCVsp infection only when they 
exhibit a differentiated and depolarized epithelial phenotype. Consistent with 
our observations, infection with JFH1 virus apparently yielded only weak 
transient replication (Ndongo-Thiam et al., 2011). HepaRG cells do possess some 
unique features such that they can differentiate into hepatocyte-like or biliary-
like cells under appropriate culture conditions. It would be interesting to 
determine whether the permissiveness of HepaRG cells to either SGR replication 
or infection with HCVcc would improve by growing them under conditions where 
they would adopt a more biliary- or hepatocyte-like phenotype. 
There are other reasons that may dictate the permissiveness of a cell line 
to viral replication and extensive attention has been directed to the 
identification of cellular factors required for efficient HCV replication. The 
human microRNA 122 (mir122), a liver-specific factor involved in lipid 
metabolism, was previously identified as a required factor for robust HCV 
replication in Huh-7 cells (Jopling et al., 2005). Recent findings have shown that 
cell lines which exhibited low permissiveness for HCV replication, such as Hep3B 
and HEK 293T cells, would support HCV replication and secretion of infectious 
particles upon exogenous expression of mir122 (Da Costa et al., 2012; Kambara 
et al., 2012). Thus, it is possible that insufficient levels of mir122 are present in 
HepaRG cells and this contributes to their lower competence for replicating HCV 
RNAs. 
Alternatively, low permissiveness could result from the presence of cellular 
inhibitory factors, such as those involved in mounting a robust innate or intrinsic 
response to infection. In the case of Huh-7 cells, transcription of type I IFNs 
through the TLR3 signalling cascade is defective and this has been suggested to 
be linked with their higher permissiveness to HCV replication (Li et al., 2005a). 
Similarly, Huh7.5 cells, have a further defect in RIG-I signalling, which 
apparently renders this cell line more permissive for viral replication than the 
parental Huh-7 cells. Based on these observations, it is possible that lower 
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permissiveness of HepaRG cells for HCV replication could result from a robust 
innate response. 
Our data demonstrated that HepaRG cells possess fully functional TLR3 and 
RIG-I signalling pathways, as ISG15 mRNA expression was induced upon 
stimulation with extracellular or intracellular poly-I:C, a dsRNA analogue. Huh-7 
cells only responded to intracellular poly-I:C, whereas Huh-7.5 cells did not 
respond to either extracellular or intracellular poly-I:C, consistent with 
previously reports (Li et al., 2005a). Surprisingly, transfection of viral RNA into 
Huh-7 and HepaRG cells did not mediate observable changes in the expression 
levels of IFNβ mRNA in either cell line. Although no changes in IFN induction 
were observed, ISG15 was induced in response to viral RNA in HepaRG cells. This 
could suggest that ISG15, possibly along with other interferon-stimulated 
factors, could play a role in regulating initiation of virus replication. Further 
studies that would block the interferon-stimulating pathways would help to 
address this question. Paramyxovirus V proteins have been previously described 
to counter the IFN signalling pathways (Goodbourn & Randall, 2009). This control 
was shown to be mediated by targeting STAT1 for proteasome degradation and 
disruption of induction of ISGs (Parisien et al., 2002). Recently, Andrus et al. 
(2011) demonstrated that expression of the parainfluenza virus V protein in 
human foetal liver cells significantly enhanced productive HCVcc infection 
(Andrus et al., 2011). In addition, regulation of IFN induction was demonstrated 
to be disabled by the BVDV N-terminal protease fragment (Npro) (Hilton et al., 
2006). Npro specifically blocks the activity of IRF-3, which is essential for IFN 
promoter activation. Thus, a feasible approach for addressing the impact of IFN 
signalling pathways in HepaRG cells permissiveness could be tested through 
expression of either V or Npro viral proteins. 
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4 Antiviral activities of ISG15 during HCV infection 
4.1 Introduction 
As shown in the previous chapter, cell line permissiveness to HCV 
replication is not only regulated by viral factors, but may also be controlled by 
the activities of host factors. In particular, ISG15 was shown to possibly play a 
role in determining permissiveness of HepaRG cells to HCV replication. From a 
siRNA library screen developed in our group to identify novel host proteins 
involved in HCV replication (Jones et al., 2010), ISG15 had been identified as a 
modulator of HCV RNA synthesis. Since ISG15 has antiviral activities in other 
virus systems (see Chapter 1, section 1.6), we sought to investigate and 
characterise its role during clearance of HCV infection, and determine its 
mechanism of action. 
4.2 Type I IFNs are strong inducers of ISG15 and can 
efficiently regulate HCV replication 
To investigate the role of ISG15 in controlling HCV replication, Huh-7 and 
U2OS cells (human osteosarcoma) were used. U2OS cells have previously been 
shown to support HCV replication, albeit at lower efficiency than Huh-7 cells 
(Targett-Adams & McLauchlan, 2005). U2OS SGR cells yield ~10-fold less viral 
RNA and lower expression of the viral protein NS5A than Huh-7 cells (Figure 4.1). 
4.2.1 Huh-7 and U2OS cells induce ISG15 in response to IFN 
treatment 
To examine whether the ISG15 gene in Huh-7 and U2OS cells responded to 
IFN stimulation, naïve cells were treated with increasing amounts of IFNα, β and 
γ (0, 50, 100 and 200U/ml). At 48h after treatment, ISG15 induction was 
assessed at both RNA and protein levels by RT-qPCR and Western blot analysis, 
respectively. As shown in Figure 4.2, the basal levels of ISG15 in both cell types 
were very low. Exposure of Huh-7 cells to IFN increased ISG15 RNA by up to 140- 
and 50-fold in response to IFNα and β, respectively (Figure 4.2-A). In U2OS cells, 
treatment with IFNα and β resulted in 40- and 20-fold increases in ISG15 mRNA 
levels (Figure 4.2-C). As expected (see Chapter 3, section 3.3.5.1), IFNγ failed to 
induce high levels of ISG15 in either cell line. The rise in ISG15 RNA levels was 
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mirrored at the protein level in Huh-7 cells, where both conjugated and 
unconjugated forms of ISG15 protein were readily detected following 
IFNα/β treatment (Figure 4.2-B). In U2OS cells, lower levels of unconjugated 
ISG15 were detected following type I IFN treatment compared to Huh-7 cells 
(Figure 4.2-D). Interestingly, considerably few ISG15 protein conjugates were 
produced in U2OS cells. Nonetheless, these data do indicate that IFN signalling 
through the Jak/STAT pathway is intact in Huh-7 and U2OS cells and ISG15 could 
be strongly induced in response to type I IFNs. 
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Figure 4.1– Stable HCV replication in Huh-7 and U2OS cells. RT-qPCR analysis of steady-
state levels of replicon RNA in Huh-7 and U2OS replicon-containing cells. HCV RNA levels 
were normalised against endogenous levels of GAPDH mRNA (upper graph). 
Immunofluorescence analysis of NS5A expression in Huh-7 and U2OS replicon cells (lower 
panels). 
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Figure 4.2 – Type I IFNs are strong inducers of ISG15. Huh-7 and U2OS cells were treated 
with increasing doses (0, 50, 100 and 200U/ml) of IFNα, β and γ. At 48h after treatment cells 
extracts were used for RT-qPCR analysis of ISG15 mRNA expression in Huh-7 (A*) and 
U2OS (C) cells and Western blot analysis of ISG15 free and conjugated forms using anti-
ISG15 antisera in Huh-7 (B*) and U2OS (D) cells. Actin expression was examined using anti-
actin antisera. *The data used in panels A) and B) are duplicated from Figure 3.20-A&B. 
Unpaired t test statistical comparison of IFNα, β and γ efficacy in inducing ISG15 mRNA 
expression are shown: * p<0.05 and ** p<0.005. 
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4.2.2 Type I IFNs efficiently reduce HCV replication in Huh-7 
and U2OS cells 
To examine the effects of type I and II IFNs on HCV replication in vitro, 
naïve- and replicon-bearing Huh-7 and U2OS cells were treated with 200U/ml 
IFNα, β and γ. 48h after treatment, viral replication was assessed by measuring 
HCV RNA and protein expression. As observed in Figure 4.3 (A and D), all IFNs 
decreased viral RNA levels in both Huh-7 and U2OS replicon cells, although in 
Huh-7 SGR cells differing efficiencies were observed. In Huh-7 cells, IFNα and β 
had the greatest impact on replication, reducing HCV RNA levels by 85-90% 
respectively. NS5A expression was also reduced to a greater extent by type I IFNs 
in Huh-7/SGR cells, when compared with the effects of IFNγ (Figure 4.3-C). By 
contrast in U2OS SGR cells, all IFNs reduced viral RNA levels and NS5A expression 
to a similar extent (Figure 4.3-D&F). The higher efficiency of IFNγ in reducing 
viral RNA in U2OS SGR cells, could be explained by the fact that these cells 
support lower replication than Huh-7 cells (Figure 4.1). Hence, the differential 
effect of the three IFNs on replication was not observed in U2OS SGR cells. Since 
IFNα and β induced higher expression of ISG15 and reduced HCV replication more 
efficiently in Huh-7 cells, there was a possible correlation between ISG15 and 
IFN antiviral efficacy. Interestingly, upregulation of ISG15 RNA following IFNα 
and β treatment in naïve Huh-7 and U2OS cells was ~5.5 to 7.5 and ~1.5 to 2 fold 
lower than in the respective replicon cells (Figure 4.3-B and E). This enhanced 
rise in ISG15 RNA in replicon cells was not accompanied by a corresponding 
increase in either free or conjugated forms of ISG15 protein following IFNα/β 
treatment. Instead protein levels were similar to those found in naïve Huh-7 and 
U2OS cells respectively (Figure 4.3-C and F). 
Thus, from these observations it suggests that 1) type I IFNs, can more 
efficiently reduce HCV replication than IFNγ in Huh-7 cells, 2) ISG15 may 
contribute to the IFNα/β-mediated repression of HCV replication. 
Figure 4.3 – Type I IFNs efficiently reduce HCV replication. The effects of different IFNs on 
ISG15 expression and HCV RNA replication were examined by treating naïve or SGR cells 
with 200U/ml of each IFN for 48h. RT-qPCR analysis of HCV replicon RNA in Huh-7 and Huh-
7/SGR (A) or U2OS and U2OS/SGR (D) and ISG15 mRNA levels in Huh-7 and Huh-7/SGR (B) 
or U2OS and U2OS/SGR [E] are shown. [C] and [F] indicate Western blot analysis of ISG15, 
NS5A and actin proteins in Huh-7 and Huh-7/SGR or U2OS and U2OS/SGR, respectively. 
Unpaired t test statistical comparison of IFNα, β and γ efficacy in reducing HCV RNA levels 
are shown: * p<0.05, ** p<0.005 and *** p<0.0005. 
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4.3 siRNA silencing of ISG15 enhances constitutive HCV 
replication in Huh-7 and U2OS cells 
4.3.1 ISG15 knockdown partially alleviates IFN-mediated 
repression of HCV replication 
To examine whether ISG15 could contribute to repression of HCV 
replication mediated by IFNα, its expression was abrogated during IFN 
stimulation. To that end, Huh-7 and U2OS SGR cells were transfected with a pool 
of ISG15 (siISG15) or scrambled (siCtrl) siRNAs for 24h, followed by treatment 
with IFNα (200U/ml) for a further 48h. Transfection of siRNAs against ISG15 
resulted in a reduction of ISG15 mRNA stimulation upon IFNα treatment by 3-5 
fold in both Huh-7/SGR and U2OS/SGR cells, when compared with the siCtrl-
transfected cells (Figure 4.4-A). This effect was specific for ISG15 mRNA, as the 
levels of USP18 stimulation following IFNα treatment did not decrease upon 
transfection of siISG15 in either Huh-7 or U2OS/SGR cells (Figure 4.4-B). Instead, 
ISG15 knock-down enhanced USP18 levels in both cell lines. Quantification of 
HCV RNA levels in siCtrl-transfected cells demonstrated a reduction of ~90 to 
95% in viral RNA following IFNα treatment when compared with untreated Huh-
7/SGR and U2OS/SGR cells (Figure 4.4-C). However, the decrease in ISG15 
stimulation observed in IFNα-treated Huh-7/SGR and U2OS/SGR cells transfected 
with siISG15, gave a lower decrease in HCV RNA levels. These data suggested 
that ISG15 may contribute to IFN-mediated repression of HCV replication. 
4.3.2 ISG15 silencing increases HCV RNA abundance in the 
absence of exogenous IFN stimulation 
In addition to IFN-dependent antiviral activities, many ISGs are expressed at low 
basal levels and have a role in facilitating surveillance and response to virus 
infection before IFN is induced. 
Patricia Domingues  Chapter 4 
 
181 
 
 
Figure 4.4 – ISG15 silencing alleviates the IFN-mediated reduction of HCV RNA. Huh-7 and 
U2OS replicon cell lines were transfected with ISG15-specific and scrambled siRNAs (siCtrl) 
for 24h, followed by treatment with IFNα for 48h. RT-qPCR analysis in Huh-7/SGR (left panel) 
and U2OS/SGR (right panel), is shown for ISG15 (A), USP18 (B) and HCV RNA (C) levels 
respectively. Unpaired t test statistical comparison of IFNα efficacy in reducing HCV RNA 
levels in siCtrl and siISG15 transfected cells are shown, where * indicates p<0.05. 
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To investigate whether basal levels of ISG15 play a role in lowering viral 
RNA levels, ISG15 expression was reduced in Huh-7/SGR and U2OS/SGR cells 
using ISG15 (siISG15) and scrambled siRNAs (siCtrl), in the absence of exogenous 
IFNα stimulation. 48h after siRNA transfection, the effect on HCV replication was 
assessed by examining viral RNA and protein synthesis. As shown in Figure 4.5 (A 
and C), transfection of ISG15 siRNAs resulted in a 1.8- to 2-fold reduction in the 
basal levels of ISG15 transcripts in Huh-7/SGR and U2OS/SGR cells respectively, 
when compared with the siCtrl-transfected cells. This decrease in ISG15 mRNA 
resulted in a 30 to 150% increase in viral RNA levels in Huh-7 and U2OS cells 
respectively, when compared with siCtrl-transfected cells (Figure 4.5-B&D). This 
effect was also found in viral protein levels in U2OS/SGR cells as silencing of 
ISG15 resulted in a small but observable increase in NS5A expression (Figure 4.5-
E). By contrast, there was no visible rise in NS5A expression in Huh-7/SGR cells. 
It was possible that a 30% rise in RNA would impact on increased levels of NS5A 
expression, however these changes may be too small to be detected by Western 
blot analysis. Alternatively, if NS5A were produced at its maximum in Huh-7/SGR 
cells, then small changes in viral RNA may not be seen at the protein level. To 
investigate whether the latter possibility was the case, Huh-7/SGR cells were 
treated with MG132 (proteasome inhibitor) and NS5A expression analyzed for up 
to 8 or 20h after treatment. As shown in Figure 4.6, blocking protein degradation 
did not result in an increase of NS5A levels, even at longer MG132 incubation 
times. However, actin protein levels did decrease during MG132 treatment at 
later times, indicating that NS5A could have increased when protein degradation 
was blocked. Alternatively, inhibition of proteasome activity may have caused 
cell toxicity, without having a direct impact on NS5A levels. Overall, these data 
indicate that NS5A expression may not normally rise in siISG15-transfected cells 
to levels higher than those observed in untreated Huh-7/SGR cells. 
In similar experiments using a genotype 1b replicon, Huh-7/5-15 (gt1b SGR) 
cells were transfected with siRNAs against ISG15 and the effect on viral 
replication assessed by RT-qPCR analysis. Transfection of siISG15 into Huh-7/5-
15 cells resulted in a modest reduction of ISG15 expression by 1.5-fold, when 
compared with the levels in siCtrl-transfected cells (Figure 4.7-A). Consequently, 
only a 20% rise in viral RNA was detected in the siISG15-transfected cells (Figure 
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4.7-B). Nevertheless, the data indicated that ISG15 exerted an inhibitory effect 
on HCV RNA for both gt1b and -2a replicons. 
Overall, the data from these and the previous experiments demonstrated 
that silencing ISG15 increased HCV RNA levels in both Huh-7/SGR and U2OS/SGR 
cells, suggesting an inhibitory role for ISG15 on HCV replication both in an IFN-
dependent and -independent manner. 
 
Figure 4.5 – ISG15 silencing promotes HCV replication. Huh-7/SGR and U2OS/SGR cells 
were transfected with ISG15-specific and scrambled siRNAs for 48h. The abundance of 
ISG15 mRNA (A and C) and HCV RNA (B and D) were determined at 48h post-transfection by 
RT-qPCR in Huh-7/SGR (A and B) and U2OS/SGR (C and D) cells. (ISG15 and HCV RNA 
levels normalised against GAPDH). [E] Western blot analysis of NS5A and actin proteins in 
Huh-7/SGR (left panel) and U2OS/SGR (right panel). Lower panel represents 1:10 dilution of 
NS5A expression levels in Huh-7/SGR cells. Unpaired t test statistical comparison of siCtrl 
and siISG15 impact on HCV RNA levels are shown: ** p<0.005 and *** p<0.0005. 
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Figure 4.6 – NS5A turnover levels in Huh-7/SGR cells. Huh-7 SGR cells were treated with 
proteasome inhibitor MG132 at 10uM for up to 8h (A) or 20h (B). Western blot analysis of 
NS5A and actin expression during MG132 treatment; lower panels show longer exposure of 
NS5A and actin. 
 
 
 
 
 
Figure 4.7 – ISG15 silencing promotes HCV replication. Huh-7/5-15 cells (gt1b SGR) were 
transfected with ISG15-specific and scrambled siRNAs at a final concentration of 10nM, for 
48h. The abundance of ISG15 mRNA (A) and HCV RNA (B) were determined at 48h post-
transfection by RT-qPCR in the absence of exogenous IFN stimulation. ISG15 and HCV RNA 
levels normalised against abundance of GAPDH mRNA. 
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4.4 shRNA silencing of ISG15 enhances HCV replication 
during infection 
To further examine the processes by which ISG15 may impair not only viral 
replication but also infection, the study was extended to include use of 
infectious HCVcc. For this analysis, U2OS cells were not used since they are 
refractory to HCV infection and virion production. 
To avoid any off-target effects resulting from siRNA transfection and the 
inherent toxicity that can accompany transfection, an alternative approach was 
used to silence ISG15. This method utilized a lentivirus system to create cell 
lines that constitutively expressed short-hairpin RNAs (shRNAs) that would inhibit 
endogenous ISG15 expression. The following section describes the strategy used 
to design ISG15 shRNAs as well as construction and validation of the resulting 
shRNA lentiviral cell lines. 
4.4.1 Generation and characterisation of ISG15 shRNA 
lentiviral cell lines 
To identify appropriate shRNA sequences that would target ISG15, siRNA 
sequences supplied by different manufacturers (and including the ISG15 siRNAs 
used in section 4.3 [Ambion siRNA#1 to #3]), were aligned with the ISG15 coding 
region (Figure 4.8-A). From this alignment, it was possible to identify 4 distinct 
siRNA clusters across the gene (numbered I to IV in Figure 4.8-A). To maximise 
the likelihood of selecting a shRNA with efficient targeting, 6 consensus 
sequences were designed (Figure 4.8-B) according to the following criteria: 
1) The shRNA targeting region was based on siRNA sequences with a length 
of 19bp. 
2) Each sequence contained between 40 and 70% GC content and started 
with G or A, as RNA polymerase III prefers to initiate transcription with a 
puridine. 
3) Sequences with 4 consecutive bases or 7 consecutive GC doublets were 
avoided, as their presence may create intra-molecular secondary 
structure or reduce specificity of the target sequence. 
Patricia Domingues  Chapter 4 
 
186 
 
4) No shRNA sequences with internal loops and palindromic sequences were 
selected. 
5) GC content was higher at the 5’ end than at the 3’ end. 
6) Each shRNA sequence ended with 6Ts (polymerase III termination signal). 
shRNA sequences were further modified to contain 5’ and 3’ terminal 
sequences compatible with insertion into BamHI and EcoRI sites (Figure 4.8-C). 
These sequences were introduced to allow their insertion into the pLKO plasmid 
(Figure 4.8-C and D). The central region of the shRNAs contained the sense and 
antisense siRNA sequences (#1 to #6) connected by a loop region (TTCAAGAGA). 
The antisense siRNA region was followed by a poly-T motif and an additional 
restriction site (MluI), which was used for diagnostic restriction analysis. In 
parallel for comparative purposes, a shRNA composed of a scrambled sequence 
was also created (Figure 4.8-C). Sense and antisense oligonucleotides for each 
shRNA were synthesised and subsequently annealed (Figure 4.8-D). The pLKO 
acceptor vector (pLKO-shPML) was digested with BamHI and EcoRI, thereby 
allowing insertion of duplexes encoding each ISG15 shRNA (#1 to #6) as well as 
shCtrl (Figure 4.8-D). The generated constructs were designated pLKO-shISG15#1 
to #6 and pLKO-shCtrl. 
In order to produce lentiviral stocks to transduce cells (Figure 4.10), HEK-
293T cells were transfected with each of the pLKO-shISG15 plasmids together 
with plasmids that would generate lentivirus components (pCMV-DR8.91 and 
pVSV-G, Figure 4.9), according to the method described in Chapter 2 (sections 
2.2.7.3 and 2.2.7.4). At 60h after transfection, the supernatants were harvested 
and used to transduce monolayers of Huh-7 cells (Figure 4.10). Cell lines that 
incorporated the shRNA sequences were selected by culturing cells in the 
presence of puromycin. The generated cell lines were named Huh-7-shISG15-1 to 
-6 (hereafter referred as to sh1, sh2, sh3, sh4, sh5 and sh6) and Huh-7-shCtrl 
(hereafter referred as to shCtrl). Following continuous growth, only four cell 
lines survived (sh1, sh5, sh6 and shCtrl), which were used to further validate any 
knock-down in ISG15 expression. Given the low basal levels of ISG15 RNA and 
protein in Huh-7 cells, validation of knock-down efficiency by the shRNAs was 
examined by treating the cells with IFNα. Thus, the inhibitory effect of each 
shRNA on ISG15 could be tested under conditions that normally stimulate 
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expression of the gene. Moreover, the effect of the shRNAs in each of the 3 cell 
lines was compared with knockdown by the siRNA against ISG15. In these 
experiments, levels of both ISG15 RNA (by RT-qPCR) and protein (by Western 
blot and indirect immunofluorescence analysis) were examined (Figure 4.11). 
The results revealed that ISG15 induction by IFNα was not considerably affected 
in siCtrl and shCtrl Huh-7 cells (Figure 4.11). Compared with cells transfected 
with siCtrl, siISG15 lowered RNA expression by 4-fold (Figure 4.11-A). The cell 
line expressing the ISG15 shRNA 1 (sh1) did not repress induction of ISG15, as 
compared to the shCtrl cells (Figure 4.11-A). sh5 and sh6 cell lines on the other 
hand inhibited ISG15 expression by 2- and 4-fold, respectively. The sh6 cell line 
gave comparable levels of ISG15 inhibition to siISG15 following IFNα stimulation. 
This knockdown was specific for ISG15 as levels of USP18 (also called UBP43), 
the ISG15 IFN-inducible deconjugating enzyme for ISG15, were not reduced in 
cells either transfected with ISG15 siRNA or in sh1, sh5 and sh6 cells (Figure 
4.11-B). Indeed, inhibition of ISG15 during IFN stimulation appeared to enhance 
USP18 levels, in agreement with the data presented in Figure 4.4. 
Western blot analysis of cell extracts revealed stimulation of both 
conjugated and free ISG15 protein in Huh-7, siCtrl, shCtrl and sh1 cell lines in 
response to IFNα treatment (Figure 4.11-C). By contrast, cells either transfected 
with siISG15 or sh6 cells gave barely detectable expression of both single and 
conjugated ISG15 protein, consistent with the RNA data; sh5 cells did produce 
ISG15 protein but at slightly lower levels than shCtrl cells. Similarly, 
immunofluorescence analysis revealed that ISG15 was widely distributed 
throughout the cell cytoplasm and nucleus in Huh-7, siCtrl, shCtrl, sh1 and sh5 
cells following IFN stimulation (Figure 4.11-D). However, in siISG15-transfected 
cells and sh6 cells, expression was greatly abrogated and ISG15 protein was 
barely detected. Thus, ISG15 expression could be efficiently inhibited following 
IFN stimulation using shRNA methodology, with no visible effects on cell viability 
and growth. The cell line which gave efficient knockdown of ISG15 to similar or 
greater levels compared to siRNAs was sh6. This cell line, together with the 
shCtrl cells, were selected for use in subsequent experiments. 
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5‘ –gatccGCGCAGATCACCCAGAAGATTCAAGAGATCTTCTGGGTGATCTGCGCTTTTTTACGCGTg‐‐‐‐‐‐3' 
3’ ‐‐‐‐‐‐gCGCGTCTAGTGGGTCTTCTAAGTTCTCTAGAAGACCCACTAGACGCGAAAAAATGCGCActtaa‐ 5’
#1
5'‐gatccGCGACGAACCTCTGAACATTTCAAGAGAATGTTCAGAGGTTCGTCGCTTTTTTACGCGTg‐‐‐‐‐‐3' 
3'‐‐‐‐‐‐gCGCTGCTTGGAGACTTGTAAAGTTCTCTTACAAGTCTCCAAGCAGCGAAAAAATGCGCActtaa‐5'
#3
5'‐gatccGAACATCCTGGTGAGGAATTTCAAGAGAATTCCTCACCAGGATGTTCTTTTTTACGCGTg‐‐‐‐‐‐‐3' 
3'‐‐‐‐‐‐gCTTGTAGGACCACTCCTTAAAGTTCTCTTAAGGAGTGGTCCTACAAGAAAAAATGCGCActtaa‐5'
#4
5'‐gatccGCGGGCTGGAGGGTGTGCATTCAAGAGATGCACACCCTCCAGCCCGCTTTTTTACGCGTg‐‐‐‐‐‐3' 
3'‐‐‐‐‐‐gCGCCCGACCTCCCACACGTAAGTTCTCTACGTGTGGGAGGTCGGGCGAAAAAATGCGCActtaa‐5'
#5
5'‐gatccGCACCGTGTTCATGAATCTTTCAAGAGAAGATTCATGAACACGGTGCTTTTTTACGCGTg‐‐‐‐‐‐3' 
3'‐‐‐‐‐‐gCGTGGCACAAGTACTTAGAAAGTTCTCTTCTAAGTACTTGTGCCACGAAAAAATGCGCActtaa‐5' 
#6
#2 5'‐gatccGGCGCAGATCACCCAGAAGTTCAAGAGACTTCTGGGTGATCTGCGCCTTTTTTACGCGTg‐‐‐‐‐‐‐3‘
3‘‐‐‐‐‐‐gCCGCGTCTAGTGGGTCTTCAAGTTCTCTGAAGACCCACTAGACGCGGAAAAAATGCGCActtaa‐5' 
BamHI siRNA sense sequence siRNA antisense seqn MluIPoly-TLoop EcoRIshRNA
[C]
5'‐gatccTTATCGCGCATATCACGCGTTCAAGAGACGCGTGATATGCGCGATAATTTTTTACGCGTg‐‐‐‐‐‐3' 
3'‐‐‐‐‐‐gAATAGCGCGTATAGTGCGCAAGTTCTCTGCGCACTATACGCGCTATTAAAAAATGCGCActtaa‐5' 
Ctrl
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Figure 4.8 – Design and construction of pLKO-ISG15-specific shRNA lentiviral plasmids. [A] 
Alignment of siRNA sequences to the ISG15 gene. I to IV represent the 4 clusters resulting 
from the siRNA alignments. [B] Consensus siRNA sequences used to generate 6 ISG15 
shRNAs. [C] shRNAs generated for targetting ISG15. [D] Construction of pLKO-shISG15 
vectors: 1) Digestion of pLKO-shPML with BamHI, NcoI and EcoRI enzymes, generating 
BamHI-NcoI and NcoI-EcoRI DNA fragments; 2) Ligation of BamHI-NcoI, NcoI-EcoRI and 
each ISG15 shRNA or Ctrl shRNA, to generate pLKO-shISG15 (1 to 6) and –shCtrl vectors. 
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Figure 4.9 – Map showing the features of the lentiviral vectors. [A] pLKO-shRNA vectors. 
Lentiviral packaging vectors pCMV-Dr8.91 [B] and pVSV-G [C]. The lentivirus features are 
represented and include RRE – rev response element, cPPT – polypurine tract, LTR - long 
terminal repeats, si – self-inactivating, hCMV IEp – human cytomegalovirus immediate early 
promoter, hPGKp – human phosphoglycerate kinase promoter, IVS – intervening sequence, 
VSV-G – vesicular stomatitis virus glycoprotein. The vector also contains a gene for 
puromycin (Puro r) and ampicillin resistance (Amp r). The site of shRNA sequence insertion 
is indicated as shRNA. 
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Figure 4.10 – Generation of lentiviral cell lines stably expressing ISG15 shRNAs. 
Lentiviruses were produced by transfection of pLKO-shRNA vectors together with pCMV-
DR8.91 and pVSV-G packaging vectors into 293T cells (I). At 60h post-transfection, the 
supernatant containing lentivirus particles was used to transduce Huh-7 cells (II). The stable 
cell lines were generated by puromycin selection of shRNA expressing cells and used for 
HCV replication (III; luciferase assays and stable replication assays) and infection assays 
(IV). Detailed protocol descriptions in Chapter 2, sections 2.2.7.3 and 2.2.7.4. 
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4.4.2 Transient HCV replication in sh6 cells 
To examine whether the effect of reducing ISG15 levels could be assessed 
in transient replication assays, Luc-WT and –GND transcripts were electroporated 
into Huh-7, shCtrl and sh6 cell lines and replication was assessed for up to 72h, 
by measuring luciferase activity (Figure 4.12-A). In addition, to verify the effect 
of IFN during transient replication in these cell lines, 100U/ml of IFNα was added 
at 24h after electroporation. Luciferase activity for Luc-WT in Huh-7 cells (Huh-
7/WT) increased at all time points after electroporation (Figure 4.12-B). By 
contrast, luciferase values decreased throughout all the time points for Luc-GND 
(Huh-7/GND). In shCtrl and sh6 cells, the luciferase values produced by the Luc-
WT (shCtrl/WT and sh6/WT) followed a similar pattern to Huh-7/WT between 4 
and 72h. The correlation between luciferase activity and viral protein synthesis 
was examined at 72h post-electroporation by Western blot analysis (Figure 4.12-
C). Examination of cell extracts revealed that NS5A protein was detected in Huh-
7/WT, whereas in Huh-7/GND cells, NS5A expression was not observed. NS5A was 
found at similar levels in shCtrl/WT and sh6/WT cells, although its abundance 
was slightly lower than in Huh-7/WT cells. 
As shown in Figure 4.12-B, addition of IFNα at 24h after electroporation 
resulted in a 34-fold reduction of luciferase activity at 72h in Huh-7/WT. 
Luciferase activity in Huh-7/GND cells treated with IFNα followed similar levels 
as untreated Huh-7/GND. Treatment with IFNα resulted in a 20- and 14-fold 
reduction in viral replication in shCtrl/WT and sh6/WT respectively between 24 
and 72h under the same treatment conditions as in Huh-7 cells (Figure 4.12-B). 
These data suggested that silencing of ISG15 possibly alleviated some of the 
IFNα-mediated reduction in viral replication. Western blot analysis of cell 
extracts at 72h after electroporation revealed that, in response to IFNα 
treatment, high levels of both conjugated and free ISG15 protein were induced 
in Huh-7/WT, Huh-7/GND and shCtrl cells (Figure 4.12-C). As expected, 
induction of ISG15 in sh6 cells was abrogated. Although luciferase activity was 
detected at 48h after IFN treatment (72h after electroporation), NS5A 
expression was not detected in any of the cell lines by Western blot analysis 
(Figure 4.12-C). 
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Taken together, the small differences observed in luciferase activity as a 
result of the repression of ISG15 expression following IFN treatment in sh6 cells 
suggested that ISG15 silencing may partially alleviate IFNα repression of viral 
replication in transient assays. However, it was concluded that this assay may 
not be sensitive enough to study the effects of ISG15 on HCV replication. Hence, 
the significance of the results was inconclusive. 
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Figure 4.11 – Characterisation of Huh-7 cells expressing ISG15 specific shRNAs. Three Huh-
7 lentiviral cell lines that express ISG15-specific shRNAs were generated and validated for 
their ability to deplete ISG15 expression, following exposure to 200U/ml of IFNα for 24h. RT-
qPCR analysis of ISG15 (A) and USP18 (B) mRNA levels normalised against GAPDH 
abundance. C) Western blot analysis of cell extracts using monoclonal antibodies against 
ISG15 and actin. D) Indirect immunofluorescence analysis using ISG15 antibody and DAPI 
for nuclear staining. 
Patricia Domingues  Chapter 4 
 
197 
 
 
Figure 4.12 – Transient HCV replication assay in shISG15 expressing cell lines. [A] Outline 
of the experiment. [B] Huh-7, shCtrl and sh6 cells were electroporated with Luc-WT and Luc-
GND RNAs. At 24h after electroporation cells were treated with 100U/ml of IFNα or left 
untreated. Cell extracts were assayed for luciferase activity at 4, 24, 48 and 72h after 
electroporation. RLU, relative light units. [C] Cell extracts were prepared at 72h post-
electroporation and examined by Western blot analysis with anti-ISG15, anti-NS5A and anti-
actin antisera. 
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4.4.3 Infection assays in sh6 cells 
With the assay used in the previous section, translation and replication 
efficiencies of viral RNA could be monitored in a transient manner by 
electroporation of in vitro synthesised HCV RNA into cells. Given the somewhat 
low sensitivity of this system for examining differences exerted by ISG15 
silencing on viral replication, a different approach using infectious virus was 
employed to address this question. This system is biologically more relevant than 
transient replication assays, as it allows the study of not only replication but the 
complete cycle of viral infection. Moreover, it avoids any problems associated 
with electroporation of cells with large amounts of RNA. 
To examine whether expression of shCtrl could affect the infectious 
process, Huh-7 and shCtrl cell lines were compared initially for their ability to 
support infection and replication of JC-1 virus. To that end, viral stocks were 
generated by electroporating JC-1 RNA into Huh-7 cells, as described before 
(Chapter 2, section 2.2.8.2). The supernatant from the JC-1 RNA-electroporated 
cells was titrated (5x105 TCID50/ml) and then used as the inoculum to infect Huh-
7 and shCtrl cells at a MOI of 1. At 4, 24 and 48h after infection, replication was 
assessed by measuring viral RNA and protein levels. As shown in Figure 4.13-A, 
JC-1 RNA levels in shCtrl cells were similar to those in Huh-7 cells between 4h 
and 48h post-infection. Immunofluorescence analysis revealed that expression of 
NS5A protein was similar in both cell lines at 48h post-infection (Figure 4.13-B). 
Together, these data suggest that shCtrl cells were able to support viral 
replication at a similar efficiency to parental Huh-7 cells. 
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Following the above experiment, shCtrl and sh6 cells were infected with 
JC-1 virus at a range of MOIs (0.2, 0.4 and 0.8), to investigate the role of ISG15 
on HCV replication during productive infection. HCV RNA levels and ISG15 
expression was assessed at 24h and 48h after infection by RT-qPCR analysis. As 
shown in Figure 4.14-A, uninfected sh6 cells had lower ISG15 basal mRNA levels, 
when compared with the levels in shCtrl cells. Moreover, ISG15 mRNA levels 
remained consistently low in sh6 cells throughout infection. Interestingly, 
between 24 and 48h after infection, a reduction in ISG15 transcript levels was 
observed in shCtrl cells, when compared with the levels in uninfected cells. At 
the later time point, ISG15 levels in shCtrl cells approached those in sh6 cells 
(Figure 4.14-A). In the case of viral RNA, higher levels were found in sh6 as 
compared to shCtrl cells, particularly at 48h (Figure 4.14-B). The increase in 
viral RNA in sh6 cells was not dependent on MOI (Figure 4.14-B). These results 
indicated that lowering the abundance of ISG15 leads to a rise in HCV RNA 
levels, suggesting that ISG15 partially regulates viral replication during infection. 
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Figure 4.13 – JC-1 infection efficiency in Huh-7 and shCtrl cell lines. Huh-7 and shCtrl cells 
were infected with JC-1 virus at a MOI of 1 for 4, 24 and 48h. [A] Levels of HCV RNA were 
determined by RT-qPCR analysis normalised against abundance of GAPDH mRNA. [B] 
Immunofluorescence analysis of NS5A expression (Red). For visualization of nuclei, the 
cells were stained with DAPI. 
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Figure 4.14 – ISG15 silencing promotes HCV replication. Huh-7 shCtrl and sh6 cells were 
infected at MOIs of 0.2, 0.4 and 0.8 for up to 48h. Levels of ISG15 [A] and HCV RNA [B] were 
determined by RT-qPCR analysis and normalised against abundance of GAPDH mRNA. 
Unpaired t test statistical comparison of HCV RNA levels in shCtrl and sh6 cells are shown: 
* p<0.05 and ** p<0.005. 
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To examine whether the impact of ISG15 on HCV replication could be 
detected in the presence of IFN, shCtrl and sh6 cell lines were infected with JC-
1 virus at a MOI of 0.8 in the presence or absence of 10U/ml of IFNα. At 6, 24 
and 48h, replication was assessed by measuring viral RNA and protein expression 
levels. As shown in Figure 4.15-A, ISG15 basal levels in untreated shCtrl and sh6 
cells were low, and in sh6 cells these levels were further reduced compared with 
shCtrl cells. Consistent with the data from the previous experiments, abundance 
of JC-1 RNA was higher in sh6 cells throughout infection, when compared with 
shCtrl cells (Figure 4.15-B). Western blot analysis of cell extracts at 48h p.i. 
revealed that sh6 cells expressed slightly higher levels of NS5A protein, when 
compared with shCtrl cells (Figure 4.15-C), in agreement with the RNA data. 
After IFNα treatment, ISG15 expression increased by 66- and 21-fold in 
shCtrl and sh6 cells, respectively at 6h. By 24 and 48h, ISG15 levels remained 
higher than in untreated cells, but were reduced when compared with the levels 
at 6h. At 6h and, to a less extent at 24h after IFNα treatment (6 and 24h p.i), 
viral RNA levels were lower in the shCtrl cells when compared with the levels in 
sh6 cells. Following those times, RNA levels decreased further and, by 48h, JC-1 
RNA was slightly lower in sh6 cells than in the respective control cells (Figure 
4.15-B). From analysis of cell extracts at the latest time point after IFNα 
treatment, NS5A expression was not detected in the cell extracts. Thus, ISG15 
depletion may partially alleviate the anti-viral activities of IFNα during HCV 
infection, however those effects were only observed at early time-points 
following virus inoculation. 
Taken together, the data from this and the previous experiments suggest 
that ISG15 plays an anti-HCV role both in an IFN-dependent (only at early time-
points after infection, in the case of HCVcc studies) and -independent manner. 
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Figure 4.15 – IFN antiviral activities during HCV infection in ISG15 depleted cells. shCtrl and 
sh6 cells were infected with JC-1 virus at MOIs of 0.2, 0.4 and 0.8 for up to 48h in the 
presence or absence of 10U/ml of IFNa. Levels of ISG15 (A) and HCV (B) RNA were 
determined by RT-qPCR analysis and normalised against abundance of GAPDH mRNA. [C] 
cell extracts were prepared at 48h after infection and examined by Western blot analysis 
with anti-NS5A and anti-actin antisera. 
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4.5 Discussion 
In this study, it was found that ISG15 has an inhibitory role during HCV 
replication. siRNA-mediated depletion of ISG15 from both Huh-7/SGR and 
U2OS/SGR cells repressed ISG15 expression, which resulted in a suppression of 
the antiviral activity of IFNα. Moreover, lowering the expression of ISG15 by 
transfection of siRNAs into SGR cells increased viral RNA levels in Huh-7 and 
U2OS cells (Figure 4.5) in the absence of IFN. These data indicate that ISG15 
plays an inhibitory role during HCV replication both by augmenting IFN-mediated 
antiviral activity and in a mechanism independent from IFN-activation. Further 
experiments using the HCVcc system confirmed these results. Infection of Huh-7 
cells stably expressing shRNA directed against ISG15 (referred to as sh6 cells), 
resulted in higher levels of HCV RNA accumulation, when compared with shRNA-
Ctrl cells. Together, these findings imply a role of ISG15 in limiting HCV 
replication. 
Type I IFNs play a central role in the innate immune responses to control 
virus infection. Such responses are in part mediated by a plethora of host genes 
stimulated by IFN. One of these genes is ISG15 (Farrell et al., 1979). ISG15 
encodes a 17-kDa protein which belongs to the family of ub–like proteins and, 
like other members of this family is capable of forming conjugates to cellular 
proteins, through a conserved C-terminal di-Glycine motif (Hochstrasser, 2000). 
Attachment of Ub to proteins (ubiquitination) employs a sequential enzymatic 
cascade, involving multiple enzymes (Figure 4.16). ISG15 conjugation 
(ISGylation) is attained through a similar set of reactions, which uses enzymes 
that are unique to ISG15 conjugation as well as enzymes involved in Ub protein 
modification [Figure 4.16; (Staub, 2004)]. 
ISG15 conjugation targets a large number of cellular factors involved in 
diverse cellular pathways (Loeb & Haas, 1992; Zhao et al., 2005). Many of these 
substrates are IFNα/β-inducible proteins, including STAT1, Jak1, PKR, MxA and 
RIG-I, suggesting that ISG15 conjugation might play a role in the innate immune 
response to both DNA and RNA viruses. Studies using ISG15-deficient mice 
showed increased susceptibility to infection with several viruses, such as Sindbis 
virus, herpes simplex virus 1 and murine γ-herpesvirus (Lenschow et al., 2005; 
Lenschow et al., 2007). In addition, ISG15 has been reported to possess antiviral 
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activities against Ebola, HIV-1 and Influenza A and B viruses. ISG15 mediates 
resistance to Ebola virus through ISGylation of the E3 ubiquitin ligase Nedd4, 
thereby blocking Nedd4 activity and Nedd4-dependent release of virions from 
cells (Malakhova & Zhang, 2008). Similarly, ISG15 blocks ubiquitination of Gag 
and Tsg101 proteins (Okumura et al., 2006), thus inhibiting Gag or Tsg101 
ubiquitination-dependent release of HIV virions from cells. Moreover, IFN-
mediated ISG15 conjugation has been suggested to negatively regulate influenza 
A virus replication (Hsiang et al., 2009). On the other hand, the influenza B NS1 
protein has been reported to bind to ISG15 and block ISGylation of cellular 
proteins after virus infection (Yuan & Krug, 2001). Thus, there is a growing body 
of work supporting an important role of ISG15 and ISGylation in the IFN-
mediated antiviral response both through the modification of the components of 
the host immune response and modification of viral proteins. 
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Figure 4.16 – Protein modification by ubiquitin (Ubiquitination) and ISG15 (ISGylation). Both 
processes employ similar enzymatic cascades involving E1 activating enzyme (UBE1L), E2 
conjugating enzyme (UBcH8/ UBcH6) and an E3 ubiquitin ligase [HERC5, Efp (Trim25) and 
HHARI]. Ubiquitination and ISGylation are both reversible by the action of deconjugating 
enzymes, only one of each has been identified in the case of ISG15 (UBP43/USP18). 
Similarly to ISG15, the proteins involved in ISGylation process is also induced by type I 
IFNs. 
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I. Lack of ISG15 conjugation in U2OS cells; possible role of HERC5 
Exogenous treatment of the two cell lines used in this study, Huh-7 and 
U2OS cells, with IFNα and β induced high expression of both ISG15 mRNA and 
unconjugated protein. However, U2OS cells produced low amounts of ISG15 
conjugates in response to type I IFNs, in contrast to the levels detected in Huh-7 
cells. From further analysis, it was found that U2OS cells lack HERC5, the major 
E3 ligase involved in ISG15 conjugation (Figure 4.18). Thus, the reduced levels of 
ISG15 conjugates in U2OS cells are likely to result from absence of HERC5. It is 
presumed that ectopic expression of HERC5 in U2OS cells could restore their 
ability to produce higher amounts of conjugated ISG15 in response to IFN. 
Alternatively, other enzyme factors involved in ISGylation in addition to HERC5 
may be downregulated or absent in U2OS cells; addressing these two possible 
explanations for the decreased amounts of conjugated ISG15 in U2OS cells would 
require further experiments. 
Given that silencing of ISG15 in U2OS cells resulted in an increase in HCV 
RNA levels, it implies that ISG15 plays an inhibitory role against HCV replication 
in these cells as well as in Huh-7 cells. Since U2OS cells do not produce 
conjugated ISG15 to the same extent as in Huh-7 cells, it is feasible that 
different mechanisms may be employed by ISG15 for countering viral replication 
in the two cells lines. In the case of U2OS cells, free ISG15 may be sufficient for 
anti-HCV activities, possibly by acting primarily as a transcription factor or 
cytokine (Recht et al., 1991). By contrast, in Huh-7 cells ISG15 may require 
conjugation to limit viral replication, either by conjugating to a viral or host 
protein required for optimal viral replication. Kim & Yoo (2010) have previously 
demonstrated that the viral protein NS5A is indeed a target for ISGylation. 
Alternatively, it is possible that ISG15 may act primarily in both cell lines as an 
unconjugated protein to regulate viral replication. To investigate the 
conjugation requirements of ISG15 for its anti-HCV activities, preliminary 
experiments were undertaken and are presented in Chapter 5. 
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II. Interplay between ISG15 and USP18 
As well as the lack of HERC5 in U2OS cells, it was observed that lowering 
the expression of ISG15 mRNA levels in both Huh-7 and U2OS cells treated with 
IFNα resulted in a relative rise in USP18 mRNA levels. Such observations have 
been reported by others (Chua et al., 2009; Randall et al., 2006). This 
differential response could imply a feedback mechanism between ISG15 and 
USP18, the enzyme involved in removal of ISG15 from conjugated forms, and 
indeed, that transcriptional control of the genes involved in ISGylation are 
intimately interconnected. ISG15 both positively and negatively regulates 
activation of type I IFNs, by preventing degradation of IRF-3 or activation of RIG-
I, respectively (Kim et al., 2008; Lu et al., 2006). Thus, it is possible that ISG15 
and/or ISGylation may also be involved in further regulatory mechanisms to 
guarantee the optimal response of IFN to invading pathogens. 
The activities of IFNs must be tightly regulated to function optimally and 
provide an adequate response to a stimulus. For example, several mechanisms 
have been described to coordinate IFN-mediated JAK/STAT signalling. In a study 
by Sarasin-Filipowicz et al (2009) repeated treatment of mice with IFNα led to a 
refractory activity to further IFNα stimulation (Sarasin-Filipowicz et al., 2009). 
Previous studies have shown that USP18 plays a role in modulating the antiviral 
activities of type I IFNs and in IFN-induced desensitization (Murray et al., 2011; 
Randall et al., 2006). Silencing of USP18 results in prolonged phosphorylation of 
STAT1, and consequently in an increase in the IFNα-mediated induction of ISG15 
and other ISGs (Randall et al., 2006). USP18 has been shown to negatively 
regulate IFN signalling by binding to IFNR2 and blocking downstream signalling 
through the JAK/STAT pathway (Malakhova et al., 2006). Further studies that 
identify the mechanism underlying stimulation of USP18 transcription through 
impairing ISG15 expression may shed light on the interplay between the genes 
involved in ISGylation. 
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III. The impact of ISG15 on HCV replication 
To date, there have been four other studies that have specifically 
examined the effect of ISG15 on HCV replication and, in some cases, virion 
production (Broering et al., 2010; Chen et al., 2010; Chua et al., 2009; Kim & 
Yoo, 2010). Combined with the results presented here, the findings do not 
provide a consensus on whether ISG15 promotes or disrupts replication; a 
summary of the findings from each study is presented in Table 1. As well as the 
summarised information in the table, which illustrates the range of model 
systems used, there are some points worth noting in terms of differences 
observed with the data presented in this study. For example, Chen et al (2010) 
found that transfection of a construct expressing ISG15 yielded higher levels of 
HCV RNA and infectious virus even in the presence of low amounts (up to 1U/ml) 
of IFNα. In their data to support evidence for over-expression of ISG15, they 
were apparently able to detect conjugated ISG15 without the need to stimulate 
the levels of the enzymes required for ISGylation and also could detect 
unconjugated ISG15 in untransfected cells in the absence of IFNα. From the data 
presented here, conjugated forms of ISG15 could not be detected following 
over-expression of ISG15 alone (Chapter 5). Moreover, unconjugated ISG15 
cannot be detected without the addition of IFN. Hence, there are fundamental 
differences in the characteristics of ISG15 between Chen et al (2010) and the 
results in this study. One striking example of the conflicting data observed was 
made by Kim & Yoo (2010) who reported decreased levels of replication with the 
Con-1 replicon in Huh-7 cells, which had been transfected with plasmids 
expressing ISG15, UbE1L (an E1 activating enzyme for ISG15 conjugation) and 
UbcH8 (an E2 enzyme for ISG15 conjugation); by contrast in Huh-7.5 cells 
infected with JFH-1, this combination of vectors enhanced HCV replication (Kim 
& Yoo, 2010). Thus, it is very likely that the contradictory findings in the data 
presented in Table 1 are a combination of differences in the replication system 
used (gts1a, 1b and 2a), the cell lines (Huh-7 from different sources including 
use of cell lines cured by IFN and a polymerase inhibitor) as well as alternative 
experimental strategies (e.g. the ranges of IFN employed in the various studies). 
Based on the pooled data in Table 1 and the study by Kim & Yoo (2010), 
analysis of the effects of ISG15 in Huh-7.5 cells harbouring the JFH1 SGR would 
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have been valuable to determine whether inhibiting ISG15 in these cells had the 
same effect as in Huh-7 and U2OS cells. However, time constraints did not 
permit such studies to be performed. Nonetheless, comparative proteome 
analysis of Huh-7 and Huh-7.5 cells has shown that there are differences 
between the two cell lines (C. Hinds, pers. comm.) and it is known that Huh-7.5 
cells express an inactivated, mutated form of RIG-I (Sumpter et al., 2005). In 
addition, inherent variability between Huh-7 cells from different sources, at the 
level of permissiveness to HCV replication as well as to response to dsRNA 
stimuli, has been reported previously (Binder et al., 2007; Sainz et al., 2009a). 
Indeed, Huh-7 cells from different sources have yielded different host genotypes 
at the IL28B locus (Bensadoun et al., 2011). In an attempt to partially address 
variation between cell lines as a possible explanation for the discordant results, 
the ISG15 expression levels induced by IFNα were examined in three different 
batches of Huh-7 cells that were available (referred to as Huh-7 A, Huh-7 B and 
Huh-7 C) and Huh-7.5 cells (Figure 4.17). ISG15 expression levels were very 
similar in all untreated Huh-7 cells but there were approximately 2-fold higher 
levels in Huh-7.5 cells (Figure 4.17-B). Treatment with increasing doses of IFNα 
induced comparable levels of ISG15 mRNA in all cell lines including Huh-7.5 cells 
(Figure 4.17-A). At the protein level, it was noted that unconjugated ISG15 could 
be induced to similar levels in all cell lines but the abundance of conjugated 
protein was considerably less in Huh-7.5 cells (Figure 4.17-C). Moreover, the 
abundance of phosphorylated STAT1 protein (P-STAT1) was somewhat less in 
Huh-7.5 cells (Figure 4.17-C). More detailed analysis on the characteristics of the 
cell lines is needed to provide a possible explanation for the differences in the 
reported literature and the findings in this study on the impact of ISG15 on HCV 
replication. 
IV. Approaches for inhibiting ISG15 expression 
Given that all of the previous studies had utilised short-term inhibition (by 
siRNA transfection) or over-expression (by transfection of plasmids expressing 
ISG15), an alternative approach using shRNAs was adopted to try to overcome 
possible undesired effects in transient assays. For example, siRNA-mediated 
silencing can cause effects other than the intended mRNA suppression 
(commonly regarded as off-target effects). Rao et al (2009) has reviewed the 
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major problems associated with off-target effects for siRNA-mediated gene 
knockdown (Rao et al., 2009). Briefly, specific off-target effects are observed 
through partial sequence complementarities of the siRNA construct to mRNA, 
other than the intended target. These off-target effects are often unrelated to 
the ability of the siRNA to silence the gene of interest. Improvements have been 
made in recent years to address these problems, by designing siRNAs with 
reduced off-target effects. However, in some cases such modifications are 
sometimes accompanied with a decrease in overall potency of suppression of the 
siRNA (Snove & Rossi, 2006; Watts et al., 2008). In addition, non-specific off-
target effects associated with siRNA silencing can result from immune-mediated 
responses to exogenous RNAi and cellular toxicity. Some studies have 
demonstrated that a partial interferon response is induced through activation of 
TLR3 dsRNA sensors and are often dependent on the siRNA sequence (GU-
dependent, 5’-UGUGU-3’ and GU-independent, 5’-GUCCUUCAA-3’) (Kariko et al., 
2004; Sledz et al., 2003). Moreover, siRNAs are delivered into the cells typically 
via the action of cationic preparations. These facilitate the binding of siRNAs to 
the cell membrane and promote endocytosis and escape from endosomes. This 
method improves significantly the transfection efficiency of siRNAs, although it 
is often associated with increased toxicity. 
In the case of shRNAs, sequence-dependent induction of immune responses 
could also promote non-specific off-target effects. However, shRNAs use the 
endogenous processing machinery, an advantage over siRNAs in terms of a lower 
propensity for induction of IFN. In addition, delivery of shRNAs into cells using 
viral vectors provides higher efficiency in transfection and integration into 
chromosomal DNA allows selection of stable cell lines that express the inhibitory 
shRNA. Since transcription of any insert occurs in the nucleus with further 
processing through endogenous machinery, shRNAs are less susceptible to 
degradation in the cytoplasm. Thus, higher efficiency in gene silencing by 
shRNAs can be achieved using low copy numbers and thus fewer off-target 
effects. 
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Table 1 – Summary of the findings regarding ISG15 activities on HCV replication. 
Study Effect of ISG15 (-IFN) 
Effect of 
ISG15 (+IFN) Replication system Cell lines 
(Chua et al., 
2009) 
No effect Stimulates 
(increased 
sensitivity to 
IFNα at low 
values of IFN 
[<10 U/ml]) 
• SGR: Con-1 [gt1b]; 
• HCVcc studies: H77-S 
[gt1a] 
• Huh-7 [for Con-1]; 
• Rof-0c [for H77-S; 
cured replicon cells 
using polymerase 
inhibitor] 
(Broering et 
al., 2010) 
Stimulates Stimulates • SGR: Con-1 [gt1b]; 
• HCVcc studies: JC-1 
[gt2a chimera] 
• MH1 [for Con-1; 
mouse hepatoma 
cells]; 
• ‘con1’ [presumed 
to be Huh-7 for 
Con-1]; 
• Huh-7.5 [HCVcc 
studies] 
(Chen et al., 
2010) 
Stimulates Stimulates • HCVcc studies: JC-1 
[gt2a chimera] 
Huh-7.5 
(Kim & Yoo, 
2010) 
Inhibits  Inhibits • SGR: Con-1 [gt1b] Huh-7 
(Kim & Yoo, 
2010) 
(Supplementary 
data) 
Stimulates  Not tested • HCVcc studies: JFH-1 
[gt2a] 
Huh-7.5 
This study Inhibits  Inhibits • SGR: JFH-1 [gt2a] & 
Con-1 [gt1b]; 
• HCVcc studies: JC-1 
[gt2a chimera] 
• Huh-7 [for Con-1, 
JFH-1 SGR/HCVcc]; 
• U2OS [for JFH-1 
SGR] 
 
Using shRNAs, one cell line, sh6, was selected that constitutively expressed 
lower levels of ISG15 both in the presence and absence of IFNα. Studies with this 
cell line indicated that electroporation of viral SGR RNA did not result in any 
increase in HCV replication compared to cells expressing a control shRNA. By 
contrast, it was possible to reproducibly detect higher viral RNA levels across a 
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range of multiplicities of infection with infectious JC-1. It is possible that the 
amount of RNA introduced into cells for transient assays (of the order of as many 
as 106 copies of in vitro transcribed RNA per cell) masked any possible effect of 
the lower ISG15 levels in sh6 cells. Indeed, ISG15 protein, either in the 
unconjugated or conjugated form, could not be detected in shCtrl or cells not 
transduced with lentivirus. With the HCVcc system, the number of infectious 
genomes entering the cell will be at most 1-2 copies per cell, which is more 
representative of the infectious process in vivo. The fact that infectious assays 
in sh6 cell did reproduce the data using transiently transfected siRNAs adds 
weight to the overall conclusion that ISG15 impairs HCV RNA replication in cells 
that are not stimulated by IFN. 
Given that there are caveats even with the shRNA system used, another 
alternative method for future studies on ISG15 function during HCV infection 
would be to generate cell lines with a deletion of the gene. Recently, a new 
technology based on employing gene-targeted zinc-finger nucleases (ZFNs) has 
been used to produce cell lines with gene-targeted deletions. ZFNs are synthetic 
fusion proteins consisting of two main functional domains; an engineered zinc 
finger, which mediates recognition of nucleotide sequences (DNA-binding 
domain) that is fused to the cleavage domain of the FokI restriction 
endonuclease (cleavage domain). The FokI restriction endonuclease cleaves the 
phosphodiester bond in the DNA backbone. ZFNs can be designed to recognise 
and cleave specific nucleotide sequences in the genome to create double strand 
DNA breaks (DSB). This event consequently activates the cellular mechanisms of 
DSB repair, either by error-prone non-homologous end joining (NHEJ) or by 
stimulation of homologous recombination with a donor DNA template (HDR). 
Among other applications, this approach using ZFNs exploits NHEJ-derived 
modifications, which lead to a mutated gene with a knock-out phenotype. The 
technology has been reported to successfully mediate gene knockout in cultured 
cells (Santiago et al., 2008). Applying this approach to studies on ISG15 function 
would be highly beneficial to overcome the limitations on siRNA- and shRNA-
meditated targeting. 
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Figure 4.17 – Expression levels of ISG15 in Huh-7 and Huh-7.5 cells. Three batches of Huh-7 
cells (A, B and C) and Huh-7.5 cells were treated with increasing doses (0, 50, 100 and 
200U/ml) of IFNα, β and γ. At 48h after treatment cells extracts were used for RT-qPCR 
analysis of ISG15 mRNA expression [A] and [B] and Western blot analysis of ISG15 free and 
conjugated forms using anti-ISG15 antisera [C]. Expression of phosphorylated form of 
STAT1 protein and actin were examined using anti-P-STAT1 and anti-actin antisera. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 – Analysis of HERC5 silencing in U2OS/SGR cells. U2OS/SGR cells were 
transfected with control, ISG15 and HERC5 siRNAs (siCtrl, siISG15 and siHERC5, 
respectively) for 24h, followed by treatment with increasing doses (0, 1, 10 and 100 U/ml) of 
IFNα for 48h. U2OS cells were treated with 0 and 100U/ml IFNα for 48h. RT-qPCR analysis of 
ISG15 [A] and HERC5 [B] mRNA expression levels. [C] Western blot analysis of ISG15 
conjugated and unconjugated forms, HERC5 and actin protein expression levels, using anti-
ISG15, anti-HERC5 and anti-actin antisera. 
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5 Investigation of the ISG15 mechanisms against 
HCV replication 
5.1 Introduction 
Following the observations from the previous sections, we sought to further 
investigate the antiviral mechanism of ISG15 in HCV replication. To that end two 
approaches were used to understand the pathways through which ISG15 delivers 
its activities to control replication, i.e. whether free ISG15 or conjugated ISG15 
are required for such functions, and the stage of the viral life cycle that is 
targeted. To answer the latter question, we sought to investigate whether ISG15 
affects the rates synthesis or degradation of viral RNA during HCV replication. 
5.2 Effect of ISG15 on viral RNA synthesis 
To determine the mechanism through which ISG15 modulates HCV 
replication, the reasons for the differences observed in the steady-state levels of 
viral RNA between shCtrl- and sh6-infected cells were investigated. For every 
transcript, steady-state RNA levels result from a balance between RNA synthesis 
and decay. To examine whether the differences observed in steady-state viral 
RNA levels could reflect changes in either the relative rates of RNA stability or 
synthesis, a recently described method for metabolic tagging of de novo 
synthesized transcripts was adopted [(Dolken et al., 2008); Figure 5.1]. 
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Figure 5.1– Metabolic tagging of nascent RNA. 4-thiouridine (4sU), a thiol-group containing 
nucleoside (I.), was used to metabolically label newly transcribed RNA. Following labelling 
(II.), newly transcribed RNA can be isolated from untagged pre-existing transcripts 
molecules using thiol-specific biotinylation and purified on streptavidin-coated magnetic 
beads. The different fractions of RNA can then be quantified using RT-qPCR (absolute 
quantification). Modified from Friedel & Dolken, 2009. 
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In this method, labelling of newly synthesised RNA is achieved by 
incubating cells in the presence of 4sU (4-thiouridine), a thiol-containing uridine 
analogue (Figure 5.1-I). The modified nucleoside is readily incorporated into 
nascent RNA in the place of uridine, with minimal effects on normal cellular 
gene transcription (Melvin et al., 1978). Newly synthesized transcripts can then 
be separated from unlabelled RNA using the thiol groups in 4sU-labelled RNAs, 
which serve as an attachment point for a biotin tag. This interaction allows the 
subsequent separation of de novo synthesised transcripts from the total RNA 
population using streptavidin-coated magnetic beads. 
Under steady-state conditions, RNA synthesis and decay are in equilibrium 
in order to maintain a pool of stable transcripts. Using the newly transcribed 
labelled RNA data, together with total RNA ratios and the duration of labelling, 
RNA half-life can be calculated. Thus, changes in RNA decay and synthesis as 
well as their impact on total RNA levels can be analysed. In this series of 
experiments, 4sU-labelling of RNA was applied to determine the abundance of 
newly synthesised viral transcripts during HCV infection to evaluate the effects 
of ISG15 silencing on rates of viral RNA synthesis and/or degradation. 
5.2.1 Optimisation of 4sU labelling of HCV RNA 
As reported previously (Rabani et al., 2011), short-term labelling periods 
can be sufficient for efficient incorporation of 4sU into newly transcribed RNA. 
To examine the feasibility of labelling nascent viral RNA, cells that constitutively 
replicated HCV SGR RNAs were used. 4sU was added to the culture medium at a 
final concentration of 100uM, which has proven to be non-toxic to cells (Friedel 
& Dolken, 2009). Huh-7/SGR cells were labelled with 4sU for 0, 30, 60 and 120 
min, followed by immediate RNA extraction. After isolation of total RNA and 
thiol-specific biotinylation, total and 4sU-labeled viral RNA was detected and 
quantified by absolute quantitative PCR of reversed transcribed RNA pools (as 
described in Chapter 2, section 2.2.8.5). The following sections describe the 
method used to determine absolute quantification of total and newly transcribed 
viral RNA and their relative ratios (Figure 5.2). 
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Figure 5.2 – Schematic representation method used to determine absolute quantification of 
total and newly transcribed viral RNA. RNA was extracted from 4sU-labelled cells, quantified 
and used for I) calculation of copy number of total viral RNA (SGR or full-length) in the 
sample by RT-qPCR; and II) biotinylation of labelled RNA and purified on streptavidin-
coated magnetic beads, followed by calculation of copy number of labelled/newly 
transcribed viral RNA (SGR or full-length) in the sample by RT-qPCR. To determine the 
relative proportion of newly transcribed viral RNA in each sample, the calculated copy 
numbers for each RNA fraction (I and II) were combined and expressed as percentage (%) of 
NT viral RNA per total viral RNA in the sample. 
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5.2.1.1 Absolute quantification of viral RNA copy number 
For calculating the copy number of viral RNA isolated from cells, a standard 
curve containing a range of known quantities of HCV transcripts was 
constructed. In these experiments, a standard dilution series was prepared by 
serial 10-fold dilutions of in vitro transcribed (IVT) viral RNA (SGR RNA or in later 
experiments, full-length RNA). The standard curve, generated by this approach, 
is represented in Figure 5.4-B. Based on the length of IVT RNA (SGR = 8032bp and 
JC-1 = 9605bp), the copy number was calculated as shown in Figure 5.3. 
 
Figure 5.3 – Calculation of HCV RNA copy number. [1] Molecular weight, MW, of viral ssRNA 
is calculated using the number of nucleotides in one RNA molecule multiplied by the 
average MW per ribonucleotide (320.5 Da or g/mol). Addition of 159 to the MW takes into 
account the MW of a 5’ triphosphate. [2] The number of molecules in 1 mole is calculated by 
dividing the MW of viral transcripts by Avogadro’s number (6.02214199x1023). [3] Using the 
concentration of viral RNA per sample, and dividing by the number of molecules per mole 
calculated in [2], the copy of viral RNA transcripts per µl can be calculated. 
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The copy number per pg of IVT RNA (e.g SGR RNA) was calculated using the 
equations represented in Figure 5.3: 
 
From the formulae used in Figure 5.3, the copy number in the serial 
dilutions of IVT HCV RNA was calculated (Table 2). These values were plotted 
against the CT values obtained by RT-qPCR (Table 3), giving the standard curve 
shown in Figure 5.4. From the standard curve, the copy number of viral RNA in 
unknown samples was derived (either total amount of viral RNA or newly 
transcribed viral RNA in each sample). 
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Table 2 – Copy number of HCV IVT standards. 
Standard 
sample 
Concentration 
(pg/µl) 
Copies of 
transcript/µl 
(SGR RNA) 
Copies of 
transcript/µl 
 (JC-1 RNA) 
S1 1000 233923600.5 195615451.9 
S2 100 23392360.05 19561545.19 
S3 10 2339236.005 1956154.519 
S4 1 233923.6005 195615.4519 
S5 0.1 23392.36005 19561.54519 
S6 0.01 2339.236005 1956.154519 
S7 0.001 233.9236005 195.6154519 
S8 0.0001 23.39236005 19.56154519 
 
Table 3 – Standards vs CT. 
Standard 
sample 
AVR CT (SGR RNA) AVR CT (JC-1 RNA) 
S1 8.6 8.6 
S2 11.1 10.6 
S3 14.1 13.8 
S4 17.9 17.4 
S5 21.6 20.8 
S6 25.4 24.2 
S7 29.1 28.0 
S8 32.3 31.6 
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R2: 0.998
Slope: -3.75
[A]
[B]
Copy number
S1 S2 S3 S4 S5 S6 S7 S8
 
Figure 5.4 – Amplification plot of IVT SGR standards (A) and the derived standard curve (B). 
The standard curve is calculated by applying linear regression (best-fit line) in a plot of the 
Ct values from the standard reactions plotted against standard quantities The regression 
line formula is Ct=m[log(Qty)]+b, where m is the slope, b is the y-intercept and Qty is the 
standard quantity. The R2 values indicate the closeness of fit between the standard curve 
and the individual Ct data points from the standard reaction. A value of 1.00 indicates a 
perfect fit between the regression line and the data points. The slope indicates the PCR 
amplification efficiency for the assay. A slope of -3.32 indicates 100% amplification 
efficiency. 
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5.2.1.2 Labelling of newly transcribed viral RNA in Huh-7/SGR cells 
To determine whether addition of 4sU affected viral RNA replication, Huh-
7/SGR cells were labelled with the nucleoside for up to 2h and RNA was isolated 
at the times indicated in Figure 5.5-A. Following RT-qPCR analysis, the copy 
number of total viral transcripts was determined. The data indicated that the 
number of copies of viral RNA did not change during the labelling period and 
therefore, it was concluded that addition of 4sU to cells had no dramatic effect 
on replication (Figure 5.5-B). Labelled RNA also was purified from the total RNA 
to examine whether there was any evidence of incorporation of the modified 
nucleoside into replicated HCV RNA (Figure 5.5-C). By 30min, no labelled viral 
RNA was found, however, it was possible to detect approximately 2x107 HCV 
transcripts at 1h (equivalent to less than 1% of labelled viral RNA in the overall 
amount of viral RNA, Figure 5.5-D). This figure rose to 2x108 molecules by 2h 
after addition of 4sU (equivalent to ~5% viral RNA) (Figure 5.5-C&D). This 
preliminary experiment revealed that it was possible to label, isolate and 
quantify viral RNA with 4sU. However, it was concluded that longer labelling 
times might be necessary for accurate quantification of newly synthesised viral 
RNA. 
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Figure 5.5 – Labelling and quantification of newly transcribed viral RNA during HCV 
replication. Huh-7/SGR cells were labelled (100uM 4sU) for 0, 30, 60 and 120min. A) 
Experimental outline. B) Total abundance of viral RNA. C) Amount of labelled viral RNA. D) 
Percentage of labelled SGR RNA relative to total viral RNA in the sample. Dashed lines 
represent cut-off of labelling nascent RNA. 
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5.2.1.3 Optimization of labelling duration suitable for infection assays 
Given that in cells stably expressing the HCV SGR, only ~5% of newly 
transcribed viral RNA could be labelled in 2h, this number would be expected to 
be even lower in infected cells, as the levels of viral RNA are less than in stably 
expressing SGR cells. Thus, in order to guarantee labelling of RNA during viral 
infection, longer 4sU labelling times and/or higher concentrations were 
required. To that end, the effect of longer times (2, 16, 24 and 48h) and 
increased concentrations (0, 50, 100, 200 and 400uM) of 4sU labelling on cell 
viability were examined in Huh-7 cells using the resazurin reduction assay (as 
described in Chapter 2, section 2.2.8.6). As shown in Figure 5.6, labelling Huh-7 
cells for up to 16h did not affect substantially cell viability at most 4sU 
concentrations, although at 400uM some negative effects started to appear, as 
cell viability decreased by about 20% when compared with untreated cells. At 
24h, cell viability was partly affected with 50, 100 or 200uM of 4sU, as the 
values were at or higher than 80% viability. Exposing the cells to 400uM of 4sU on 
the other hand had a greater effect, reducing viability to 65%. By 48h, all 4sU 
concentrations were shown to impact on cell viability, as the levels were lower 
than 80%, and at 400uM cell viability reduced further to about 40%. These 
results, indicated that was possible to label Huh-7 cells using either 50 or 100uM 
of 4sU for up to 24h, without substantial effects on cell viability. Thus, for the 
following infection assays, 100uM 4sU was selected for labelling viral RNA for up 
to 24h. 
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Figure 5.6 – Cell viability of Huh-7 exposed to increasing concentrations of 4sU. Huh-7 cells 
were labelled with 0, 50, 100, 200 and 400uM of 4sU for up to 48h. The toxicity associated 
with 4sU exposure was assessed using the resazurin reduction test. The viable cells retain 
the ability to reduce resazurin and generate a fluorescent signal. This signal was normalised 
to the untreated cells and expressed as percentage of viable cells. 
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5.2.2 Labelling of nascent viral RNA during infection assays 
Using the information from the previous section, we sought to examine 
whether ISG15 affected viral RNA synthesis during HCV infection. As shown 
before, up to 24h of labelling could be used without reducing cell viability. 
Therefore, to cover a 48h period, the experimental strategy encompassed two 
approaches in which cells were labelled with 4sU during either the 24h period 
immediately following infection or for 24-48h after infection. To that end, shCtrl 
and sh6 cells were infected with JC-1 virus at a MOI of 0.8 in the presence of 
100uM 4sU (Figure 5.7-A). Transcript levels were monitored for up to 24h p.i. 
and the RNA populations (total and NT viral RNA) quantified as described earlier. 
Given the variability in the number of viral RNA copies detected between 
independent experiments, the copy number for viral transcripts in sh6-infected 
cells at the last time point (in this case 24h) was expressed as 100% and the copy 
numbers at earlier times in sh6 and shCtrl cells expressed relative to this value. 
As shown in Figure 5.7-B, the amount of total viral RNA was slightly higher 
between 6 and 24h p.i in JC-1-infected sh6 cells when compared with the 
respective shCtrl cells. Analysis of labelled viral RNA indicated that similar levels 
of viral RNA were generated between 6 and 12h p.i in both shCtrl and sh6 cells 
(Figure 5.7-C). By 24h p.i., 22% of newly synthesized JC-1 RNA could be detected 
in shCtrl cells, indicating the higher efficiency in labelling viral RNA during 
longer 4sU exposure times. In addition, a further 6% increase in the relative 
amount of NT JC-1 RNA was detected in sh6 cells (28%) when compared to shCtrl 
cells. Thus, although small differences were observed in total steady-state levels 
of JC-1 RNA in shCtrl and sh6 cells throughout the first 24h of infection, only at 
the latest time point were those differences reflected in higher levels of viral 
RNA synthesis in the sh6 cells. These results indicate that any negative influence 
of ISG15 on viral RNA synthesis could be detected as early as 24h after infection. 
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To examine whether ISG15 affects viral RNA synthesis in the second 24h 
period after infection, shCtrl and sh6 cells were infected with JC-1 virus at a MOI 
of 0.8 for 24h, followed by labelling with 100uM 4sU for the following 24h (i.e. 
from 24 to 48h p.i.). Transcript levels were monitored between 24 and 48h p.i. 
and the RNA populations quantified as described before. In agreement with the 
data presented earlier (Figure 4.15-A), total levels of viral RNA were consistently 
higher in sh6 cells when compared with the shCtrl up to 48h p.i (Figure 5.8-B). 
Similarly, newly transcribed JC-1 RNA levels were also higher in sh6 cells in 
comparison to shCtrl cells up to 48h p.i, mirroring the differences observed in 
the total HCV RNA levels (Figure 5.8-C). 
To determine whether the higher levels of synthesized viral RNA observed 
in the sh6 cells were due to increased RNA stability, JC-1 infected shCtrl and sh6 
cells were pulse-labelled for 6h with 200uM 4sU at 24h p.i. and the loss of 
labelled RNA monitored for a further 48h. As before, total levels of JC-1 RNA 
were consistently higher in sh6 cells when compared with the shCtrl during the 
period of infection (up to 78h, Figure 5.9-B). The amount of labelled JC-1 RNA 
present at the end of the labelling period is represented in Figure 5.9-C. In order 
to better evaluate the differences in the rate of decay of viral RNA (i.e. loss of 
labelled viral RNA) in infected cells, the data generated in Figure 5.9-C was 
normalized to the samples corresponding to the time point at which labelling 
was stopped (i.e. 30h p.i.), in each cell line (Figure 5.9-D). Following this 
normalization, nonlinear regression (curve) fit analysis was applied (using 
GraphPad Prism 5 software) in order to verify whether the constant rate (K) of 
decay of labelled RNA were significantly different in the two cell lines. As shown 
in Figure 5.9-D, the curves generated from the nonlinear regression were similar 
and not statistically different in shCtrl and sh6 cells. Since the curves were not 
significantly different, the data gathered from the pulse-chase experiments 
suggest that ISG15 does not affect the rate of decay of viral RNA, favouring the 
conclusion that ISG15 interferes with the synthesis of viral RNA. 
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Figure 5.7 – Labelling and quantification of newly transcribed viral RNA during HCV 
infection. shCtrl and sh6 cells infected with JC-1 at a MOI of 0.8 in the presence of label 
(100uM 4sU) for up to 24h. A) Experimental outline. B) Total abundance of viral RNA. C) Rate 
of synthesis of viral RNA. 
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Figure 5.8 – Labelling and quantification of newly transcribed viral RNA during HCV 
infection. shCtrl and sh6 cells infected with JC-1 at a MOI of 0.8 and then labeled (100uM 
4sU) for up to 24h (48h p.i.). A) Experimental outline. B) Total abundance of viral RNA. C) 
Rate of synthesis of viral RNA. 
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Figure 5.9 – Labelling and quantification of newly transcribed viral RNA during HCV 
infection. shCtrl and sh6 cells infected with JC-1 at a MOI of 0.8 for 24h, followed by 6h 
pulse-label (4sU 200uM). After 6h, the label was removed and the loss of labelling was 
monitored for up to 48h. A) Experimental outline. B) Total abundance of viral RNA. C) Decay 
of labelled viral RNA. D) Decay of labelled viral RNA, expressed relative to values at 30h p.i., 
when labelling was terminated. Dashed lines represent slopes generated from nonlinear 
regression (curve) fit analysis (using GraphPad Prism 5 software) of the values from shCtrl 
(blue) and sh6 cells (red). 
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5.3 Preliminary studies on the conjugation requirements 
for ISG15 anti-HCV activities 
The conjugation status of ISG15 has been linked with its antiviral activities, 
since it has been shown that it can covalently attach to a variety of cellular 
proteins, some of which function in the interferon-response pathway (Loeb & 
Haas, 1992; Zhao et al., 2005). With other viruses, ISG15 conjugation appears to 
be required for antiviral activities against Sindbis, as well as influenza A and B 
viruses (Lenschow et al., 2005; Yuan & Krug, 2001). Alternatively, it has also 
been demonstrated that unconjugated ISG15 mediates resistance to Ebola and 
HIV-1, by inhibiting ubiquitination of viral proteins involved in egress (Malakhova 
& Zhang, 2008; Okumura et al., 2006). 
5.3.1 Generation of inducible Huh-7 cell lines to express ISG15 
WT and mutant protein forms 
5.3.1.1 Construction of ISG15 expression vectors 
To investigate whether conjugated or unconjugated forms of ISG15 are 
required for reducing HCV RNA replication, cell lines were generated that 
express wt (GG) and mutant (AA) forms of ISG15. The mutated form has alanine 
substitutions at the di-GG residues, which are essential for ISG15 conjugation 
(Figure 5.11-B). Recently, Everett et al (2009) developed a tetracycline-
inducible system (Tet-On) built into lentivirus vectors, which allowed controlled 
expression of the protein of interest close to its physiological levels (Everett et 
al., 2009). This system was used to generate ISG15-inducible cell lines. The 
strategy employed to construct the tetracycline-inducible ISG15 lentiviral 
plasmids is detailed in Figure 5.11 and described below. 
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The expression vector used for cloning the ISG15 cDNA sequence was 
pLKO.dCMV.TetO.mcs. This plasmid contained, in addition to the elements 
required for lentivirus production, a tandem TetO operator sequence and dCMV 
promoter (Figure 5.10). The plasmid pOTB7-ISG15, expressing native ISG15 
(GeneBank accession number BC009507) was used as a template for 
amplification of a DNA fragment encoding ISG15, using the primers listed in 
Figure 5.11-C. These primers were designed such that the amplified region 
corresponded to the coding sequence for the mature form of ISG15 protein. To 
generate the WT form of ISG15 protein (C-terminus ending as LRLRGG) or a 
mutant version of the protein (LRLRAA), the C-terminal region of ISG15 was 
amplified using Rev primers which contained either the WT sequence or the 
respective changes to create the mutant AA sequence (Figure 5.11-A & C). In 
addition, Fwd and Rev primers introduced HindIII and XbaI/BamHI restriction 
sites at the 5’ and 3’ ends respectively. Each amplified DNA fragment, HindIII-
ISG15-GG-XbaI/BamHI or HindIII-ISG15-AA-XbaI/BamHI, was then digested with 
HindIII and BamHI and ligated into an intermediate cloning vector pCMV-FLAG-
Ubch7 (also digested with HindIII and BamHI) to generate the pCMV-FLAG-ISG15-
GG and –AA constructs (Figure 5.11-B). 
Flag-ISG15-GG and –AA DNA fragments were amplified from the previous 
constructs using the primers listed in Figure 5.11-D, which inserted an additional 
NheI restriction site followed by a Kozak sequence at the 5’ end of the FLAG 
sequence to enhance protein translation. The resultant PCR fragments were 
digested with NheI and XbaI and ligated into the pLKO.dCMV.TetO.mcs (also 
digested with NheI and XbaI), to yield the pLKO.dCMV.TetO.FLAG.ISG15-GG and –
AA constructs (Figure 5.11-A). 
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Figure 5.10 – Map of the lentivirus vectors used to express WT (GG) and mutant (AA) ISG15 
from a cDNA fragment under the control of a tetracycline inducible promoter (A) and 
eGFPnls.TetR fusion protein (B). Additional to some of the features listed in Figure 4.10, 
these expression vectors also contained: complete (hCMV IEp) or truncated (dCMVp) 
human cytomegalovirus immediate early promoter; mcs, multiple cloning site, used to 
insert FLAG-ISG15-GG and –AA cDNA; nls, nuclear localization signal. 
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[C]
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CTG  CGC  CTG  CGG  GGA  GGC  TAA TCT AGA GGA TCC ACC
ISG15-GG_Rev: 5’-GGT  GGA TCC TCT AGA TTA  GCC TCC CCG  CAG  GCG  CAG-3’
ISG15-AA_Rev:   5’-GGT  GGA TCC TCT AGA TTA  GGC TGC CCG  CAG  GCG  CAG-3’
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PCR 2 primers:
XbaI BamHI
FLAG HindIII
pCMV‐FLAG‐ISG15‐GG/AA
Fwd: 5’-AA AAA GCT AGC TCT ACC ATG GAC TAC AAA GAC G-3’
NheI Kozak
PCR 1 Rev primers
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Figure 5.11 – Construction of pLKO.dCMV.TetO.FLAG.ISG15-GG/AA lentiviral plasmids. [A] 
Overall strategy to create WT (GG) or mutant (AA) ISG15 protein expression vector. [B] 
Cloning steps used to insert ISG15 cDNA into pLKO-dCMV.TetO.mcs vectors: 1) PCR 
amplification of ISG15 cDNA from pOTB7-ISG15 plasmid; 2) digestion of ISG15-GG and -AA 
cDNA fragment with HindIII and BamHI restriction enzymes and insertion into pCMV-FLAG-
UbcH7 plasmid; 3) PCR amplification of FLAG-ISG15-GG/AA from pCMV-FLAG-ISG15-
GG/AA vector; 4) Digestion of amplified FLAG-ISG15-GG/AA DNA fragment with NheI and 
XbaI and insertion into pLKO-dCMV.TetO.mcs vector, to generate the final constructs pLKO-
dCMV.TetO.FLAG-ISG15-GG and –AA. [C] PCR primers used to amplify ISG15 cDNA from 
pOTB7-ISG15 vectors (PCR 1) [D] PCR primers used to amplify FLAG-ISG15-GG and –AA 
DNA fragments from pCMV-FLAG-ISG15-GG/AA vectors (PCR 2). 
 
To examine whether FLAG-tagged ISG15 protein could be expressed, Huh-7 
cells were transfected with pLKO.dCMV.TetO.FLAG.ISG15-GG and –AA plasmids 
(hereafter referred to as FLAG-ISG15-GG and –AA), alongside pCMV-FLAG-UbcH7 
plasmid, as a positive control. After 16h, expression of FLAG protein was 
assessed by indirect immunofluorescence. As expected, no FLAG was detected in 
mock-transfected Huh-7 cells (Figure 5.12), whereas in FLAG-UbcH7 transfected 
cells the tagged protein was expressed and distributed throughout the cell. 
Similarly, both FLAG-ISG15-GG and –AA transfected cells expressed FLAG-tagged 
ISG15 to levels close to the FLAG-UbcH7control cells. These data indicated that 
Flag-ISG15-GG and –AA constructs were capable of expressing the –GG and –AA 
forms of tagged ISG15. 
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Figure 5.12 – Immunofluorescence analysis of FLAG expression. Huh-7 cells were 
transfected with 400ng of pLKO-dCMV.TetO.FLAG-ISG15-GG, pLKO-dCMV.TetO.FLAG-
ISG15-AA, plasmids, or pCMV-FLAG-UbcH7, as a positive control. At 16h post-transfection, 
the cells were fixed and stained for FLAG protein using anti-FLAG antisera. 
 
5.3.1.2 Generation and characterisation of inducible Huh-7 cell lines 
expressing WT and mutant ISG15 
The purpose of creating the pLKO vectors expressing the WT (GG) or 
mutant (AA) forms of ISG15 was to create inducible cell lines with the lentivirus 
system. To create such cell lines, a two step strategy was used. First, a lentiviral 
cell line expressing the tetracycline repressor was created, and then used as a 
parental cell line for transfecting the ISG15 lentiviral expressing plasmid, which 
contains a tetracycline operator sequence. The strategy is described in the 
following paragraphs and represented in Figure 5.13. 
In order to produce lentiviral stocks (Figure 5.13-A), HEK-293T cells were 
transfected with either pLKO-dCMV-eGFP-TetR or pLKO-dCMV.TetO.FLAG.ISG15-
GG and -AA plasmids together with plasmids encoding the lentivirus components 
(pCMV-DR8.91 and pVSV-G), according to the method described in Chapter 2 
(sections 2.2.7.3 and 2.2.7.4). After the first round of transfections, with pLKO-
dCMV-eGFP-TetR plasmids, the supernatants were harvested and used to 
transduce monolayers of Huh-7 cells (Figure 5.13-A-I & II). Cell lines that 
incorporated the eGFP-TetR sequences were selected by culturing in the 
presence of neomycin and further sorted according to GFP expression intensity. 
The generated cell line was named Huh-7-GFP. Subsequently, the supernatants 
harvested from a second round of transfections, with pLKO-
dCMV.TetO.FLAG.ISG15-GG and –AA plasmids, were used to transduce Huh-7-GFP 
cells (Figure 5.13-III & IV). Cell lines that incorporated the eGFP-TetR as well as 
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FLAG.ISG15-GG and –AA sequences were selected by culturing in the presence of 
both puromycin and G418. The generated cell lines were named Huh-7-eGFP-
FLAG-ISG15-GG and -AA. 
Huh-7-eGFP-FLAG-ISG15-GG and –AA were then treated with tetracycline 
(1ug/ml) and examined at 24, 48 and 72h for their ability to express FLAG-ISG15 
by Western blot analysis (Figure 5.14). Cell extracts from inducible cells 
expressing FLAG-PIAS protein (Protein Inhibitor of Activated STATs) were used as 
positive control for FLAG expression. As shown in Figure 5.14, no expression was 
detected in either FLAG-ISG15-GG or –AA cells, even at longer tetracycline 
treatment times, when compared with the control. Lower tetracycline 
concentrations were also tested to rule out the possibility that excess antibiotic 
could have an inhibitory effect on the inducible system. However, even at lower 
concentrations (0.1 and 0.5ug/ml) no expression of FLAG protein was observed 
(data not shown). Thus, the inducible system used to express ISG15 was 
unsuccessful in Huh-7 cells. 
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Figure 5.13 – Generation of inducible lentiviral cell lines to express FLAG-ISG15-GG and –
AA proteins. [A] (I) Lentiviruses were produced by transfection of pLKO-dCMV-eGFP-TetR 
together with pCMV-DR8.91 and pVSV-G packaging vectors into HEK 293T cells. (II) At 60h 
post-transfection, the supernatant was harvested and used to transducer Huh-7 cells. The 
cell lines were generated by neomycin selection followed by FACS sorting of eGFP 
expressing cells (Huh-7-GFP). (III) Lentiviruses were produced by transfection of pLKO-
dCMV.TetO.FLAG-ISG15-GG or pLKO-dCMV.TetO.FLAG-ISG15-AA together with the 
packaging vectors into HEK 293T cells and (IV) the supernatants used to transduce Huh-7-
GFP cells as before. Cells potentially expressing the Tet repressor and ISG15 under the 
control of the Tet operator were selected by puromycin and neomycin resistance. Detailed 
protocol is described in Chapter 2, sections 2.2.7.3 and 2.2.7.4. [B] The generated cell lines 
can be used in (I) HCV infection assays and (II) tetracycline induction of FLAG-ISG15-GG 
and –AA proteins. 
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Given the problems encountered in establishing inducible cell lines, an 
alternative method was use to express ISG15. To that end, the pLKO-TetO-FLAG-
ISG15-GG and –AA lentiviral plasmids were utilised, this time without the 
presence of the TetR plasmid, to transduce naïve Huh-7 cells (as described 
before). Examination of the derivative cell lines, Huh-7-FLAG-ISG15-GG and –AA, 
revealed that constitutive expression of ISG15 did not impact on cell viability 
(data not shown). The ability of Huh-7-FLAG-ISG15-GG and –AA cells to express 
FLAG-ISG15 was examined by Western blot analysis. As shown in Figure 5.15, two 
low molecular weight species were detected by the ISG15 antibody, which were 
presumed to correspond to unconjugated protein. The upper band also was 
recognised by the FLAG antibody. The appearance of two bands was somewhat 
unexpected. From the data, it was assumed that the upper species identified by 
the ISG15 antibody was the FLAG-tagged protein. Since free ISG15 was not 
detected in naïve cells, it was presumed that the lower species could correspond 
to FLAG-tagged ISG15, which has been cleaved by a cellular protease, thereby 
removing the FLAG sequences. Alternatively, its production may result from 
internal translation initiation at an AUG start codon, downstream from the FLAG 
sequences. A third, less likely possibility, is that endogenous ISG15 is induced in 
the ISG15-expressing cell lines. FLAG-ISG15 was more efficiently expressed in 
the Huh-7-FLAG-ISG15-GG cells, when compared with the levels in the respective 
–AA cells. As expected, no ISG15 conjugates were observed in the FLAG-ISG15-AA 
expressing cells, since mutation of the –GG residues would prevent formation of 
conjugates. In the FLAG-ISG15-GG expressing cells, ISG15 conjugates also were 
not observed. The reasons for the lack of conjugates in FLAG-ISG15-GG cells is 
not known, but it could be that, in order to produce ISG15 protein conjugates in 
these cells in an IFN-independent manner, co-expression of E1, E2 and E3 
enzymes might be required. 
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Figure 5.14 – Analysis of the expression of FLAG protein in inducible lentiviral cells. Huh-7-
GFP-FLAG-ISG15-GG and -AA cells were treated with tetracycline (1ug/ml) for 24, 48 and 
72h. Expression of FLAG protein was determined by Western blot analysis using anti-FLAG 
antisera. 
 
Figure 5.15 – Western blot analysis of ISG15 and FLAG protein expression in Huh-7-FLAG-
ISG15-GG and –AA cell lines, using anti-ISG15 and anti-FLAG antisera. This figure was 
provided by S. McFarlane. 
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5.3.2 Silencing of ISG15 major E3 ligase, HERC5 
Since it did not prove possible to generate cell lines expressing WT (GG) 
and mutant (AA) forms of ISG15, an alternative approach was used to investigate 
the conjugation requirements for ISG15 antiviral activities against HCV. Here, we 
explored the ability to block ISG15 conjugation both in the presence and absence 
of IFN induction, by silencing the major ISG15 E3 ligase, HERC5 (Figure 4.16). To 
that end, Huh-7/SGR cells were transfected with Ctrl, ISG15 and HERC5 siRNAs 
for 24h, followed by treatment with 0, 1, 10 and 100U/ml IFNα. ISG15 and 
HERC5 expression levels in replicon cells were compared to the levels in the 
respective naïve cells treated with 0 or 100U/ml IFNα for 48h. The effects on 
HCV replication were assessed at 48h after IFNα treatment by measuring viral 
RNA and protein expression levels. As shown in Figure 5.16-A, following IFNα 
treatment, an 80-fold rise in ISG15 RNA levels was detected in naïve Huh-7 cells. 
By contrast, about an 8-fold increase was observed in HERC5 RNA levels in Huh-7 
cells under the same treatment conditions (Figure 5.16-B). RNA levels of ISG15 
and HERC5 in Huh-7/SGR cells transfected with siCtrl yielded the same induction 
with 100U/ml IFNα as naïve cells (Figure 5.16-A & B). As expected transfection 
of ISG15 and HERC5 siRNAs in Huh-7/SGR cells specifically attenuated induction 
of ISG15 and HERC5, respectively, following IFNα stimulation (Figure 5.16-A & 
B). Interestingly, silencing of HERC5 resulted in an increase in ISG15 transcript 
levels both in the absence and presence of IFNα (Figure 5.16-A), and the same 
phenotype was observed on HERC5 levels when ISG15 was repressed (Figure 
5.16-B). 
Western blot analysis mirrored the ISG15 RNA data such that, following IFN 
treatment, high levels of conjugated and unconjugated ISG15 protein were found 
in Huh-7 and in Huh-7/SGR cells transfected with siCtrl (Figure 5.16-D). Silencing 
of ISG15 in Huh-7/SGR cells blocked expression of any ISG15 protein during IFNα 
stimulation. Surprisingly, HERC5 silencing did not completely prevent production 
of ISG15 conjugates in Huh-7/SGR cells. Nonetheless, a small increase in the 
unconjugated form of ISG15 was observed as a result of HERC5 silencing, 
suggesting that some conjugation was inhibited in these cells (Figure 5.16-D). 
The slight reduction in ISG15 conjugation was not due to lack of silencing HERC5, 
as siHERC5-transfected Huh-7/SGR cells gave apparently complete abrogation of 
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detectable HERC5 protein (Figure 5.16-D). For HERC5, there was some evidence 
that increased protein levels were produced with 10U/ml IFNα in cells 
transfected with siISG15 compared to siCtrl (Figure 5.16-D). However, there was 
little evidence of enhanced HERC5 protein at the higher doses of cytokine 
(100U/ml). 
Consistent with data shown earlier, silencing of ISG15 in Huh-7/SGR cells 
resulted in a relative rise in HCV RNA levels in the absence of exogenous IFNα 
stimulation (Figure 5.16-C). In Huh-7/SGR cells transfected with ISG15, ~2-fold 
less of a decrease in HCV RNA was observed following 100U/ml of IFNα 
treatment, but not at lower concentrations, when compared with the levels in 
the siCtrl cells. HERC5 silencing in Huh-7/SGR cells resulted in a 15% increase in 
HCV RNA levels, when compared with the control cells (Figure 5.16-C). By 
contrast, silencing HERC5 followed by IFNα treatment, did not affect the 
efficiency of IFNα in reducing HCV RNA levels, when compared with siCtrl cells. 
Western blot analysis revealed that in the absence of exogenous IFNα 
stimulation no substantial effects were observed in NS5A expression in Huh-
7/SGR cells transfected with siCtrl, siISG15 or siHERC5. Following IFNα 
treatment, a small reduction in NS5A expression was observed with ISG15 siRNA 
but not HERC5 siRNA transfected cells, when compared with control cells. 
These results have shown that 1) silencing of either ISG15 or HERC5 in Huh-
7/SGR cells resulted in a corresponding increase in HERC5 or ISG15 RNA levels, 
respectively; 2) HERC5 silencing reduced, to some extent, production of ISG15 
protein conjugates; 3) silencing of HERC5 resulted in a smaller rise in viral RNA 
levels when compared with the effects of ISG15 silencing in Huh-7/SGR cells in 
the absence of exogenous IFNα stimulation, and 4) the small reduction on ISG15 
conjugate formation did not have an appreciable effect on viral RNA levels 
following IFNα treatment as observed previously in the cells transfected with 
ISG15 siRNAs. Together, these data suggest that the IFN-mediated antiviral 
activities of ISG15 on HCV replication may not be dependent on ISG15 
conjugation. However, given that silencing of HERC5, the major E3 ligase for 
ISGylation, did not completely abrogate the formation of ISG15 conjugates, 
further experiments are needed to verify whether ISGylation is required for its 
anti-viral activities against HCV replication. 
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Figure 5.16 – Analysis of HERC5 silencing in Huh-7/SGR cells. Huh-7/SGR cells were 
transfected with control, ISG15 and HERC5 siRNAs (siCtrl, siISG15 and siHERC5, 
respectively) for 24h, followed by treatment with increasing doses (0, 1, 10 and 100 U/ml) of 
IFNα for 48h. Huh-7 cells were treated with 0 and 100U/ml IFNα for 48h. RT-qPCR analysis of 
ISG15 [A], HERC5 [B] and HCV [C] RNA expression levels. [D] Western blot analysis of 
ISG15 conjugated and unconjugated forms, HERC5, NS5A and Actin protein expression 
levels, using anti-ISG15, anti-HERC5, anti-NS5A and anti-Actin antisera. 
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5.4 Discussion 
Following the findings observed in Chapter 4, the aim of this section was to 
investigate mechanisms used by ISG15 to limit HCV replication. Two approaches 
were adopted to determine whether 1) ISG15 affected the rates of synthesis or 
degradation of viral RNA and 2) ISG15 conjugation was necessary to inhibit HCV 
RNA replication. 
1) Impact of ISG15 on the rates of viral RNA synthesis or degradation 
Steady-state levels of mRNAs are the result of a tightly regulated balance 
between de novo transcription and mRNA decay. Standard methods such as 
Northern blot and microarray analysis on total RNA provide a measure of mRNA 
abundance but do not distinguish between changes in the rates of RNA synthesis 
or decay. Early studies to investigate rates of transcriptional activity in cells 
were based on incorporation of radioactive ribonucleosides into RNA. The 
method relied on analysis of incorporation of 3H- or 14C-uridine into mRNA 
transcripts followed by autoradiography (Forsdyke, 1967; Harwood & Itzhaki, 
1973). While this approach was successful, it had the disadvantage of using 
hazardous radioisotope molecules and required time consuming autoradiography, 
sometimes taking the order of weeks. An alternative method measured 
incorporation of bromo-containing nucleosides into nascent mRNA, such as 5-
bromouridine (BrU) (Haider et al., 1997; Ohtsu et al., 2008). BrU is taken up by 
cells and converted to nucleotide phosphates through the ribonucleoside salvage 
pathway. Quantitation of BrU-tagged RNA can be determined by 
Northern/Western blot analysis using anti-BrdU monoclonal antibodies (Haider et 
al., 1997). This approach has also been employed for indirect 
immunofluorescence studies since BrU-labelled RNA can be detected by staining 
cells with the same antibodies. Indeed, the method revealed sites of RNA 
replication in cells harbouring the HCV SGR (Gosert et al., 2003). However, the 
method does present some limitations, as it is associated with toxicity and the 
rates of incorporation and isolation of BrU-tagged RNA containing low uridine 
content are variable. 
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Improvements to the metabolic tagging of transcribed RNA and downstream 
purification techniques have been developed in recent years. Thiol-containing 
nucleosides, such as 4-thiouridine, were described more than 30 years ago, and 
could readily incorporate into nascent RNA with minimal toxic effects (Melvin et 
al., 1978). This method can be used for both in vitro and in vivo studies, since it 
is well tolerated by mice following injection with 4sU nucleosides (Kenzelmann 
et al., 2007). Isolation of nascent 4sU-tagged RNA can be achieved using mercury 
affinity chromatography and further analysed by Affymetrix microarrays 
(Kenzelmann et al., 2007). More recently, an improved version of the method 
has been developed in which incorporation of 4sU into nascent RNA was 
combined with thiol-specific biotinylation and subsequent magnetic separation 
of total RNA into nascent and pre-existing untagged RNA (Dolken et al., 2008). 
The three fractions of isolated RNA (labelled, pre-existing and total RNA) are 
suitable for further analysis using RT-qPCR, microarray and next-generation 
sequencing (Dolken et al., 2008; Marcinowski et al., 2012; Rabani et al., 2011). 
Traditionally, assessment of RNA decay could be achieved by blocking global 
transcription with transcriptional inhibitors, such as actinomycin D (ActD) and 
monitoring RNA decay over time. These approaches have negative impacts on 
cellular physiology and may interfere with the determination of the RNA 
degradation rate. By contrast, 4sU labelling methods allow monitoring of RNA 
under non-disruptive conditions (Friedel & Dolken, 2009). Thus, use of metabolic 
labelling of RNA with 4sU nucleosides can enable both the rates of RNA synthesis 
and decay to be determined. 
In the study presented here, the method was applied to labelling newly 
transcribed HCV RNA and to determine whether ISG15 could affect the rates of 
synthesis or decay of viral RNA. The results show that it is possible to label 
newly transcribed viral RNA during infection of Huh-7 cells with infectious virus. 
While short labelling periods were ideal for detecting changes in cellular mRNA 
transcripts (Dolken et al., 2008), longer labelling periods were required for 
accurate detection of HCV labelled RNAs. Huh-7 cells were exposed to 100uM 
4sU for up to 24h, which was well tolerated by the cells and there was no 
apparent significant effect on cell viability. Quantification of the levels of 4sU-
labelled viral RNA transcripts demonstrated that in cells stably expressing ISG15 
shRNAs (sh6 cells), higher levels of viral RNA were produced (Figure 5.8) 
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compared with the levels in cells expressing a non-targeting shRNA (shCtrl cells). 
These changes in the levels of newly synthesised viral RNA mirrored the 
differences in total steady-state levels of viral RNA in both cells lines, indicating 
that ISG15 can negatively regulate the amount of viral RNA produced during HCV 
replication. Furthermore, data from experiments in which infected shCtrl and 
sh6 cells were pulse-labelled with higher concentrations of 4sU (200uM) for a 
period of 6h revealed that the rates of loss of labelled viral RNA were similar in 
both cells. These data suggest that ISG15 does not affect stability of HCV RNA 
but specifically affects viral RNA synthesis.  
In a recent paper by Durfee et al (2010), ISG15 was implicated in broadly 
targeting newly synthesised proteins. HERC5, the major E3 ligase involved in 
ISGylation, was shown to localise with ribosomes and thus mediate ISG15 
conjugation to newly synthesised proteins (Durfee et al., 2010). It is possible 
that ISG15 may be able to target some of the viral replicase proteins during 
translation and prevent their normal function on replication by either disrupting 
protein–protein interactions between viral and host factors or protein-RNA 
interactions as part of replication complexes. It may be feasible to isolate HCV 
replication complexes by immunoprecipitation of 4sU-labelled viral RNAs, which 
could uncover possible interactions between ISG15 and the viral replicative 
machinery. Such immunoprecipitates could then be analysed by mass 
spectrometry or Western blot analysis to identify any factors that are conjugated 
to ISG15. One previous report has indicated that NS5A is conjugated to ISG15 
(Kim & Yoo, 2010) but whether ISGylated NS5A is incorporated into sites of viral 
RNA replication is not known. Thus, the approach presented here could be 
developed further to examine the role of ISG15 in regulating HCV replication. 
2) Conjugation requirements for ISG15 anti-HCV activities 
Previous studies have demonstrated that ISG15 plays an antiviral role 
against Sindbis virus replication, which is dependent on the ability of ISG15 to 
conjugate to other proteins. By contrast, unconjugated ISG15 has been 
implicated in controlling replication of other viruses, such as HIV-1 and Ebola 
virus; these viruses use Gag-mediated and VP40-mediated budding from cells, 
respectively (Malakhova & Zhang, 2008). ISG15 disrupts ubiquitination of Gag 
protein, thereby limiting egress of HIV-1 virus (Okumura et al., 2006). In the 
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case of Ebola, ISG15 binds specifically to Nedd4, an E3 ligase involved in 
ubiquitination of VP40, to prevent ubiquitination of VP40 and thus blocking 
egress (Malakhova & Zhang, 2008). In the case of HCV, the precise mode of 
action of ISG15 is not fully understood. Randall et al (2006) demonstrated an 
increase in ISG15 transcription and protein conjugates by silencing the ISG15 
protease USP18. Decreased expression of USP18 resulted in enhancement of the 
negative effects of IFN against HCV replication (Randall et al., 2006). Consistent 
with this notion, increased expression of ISG15 and ISG15-conjugation 
components in HCV replicon cells also resulted in inhibition of HCV replication 
(Kim & Yoo, 2010). Moreover, ISG15 was shown to directly interact with NS5A 
protein, suggesting that the anti-HCV activities of ISG15 against HCV were 
mediated by ISGylation and inhibition of function of NS5A protein (Kim & Yoo, 
2010). 
Given the data presented in the previous chapter regarding the IFN-
dependent and –independent anti-viral role of ISG15 during HCV replication, two 
approaches were taken to evaluate the conjugation requirements of ISG15 for its 
anti-HCV activities. As stated earlier, IRF-3 and NF-KB can directly activate 
transcription of ISG15 following activation of cytoplasmic sensors with dsRNA or 
LPS (Li et al., 2001; Memet et al., 1991). Therefore, ISG15 can be produced in 
an IFN-independent manner and may possibly have a role as an early gene in 
controlling viral infection. To investigate whether these IFN-independent 
antiviral activities of ISG15 during HCV replication were dependent on its 
conjugation status, attempts were made to generate tetracycline-inducible cell 
lines to express a FLAG-tagged WT version of the mature ISG15 protein, which 
retained the C-terminal di-GG residues involved in conjugation, and a FLAG-
tagged mutant version of ISG15 protein, in which these di-GG residues were 
converted to Ala (FLAG-ISG15-AA); introduction of these two mutations would 
prevent ISG15 conjugation. Increased protein expression by addition of 
tetracycline to the cells did not result in induction of ISG15 expression, in either 
ISG15-GG or ISG15-AA cells. Transient expression of FLAG-ISG15-GG and FLAG-
ISG15-AA plasmids confirmed that both constructs were capable of expressing 
FLAG protein. Further analysis using tetracycline-inducible Huh-7 cells 
expressing YFP or luciferase revealed that expression of these proteins also 
failed upon addition of tetracycline (data not shown). Hence, it was concluded 
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that the tetracycline-inducible system is not well tolerated by Huh-7 cells and 
the problems encountered with expressing ISG15 are likely to be independent 
from the nature of the protein. Given those difficulties, Huh-7 cells stably 
expressing FLAG-ISG15-GG and FLAG-ISG15-AA proteins were generated. These 
cells apparently tolerated constitutive expression of ISG15 given that no changes 
in phenotype or cell viability were observed compared to parental Huh-7 cells. 
Western blot analysis demonstrated that FLAG-tagged unconjugated ISG15 was 
produced in FLAG-ISG15-GG and FLAG-ISG15-AA Huh-7 cells. However, a lower 
molecular weight band, presumed to correspond to untagged, free ISG15 protein 
was also detected. While ISG15 conjugates were not expected in the FLAG-
ISG15-AA expressing cells, conjugated forms of ISG15 were also not found in the 
FLAG-ISG15-GG expressing cells. Thus, expression of ISG15 alone did not lead to 
production of ISG15 conjugates, indicating that concomitant expression of the 
E1, E2 and E3 ISG15 enzymes might be required for production of ISG15 
conjugates in Huh-7 cells. Moreover, the data suggest that endogenous levels of 
the ISGylation machinery in the absence of IFNα are insufficient to support ISG15 
conjugation.  
Parallel to the above approach, the effects of ISG15 conjugation during IFN 
activation, i.e, when acting as an ISG, were also investigated. To that end, 
inhibition of ISG15 conjugation during IFN induction, was conducted by silencing 
HERC5, the major ISG15 E3 ligase. Previous reports have shown that, upon 
silencing HERC5, the majority of ISG15 conjugates are not produced (Dastur et 
al., 2006). However, in our experiments silencing of HERC5 did not result in a 
substantial decrease in the detection of protein conjugates. A small reduction in 
conjugate formation was detected during IFN treatment but this did not have an 
appreciable effect on viral replication. By contrast, inhibition of HERC5 
expression in the absence of IFN treatment did give a small rise in HCV 
replication. Thus, any anti-viral activity of ISG15 as a conjugating protein were 
not conclusively shown from the studies undertaken. Nevertheless, the 
approaches adopted and results acquired lay the foundation for further work to 
explore the question of which form of ISG15 regulates HCV replication. 
Alternative approaches could include silencing of UbE1L, the only E1 enzyme 
described for ISG15. However, this could also affect other substrates for UbE1L 
and thus a simple method to study ISG15 conjugation is not immediately obvious.  
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6 Final discussion and future perspectives 
6.1 Summary 
Two main lines of investigation were explored in this thesis that 
contributed to the understanding of viral and cellular requirements essential for 
HCV RNA replication in cell culture and the central role of host immune 
responses in this process. The major findings are summarised below: 
I) To expand the range of viral genotypes that can replicate in cell culture, 
two regions of the JFH1 genome (the C-terminus of NS4B and the NS3P-4A coding 
segments) were substituted by sequences from a genotype 3a isolate (Glasgow-3 
strain). Eleven amino acid changes were required to convert the C-terminus of 
NS4B from gt2a to gt3a. It was possible to make as many as 10 amino acid 
changes (Luc-M1-11/ΔM8) while retaining the ability to replicate. Interestingly, 
insertion of the gt3a NS3P-4A sequences into the JFH-1 SGR produced a replicon 
that failed to replicate in Huh-7 cells but was capable of some replication in 
Huh-7.5 cells. 
II) The feasibility of using HepaRG cells for studies on replication was 
explored. No replication could be detected in transient assays but it was possible 
to generate drug-resistant colonies that harboured the replicon. It was presumed 
that the low permissiveness of these cells to replication was linked, at least in 
part, to an intrinsic or innate response. Results showed that ISG15 was 
upregulated in the cells although there was no evidence for stimulation of IFNβ 
transcription. Therefore, ISG15 presumably along with other ISGs could perhaps 
play a role in modulating the permissiveness of HepaRG cells to the initiation of 
viral replication. 
III) ISG15 was identified as an antiviral factor against HCV replication. From 
experiments using both the SGR and HCVcc systems combined with siRNA and 
shRNA approaches, knockdown of ISG15 led to an increase in HCV RNA levels. 
Further studies examining de novo labelled viral RNA suggested that ISG15 
exerted its anti-viral activity on the rate of viral RNA synthesis and not RNA 
degradation. In addition to identifying the mechanism of action of ISG15, 
attempts were made to determine whether conjugation of ISG15 to protein 
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substrates was needed to reduce viral RNA replication. However, no conclusions 
could be drawn due to technical problems with the systems used. 
6.2 Expanding the range of genotypes for study of HCV 
infection 
Since the development of the first sub-genomic replicon for HCV in 1999 by 
Lohmann et al using a Con-1 (gt1b) isolate, a large body of literature has 
explored various avenues to expand the repertoire of replicon and infectious 
cDNAs that can be used to examine the viral life cycle. To date, the system that 
yields the highest levels of replication is based on the JFH-1 (gt2a) strain and 
chimeric constructs have been generated that incorporate sequences from other 
genotypes to enable their characteristics to be examined. This approach has 
yielded valuable insights into the differing properties of the viral proteins from 
the various genotypes. For example, the NS3 protease from gt3a used in this 
study has been utilised to demonstrate its lower susceptibility to telaprevir 
(Imhof & Simmonds, 2011). Such studies are important since telaprevir is not 
currently prescribed for use in patients infected with HCV gt3 strains. Moreover, 
incorporation of NS5A sequences from the different HCV genotypes into the JFH-
1 backbone has been employed as a strategy to show that gt2a and 3a strains are 
more resistant to BMS-790052, a drug that is currently undergoing clinical trials 
(Scheel et al., 2011). The approach adopted in this study was guided largely by 
previous failed attempts to create a gt3 replicon based on the sequences of the 
Glasgow-3 isolate. It was possible to modify the C-terminus of NS4B to gt3a 
sequences with the exception of one substitution, which ablated replication. The 
constructs generated could provide the platform for further constructs. 
Future construction of any chimeras for gt3 replicons should now be 
considered in light of the recent publication demonstrating replication of SGRs 
composed entirely of gt3a (strain S52) sequences (Saeed et al., 2012). 
Replication required introduction of a serine to isoleucine substitution in NS5A 
(equivalent to S2204I in strain H77), which enabled adaptation of a gt1a replicon 
(Blight et al., 2003). The strain S52 SGR acquired adaptive mutations in NS3 and 
NS4B following continuous culture in Huh-7 cells, which improved replicative 
efficiency. The only sequence difference between S52 and Glasgow-3 at the C-
terminus of NS4B is a Lys at position 251 (in S52), which encodes a Gln (in 
Patricia Domingues  Chapter 6 
 
257 
 
Glasgow-3). However, substitution at this position (M6) did not affect 
replication. Further studies could build on the data presented here and that are 
now available with strain S52 to examine genetic interactions between gt3a 
sequences. This would help to explore any functional differences between the 
genotypes. For example, infection with gt3a has been linked with steatosis. In 
addition, those infected with gt3a strains are more likely to respond to 
IFNα/RBV therapy for reasons that are as yet not understood. 
Ultimately, the aim of much HCV research is to be able to examine the 
infectious process with natural isolates without the need for adaptive mutations. 
To date, the only strain capable of robust replication and virus production in the 
absence of any mutations is JFH-1. However, this isolate is somewhat unique 
since it originated in a patient who developed fulminant hepatitis and thereafter 
cleared infection. Studies with natural isolates will almost certainly require 
alternatives to Huh-7 cells. One example of continuous cells capable of infection 
by HCV is the LH86 line, which was developed from a patient with HCC (Zhu et 
al., 2007). Creation of 3-D culture systems with Huh-7 cells capable of 
productive infection by HCVcc has been achieved (Sainz et al., 2009b). There 
have also been successes with human fetal liver cells (Marukian et al., 2011) and 
hepatocytes derived from pluripotent stem cells (Roelandt et al., 2012). With 
the ongoing advances in stem cell technology, it should perhaps be feasible to 
generate cell lines that can support infection by virus isolated from patient 
serum. 
6.3 The mechanisms of action of ISG15 
6.3.1 ISG15, an antiviral or proviral factor in HCV infection? 
During the phase of acute infection, the complex interplay between HCV 
and the host can lead to two possible outcomes. In one, host immune responses 
can efficiently inhibit replication and eliminate the virus, resulting in clearance 
of infection. However, in the majority of the cases, HCV is able to subvert the 
host immune responses, leading to persistence. HCV has been shown to target 
host IFN signalling pathways at different levels. In infected cells, NS3/4A-
mediated cleavage of signalling factors inhibits IRF-3 activation and NS5A 
suppresses PKR activity (Gale et al., 1997; Li et al., 2005b; Li et al., 2005c). 
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Other arms of innate host defence, such as NK cell activation, macrophages and 
DC function, and consequent activation of adaptive immune responses, can also 
be controlled by the virus (Edwards et al., 2012; Petrovic et al., 2012; Saito et 
al., 2008). The efficiency by which HCV controls the different waves of host 
antiviral response are highly dependent on genetic characteristics of different 
viral strains and genotypes as well as intrinsic host factors (such as IL28B 
polymorphisms) (Mangia et al., 2010; Thompson et al., 2010). 
The current standard of care for treating chronic HCV infection is based on 
a combination of Peg-IFNα and ribavirin. This regimen can successfully clear 
infection in ~50% of the patients. By comparing host genes expressed in liver 
biopsies from responders and non-responders, it has been possible to identify a 
subset of four genes that could act as predictors of response to treatment (Dill 
et al., 2011). All of the genes are IFN-induced and include ISG15. Interestingly, 
determining the expression of these genes in the liver proved to be a better 
predictor of response compared to IL28B genotype. Moreover, unpublished 
studies from our group indicate that IFN-induced genes, including ISG15 and 
those involved in the ISGylation pathway, are expressed at higher levels in 
biopsies from infected patients compared to uninfected patients (M. Robinson et 
al., unpublished). The mechanisms underlying these changes are not known but 
highlight the importance of studying IFN-regulated genes such as ISG15 with in 
vitro systems.  
The data presented in this study and others have reached conflicting 
conclusions with regard to whether ISG15 acts as a pro- or antiviral factor in HCV 
infection. Part of the difficulty could result from use of different sources of Huh-
7 cells and the use of cells previously carrying but cured of the HCV SGR (e.g. 
Huh-7.5 cells). Added weight for ISG15 acting as an antiviral factor comes from 
data obtained with U2OS cells that are also able to support replication. Indeed, 
knockdown of ISG15 in U2OS cells increased viral RNA cells to a much greater 
extent compared to Huh-7 cells. It is known that immune cells isolated from 
cancer patients have defective interferon signalling (Critchley-Thorne et al., 
2009) and it is reasonable to assume that tumour-derived cell lines have similar 
characteristics. Since both U2OS cells and Huh-7 cells are tumour-derived, they 
would be expected to have impaired interferon signalling pathways and indeed it 
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is known that Huh-7 cells lack TLR3 and RIG-I is mutated in Huh-7.5 cells. There 
is not an extensive literature on the use of U2OS cells for interferon signalling 
studies but the membrane sensor TLR9 is absent from the surface of the cells 
(Laredj & Beard, 2011). Nevertheless, the fact that the data in the study 
presented here is reproducible in cells from different tissue lineages gives 
greater confidence that ISG15 is an antiviral factor. It would be preferable to 
conduct the studies in other cell lines or indeed primary liver cells. 
Unfortunately, HepaRG cells were unable to support replication for a sufficiently 
long period to enable ISG15 knockdown studies. It is known that HCVcc induce 
ISG expression in human fetal cells and ISG15 is among those that are stimulated 
upon infection (Marukian et al., 2011). However, replication levels in these cells 
tend to be low and vary between donors. Manipulation of the cells by expressing 
the paramyxovirus V proteins to impair STAT signalling does enhance productive 
infection (Andrus et al., 2011). Therefore, limiting ISG15 expression using the 
shRNA system could be utilised to conclusively determine its impact in human 
fetal cells since they have an authentic interferon-response pathway. 
6.3.2 Is conjugation necessary for ISG15 to impair HCV RNA 
replication? 
One of the important questions not fully addressed in this study was whether 
conjugated or free ISG15 was responsible for limiting viral RNA replication. The 
approaches adopted were to generate Huh-7 cells in which HERC5 expression 
was inhibited using siRNAs and separately, express a mutant form of ISG15 that 
could not form conjugates; the cells produced using these methods would have 
allowed analysis not only with the SGR but also the HCVcc system. Although 
neither approach in Huh-7 cells was successful, HERC5 expression was not 
detected in U2OS cells and very few conjugated forms of ISG15 were detected in 
cells stimulated with IFN. Despite the reduced capacity for U2OS cells to 
produce conjugated ISG15, knockdown of ISG15 had a greater effect on viral RNA 
levels. This would perhaps suggest that ISGylation is not a prerequisite for ISG15 
to exert its antiviral effect and free ISG15 may be sufficient. 
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The potential role of unconjugated ISG15 has been the subject of considerable 
debate for more than a fifteen years. Early studies showed that unconjugated 
ISG15 could be secreted by corneal cells (Taylor et al., 1996) and a range of 
immune cell types (D'Cunha et al., 1996a; D'Cunha et al., 1996b). Experimental 
evidence indicated that ISG15 could act as a cytokine, capable of stimulating 
production of IFNγ from NK and T-cells (D'Cunha et al., 1996a; D'Cunha et al., 
1996b). By contrast, data obtained from ISG15-/- mice contradicted these 
findings and reached the conclusion that ISG15 lacked any cytokine activity 
(Osiak et al., 2005). However, recent evidence from patients who have 
mutations in the ISG15 gene and are susceptible to mycobacterial disease 
apparently confirms the earlier findings that the protein has immunomodulatory 
properties (Bogunovic et al., 2012). The mutations introduce either a premature 
stop codon or frameshift into the protein coding region, thereby generating non-
functional ISG15. Leukocytes isolated from these patients produced only small 
amounts of IFNγ after stimulation by mycobacteria. IFNγ stimulation could be 
restored by addition of human recombinant ISG15. Thus, free ISG15 is a 
functional factor whose properties have not yet been fully explored. Further 
experiments that built on the approach to express mutant ISG15 that was 
incapable of participating in ISGylation would help to address this issue as would 
attempts to treat infected Huh-7 cells with recombinant ISG15. If the results 
demonstrated that unconjugated ISG15 could affect HCV replication, this would 
open entirely new avenues for future research. In addition, ISG15 transcription is 
elevated in infected liver and also to yet higher levels in those who fail to 
respond to therapy. If it could be demonstrated that this increased transcription 
leads to a rise in free ISG15, then further studies would be warranted to 
determine how it functions in the complex cytokine milieu that resides in the 
liver.  
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